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SUMMARY OF THESIS:
Prolyl oligopeptidase (PO, Prolyl Endopeptidase, PE, PEP) is a member o f the serine 
protease family and shares a good structural homology with other a /p  hydrolase fold 
enzymes. PO specifically cleaves oligopeptides after a proline residue.
The PO homologue, DpoA, was identified in the cellular slime mould Dictyostelium  
Discoideum  following a lithium screen. Loss o f DpoA confers resistance to both lithium and 
valproic acid (VPA), through regulation o f inositol phosphate pathways.
The intracellular substrate and cellular role o f PO remain uncertain. However, it is known to 
inhibit dephosphorylation o f the higher order inositol phosphates IP 5 and IP4  to IP3 , a 
reaction catalysed by Multiple Inositol Polyphosphate Phosphatase (MIPP), by an unknown 
mechanism.
In this study it has been determined that DpoA is highly similar to the mammalian enzyme.
It has also been demonstrated that while some variation was observed at the sequence level 
there is clear homology around the active site and the catalytic triad is conserved. Enzyme 
activity and inhibition studies reveal similar K M and Kf values in the presence o f known 
specific inhibitors. Thus making it a relevant model for the mammalian enzyme. 
Characterisation o f the direct effects o f three mood stabilisers on PO activity has revealed no 
effect o f lithium, carbamazapine or valproic acid at therapeutic concentrations. However, 
VPA while exerting no clear effect in vivo was able to inhibit PO in vitro at increased 
concentrations. This inhibition was also seen using VPA analogues lacking either the 
carboxylic acid domain or branching structure.
Significant to the elusive intracellular role for PO is the identification of a clear inhibitory 
effect o f PO on MIPP activity in vitro. While identification o f PO presence within the 
nucleus as well as distributed throughout the cytoplasm may also be significant to its role in 
inositol signalling.
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Abstract
Prolyl oiigopeptidase (PO, Prolyl Endopeptidase, PE, PEP) is a member of the serine 
protease family and shares a good structural homology with other a /p  hydrolase fold 
enzymes. PO specifically cleaves oligopeptides after a proline residue.
The PO homologue, DpoA, was identified in the cellular slime mould Dictyostelium 
Discoideum following a lithium screen. Loss of DpoA confers resistance to both 
lithium and valproic acid (VPA), through regulation of inositol phosphate pathways.
The intracellular substrate and cellular role of PO remain uncertain. However, it is 
known to inhibit dephosphorylation of the higher order inositol phosphates IP5 and IP4  
to IP3 , a reaction catalysed by Multiple Inositol Polyphosphate Phosphatase (MIPP), 
by an unknown mechanism.
In this study it has been determined that DpoA is highly similar to the mammalian 
enzyme. It has also been demonstrated that while some variation was observed at the 
sequence level there is clear homology around the active site and the catalytic triad is 
conserved. Enzyme activity and inhibition studies reveal similar Km and K{ values in 
the presence of known specific inhibitors. Thus making it a relevant model for the 
mammalian enzyme.
Characterisation of the direct effects of three mood stabilisers on PO activity has 
revealed no effect of lithium, carbamazapine or valproic acid at therapeutic 
concentrations. However, VPA while exerting no clear effect in vivo was able to 
inhibit PO in vitro at increased concentrations. This inhibition was also seen using 
VPA analogues lacking either the carboxylic acid domain or branching structure.
Significant to the elusive intracellular role for PO is the identification of a clear 
inhibitory effect of PO on MIPP activity in vitro. While identification of PO presence 
within the nucleus as well as distributed throughout the cytoplasm may also be 
significant to its role in inositol signalling.
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1 INTRODUCTION
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1.1 Introduction
Prolyl oiigopeptidase (PO, Prolyl Endopeptidase, PE, PEP) is a member of the serine 
protease protein family. It also shares structural similarity with the family of a /p  
hydrolase fold enzymes, such as, oiigopeptidase B, dipeptidyl peptidase IV and 
acylaminoacyl peptidase (Polgar 2002). PO also contains a seven-bladed beta- 
propeller domain that confers selectivity for small peptide substrates, which PO 
cleaves specifically after a proline residue (Fulop et al. 2000).
PO homologues have been identified in multiple species from archaea, bacteria and 
eukaryotes. In the model organism Dictyostelium discoideum the PO homologue, 
DpoA, was identified following a lithium screen. Loss of DpoA is able to confer 
resistance to treatment with both lithium (Williams et al. 1999) and valproic acid 
(VPA) (Williams et al. 2002).
Lithium and VPA are both drugs commonly prescribed to treat Bipolar disorder. Both 
have multiple intracellular targets, however both affect the inositol phosphate 
pathway, causing inositol depletion, suggesting a common therapeutic mechanism.
The intracellular substrate and cellular role of PO remain uncertain. Inhibition of PO 
results in an increase in intracellular IP3 through increased dephosphorylation of 
higher order inositol phosphates. PO is also able to cleave a number of extracellular 
neuropeptides however there is strong evidence that this enzyme is not secreted from 
the cell but localised throughout the cytoplasm (Dresdner et al. 1982; Goossens et al. 
1995; Williams et al. 1999; Schulz et al. 2005).
Dictyostelium is a highly tractable model organism. A sequenced genome and multi­
staged life cycle, which provides clear mutant phenotypes, makes it an ideal model 
organism for molecular genetic and biochemical studies of cellular processes. Thus
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Dictyostelium may provide a suitable model for understanding the cellular role of 
prolyl oiigopeptidase.
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1.2 Prolyl Oiigopeptidase
1.2.1 Enzymes Related To PO
1.2.1.1 The Serine Protease Family
The serine proteases include several families of enzymes involved in a wide variety of 
roles throughout the cell. This family contains examples of both divergent and 
convergent evolution, showing conservation or development of the same proteolytic 
mechanism. As implied by the name, the serine proteases are characterised by a 
catalytic serine residue at the active site. This residue attacks the carbonyl carbon 
atom of a peptide bond, resulting in peptide bond hydrolysis and cleavage of the 
peptide on the carboxyl side of the residue attacked.
Despite showing an identical catalytic site the three serine protease classes; 
chymotrypsin, subtilisin and serine carboxypeptidase, exhibit no secondary or tertiary 
structure similarity (Perona and Craik 1995). Thus the serine protease family show a 
wide range of specificities with preferences for small peptides or large proteins and 
different target sequences at and around the cleavage site.
1.2.1.2 Proline Specific Peptidases
1.2.1.2.1 Proline is a unique amino acid
Out of the 20 amino acids proline is unique; it has a cyclic structure whereby the side 
chain forms a covalent bond with the nitrogen of the peptide bond thus forming an 
imino acid structure. This has several consequences; restriction of the proline 
backbone conformation, restriction of the conformation of the residue preceding 
proline and an inability to act as a hydrogen donor (Williamson 1994). Because of this
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the presence of a proline residue results in a kink in the peptide chain (MacArthur and 
Thornton 1991). It also affects the formation of an a-helix structure as the proline 
nitrogen atom is unable to form the normal hydrogen bonds involved in the helical 
structure. This proline induced distortion of the a-helix probably plays a structural or 
functional role as it is highly conserved (Barlow and Thornton 1988). Proline also 
results in pre-disposition of the X-Pro peptide bond to be in the cis rather than trans 
position (10-30% compared to <1% of other amino acid’s), because of this 
isomerisation the peptide-proline bond often acts as the limiting step in protein 
folding (Brandts et al. 1975).
I.2.1,2.2 Function o f proline residue
Because of its unique structure proline plays an important role in degradation, 
protection and maturation of a variety of biologically active peptides. The presence of 
a proline residue may prevent degradation by non-specific amino peptidases however, 
in some conditions a proline residue causes a conformational change such that the 
peptide becomes susceptible to hydrolysis, for example; proline-directed arginyl 
cleavage (Schwartz 1986; Vanhoof et al. 1995).
A large proportion of neuropeptides, cytokines and growth factors have a proline 
residue at the second amino acid of the mature peptide, e.g. Substance P, Interleukin
II, V and X and Tumour necrosis factor p. This proline prevents further degradation 
by the proteases involved in formation of the mature peptide as these proteases cannot 
cleave the X-Pro bond (Mentlein 1988; Vanhoof et al. 1995). A number of neuro- and 
vaso-active peptides also contain proline residues which may confer both resistance to 
non-specific proteases and conformation required for activity (Yaron and Naider 
1993; Vanhoof et al. 1995). Proline rich regions show additional functions, acting as
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spacers between functional protein moieties and non-specific binding regions 
important in protein-protein interactions (Williamson 1994).
1.2.1.2.3 Specific cleavage at proline residues
A family of proline specific peptidases able to cope with cleavage of peptides 
containing proline residues have been identified. This family consists of a variety of 
enzymes able to cleave at the carboxyl or amino side of a proline residue in a wide 
range of sequences and positions. They have been attributed roles in protein 
activation, bioactive peptide degradation and catabolism.
Members of this family include: Prolyl oiigopeptidase; a serine protease which 
cleaves small peptides at the carboxyl side of proline. Dipeptidyl peptidase IV; 
another serine protease which exists in a membrane bound or soluble form, it is 
involved in activation of immune cells and removes X-Pro N-terminal dipeptides 
(Heins et al. 1988). Dipeptidyl peptidase II; has a lysosomal localisation and shows 
similar specificity to Dipeptidyl peptidase IV (Mentlein and Struckhoff 1989). 
Aminopeptidase P; a glycoprotein with a possible role in cardiovascular and 
pulmonary function, classed as a metalloprotease, it cleaves the N-terminal amino 
acid where the penultimate residue is proline (Fleminger et al. 1982; Hendriks et al. 
1991; Ward et al. 1991). Prolidase; this enzyme shows a similar activity to 
Aminopeptidase P but will only cleave dipeptides, it has an important role in proline 
recycling (Yoshimoto et al. 1983; Freij et al. 1984). Proline Iminopeptidase; an 
aminopeptidase which can release an N-terminal proline residue from a peptide of any 
size (Fujimura et al. 1985). Prolinase; an enzyme thought to have a similar role to 
prolidase, it is highly specific for dipeptides with an N-terminal proline (Akrawi and 
Bailey 1976; Imai et al. 1982). Prolyl carboxypeptidase; cleaves the carboxyl terminal 
amino acid following a proline residue, and may be involved in metabolism of
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angiotensin (Yang et al. 1968). Carboxypeptidase P; shows a similar specificity to 
Prolyl carboxypeptidase (Hedeager-Sorensen and Kenny 1985). Finally, Human 
Immunodeficiency Virion-1 protease; cleaves X-Pro bonds within a protein, and is 
necessary for HIV-1 virion maturation (Graves et al. 1988; Meek et al. 1989) (Figure 
1-1) (Summarised in Cunningham and O'Connor 1997).
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Prolyl Oiigopeptidase X-X-X-X-X-X-P-X-X
Dipeptidyl Peptidase IV X-P-X-X-X-X-X-X-X
Dipeptidyl Peptidase II X-P-X-X-X-X-X-X-X-X
Aminopeptidase P X-P-X-X-X-X-X-X-X-X
Prolidase X-P
Proline Iminopeptidase A -x-x-x-x-x-x-x-x
%Prolinase P-X
Prolyl carboxypeptidase X-X-X-X-X-X-X-X-P-X
Carboxypeptidase P X-X-X-X-X-X-X-X-P-X
Human Immunodeficiency Virion-1 Protease X-X-X-X-P-X-X-X-X-X
Figure 1-1 Cleavage Sites of Proline Specific Peptidases
A number of peptidases cleave small peptides specifically at or near a proline residue each of these 
peptidases shows slightly different cleavage site specificities. Arrow indicates the peptide bond that is 
specifically cleaved, X indicates any amino acid, P indicates position of proline.
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1.2.1.3 The Prolyl Oiigopeptidase Family
PO is a key member of the S9 family of serine proteases, which is also known as the 
Prolyl Oiigopeptidase family. This family also contains, dipeptidyl peptidase IV, 
acylaminoacyl-peptidase, dipeptidyl peptidase B, oiigopeptidase B (Rawlings et al. 
1991) and the more recently identified prolyl endopeptidase like A (PREPL A) 
(Szeltner et al. 2005). These are not all proline specific enzymes but can be placed 
into the same evolutionary family by virtue of their sequence homology around the 
active triad (Rawlings et al. 1991). Sequencing of the human prolylcarboxypeptidase 
(PCP) provided an evolutionary link between the prolyl oiigopeptidase family and the 
serine carboxypeptidases by showing clear sequence homology, especially around the 
active site, between both families of enzymes (Tan et al. 1993). In fact, despite 
sharing many characteristics with the serine carboxypeptidase family, the sequence 
surrounding the active serine residue of human PCP fits with the consensus sequence 
of the prolyl oiigopeptidase family (GXSXGGZZ, X=any aa, Z=hydrophobic aa).
1.2.2 Structure Of Prolyl Oiigopeptidase
1.2.2.1 Identification O fP O
Walter et al. first reported potential prolyl oiigopeptidase activity in 1971. They 
identified an enzyme activity in human uterine tissues, which cleaved the prolyl- 
leucyl bond of the hormone oxytocin thus releasing leucylglycinamide (Walter et al. 
1971). This was the first identification of endopeptidase activity directed specifically 
at the Pro-X peptide bond.
1-9
1.2.2.1.1 Size ofPO
PO was purified from lamb kidney by Koida and Walter in 1976 and estimated to 
have a molecular weight of 57kDa. They further characterised the post-proline 
cleaving activity reporting maximal activity at pH 7.5-8.0. They also observed 
preferential cleavage of Pro-X bonds where X is a hydrophobic residue and Pro is not 
the N-terminal residue, a lower rate of cleavage for basic then acidic X residues and 
complete inhibition by Z-Pro-X dipeptides (Koida and Walter 1976). PO has since 
been determined to have a molecular mass of approximately 80kDa (Rennex et al.
1991). Human PO was first cloned and sequenced in 1994 from human lymphocyte 
mRNA. The resulting cDNA was 2562 nucleotides (nt) long and encoded a 710 aa 
protein sharing 97% identity with the PO sequence from porcine brain (Vanhoof et al.
1994).
1.2.2.1.2 Specificity for proline and short peptides
A potential PO activity was identified in the brain by partial purification of an 
enzyme, referred to as Brain kininase B, able to cleave the Pro-Phe bond within 
Bradykinin (Oliveira et al. 1976). Koida and Walter also identified in vitro cleavage 
of the bio-active peptides; Insulin, Oxytocin, Angiotensin II, Bradykinin and 
Bradykinin potentiating factor, all of which were cleaved at the carboxyl bond of a 
proline residue (Koida and Walter 1976). The specificity of PO towards oligopeptides 
was identified by its inability to cleave the substrate bradykinin when covalently 
attatched to a larger peptide; this is in contrast to other serine protease family 
members, trypsin and chymotrypsin whose activity was unaffected by the larger 
substrate size (Camargo et al. 1979). PO was subsequently renamed Prolyl
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Oligopeptidase from Prolyl Endopeptidase, as it was originally called, in order to 
reflect this property (Polgar 2002).
1.2.2.2 Catalytic Domain
PO consists of two distinct structural domains. Partial trypsin proteolysis revealed the 
catalytic domain at the C-terminal with a proteolytically susceptible link between 
residues Lysl96 and Seri97 (porcine PO). Following cleavage of this linker domain 
the two fragments remained associated revealing a clear close interaction between the 
two domains in the functional protein (Polgar and Patthy 1992). For a protein 
structure diagram of PO see Figure 1-2.
The structure of the a /p  hydrolase fold, which forms the catalytic domain of the 
prolyl oligopeptidase (S9) family of enzymes and the carboxylase serine proteases, 
was first modelled in wheat serine carboxylase. It was found to consist of a central 11- 
stranded p-sheet with 15 a-helices arranged on either side. The active triad was 
located within a hydrophobic pit and arranged in such a way as to suggest the 
existence of two active diads (His-Asp and His-Ser) rather than a single active triad 
(Liao and Remington 1990; Liao et al. 1992).
Analysis of the primary and secondary structure of PO from human lymphocytes 
revealed poor sequence homology yet striking structural similarity between PO, 
dipeptidyl peptidase IV (DPPIV) and acylaminoacyl peptidase (AP). The sequence of 
a  and p structures formed by the last 250 residues are consistent with the a/p 
hydrolase fold and form 8  p-strands interconnected by five a-helices (Goossens et al. 
1995). The residues of the catalytic triad are all located in loop regions and an 
interdomain linking oligopeptide was predicted around residue 2 0 0  (agreeing with the
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proteolytic susceptibility observed between residues 196 and 197 (Polgar and Patthy
1992)) (Goossens et al. 1995).
This sequence predicted structure was confirmed by the X-Ray crystal structure of the 
porcine PO. This revealed an a /p  hydrolase fold consisting an eight stranded p-sheet 
and six a-helices formed from residues 428-710, as predicted and an additional two p 
strands and two a  helices formed from residues 1-72. The N-terminal region interacts 
with the C-terminal domain via twenty three hydrogen bonds and salt bridges as well 
as several hydrophobic interactions (Fulop et al. 1998).
NMR studies carried out by Kahyaoglu et al. on Prolyl Oligopeptidase and 
Oligopeptidase B identified resonance spectrums indicating the presence of two non- 
catalytic histidine residues participating in strong hydrogen bonds (low barrier 
hydrogen bonds, LBHB). It also showed an absence of clear hydrogen bonds between 
the catalytic His and Asp residues, in contrast to the chymotrypsin and subtilisin 
families of serine proteases (Kahyaoglu et al. 1997b).
1.2.2.3 (3-Propeller Domain
The second functional domain of PO is a 7-bladed P-propeller domain, p-propeller 
domains, of between four and eight p-sheets, are present in a number of different 
proteins including G-protein p-subunits and collagenase (Li et al. 1995; Wall et al. 
1995; Fulop and Jones 1999). Identified in PO following x-ray crystal structure 
analysis, the p-propeller domain is formed by seven 4-stranded antiparallel p-sheets 
arranged around a central tunnel. The p-propeller of PO is unusual in that the first and 
last p-sheets are not physically joined to close the tunnel (Figure 1-2) (Fulop et al. 
1998). In other p-propellers this gap is closed by disulphide bridges (Faber et al.
1995) or formation of one p-sheet from strands of both the C and N-terminus (Neer
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and Smith 1996; Baker et al. 1997). The non-closing of the PO tunnel may play an 
important role in the function as introduction of an additional cysteine residue, 
resulting in disulphide bonding across the gap, greatly reduces the enzyme activity 
(Fulop et al. 2000).
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|3-propeller
domain
a/p  hydrolase fold 
(active site)
p-propeller domain 
(perpendicular view)
a/p hydrolase fold 
(active site, perpendicular view)
Figure 1-2 Structure of DpoA
The structure of Dictyostelium PO, DpoA, as modelled by SwissModel using prolyl oligopeptidase 
from porcine brain, accession no. Ih2w, as a template. Images were produced using MacPyMol 
software. Additional sequence not present in the mammalian P-propeller domain (see section 3.2.1.7) is 
highlighted in red. Active site residues are shown in purple. A. Ribbon representation of entire 
protein structure, el and e2 indicate the 2 potential routes of substrate entry to the active site. Active 
site residues are represented by purple stick structures. B. Perpendicular view of the P-propeller 
domain. The catalytic domain is coloured in white for simplicity, active site residues are represented 
by purple stick structures. C. Perpendicular view of the catalytic domain. The active site residues are 
represented by purple space filling models. Also shown as space filling models are the proline binding 
residues (light blue) and the oxyanion binding residues (dark blue).
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1.2.2.3.1 Multiple functions o f p-propeller domains
The role of the propeller domain varies depending on the protein. In proteins other 
than PO it is commonly associated with binding of enzyme co-factors (e.g. d\ haem in 
cytochrome cd\ (Baker et al. 1997)), binding various anions and cations (e.g. Na+ or 
Mg2+ and Cl' in haemopexin (Faber et al. 1995)) and mediating protein-protein 
interactions (e.g. interactions of both hemopexin and vitronectin with cellular 
receptors and binding of Gp to the a  and y subunits (Jenne and Stanley 1987; Neer 
and Smith 1996)).
(3-propeller domains are generally lined with hydrogen donors and acceptors that can 
interact with water molecules, anions and cations and enzyme co-factors (Fulop and 
Jones 1999). In PO the (3-propeller appears to play a regulatory role, controlling 
substrate access to the active site of the enzyme.
1.2.2.3.2 Access to the active site
Two models have been proposed to explain how the |3-propeller domain is able to 
control access of the substrate to the active site of PO. In the first model, the propeller 
forms a central tunnel, which lines up with and was thought to control access to the 
active site. The opening at the bottom of the tunnel is covered by flexible side chains. 
It is too narrow, in the steady state, to allow substrate entry therefore, may be 
responsible for the rate determining conformational change involved in PO activity. 
The tunnel is large enough to theoretically accommodate peptides larger than 30aa, 
however, it is thought that such peptides would contain secondary structures thus 
excluding them from entering (Fulop et al. 1998). Regulation of substrate entry by a 
conformational change is supported by the inability of the fluorescent substrate Abz- 
Gly-Phe-Gly-Pro-Phe-Gly Phe(N0 2 )-Ala-NH2 to bind to the enzyme in the presence
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of disulphide bonds between the 1st and 7th blades of the propeller domain or between 
the propeller and catalytic domains (Szeltner et al. 2004).
In the PO family member DPPIV a similar mechanism is unlikely. This protein 
contains a much looser 8 -bladed (3-propeller domain as well as a large gap or ‘cave’ at 
the base of the propeller, thus, allowing access to the active site without entering via 
the tunnel of the propeller (Hiramatsu et al. 2003). It is possible that substrate binding 
to PO may also occur, not via the (3-propeller tunnel, but via a gap between the two 
domains.
This second model is supported by; the inhibitory effect of disulphide bonds between 
the two domains and the highly stable structure of the p-propeller region when 
expressed without the peptidase domain, despite the absence of a closing mechanism 
(Szeltner et al. 2004; Juhasz et al. 2005). However, it is of note that the ^-propeller 
region is less stable when present as part of the complete enzyme. Also, the Cys 
residue involved in formation of the interdomain disulphide bond is the Cys close to 
the active site, which, affects substrate binding in the presence of thiol inhibitors 
(Polgar 1991). It is therefore difficult to make a distinction between the effect of the 
disulphide bond on domain motility and a steric effect at the active site.
Subsequent determination of the crystal structure of PO from the bacterium 
Sphingomonas capsulata revealed an open configuration of the active site, providing 
strong evidence for the interdomain entry model (Shan et al. 2005). Shan et al 
compared this structure with the closed structure obtained from Myxococcus xanthus 
PO complexed with the inhibitor Z-Ala-prolinal. They proposed a model involving a 
conformational change, induced by the incoming peptide, resulting in opening of a 
large cavity leading to the active site. The specificity for oligopeptides is thought to 
be mediated by limited surface area for binding at the active site. The nature of this
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conformational change has been characterised using molecular dynamics and FIRST 
(Floppy Inclusion and Rigid Substructure Topology) simulations on porcine PO. 
Identification of highly flexible regions within the enzyme has revealed a tunnel 
formed by; the N-terminal region (residues 10-40), a hydrophilic loop of the 13- 
propeller domain (residues 192-205) and some C-terminal residues including the 
active site Asp (637-641, 645-647, 650, 674) that is able to expand following 
disruption of a salt bridge between Asp35 (N-terminal region) and Lysl96 
(hydrophilic loop) (Fuxreiter et al. 2005).
1,2.2.4 Variations
PO has now been cloned from a number of sources revealing a number of enzyme 
variations between different organisms, in particular those of microbial origin.
1.2.2.4.1 Cleavage o f larger proteins
PO from the hyperthermophilic archaeon Pyrococcus furiosus is active at 85°C and 
shows evidence of sequential halide binding which may cause a conformational 
change at the interdomain hinge region. Despite retaining both the a/(3-hydrolase fold 
region and (3-propeller domain structures, the P.furiosus enzyme is able to cleave 
large proteins and shows increased activity towards Ala-X peptide bonds compared 
with its mammalian counterparts (Harris et al. 2001). An ability to cleave large 
proteins, specifically fibronectin and collagen, has also been reported for the parasitic 
Trypanosoma cruzi PO (Tc80). Structural models of this protein have revealed that 
binding of a large protein, such as the collagen helix, would not significantly affect 
the overall structure of the enzyme (Bastos et al. 2005).
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In addition, identification of a bacterial PO in Flavobacterium meningosepticum has 
uncovered a 2 0 aa signal motif which is responsible for a periplasmic distribution of 
PO and is cleaved to form the mature enzyme (Chevallier et al. 1992).
1.2.2.4.2 ZIP
Existence of another enzyme also able to cleave the PO specific substrate Z-Gly-Pro- 
MCA, but insensitive to the specific inhibitor Z-Pro-Prolinal, has been reported and 
named Z-Pro-prolinal insensitive Z-Gly-Pro-MCA hydrolyzing peptidase (ZIP) 
(Bimey and O'Connor 2001). ZIP was isolated from Bovine serum and despite 
sharing a similar pH profile, specificity for oligopeptides and propensity for cleaving 
Pro-X peptide bonds, ZIP was unable to cleave PO substrates bradykinin, substance P, 
vasopressin and neurotensin. ZIP also exhibited different inhibition profiles with a 
number of serine protease inhibitors and exists as a homodimer more than twice the 
size of PO.
1.2.3 Mechanism Of PO Catalysis
In the more traditional members of the serine protease family; chymotrypsin and 
subtilisin, the rate of enzyme reaction is dependent on a general base/general acid 
chemical catalysis step. In PO it appears that this is not the case. Studies of the rate of 
acyl-enzyme formation, using substrates with a variety of leaving groups, suggest that 
the rate is independent of the leaving group (Polgar 1992c). This is different to 
observations made on the other serine proteases, where, leaving groups which were 
readily hydrolysed were degraded several orders of magnitude faster than those with 
leaving groups which were not readily hydrolysed (nitrophenyl ester compared to 
corresponding amide) (Zemer and Bender 1964). This difference led Polgar to 
conclude that the rate limiting step is in fact physical, rather than chemical, and may
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rely on either diffusion controlled binding of the substrate or a conformational change 
during catalysis (Polgar 1992c).
1.2.3.1 General Serine Protease Catalysis
The serine residue at the active site forms part of a catalytic triad along with (in the 
majority of cases) aspartic acid and histidine. Serine reacts with the substrate via its 
hydroxyl group. This nucleophilic attack is facilitated by stabilisation by the other 
residues in the triad.
1.2.3.1.1 Interaction o f catalytic triad residues
Two models have been put forward to describe the peptidase action at the molecular 
level. The first is the charge relay model, described by Polgar and Bender in 1969. 
This model involves proton transfer from the serine residue to the substrate leaving 
group, via the imidazole ring of the histidine residue, to explain the reactivity of the 
hydroxyl group (Polgar and Bender 1969). This also explains stabilisation of the 
protonated imidazole ring, by proton transfer between the non-protonated N atom of 
the imidazole ring and the carboxyl group of the, catalytically important, aspartic acid 
residue (Blow et al. 1969). This model is supported by NMR and proton inventory 
studies (Hunkapiller et al. 1973; Pollock et al. 1973; Hunkapiller et al. 1976; Elrod et 
al. 1980).
The second model favours formation of a hydrogen bond between the imidazole ring 
and aspartate residue rather than complete proton transfer and is also supported by 
NMR and neutron diffraction studies (Robillard and Shulman 1974a, 1974b; 
Bachovchin and Roberts 1978; Kossiakoff and Spencer 1980, 1981).
It is beleived that the role of the aspartate ion is to stabilise the imidazole-tetrahedral 
intermediate (Kollman and Hayes 1981; Umeyama et al. 1981). The hydrogen bond
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between the imidazole ring and the aspartate residue plays a role only during the 
tetrahedral transition state (Jordan and Polgar 1981). The His residue moves during 
catalysis, forming a hydrogen bond with Ser during formation of the tetrahedral 
intermediate, then shifting position to form a hydrogen bond with Asp assisting 
formation of the acyl enzyme (Bachovchin 1986).
1.2.3.1.2 Role o f the oxyanion hole
The tetrahedral intermediate is further stabilised by formation of hydrogen bonds 
between the negative oxyanion of the substrate and two hydrogen atoms in the protein 
(Robertus et al. 1972). This ‘oxyanion hole’ in the protein plays an important role in 
the specificity of the catalytic site, as has been shown by studies comparing binding of 
substrates and their enantiomers (DeTar 1981). Serine proteases differ from the 
catalytically similar cysteine proteases in this way as the oxyanion hole does not 
appear to be essential in the latter (Asboth et al. 1985).
Mutational analysis also places great importance on the structure around the active 
site especially the oxyanion hole, to hold the peptide substrate in a conformation 
favourable to hydrolysis (Corey and Craik 1992).
1.2.3.2 Catalytic Triad
The catalytic triad is arranged differently within the sequence of the three serine 
protease families, chymotrypsin has H is-A sp-Ser, subtilisin has Asp---His-"Ser 
while prolyl oligopeptidase has Ser-Asp--His.
1.2.3.2.1 Identification o f the catalytic triad in PO
Using the porcine enzyme, the active site serine residue was identified by the use of 
radiolabelled diisopropylfluorophosphate [3HJDFP, a potent serine protease inhibitor
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which binds to the active serine residue (Rennex et al. 1991). The His residue of the 
active site was identified in a similar manner. His 680 was alkylated following 
treatment with the radiolabled chloromethane [3 H]acetyl-Ala-Ala-Pro-CH2 Cl a 
competitive inhibitor of PO (Stone et al. 1991).
The final residue of the catalytic triad to be identified was the aspartate residue. 
Asp529 and Asp 642 of the porcine enzyme were put forward as candidates due to 
their conserved presence throughout the prolyl oligopeptidase family (Rawlings et al. 
1991). The latter of these two was presumed correct following identification of a 
striking homology between the catalytic triad and surrounding sequence between 
lipases, especially the microbial lipases, and prolyl oligopeptidase family enzymes 
(Polgar 1992a).
Active site residues in human PO are Ser554 and His680 (Vanhoof et al. 1994), as 
identified by sequence homology within the PO family, and Asp641, as confirmed by 
structural modelling of the catalytic domain (Goossens et al. 1995). Crystal structure 
of the human PO has revealed the presence of the active site residues exposed on loop 
or bend structures within a large hydrophobic cavity. Ser, in particular, is held in an 
energetically unfavourable conformation. This results in exposure of the OH group to 
both the substrate and the His residue imidazole ring, which in turn is located in the 
same plane as the Asp oxygen atom thereby favouring hydrogen bond formation 
(Fulop et al. 1998).
1,23,2.2 A non-catalytic cysteine is present at the active site
The presence of a cysteine residue near, but not in, the catalytic site has been 
identified by studies of PO purified from porcine muscle in the presence of both bulky 
and small thiol reagents. The latter results in a much smaller inhibition suggesting a 
steric hindrance effect rather than direct interaction with the active site residues
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(Polgar 1991). Szeltner et al. identified this cysteine residue as Cys255 on the fourth 
blade of the p-propeller domain. Substitution by threonine or alanine at this position 
ablated the inhibition by thiol-reagents, interestingly it also inactivated the high pH 
form of the enzyme suggesting a role in catalysis (Szeltner et al. 2000a). The presence 
of a cysteine residue close to the active site has been reported in other members of the 
prolyl oligopeptidase family (Medrano et al. 1998).
1.2.3.3 p H  Dependence
PO may exist in two pH dependent catalytically competent forms which interconvert 
around pH6 .1-6.9, as is demonstrated by a sigmoidal distribution of pH dependence 
using purified PO from porcine muscle (Polgar 1991).
1.2.3.3.1 Two pH  dependent forms o f PO
Acid/base catalysis is the rate determining step only for the apparent low pH form 
thereby implying a conformational change is rate-limiting for the higher pH form. 
Polgar put forward the following equation for the pH dependence;
EH(ImH)XH ** EH(Im)XH ** EH(Im)X ** E(Im)X
EH3 EH2 EH E
(inactive) (active) (active) (active)
Where E= Enzyme, Im=Imidazole ring of Histidine and X=Additional enzymic 
group.
When the imidazole ring is protonated at a low pH the enzyme is inactive as the 
imidazole ring is unable to accept a proton from the catalytic serine (Polgar 1991).
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Substrates with varying side chains may show pronounced preferences for the high or 
low pH forms. Positively charged substrates are hydrolysed much more effectively by 
the high pH form which, presumably has a negatively charged active site. Negatively 
charged substrates are generally less favourable and show a preference for the low pH 
form of the enzyme (Polgar 1992b).
Studies using a thiono-substituted (reactive oxygen atom replaced by a sulphur atom) 
substrate showing slow binding to PO suggest that the rate limiting conformational 
change is substrate dependent rather than a change in the free enzyme (Polgar et al. 
1993).
1.2.3.4 Ionic Effect
There is also a clear ionic effect on PO activity. In the presence of 0.5M NaCl PO 
activity is enhanced with a much more significant increase observed at pH8  than pH6  
(Polgar 1991). However, a NaCl concentration above 1-2M results in a significant 
decrease in bacterial or mammalian PO activity (Polgar 1991; Kabashima et al. 1998). 
A compound, usually a salt, able to cause a protein to precipitate out of solution may 
be defined as a salting out agent. NaCl can act as a weak salting out agent and can 
also stabilise a protein structure by resulting in preferential hydration of the protein 
and preferential exclusion of NaCl from the water shell formed around the protein 
(Arakawa and Timasheff 1982). The pH dependence of PO unfolding, inactivation 
and urea denaturation in the presence and absence of NaCl demonstrate that NaCl 
destabilises PO, suggesting that NaCl is able to interrupt the water shell around PO 
and bind sites on the protein (Polgar 1995). This is contradictory to earlier 
observations that the linker peptide between PO’s two functional domains was 
protected from trypsin in the presence of salt (Polgar and Patthy 1992), unless the 
slightly unfolded protein becomes a less favourable substrate.
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PO has an isoelectric point of pH4.8-4.9 (Wilk 1983), therefore, the low pH form will 
have a charge close to 0 while the high pH form has a highly negative charge. This 
may explain the increased effects of salt destabilisation at increased pH. This also 
suggests that the looser structure is more catalytically active, following observation 
that reaction rates, particularly for the high pH form, are increased in the presence of 
NaCl (Polgar 1991).
It has been suggested that PO may be regulated by the intracellular redox state; PO 
activity in Murine erythroleukemia cells (MEL cells) is inactivated by treatment with 
the oxidising agents menadione or diamide, both of these treatments result in elevated 
intracellular glutathione disulfide (GSSG) and decreased glutathione (GSH) levels 
(Tsukahara et al. 1990). PO activity was also decreased by the addition of GSSG to 
cell lysates, but only following heat treatment, this inhibition was prevented by the 
addition of GSH but activity could not be rescued by GSH once lost. Another 
suggestion to the redox effect on PO activity is that PO is denatured by a high 
accumulation of GSSG.
1,2.3.5 Substrate Binding
The X-Ray structure of porcine PO in complex with the specific inhibitor Z-Pro- 
prolinal has identified the residues involved in the specificity of substrate binding by 
this enzyme (Fulop et al. 1998).
1.2.3.5.1 Binding to the proline residue
Proline binding is mediated by a hydrophobic pocket formed by residues Trp595, 
Phe476, Val644, Val580 and Tyr599 which also results in ring stacking of the proline 
residue and indole ring of the Trp residue (Figure 1-2). The oxyanion binding site, 
provided by the backbone amide groups of two residues in other serine proteases is in
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fact provided by one backbone amide and the OH group of a Tyr residue in PO (Fulop 
et al. 1998).
In contrast to chymotrypsin and subtilisin mechanisms of substrate binding, the 
orientation of the proline residue means that hydrogen bond formation between the PI 
amide (the amide group of the residue forming the tetrahedral intermediate) and the 
S1 carbonyl oxygen of the enzyme is impossible. By replacing the Gly residue of the 
effective substrate Z-Gly-Pro-Nap with the corresponding thiono substrate it appears 
that prolyl oligopeptidase instead relies on a P2S2 interaction between the 
neighbouring residue to proline and the enzyme as this substitution ablates all 
observed activity (Polgar et al. 1993).
1.2,3.5.2 Binding o f adjacent residues
Interactions with the rest of the peptide chain are also important. Unlike other serine 
endopeptidases PO shows a preference for shorter peptide substrates and is unable to 
cleave further than 3-4 residues from the end of a peptide, suggesting limited access 
to its binding site (Polgar 1992b).
The crystal structure revealed; hydrogen bonding between the enzyme and the residue 
before proline (P2), a non-polar environment preferring a hydrophobic residue before 
that in the peptide (P3) and a cysteine residue close to the active site, as was 
previously predicted, (Fulop et al. 1998). Studies using a Tyr473Phe enzyme variant 
suggest the role of the OH group in substrate binding is very much dependant on the 
substrate and ionic conditions. It also plays an important role in stabilization of the 
transition state (Szeltner et al. 2000b).
Complexes of an S554A inactive variant of the porcine PO with an octapeptide 
substrate determined substrate binding relies on residues P3-P2’ only, with residues 
outside this region remaining unbound by the enzyme. It also identified formation of a
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catalytically important intramolecular hydrogen bond between the P l ’(NH) and 
P2(OH) residues, as well as hydrogen bonding between the P2’ residue and His680 
(N e2)  during decomposition of the transition state which, facilitates proton transfer to 
the P I’ residue (Fulop et al. 2001). Despite the majority of substrate-enzyme 
interactions being between the substrate backbone groups, the charge of the non­
binding side-chains can affect the rate of substrate binding and de-acylation by 
affecting the electrostatic environment at the active site (Szeltner et al. 2003).
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Figure 1-3 Hydrogen Bonds Formed Between PO and Bound Substrate
During substrate binding hydrogen bonds are formed between the highlighted residues of PO and the 
peptide substrate as well as between individual residues within the peptide. The dashed lines indicate 
hydrogen bonds and the solid line with arrow indicates proton transfer. Residues of PO and their 
position are indicated in bold while peptide residues and their functional groups are drawn in regular 
type.
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1.23.5.3 Synthetic PO substrates
Several different synthetic substrates have been used to monitor PO activity in vitro. 
Studies of these various substrates have identified the importance of the substrate 
composition on enzyme activity as well as the variable effect of individual residues on 
activity depending on the strength of the bond to be cleaved (Szeltner et al. 2002).
The preferred substrate of PO is Yaa-Pro-Xaa where Yaa is not an N-blocked peptide 
or an additional Proline residue and Xaa is hydrophobic rather than basic or acidic. 
Synthetic fluorimetric and colourimetric substrates based on this structure are 
available for use in assaying specific activity of PO. Studies using the two fluorogenic 
substrates, Z-Gly-Pro-AMC and Suc-Gly-Pro-AMC revealed that while Z-Gly-Pro- 
AMC followed regular enzyme kinetics, Suc-Gly-Pro-AMC was able to bind non- 
specifically to the S I’ position resulting in substrate inhibition, making this an 
unreliable substrate for studying the kinetics of this enzyme (Venalainen et al. 2 0 0 2 ). 
PO may also cleave some peptides after an alanine residue. PO purified from bovine 
lens was able to cleave the carboxyl residue after an alanine residue depending on the 
nature of the surrounding amino acids, though it retained a strong preference for 
cleavage following proline residues (Sharma and Ortwerth 1994).
1.2.3.6 Inhibitors
A large majority of the PO inhibitors, both specific and non-specific, identified are 
based around modifications of the proline amino acid and peptide bond that form the 
natural substrate for PO. For a summary of PO inhibitors identified and developed to 
date, see Table 1-1.
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1.2.3.6.1 Synthetic inhibitors
PO inhibitors have been synthesized in the form of peptidyl acetals (Augustyns et al.
1995), aminodicarboxylic acid pyrrolidides (Demuth et al. 1993), acyl-prolyl- 
pyrrolidines (Wallen et al. 2002b) and dicarboxylic acid bis(prolyl-pyrrolidine) 
amides (Wallen et al. 2002a; Wallen et al. 2003).
The majority of these inhibitors are designed to mimic the proline residue, peptide 
bond and adjacent amino acid structure. Binding to the enzyme in the SI, S2 and S3 
positions requires specific structures. Subtle changes or substitutions of different 
moieties of the inhibitor structure can significantly alter enzyme inhibition. For 
example, Venalainen et al. reported increased Kt by up to two orders of magnitude by 
adding a CHO, CN or COCH2 OH functional group at the P 1 position of the inhibitor 
isophthalic acid bis(L-prolyl-pyrrolidine) (Venalainen et al. 2004).
Replacement of the PI pyrrolidine with a thiazolidine moiety retains inhibitory 
potency of the compound however replacement with larger heterocycles results in a 
loss of inhibition (Portevin et al. 1996). Acylisoxazole and acylisoxazoline groups at 
this position resulted in an inhibitor specific to the T.cruzi parasitic enzyme with very 
low toxicity towards mammalian cells (Bal et al. 2003).
It is also possible to replace the proline moiety of these inhibitors with a similar 
structure, cyclopent-2 -enecarbonyl, without causing a significant decrease in 
inhibition. Replacing proline in this way may increase the bioavailability of the 
inhibitor for use in vivo (Jarho et al. 2004). The group present at the P3 position also 
affects the inhibition constant given for the compound. Studies of different functional 
groups at this position and extending away from the proline moiety have revealed two 
potential binding modes depending on the hydrophobicity of the compound. It is 
probable that such a flexibility aids binding to multiple, varied substrates (Jarho et al.
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2005). This ability to bind a number of varied structures at the P3 end of the inhibitor 
has enabled recent development of a fluorescent PO inhibitor, containing a fluorescein 
moiety linked to the inhibitor at the P3 position, which may have several applications 
in studying the role of PO in vivo (Venalainen et al. 2005).
1.2.3.6.2 Natural inhibitors
Inhibitory substances have been isolated from sources as diverse as the mushroom 
Polyozellus multiplex (Song and Raskin 2002), the alpine plant Rhodiola 
sachalinensis (Fan et al. 2001), green tea (Kim et al. 2001) and various red and white 
wines (Yanai et al. 2003). A number of substances isolated from microbial sources 
(several of which also act as antibiotics) have been found to inhibit PO including; 
Staurosporine, isolated from Streptomyces staurosporeus (Kimura et al. 1990), 
Poststatin isolated from Streptomyces viridochromogenes (Aoyagi et al. 1991), 
Eurystatins A and B isolated from Streptomyces eurythermus (Toda et al. 1992), 
Lipohexin isolated from the funghi Moezia lindtneri and Paecilomyces (Christner et 
al. 1997) and Propeptin isolated from the mycelium of Microbispora (Kimura et al.
1997).
1.2.3.6.3 Endogenous inhibitors
Serine proteases are regulated in vivo by their own natural protein inhibitors. Studies 
of these protease inhibitor complexes have revealed approximately 2 0  structural 
families of inhibitors, varying from small proteins up to proteins of 500 amino acids 
representing a wide variety of structures (Krowarsch et al. 2003). An endogenous 
inhibitor of PO has been reported to be present in mammals; Yoshimoto et al. (1982) 
identified and partially purified a 6.5KDa protein from porcine pancreas that acted as 
a specific competitive inhibitor of prolyl oligopeptidase. This protein was found to be
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widely distributed in both rat and porcine organs. More recently Salers has reported 
that the inhibitor present in the pancreas; co-localises with PO in the cytosol of the 
cell, is absent from secretory vesicles and, importantly, is not susceptible to PO 
degradation (Salers 1994). The two polyamines, spermine and spermidine, act to 
reverse PO inhibition possibly by formation of a complex including the endogenous 
inhibitor (Soeda et al. 1986).
1.2.3.6.4 PO inhibitors as drugs
The potential role of PO in the pathophysiology of many disorders has resulted in a 
large number of studies into the development and identification of PO inhibitors as 
potential drugs. The first synthetic inhibitor of PO to be reported was Z-Pro-Prolinal. 
Several compounds consisting of a modified form of Z-Pro-Prolinal have since been 
synthesized, for example; Z-Pyr-prolinal, Z-Val-prolinal and Z-Gly-Pro-CthCl 
(Cunningham and O'Connor 1997) as well as ZTTA, which is similar to Z-Pro- 
prolinal but contains a sulphur atom in each of the proline rings (Shishido et al. 1996). 
The PO specific inhibitor Z-Pro-Prolinal (a transition state analog) forms a hemiacetal 
adduct with the active site (Kahyaoglu et al. 1997a).
JTP-4819 ((S)-2-[[(S)-2-(hydroxyacetyl)-1 -pyrrolidinyl]carbonyl]-N-(phenylmethyl)- 
1-pyrrolidinecarboxamide), developed as a PO inhibitor, also has a structure based 
around two proline residues (Toide et al. 1995a; Toide et al. 1997) and acts as a tight- 
binding competitive PO inhibitor (Venalainen et al. 2002). S I7092 ((2S,3aS,7aS)- 
1 ([(R,R)-2-phenylcyclopropyl]carbonyl)-2-[(thiazolidin-3-yl)carbonyl]octahydro-1 H- 
indole)) is a specific highly potent PO inhibitor with a Kt as low as 0.3nM for purified 
human PO. S I7092 is also cell permeant in HEK293 cells inhibiting intracellular PO 
with a Ki of 30nM (Barelli et al. 1999). Clinical trials with this inhibitor have revealed 
rapid PO inhibition, maximum inhibition was observed between 30minutes and
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with a Ki of 30nM (Barelli et al. 1999). Clinical trials with this inhibitor have revealed 
rapid PO inhibition, maximum inhibition was observed between 30minutes and
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2hours after treatment and lasted for at least 12hours. The half life of S I7092 in vivo 
varied between 7 and 31 hours (Morain et al. 2000).
Other specific inhibitors studied include; Z-321 (l-[3-(2-indanylacetyl)-L- 
thiopropyl]pyrrolidine) (Miura et al. 1997) and ONO-1603 ((S)-l-[N-(4- 
chlorobenzyl)succinamoyl]pyrrolidine-2-carbaldehyde) (Katsube et al. 1999). A 
number of these inhibitors have entered in vivo studies looking at potential 
therapeutic benefits, these are discussed in section 1.2.5.3.
1-32
Table 1-1 Summary of Prolyl Oligopeptidase Inhibitors
Inhibitor | Source | Organism Kif* IC50 Reference
Specific Inhibitors
Z-Pro-Prolinal Synthetic Rabbit brain 14nM (Wilk 1983)
ZTTA Synthetic Rat brain 2.9|iM (Shishido et al. 1996)
JTP-4819 Synthetic Rat brain 0.83nM* (Toide et al. 1995b)
F. meningosepticum 5.43nM* (Toide et al. 1995b)
Z-321 Synthetic Canine brain 0.5nM* (Tanaka et al. 1994)
SI7092 Synthetic Human brain InM (Barelli et al. 1999)
Rat brain 1.3nM* (Portevin et al. 1996)
SUAM-1221 Synthetic Bovine brain 190nM* (Portevin et al. 1996)
ONO-1603 Synthetic Rat brain 12nM (Katsube et al. 1996)
Val-Glu-Ue-Pro-Glu Wine F. meningosepticum 17.0pM* (Yanai et al. 2003)
Tyr-Pro-Ile-Pro-Phe Wine F. meningosepticum 87.8pM* (Yanai et al. 2003)
N-[N-benzyloxycarbonyl-(S)- Synthetic Human blood 120nM* (Augustyns et al. 1995)
proIyl]-(S)-pro!inal
dimethylacetal
BOC-GIu(NH-O-Ac) Synthetic Human placenta 28nM (Demuth et al. 1993)
pyrrolidide
Ac-Ala-Ala-Pro-CH2Cl Synthetic Porcine muscle 0.55pM (Stone et al. 1991)
Lipohexin M.lindtneri Human placenta 3.5mM* (Christner et al. 1997)
F. meningosepticum 25mM* (Christner et al. 1997)
Non-specific Inhibitors
Oleic acid Synthetic F. meningosepticum 26.7pM (Park et al. 2006)
Linoleic acid Synthetic F. meningosepticum Sl.OpM (Park et al. 2006)
Arachidonic acid Synthetic F. meningosepticum 91.3pM (Park et al. 2006)
Eicosapentaenoic acid Synthetic F. meningosepticum 247.5pM (Park et al. 2006)
Docosahexaenoic acid Synthetic F.meningosepticum 89.0pM (Park et al. 2006)
Prostatin Microbispora F. meningosepticum 0.70mM (Kimura et al. 1997)
Serine Protease Inhibitors
DFP Synthetic Lamb kidney (Yoshimoto et al. 1977)
T.cruzi 60nM* (Joyeau et al. 2000)
PMSF
Cysteine Protease Inhibitors
PCMB Synthetic Porcine muscle (Polgar 1991)
Non-competitive Inhibitors
Epigallocatechin gallate Green tea 142nM* (Kim et al. 2001)
Epicatechin gallate Green tea 10.2pM* (Kim et al. 2001)
Gallocatechin gallate Green tea 109nM* (Kim et al. 2001)
Kynapsin-24 P.multiflex F. meningosepticum 1.14(aM* (Song and Raskin 
2002)
1,2,3,6-tetra-O-galloy 1-0-D- R.sachaliensis F. meningosepticum 15nM (Fan et al. 2001)
glucose
l,2,3,4,6-penta-O-galloyl-0-D- R.sachaliensis F. meningosepticum 0.15pM (Fan et al. 2001)
glucose
Rhodionin R.sachaliensis F. meningosepticum 23pM (Fan et al. 2001)
Rhodiosin R.sachaliensis F. meningosepticum 28pM (Fan et al. 2001)
3-O-galloylepigallocatchin- R.sachaliensis F. meningosepticum 0.17pM (Fan et al. 2001)
(40-8)-epigallocatechin 3-0-
gallate
Rosiridin R.sachaliensis F. meningosepticum 56pM (Fan et al. 2001)
6-(8’Z-pentadecenyl)salicylic G.biloba 0.87mM (Lee et al. 2004a)
acid
6-(10’Z-heptadecenyl)salicylic G.biloba 0.80mM (Lee et al. 2004a)
acid
Staurosprorine S.staurosporeus Fla vo bacterium 0.70pM (Kimura et al. 1990)
Poststatin S. viridochromo 
genes
Porcine kidney 55pM* (Aoyagi et al. 1991)
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1.2.4 Localisation And Distribution
1.2.4.1 Tissue Distribution
Initially identified in the uterus, PO was first cloned from the brain and is now 
thought to be ubiquitously expressed throughout mammalian tissues. Northern 
analysis revealed the presence of mRNA encoding PO in brain, heart, muscle, liver, 
kidney and ovarian tissues (Rennex et al. 1991). PO activity has also been reported in 
bone marrow (Cavasin et al. 2004) and macrophages (Green and Shaw 1983).
A number of reports have found PO expression or activity levels to vary between 
tissues or tissue regions. Elevated enzyme activity has been reported in muscle, testes, 
kidney, submandibular gland and the cerebral cortex (Kato et al. 1980). Venalainen et 
al. (2002) also reported the concentration of PO in the brain, determined in porcine 
brain homogenate, to be relatively high. A significant increase in PO activity in the 
brain compared to other tissues was also reported for both rat and teleost enzymes 
(Agirregoitia et al. 2005).
Identification of PO in the bovine lens revealed an intriguing distribution of maximal 
activity in the outer cortical region, decreased activity in the inner cortex and a 
complete lack of activity in the nuclear region. It was postulated that this decrease in 
activity may be due to an alteration in the redox state of the cells moving through the 
cortex, alternatively, PO may be important in clearing peptide fragments generated 
during the differentiation of epithelial cells to fiber cells (Sharma and Ortwerth 1994).
1.2.4.2 Intracellular Localisation
The subcellular localisation of PO is generally believed to be cytosolic, as has been 
confirmed in studies of a variety of tissues and species, e.g. rabbit brain (Dresdner et
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al. 1982), human lymphocytes (Goossens et al. 1995), human glial cells (Schulz et al. 
2005) and D. discoideum (Williams et al. 1999).
1.2.4.2.1 Secretion ofPO
The majority of (3-propeller domain containing proteins are secreted, however, there 
does not appear to be any evidence that PO is a secreted enzyme. Another example of 
a non-secreted (3-propeller protein is the G-protein (3-subunit (Baker et al. 1997).
There are some exceptions, bacterial POs discovered in Flavobacterium 
meningosepticum and Sphingomonas capsulata are targeted to the periplasm by a 
signal sequence that may later be cleaved (Chevallier et al. 1992; Kabashima et al.
1998). Another bacterial PO was identified in a screen for outer membrane proteins of 
Flavobacterium columnare G4 and found to have a potential transmembrane region 
(Xie et al. 2004). A secreted or extracellular PO has also been reported in the parasite 
Trypanosoma cruzi (Bastos et al. 2005) and the fungi Lyophyllum cinerascens 
(Yoshimoto et al. 1988) and Agaricus bisporus (Sattar et al. 1990).
Another conundrum is the presence of PO activity in the serum. As PO is not thought 
to be secreted PO activity is expected to be absent from the serum, however this is not 
the case. In the study of rat and teleost tissues PO activity was reported in the serum 
but at 30-100 fold less than that observed in the other tissues (Agirregoitia et al. 
2005). Significant levels of PO activity in serum or blood plasma have also been 
reported in a number of studies reporting altered PO levels in a number of disease 
states (Maes et al. 1995; Maes et al. 1998; Maes et al. 1999b; Maes et al. 1999a; Maes 
et al. 2 0 0 1 ).
If it is true that PO is not secreted one explanation for this activity could be enzyme 
release by cell lysis in the blood. Another possibility is that these studies have in fact 
been measuring activity of the enzyme ZIP, which shows a similar specificity to PO.
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The latter option has not been ruled out by inhibitor studies in any of the mentioned 
reports, resistance to the PO specific inhibitor Z-Pro-prolinal is the accepted method 
of ZIP identification (Bimey and O’Connor 2001). Observations of serum activity in 
the presence of Z-Pro-prolinal revealed a 40% decrease implying ZIP activity 
accounts for 60% of the PO activity observed in the serum (Breen et al. 2004). It is of 
note that no ZIP activity was reported in human lymphocyte extracts and the 
combined serum activity was 4-8 fold less than that of the cell extracts. In addition 
Cunningham and O’Connor have reported the purification of an enzyme from bovine 
serum which is biochemically similar to PO, sensitive to Z-Pro-prolinal as well as 
several other PO specific inhibitors, yet has a larger molecular weight and lower 
specificity towards a number of biological peptides than the intracellular enzyme 
(Cunningham and O'Connor 1998).
1.2.4.2.2 Membrane bound form o f PO
In eukaryotic cells PO is a cytosolic enzyme, however, a membrane-associated form 
has been reported in both Bovine brain (O'Leary et al. 1996) and Ovine hypothalamus 
(Lew et al. 1994). In the latter the membrane-associated activity was significantly 
less than that observed in the cytoplasm and was diminished by sequential washing of 
the membrane fraction suggesting an association with membrane proteins rather than 
integration into the membrane. The membrane associated form reported in bovine 
brain however accounted for a much more significant proportion of the cellular PO 
activity (-30%) and showed localisation to the synaptosomal membrane fragment. 
Other studies have observed between 10 and 30% PO activity associated with the 
particulate fraction rather than the soluble fraction (Dresdner et al. 1982; Agirregoitia 
et al. 2005).
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1.2.4.2.3 Other intracellular localisations
Neither a membrane bound nor secreted form of PO has been reported in human cells 
and there is currently only one human PO encoding sequence present in the NCBI 
database. Millennium Pharmaceuticals recently applied for patents on two sequences 
claimed to encode novel human prolyl oligopeptidases (Patent No.s 21163 and 
21953), however, sequence alignments revealed these two potential proteins lack both 
the PO conserved domain and p-propeller domain (data not shown).
Schulz et al. have reported localisation of PO in human glial and neuronal cell lines, 
as well as rat primary glial and neuronal cells, to the perinuclear region and a limited 
co-localisation to the microtubules, which breaks down towards the cell periphery. 
They have identified a PO-interacting C-terminal fragment of a-tubulin which also 
includes the microtubulin-associated proteins (MAPs) binding site (Schulz et al. 
2005). In addition PO has also been observed inside the nucleus of both insect cells 
and Swiss 3T3 cells (Ohtsuki et al. 1997; Ishino et al. 1998).
1.2.5 Role of Prolyl Oligopeptidase
1.2.5.1 Degradation/regulation o f  bioactive peptides
Prolyl Oligopeptidase is able to cleave a number of neuroactive and bioactive 
peptides. However, the physiological role of this ability is somewhat questionable due 
to the cytosolic location of PO and the mainly extracellular location of the peptides 
cleaved. Despite reports of PO activity in serum there is no evidence of PO secretion 
or extracellular localisation within tissues. The potential substrates for PO include; 
Neurotensin (Checler et al. 1986b), Angiotensin I and II (Chappell et al. 1990), 
Arginine-Vasopressin (AVP) (Miura et al. 1995), Oxytocin (Walter et al. 1971), 
Bradykinin (Oliveira et al. 1976), Substance P and Thyrotropin-Releasing Hormone
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(TRH) (Wilk 1983). Cleavage of these peptides would result in a role for PO in a 
number of cellular functions.
There is some evidence in support of a physiological role for PO in bioactive peptide 
regulation. Treatment of rats with a selection of PO inhibitors resulted in decreased 
levels of the anti-fibrotic peptide Ac-SDKP, this peptide is produced in vitro by PO 
hydrolysis of thymosin-p (Cavasin et al. 2004). Oral doses of PO inhibitor also 
resulted in decreased AVP stimulated protein synthesis in rat brain slices (Shishido et 
al. 1999b). It is of note that a membrane-bound form of PO identified in the 
synaptosomal membrane fraction of bovine brain homogenates shows higher affinity 
for neuropeptides angiotensin II, LHRH, Neurotensin, Bradykinin and TRH than its 
tissue counterpart (O'Leary et al. 1996). However the question remains as to how or 
when this intracellular, largely cytosolic enzyme would come into contact with these 
secreted peptides.
PO activity has also been related to a number of inflammatory disorders. Elevated 
expression of PO has been seen in atopic dermatitis, a chronic relapsing inflammatory 
skin disease, using real-time per (Seo et al. 2006). Altered PO levels have been linked 
to arthritis (Kamori et al. 1991), systemic lupus erythematosus (Aoyagi et al. 1985; 
Aoyagi et al. 1987) and autoimmune and inflammatory responses (Shoji et al. 1989). 
In addition lowered PO levels also show correlation with increased interleukin- 6  and 
10 (IL- 6  and IL-10), interferon-y (INF-y), interleukin-1 receptor antagonist (IL-1RA) 
and granulocyte-macrophage colony stimulatory factor (GM-CSF) (Maes et al. 
1999b). A study of the proteinases present in inflammatory foci of, Mycobacterium 
tuberculosis induced, delayed-type allergic-inflammation in mice revealed significant 
amounts of PO and cathepsin B compared to a number of other proteases (Kakegawa 
et al. 2004). Though this case raises the question of the origin of the enzyme activity,
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several bacteria secrete PO during infection thus it is possible that this enzyme 
activity may be secreted from the M. tuberculosis rather than the host (this is discussed 
further below).
Conversely, PO is currently emerging as a potential treatment for Celiac sprue, an 
immune disease involving an inflammatory response to ingested wheat gluten. 
Treatment with recombinant PO greatly reduces the presence of immunostimulatory 
peptides in wheat gluten already treated with pepsin and a number of pancreatic 
peptides (Marti et al. 2005). Bacterial PO enzymes able to function at extreme pH and 
therefore work effectively in stomach acid are presently being investigated as 
potential oral supplements for sufferers of this disease (Stepniak et al. 2006).
Many of the bioactive fragments generated by PO in vitro may be produced in vivo by 
a number of different enzymes. A candidate for such a role would be the neurotensin- 
degrading peptidase, a metallopeptidase isolated from rat brain synaptic membrane, 
able to cleave neurotensin at the carboxyl side of the proline residue (Checler et al. 
1986a). Also human PCP (or Angiotensinase C) is able to cleave a C-terminal residue 
following a proline residue so is therefore able to cleave the Pro-Phe bond releasing 
angiotensin-(l-7) providing angiotensin I has first been cleaved by a deamidase 
enzyme (Tan et al. 1993). This action may be hard to detect as PCP may also be 
inhibited by the specific PO inhibitor Z-Pro-prolinal. In addition to this, Chappell et 
al. reported that Z-Pro-prolinal treatment only inhibited angiotensin-(l-7) formation 
by 30% implying another enzyme was also involved (Chappell et al. 1990). 
Endopeptidases other than PO are able to cleave bradykinin in the brain and other 
tissues (Camargo et al. 1973; Oliveira et al. 1976; Camargo et al. 1979).
PO may not target these peptides under physiological conditions; a number of studies 
have found no change in TRH or LHRH degradation in rat brain homogenates, slices
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or in vivo following treatment with Z-Pro-prolinal. This suggests another enzyme is 
responsible for degradation of these two peptides in the brain (Friedman and Wilk 
1986; Charli et al. 1987; Mendez et al. 1990).
1.2.5.2 General Proteolysis.
A number of peptidases involved in the extracellular degradation and regulation of 
neuropeptides and hormones are also found in the cytosol of the cell. These enzymes 
may play a role in regulation of intracellular peptides, which in turn regulate specific 
protein interactions playing a part in numerous cellular processes including; cell 
signalling, protein targeting and metabolism (Ferro et al. 2004).
Rates of intracellular proteinase activity are altered following cell ageing or during 
differentiation. PO activity was found to decrease in murine erythroleukemia cells 
(MEL cells) following DMSO induced differentiation, a decrease was not seen in 
DMSO resistant cells (Tsukahara et al. 1991). Another decrease in PO activity has 
been reported following heat shock treatment of HeLa cells. This was a result of 
enzyme inhibition/inactivation. No loss of protein was observed and activity was not 
diminished following heat treatments of cellular extracts (Pratt et al. 1989)
Tsukahara et al. also reported decreased PO activity in MEL cells following treatment 
with the oxidising reagents menadione or diamide or heat shock at 45 °C for 
lOminutes. This inactivation was independent of other protease action or synthesis of 
new proteins or polypeptides (Tsukahara et al. 1990).
7.2.5.3 Neuroprotection
Ischemia induced neuronal cell death in rats can be significantly reduced by treatment 
with the neuropeptides vasopressin-(4-9) and TRH, the same effect is achieved by 
treatment with Z-Pro-prolinal. The neuroprotective properties of the PO inhibitor or
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vasopressin treatment are both lost in the presence of a vasopressin receptor agonist, 
implying the protective effect of Z-Pro-prolinal is mediated by preventing degradation 
of the neuroactive peptides (Shishido et al. 1999a).
A neuroprotective role has also been reported for the PO inhibitors ONO-1603 and 
THA(Schulze et al. 1993; Katsube et al. 1999). These inhibitors delay age-induced 
apoptosis in cultured central nervous system (CNS) neurons. The mechanism remains 
unclear though may involve a decrease in expression of glyceraldehyde-3-phosphate 
dehydrogenase (a glycolytic enzyme that binds specifically to the carboxy terminal of 
the APP).
Specific PO inhibitors were reported to reverse scopolamine induced amnesia in rats 
(Yoshimoto et al. 1987). The PO specific inhibitor JTP-4819 is able to prevent 
degradation of neuropeptides by purified PO in vitro. Treatment of rats with this 
inhibitor at ineffective dose was also able to reverse scopolamine induced amnesia 
when accompanied with substance P, A VP or TRH (Toide et al. 1995a). Another 
study showed an improvement in the impaired spatial memory of aged rats following 
administration of a PO inhibitor (JTP-4819). This study also reported an improved 
central cholinergic function, possibly due to; increased acetylcholine release from 
nerve terminals, normalized choline uptake and choline acetyltransferase (ChAT) 
activity (Toide et al. 1997). JTP-4819 may also increase various neuropeptide levels 
in both the cerebral cortex and hippocampus via PO inhibition (Toide et al. 1995a; 
Shinoda et al. 1999). A similar neuroprotective effect is seen with ONO-1603, which 
prevents neurodegeneration at low potassium concentrations, upregulates m3- 
muscarinic acetylcholine receptor (mAChR) mRNA in cerebellar granule cells 
(CBCs) and increases mAChR mediated phosphoinositide hydrolysis (Katsube et al.
1996).
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Miura and colleagues reported an improvement in the potentiation of synaptic 
transmission following treatment with a PO inhibitor (Z-321). They also confirmed 
the role of PO inhibition in this effect by the use of a stereoisomer (D-Z-321) with a 
negligible effect on PO (Miura et al. 1997). Another PO inhibitor, S I7092, has 
entered clinical trials as an effective treatment for amnesia and other cognitive 
disorders associated with ageing (Morain et al. 2002). Treatment of healthy volunteers 
with S I7092 showed an improvement in verbal memory tests with no significant 
adverse effects (Morain et al. 2000). Following acute S I7092 treatment of rats, PO 
levels in the rat brain were significantly decreased and increased levels of the two 
memory enhancing neuropeptides Substance P (SP) and a-melanocyte-stimulating 
hormone (a-MSH) were seen in the frontal cortex and hypothalamus. However, 
following chronic treatment for 8  days the increase in SP and a-MSH was no longer 
seen despite continued PO inhibition (Bellemere et al. 2003).
1.2.5.4 Inositol Signalling
Inositol( 1,4,5)trisphosphate (IP3 ) is a cellular second messenger involved in a number 
of cell signalling pathways. IP3 is generated, along with diacylglycerol (DAG), by 
phospholipase C hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2 ) and by 
dephosphorylation of higher order inositol polyphosphates (mainly IP5 and IP4 ) by a, 
potentially Ca2+ sensitive, multiple inositol polyphospate phosphatase (MIPP) (Van 
Dijken et al. 1995; Van Dijken et al. 1997; van Haastert and van Dijken 1997). 
Further dephosphorylation of IP3 recycles myo-inositol for the synthesis of 
phosphatidylinositol and inositol phosphates. Inositol signalling is discussed in detail 
later.
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A Dictyostelium mutant lacking PO expression has a significant increase in IP3 , this 
mutant shows an increased rate of IP5 breakdown to IP3 as well as an increase in IP3 
breakdown. A similar increase in IP3 was observed following Z-Pro-prolinal treatment 
(Williams et al. 1999). Schulz et al. also observed increased IP3 levels in U343 
astroglioma cells following treatment with specific PO inhibitors or decreased PO 
expression by use of an antisense vector (Schulz et al. 2002).
Treatment of neural growth cones with lithium, valproic acid or carbamazepine, three 
mood stabilising drugs, results in growth cone spreading. This effect is reversed by 
either addition of inositol or treatment with PO inhibitors, in agreement with the 
inverse correlation of PO activity with cellular IP3 levels (Williams et al. 2002).
1.2.5.5 M ood Disorders
A number of studies have reported altered inositol levels in a variety of mood 
disorders. However, inositol signalling in the cell is regulated by a multitude of 
different enzymes as discussed later.
In addition to the role of PO in inositol signaling several naturally occurring peptide 
substrates of PO (see section 1.2.5.1) are neuropeptides that play a role in the 
pathophysiology of depression. In 1995 Maes and colleagues reported decreased 
levels of plasma PO activity in depressed patients while observing an increased 
plasma PO activity in both manic and schizophrenic patients. They also found that the 
plasma PO activity was significantly increased in depressed patients by treatment with 
the anti-depressant fluoxetine and decreased in manic patients by the use of valproate 
(Maes et al. 1995). An increase in serum PO levels has also been linked with both 
stress-induced anxiety and post-traumatic stress disorder (Maes et al. 1998; Maes et 
al. 1999a), while decreased levels of PO are observed in patients with anorexia and 
bulimia nervosa (Maes et al. 2001).
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A decrease in serum PO activity has also been reported following Interferon-a 
treatment. IFN-a treatment is associated with neuropsychiatric side-effects and it is 
postulated that altered serum PO may play a role in these neuro-psychoses, however, 
a decrease in leukocyte, lymphocyte and platelet count was also reported-all of which 
are known to express PO (Van Gool et al. 2004). An alternative theory to account for 
neuropsychiatric effects of IFN-a treatment is an increased platelet monoamine 
oxidase-B activity, this enzyme oxidatively deaminates amines such as dopamine, 
noradrenaline and serotonin (Bannink et al. 2005).
1.2.5.6 Alzheimers Disease
PO activity has been related to ^-amyloid plaque formation and Alzheimer’s disease. 
Rossner et al. observed an increase in PO expression in the hippocampus of aged 
adult mice that was not observed in other regions of the brain. An increase in 
hippocampal PO activity was also observed in non-aged adult transgenic Tg2576 
mice compared to non-transgenic littermates. Tg2576 mice are characterized by a 5-7 
fold over expression of human Amyloid Precursor Protein APP695 carrying a K670N 
and M671L mutation (Swedish mutation), they develop (3-amyloid plaques around 11 
months. Both PO increase and hippocampus-dependant memory deficits precede the 
appearance of (3-amyloid plaques (Rossner et al. 2005). Rossner observed that 
inhibition of PO resulted in a significant increase in secretion of (3-amyloid peptides. 
Petit et al reported no degradation of synthetic (3-amyloid peptide by purified human 
PO thus disputing any direct interaction between PO and A(3 (Petit et al. 2000). 
Johnston et al also reported no change in A(3 peptide levels following significant 
inhibition of PO (Johnston et al. 1999).
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An alternative explanation for the effect of PO inhibition on (3-amyloid secretion has 
been put forward by Schulz et al. (2005) who found PO to play a role in protein 
secretion. They observed co-localisation of PO with microtubules, involved in 
trafficking vesicles to the membrane. Decreased PO activity following addition of 
inhibitor or in an anti-sense cell line resulted in a significant increase in overall 
protein secretion. This explanation is also disputed by Petit et al. who observed no 
change in A(3 secretion from HEK293 cells over expressing wild type or Swedish 
mutated APP in the presence of PO inhibitors (Petit et al. 2000).
1.2.5.7 Infection
A secreted PO from T.cruzi is able to degrade the host extracellular matrix proteins, 
collagen types I and IV and fibronectin (Santana et al. 1997), and has been found to 
be essential for parasite entry into mammalian host cells. This parasite has elevated 
levels of PO during the infective trypomastigote phase of its life cycle compared to 
the non-infective epimastigote stage, treatment with a PO inhibitor was able to 
impede entry to host cells (Grellier et al. 2001; Bastos et al. 2005).
In both F.meningosepticum and T.denticola PO activity is localised to the periplasm. 
This localisation along with the ability of the bacterial PO to hydrolyse several human 
bioactive peptides led to suggestion of a role in exploitation of the host’s bioactive 
peptides for use by the bacteria or interference with normal bioactive peptide levels, 
e.g. those involved in inflammation, to create favourable conditions for the 
microorganism (Makinen et al. 1994). PO has been found in the non-pathogenic 
bacteria Sphingomonas capsulata (Kabashima et al. 1998) as well as a number of 
pathogenic bacteria; F.columnare, F.meningosepticum, Aeromonas hydrophila and 
Xanthomonas sp. (Yoshimoto et al. 1991; Szwajcer-Dey et al. 1992; Kanatani et al.
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1993; Xie et al. 2004) suggesting bacterial PO has cellular functions in addition to a 
potential role in infection.
1.2.6 DpoA; Dictyostelium PO homologue
A Dictyostelium homologue of the human prolyl oligopeptidase enzyme was 
identified in a lithium resistance screen (Williams et al. 1999). At high Li+ 
concentrations Dictyostelium aggregation and spore formation is severely retarded. In 
carrying out this screen Williams screened for aggregation in lOmM LiCl, and 
isolated a total of 13 Li+ resistant mutants. One of these mutants, lithium suppressor A 
(LisA), was discovered to lack the PO homologue, given the name dpoA.
Williams et al (1999) went on to show that DpoA activity is not directly affected by 
Li+ nor does it interact with GSKA (the Dictyostelium homologue to GSK-3). 
However, loss of DpoA leads to a significant (3-fold) increase in cellular IP3 ; an 
effect also observed following addition of PO inhibitors. The increase in IP3 appears 
to be due to an increase of IP5 conversion to IP3 . It is possible that a loss of DpoA 
results in removal of PO inhibition of MIPP, the Multiple Inositol Polyphosphate 
Phosphatase, which catalyzes this reaction. PO is also an inhibitor of IP3 degradation. 
Only one PO homologue has been found in the Dictyostelium genome, dpoA, and its 
disruption eliminates all activity. No secreted PO activity is observed (Williams et al. 
1999).
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1.3 Lithium
Lithium, an alkali metal, is a monovalent ion (Li+). It has been used to treat mood 
disorders, in particular Bipolar Disorder (previously known as manic depression) 
since the 1860s (Williams and Harwood 2000). Since then it has experienced periods 
of unpopularity due to potentially fatal side effects and a lack of information on the 
therapeutic mechanism of action. Despite this it is currently one of the most common 
treatments for bipolar disorder (Heit and Nemeroff 1998; NIMH 2001; Jope 2003). 
Our understanding of the molecular mechanisms of these disorders and the 
mechanism by which lithium acts to alleviate these symptoms is still very limited.
1.3.1 Bipolar Disorder
Depression affects 121 million people worldwide and is thought to be responsible for 
close to 1 million deaths by suicide every year (World Health Organisation figures). 
Bipolar disorder (BD) is thought to account for 10-20% of all cases of depression and 
affects 1% of the American population over 18years of age (NIMH 2001). BD is 
characterised by cycling between periods of depression and periods of mania often 
with periods of normal behaviour in between. Cycling between these extremes may 
occur over a time span of weeks to a single day depending on the disease progression 
and how well it is controlled by mood stabilising drugs (NIMH 2001). A clear genetic 
component to BD has been identified, a number of potential associations have been 
described though no genes have been definitively linked to the disorder yet. It is also 
clear that a genetic susceptibility to BD will not necessarily result in manifestation of 
the disorder and an environmental trigger is often associated with the onset of 
symptoms (Hayden and Numberger 2006).
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1.3.2 Other Mood Stabilisers
Lithium is the most common treatment for Bipolar Disorder, also popular are the two 
antiepileptics valproic acid (VPA) and carbamazapine (CBZ). Possible treatments for 
BD involve a number of mood stabilising drugs including atypical antipsychotics (e.g. 
clozapine, olanzapine, and risperidone) and antidepressants (e.g. imipramine and 
fluoxetine), which are often given in combination with one another to achieve the 
desired therapeutic effect. Lithium in particular has a very small window of 
therapeutic use and must be closely monitored to find an effective non-toxic dose 
(Young and Newham 2006). A number of negative effects such as increased mania 
and rapid cycling between mania and depression have been associated with 
antidepressant treatment (Sachs and Thase 2000).
The majority of mood stabilising drugs have several unwanted side effects including 
weight gain, lack of co-ordination, tremor, hypothyroidism, dry mouth and anxiety 
(NIMH 2001; Freeman and Freeman 2006), the most significant of which is that 
many, including VPA and CBZ, are highly teratogenic and therefore are undesireable 
during pregnancy. A number are also recommended to be avoided during 
breastfeeding (Burt and Rasgon 2004). It is hoped that identification of common 
mechanisms of action of multiple drugs will help identify common therapeutic 
targets.
1.3.2.1 Potential Common Therapeutic Mechanism
Mood stabilising drugs have a multitude of effects on cells which can be assigned to 
interference in a number of signalling pathways, the majority of these are unique to 
each drug. The ability of VPA to decrease the number of axons may be ascribed to its 
histone deacetylase (HDAC) inhibitory action, while the ability of Li+ to increase the
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number of axons and affect microtubules may be ascribed to its inhibition of GSK3 
(Williams et al. 2002). Neither VPA or CBZ inhibit GSK3 activity in primary 
cultured neurons (Ryves et al. 2005). However, previous studies report that, while 
unable to directly inhibit GSK3 in vitro VPA may indirectly inhibit GSK3 in some 
neuronal cell lines (Chen et al. 1999; Hall et al. 2002). Both Li+ and VPA are able to 
promote neural survival in specific cell lines, due to interplay with the ERK/MAPK 
signalling pathway, however this is not seen with CBZ treatment (Di Daniel et al. 
2005).
A study looking at the effect of Li+, VPA and CBZ on dorsal root ganglia neurons 
from rats has revealed that while the three drugs had differing effects on axon 
branching and microtubule organisation all three resulted in enlarged growth cones. 
This effect was reversed by addition of inositol, identifying inositol signalling as a 
potential therapeutic target in the treatment of mood disorders (Williams et al. 2002). 
The potential role of inositol phosphates in mood disorders is supported by a number 
of neurological studies showing altered IP levels in the brain (Shimon et al. 1998; 
Beacher et al. 2005). It is important to understand IP signalling in the context of mood 
disorders. PO has been identified in a Li+ screen for proteins involved in inositol 
signalling and has also been associated with a number of mood disorders (see above). 
Growing interest in the inositol signalling pathways has revealed a complex and 
highly regulated network of inositol and phosphatidylinositol phosphorylation and 
dephosphorylation. It will be interesting to understand the role of PO in the inositol 
phosphate signalling network.
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1.4 Inositol Signalling
1.4.1 Basic Signalling Pathways
Inositol C6 H6 (OH) 6  is a six carbon ring which can be phosphorylated at single or 
multiple positions by a number of cellular enzymes to produce a number of 
biologically active molecules. The position and number of phosphates around the 
inositol ring plays an important role in its function and is controlled by a number of 
enzymes with varying specificities. Naming of inositol phosphates indicates the 
position and number of bound phosphate groups (Figure 1-4).
It has been suggested that inositol-3-phosphate (I3P) was the first inositide to evolve, 
produced through the conversion of glucose-6 -phosphate and converted in turn to 
inositol and eventually phosphatidylinositol (Irvine 2005). Prokaryotes may contain 
inositol monophosphate and phosphatidylinositol however no polyphosphate inositols 
have been identified. The eukaryotes have a much more complex inositide 
biochemistry, we are currently aware of seven polyphosphoinositol lipids and over 
thirty inositol phosphates with an ever-expanding list of cellular functions.
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OH
Myo-INOSITOL
Myo-INOSITOL (1,4,5)-TRISPHOSPHATE PHOSPHATIDYLINOSITOL
Figure 1-4 Structure and Numbering of Myo-Inositol, Inositol (1,4,5)- 
Trisphosphate and Phosphatidylinositol
Myo-inositol represents the inositol form generally present in biological systems. 
Numbering of carbon atoms in the inositol carbon ring indicates the position of 
attachment of phosphate groups.
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1.4.1.1 PIP 2  Is Hydrolysed To IP3And DAG
1.4.1.1.1 IP3  release
IP3 is rapidly released from phosphatidylinositol (4,5) bisphosphate (PI(4 ,5 )P2 ) 
following activation by an external stimulus e.g 5-hydroxytryptamine (5-HT) or 
carbachol. The rapid increase in IP3 and IP2 observed in [3 H]inositol labelled blowfly 
salivary glands following 5-HT treatment, along with a corresponding decrease in 
PIP2  and to a lesser extent phosphatidylinositol 4-phosphate (PI(4)P) but not 
phosphatidylinositol (PI), provided the first evidence that this stimulus causes 
hydrolysis of PIP2  rather than PIP or PI (Berridge 1983; Berridge et al. 1983). 
Phospholipase C (PLC) catalyses the hydrolysis of PI(4 ,5 )P2 to produce DAG and IP3 
both of which act as second messengers in cell signalling (Berridge and Irvine 1984; 
Nishizuka 1988).
1.4.1.1.2 Roles o f IP3  and DAG
IP3 is an important cellular second messenger. We first began to understand the 
importance of this molecule when Berridge proposed the role of IP3 as a second 
messenger in calcium signalling, following observation of increased Ca2+ release from 
intracellular stores when permeabilised pancreas cells were treated with IP3 (Streb et 
al. 1983). Following this report the same effect was observed in a number of different 
cells and tissues (reviewed in (Berridge and Irvine 1984)) and the IP3 receptor and its 
Ca2+ channel activity has been identified and characterised (Mikoshiba 1993). The 
role of IP3 as a second messenger has been identified in a number of cellular 
processes.
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DAG activates the conventional and novel but not the atypical subtypes of protein 
kinase C an enzyme involved in a multitude of signalling pathways; regulating cell 
survival, development, migration and gene expression (for reviews see Tan and 
Parker 2003; Guo et al. 2004; Oka and Kikkawa 2005; Martelli et al. 2006).
1.4.1.1.3 Replenishing PIP2  levels
The PIP2 hydrolysed in response to receptor activation is thought to represent a 
distinct pool of PI from the total cellular PI (Fain and Berridge 1979; Monaco and 
Woods 1983). DAG is recycled to replenish PI(4 ,5 )P2  at the plasma membrane via 
phosphatidic acid (PA) and cytidine monophosphate-phosphatidic acid (CMP.PA) 
which recombines with inositol to form PI. PI undergoes sequential phosphorylation 
to PI(4)P then PI(4 ,5 )P2 . PI is phosphorylated by type II PI kinase to produce PI(4)P 
(Chang and Ballou 1967) and type I PI kinase producing PI(3)P, the latter 
representing just a small fraction (1-12%) of intracellular PIP (Whitman et al. 1988).
1.4.1.2 Inositol To IP 3
Intracellular inositol levels are maintained via three distinct pathways; intracellular 
transport, de novo synthesis from glucose and recycling of inositol phosphates.
1.4.1.2.1 Intracellular inositol transport
Inositol is pumped into the cell by two transporters, which operate under different 
conditions. The NaV/wyo-inositol cotransporters (SMIT1 and 2) are expressed in a 
number of tissues including kidney, brain (neuronal and non-neuronal cells) and 
placenta. They play an essential role in maintenance of intracellular inositol levels 
under normal and stress conditions (Kwon et al. 1992; Inoue et al. 1996; Guo et al. 
1997; Coady et al. 2002; Berry et al. 2003). The H+/wyo-inositol symporter is
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expressed mainly in neurons in the brain. It is present on intracellular vesicles and 
appears to be transiently localised to the plasma membrane at growth cones and 
synapses, especially the postsynaptic region, during times of upregulated inositol 
phosphate signalling, PKC activation and cell depolarisation enabling sustained 
phosphatidylinositol synthesis (Uldry et al. 2001; Uldry et al. 2004).
1.4.1.2.2 Do novo inositol synthesis
Inositol is produced in the cell by dephosphorylation of inositol monophosphate (IP) 
to inositol, catalysed by inositol monophosphatase (IMPase). IMPase is a 
homodimeric enzyme which requires Mg2+ for activity and is inhibited in an 
uncompetitive manner by Li+ with a Kt between 0.2 and ImM depending on the IP 
isomer being dephosphorylated (Gee et al. 1988). IP is generated in the cell from two 
sources representing the second and third pathways of inositol production. One 
pathway involves de-novo synthesis of IP from glucose-6 -phosphate. Glucose-6 - 
phosphate is circularised by inositol phosphate synthase to form inositol 1 -phosphate 
(I(l)P) (Culbertson et al. 1976).
1.4.1.2.3 Inositol recycling
Finally, inositol is also recycled from the second messenger I(1 ,4 ,5 )P3 and the other 
IP3 present in the cell I( 1 ,3 ,4 )P3 (see below). Inositol polyphosphate-5-phosphatases 
type I and II (IP3/IP4 5 P) are responsible for dephosphorylation of I(1 ,4 ,5 )P3 to 
I( 1 ,4 )P2 , type IIP 3 /IP4 5 P is both cytosolic and membrane associated while the type II 
IP3 /IP4 5 P shows cytosolic and mitochondrial localisation (Mitchell et al. 1989; 
Laxminarayan et al. 1993; Laxminarayan et al. 1994; Speed et al. 1995; Communi et 
al. 2001). Both enzymes require Mg2+ ions for activity and are inhibited by D-2,3- 
bisphosphoglycerate (Hansbro et al. 1994). Dephosphorylation of IP3 to IP2 occurs
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relatively rapidly (within seconds) following a stimulus induced increase in IP3 
(Berridge 1983; Berridge et al. 1983).
Further dephosphorylation to I(4)P is catalysed by inositol polyphosphate phosphatase 
(IPP), this enzyme also requires Mg for its activity and is inhibited by the other
^  1 ^  1
divalent cations Ca and Mn . IPP activity is increased in the presence of 
monovalent sodium and potassium ions, however, lithium ions show uncompetitive 
inhibition of the enzyme with a Ki of approximately 0.75mM (Inhom and Majerus 
1987). IPP is also able to remove the 1-phosphate from I( 1 ,3 ,4 )P3 to produce I(3 ,4 )P2 , 
the affinity of IPP for I( 1 ,3 ,4 )P3 is less than that for I( 1 ,4 )P2 (Km ~20pM compared to 
~4pM) however both reactions show the same maximal activity. IPP is unable to 
dephosphorylate 1(1 )P, I( 1 ,3 )P2 , 1 ( 1 ,4 ,5 )P3 or I( 1 ,3 ,4 ,5 )P4  (Inhom and Majerus 1987). 
Another enzyme, inositol polyphosphate-4-phosphatase (IP4P), is required for 
removal of the 4-phosphate from I(1,3,4)P3 and I(3,4)P2  to produce I(1 ,3 )P2 and I(3)P 
respectively while subsequent dephosphorylation of the I( 1 ,3 )P2 produced is catalysed 
by the inositol polyphosphate-3-phosphatase to form 1(1 )P. Both of these enzymes 
activities are Mg2+ independent and not inhibited by Li+ ions (Bansal et al. 1987). All 
three IP isoforms (1(1 )P, I(3)P, I(4)P) are dephosphorylated by the Li+ sensitive, Mg2+ 
dependant enzyme IMPase (Ackermann et al. 1987; Atack et al. 1995)(Figure 1-5).
1.4.1.3 Higher Order Inositol Phosphates
IP3 also undergoes further phosphorylation to generate a network of higher order 
inositol phosphates (Balia et al. 1989a). Following receptor stimulation resulting in 
elevated levels of IP3 subsequent increases in the higher order inositol phosphates IP4 
and IP5 are observed. Different isomers appear at varying intervals implying a 
complex pathway of phosphorylation/dephosphorylation reactions (Balia et al. 
1989b).
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1.4.1.3.1 IP4, IP5 and IP6
Four possible isoforms of IP4  have been identified in vivo, I(1 ,4 ,5 ,6 )P4 , I( 1 ,3 ,4 ,5 )P4 , 
I(1 ,3 ,4 ,6 )P4  and I(3 ,4 ,5 ,6 )P4  (Balia et al. 1989a). Two of these, I( 1 ,4 ,5 ,6 )P4  and 
I( 1 ,3 ,4 ,5 )P4  are phosphorylation products of I( 1 ,4 ,5 )P3 by Inositol Polyphosphate 
Multiple Kinase (IPMK) and Inositol(l,4,5)trisphosphate-3-kinase respectively 
(Takazawa et al. 1989; Takazawa et al. 1990; Nalaskowski et al. 2002). The latter two 
are produced in a seemingly more convoluted manner. I( 1 ,3 ,4 ,6 )P4  is produced 
following dephosphorylation of I(1 ,3 ,4 ,5 )P4  at the 5-position by IP3/IP4 5 P to 
I( 1 ,3 ,4 )P3 and subsequent phosphorylation of the 6 -position by I(1 ,3 ,4 )P3 5/6- 
kinase/I(3 ,4 ,5 ,6 )P4  1-kinase (Balia et al. 1989a). I(3 ,4 ,5 ,6 )P4  is not produced from IP3 
but by dephosphorylation of I(l,3,4,5,6)Ps, this dephosphorylation and subsequent 
rephosphorylation at the l ’position are both catalysed by I(1 ,3 ,4 )P3 5/6- 
kinase/I(3 ,4 ,5 ,6 )P4  1-kinase (Yang and Shears 2000; Ho et al. 2002).
I( 1 ,3 ,4 ,5 ,6 )P5 is also generated by IPMK action on I( 1 ,4 ,5 ,6 )P4  and I( 1 ,3 ,4 ,6 )P4  but 
not I( 1 ,3 ,4 ,5 )P4 , phosphorylation of I(1 ,4 ,5 ,6 )P4  can be reversed by the enzymes 
Phosphatase and Tensin Homologue (PTEN) or Multiple Inositol Polyphosphate 
Phosphatase (MIPP) (Craxton et al. 1995; Caffrey et al. 2001; Deleu et al. 2006). 
Metabolism of these higher order inositol phosphates may be controlled 
independently from receptor stimulated IP3 production (Balia et al. 1989b; Pesesse et 
al. 2004; Choi et al. 2005).
1.4.1.3.2 Role o f MIPP in inositol phosphate dephosphorylation
MIPP (Initially known as I(1,3,4,5)P4  3-phosphatase), dephosphorylates IP6, 
I(1 ,3 ,4 ,5 ,6 )P5 and I(1 ,3 ,4 ,5 )P4  at the 3’ position. MIPP preferentially 
dephosphorylates IP4  (Vmax 4,250nmol/mg/min) over IP5 (Vmax 21 lnmol/mg/min) or
1-56
IP6  ( V max 1 2 nmol/mg/min). Both IP5 and IP6 act as competitive inhibitors for IP4  
metabolism (Hodgson and Shears 1990; Nogimori et al. 1991). MIPP is also able to 
remove the 6 ’phosphate from I( 1 ,4 ,5 ,6 )P4  and any phosphate from IP6  though is 
unable to hydrolyse any of the IP3 or IP2  isoforms (Craxton et al. 1997). This enzyme 
is located principally within the rough and smooth endoplasmic reticulum (ER) thus 
questioning its physiological role (Ali et al. 1993; Craxton et al. 1995). This argument 
is supported by a report showing truncation of MIPP to remove the ER localisation 
results in a significant increase in intracellular concentrations of 1(1,4,5 )P3 and Ca2+ 
(Yu et al. 2003). Alternatively it has been reported that MIPP is both internally and 
externally localised to the plasma membrane in erythroblast and fibroblast cells 
respectively (Carpenter et al. 1989; Estrada-Garcia et al. 1991; Craxton et al. 1995). 
However, a role for the ER localised MIPP is evident as altered levels of IP5 and IP6 
observed in fibroblasts from a MIPP knockout mouse, were reversed by introduction 
of MIPP to the ER (Chi et al. 2000).
1,4.1.3.3 Inositol pyrophosphates
I P s  may be further phosphorylated via IP6 and Diphosphoinositol pentaphosphate 
([PP]-IP5 ) to Bis-Diphosphoinositol tetrakisphosphate ([PP]2 -IP4) by I(l,3,4,5,6)Ps 2- 
kinase (IPK1), IP6  kinase and [PP]-IPs kinase respectively (Voglmaier et al. 1996; 
Huang et al. 1998; Verbsky et al. 2002). Alternatively IP5 may undergo slow 
phosphorylation by IP6  kinase to Diphosphoinositol tetrakisphosphate ([PP]-IP4) and 
subsequently bis-diphosphoinositol trisphosphate ([PP]2 -IP3) (Saiardi et al. 2000). 
IP6 Kinase activity is mediated by three enzymes, IPeKl, 2 and 3 all of which are 
enriched in the brain and perform a similar function, they do however, vary in their 
intracellular localisation. IP6 K 1 is present throughout the nucleus and cytoplasm
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while IP6K2 shows a nuclear localisation and IP6K3 is mainly cytosolic (Saiardi et al. 
1999; Saiardi et al. 2001).
MIPP is also able to hydrolyse the 5-p-phosphate of [PP]-IPs or [PP]2 -IP4 , however, 
this reaction is not thought to occur in vivo (Shears et al. 1995; Craxton et al. 1997). 
Dephosphorylation of [PP]-IPs, [PP]2 -IP4  and [PPJ-IP4  in vivo is catalysed by 
Diphosphoinositol Polyphosphate Diphosphatase (DIPP), which removes the 13- 
phosphate from these molecules (Saffany et al. 1998) whereas MIPP is responsible for 
dephosphorylation of IP6  to IP5 . [PP]-IPs and [PP]2 -IP4  undergo a sustained PLC 
independent metabolic turnover that may be inhibited by fluoride ions in both 
Dictyostelium and mammalian cells (Glennon and Shears 1993; Stephens et al. 1993).
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Figure 1-5. Inositol Signalling Pathways Observed Within the Cell.
Intracellular inositol is maintained by transport mediated import across the plasma membrane, de novo synthesis from glucose-6-phosphate and recycling of the 
second messenger IP3. IP3 levels are also affected by interaction with a complex network of higher order inositol phosphates. The entire inositol phosphate 
signalling network is tightly regulated by a number of specific enzymes. Abbreviations; PA, Phosphatidic acid, IP3/IP45P, I(l,4,5)P3/I(l,3,4,5)P45-phosphatase, 
IP33K, I(l,4,5)P33-kinase, IP36K/IP41K, I(l,3,4)P36-kinase/I(3,4,5,6)P4l-kinase, PP-PDP, Diphosphoinositol-polyphosphate diphosphatase.
1.4.2 Cell Metabolism
1.4.2.1 Calcium Signalling
Undeniably the best known and most reported inositol phosphate cellular function is 
that of IP3 mobilisation of Ca2+ from intracellular stores (Berridge and Irvine 1984). A 
study using Xenopus oocytes found IP3 treatment of cells can also tngger the Ca 
dependent oscillations in membrane potential. They suggest the presence in the cell of 
an IP3 senstive and IP3 in-sensitive pool of calcium with release of the IP3 in-sensitive 
pool of calcium dependent on intracellular Ca2+ and responsible for the oscillations in 
membrane potential (Berridge 1988). As well as a central role in Ca2+ signalling IP3 
and the other cellular inositol phosphates, especially the higher order IPs, function in 
numerous and diverse pathways.
1.4.2.2 Neurological Functions
Alterations in inositol phosphate levels in the brain have been linked to a number of 
different neurological disorders including Bipolar Disease (Berridge et al. 1989), 
Schizophrenia (Shimon et al. 1998) and Down Syndrome (Berry et al. 1995; Beacher 
et al. 2005) implying an important role in the function and development of neurons. 
Both IP5 and IP6  are present in the mammalian brain, at different levels in the 
different brain regions. It is thought that these IPs may function as an extracellular 
signal as microinjection into a control region within the medulla oblongata of 
Sprague-Dawley rats resulted in a decrease in blood pressure and heart rate (Vallejo et 
al. 1987). Inositol phosphates also play a role in synaptic regulation and 
neuroplasticity (Nahorski et al. 2003).
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1.4.2.3 Vesicle Trafficking
Several IPs have been linked to endocytosis and vesicle trafficking within the cell. 
Mice deficient in the polyphosphoinositide phosphatase synaptojanin 1 show 
increased levels of PI(4 ,5 )P2 and decreased synaptic vesicle recycling (Cremona et al. 
1999). Both IP4  and IP6  disrupt interaction of visual arrestins with rhodopsin 
(Palczewski et al. 1991) and IP6 binding sites identified on non-visual arrestins 
suggest it may sequester the arrestins in the cytoplasm preventing their receptor 
binding to form clathrin coated pits, essential for endocytosis (Milano et al. 2006). A 
similar role in cytosolic binding of the clathrin adaptor protein AP-2 has been seen 
(Gaidarov et al. 1996). IP6  has also been linked to prevention of Cf channel 
desensitisation, a precursor to channel internalisation by endocytosis (Lee et al. 
2004b).
1.4.2.4 Nuclear Roles
Inositol phosphates have been assigned several nuclear roles; the ratio of the higher 
order inositol phosphates affects chromatin remodelling and gene expression by 
regulating ATP dependant SWI/SNF chromatin remodelling complexes. IP4  and IP5 
both act as positive regulators while IP6  acts to negatively regulate and suppress gene 
expression. Expression of the inol gene in yeast encoding inositol synthase is 
stimulated by increased IP4 /IP5 and inhibited by increased IP6  (Shen et al. 2003; 
Steger et al. 2003). Inositol phosphates also play a role in DNA stability. Increased 
levels of inositol pyrophosphates result in shortened telomeres caused by inhibition of 
the yeast PI3K related kinase (PIKK), Tell or an upstream activator, the reverse is 
also true with a decrease in inositol pyrophosphates causing lengthened telomeres 
(Saiardi et al. 2005; York et al. 2005).
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A yeast screen for mutants showing mRNA nuclear export defects identified yeast 
homologues for PLC and two IP kinases responsible for IP3 phosphorylation to IP6 . 
Studies of these mutants has revealed an essential role for IP6 in efficient export of 
mRNA from the nucleus, probably by interaction with factors associated with the 
nuclear pore complex (York et al. 1999). The majority of IP effects are mediated by 
IP binding to specific proteins however, [PP]-IPs appears to act as a phosphate donor 
to a number of yeast and mammalian nucleolar proteins (Saiardi et al. 2004; York and 
Hunter 2004).
1.4,2.5 In Times O f Cell Stress
Along with general cellular functions, inositol phosphates also play a central role 
during cell differentiation and at times of cell stress. It has been suggested that 
inositol signalling may play a role in bone formation following a reported up- 
regulation of MIPP expression during rat chondrocyte hypertrophy, a similar 
phenomenon to that observed with the structurally similar histidine acid phosphatase 
in chick chondrocytes (Caffrey et al. 1999).
Levels of [PPJ2 -IP4  (IPs) reportedly increase in response to heat stress and 
hyperosmotic stress in mammalian cells, though not observed in the yeast S.cerevisiae 
(Pesesse et al. 2004; Choi et al. 2005). Changes in the higher order inositol 
phosphates have also been related to cell death and apoptosis. Several reports have 
recorded an increase in IP6 K activity following exposure to apoptotic stimuli as well 
as a protective effect of IPeK deletion against cell-death stimuli (Morrison et al. 2001; 
Nagata et al. 2005).
It is clear that inositol phosphate signalling is part of a complex network, which plays 
a role in numerous processes within the cell. It is to be expected that such a network 
must be highly regulated to enable normal cell function
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1.4.3 Species Differences
1.4.3.1 Dictyostelium
Dictyostelium have similar inositol phosphate signalling networks to mammalian cells 
however there are several notable differences. The Dictyostelium enzyme equivalent 
to MIPP, MIPP A, is also able to dephosphorylate I( 1 ,3 ,4 ,5 ,6 )P5 to I( 1 ,4 ,5 )P3 via both 
I( 1 ,4 ,5 ,6 )P4  and I(1 ,3 ,4 ,5 )P4  however, unlike its mammalian equivalent, the 
Dictyostelium enzyme is reportedly a peripheral membrane protein localised at the 
inner face of the plasma membrane rather than the endoplasmic reticulum (Van 
Dijken et al. 1997). The activity of MIPP A is Ca2+ sensitive unlike its mammalian
j
counterpart (Van Dijken et al. 1997). However, this localisation and Ca dependency 
is reminiscent of the situation reported in human erythrocytes (Doughney et al. 1988; 
Estrada-Garcia et al. 1991).
Dictyostelium cells contain much higher concentrations of higher order inositol 
phosphates than that observed in mammalian cells, in particular the intracellular 
concentration of IP6  is estimated at 0.7mM in Dictyostelium compared to 5-15pM in 
mammalian cells (Martin et al. 1987; Szwergold et al. 1987). Dictyostelium are able 
to produce higher order inositol phosphates without PIP2 hydrolysis by sequential 
phosphorylation of inositol (Stephens and Irvine 1990). This pathway may be of 
importance in the Dictyostelium pic null mutant, which is able to maintain IP3 levels 
in the absence of any PLC activity (Drayer et al. 1994; Van Dijken et al. 1995).
Further analysis has revealed high concentrations of extracellular cAMP signal 
stimulate IP5 dephosphorylation to I(1 ,4 ,5 )P3 by MIPP at the plasma membrane in a 
Ca2+ dependant manner (Van Dijken et al. 1997).
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1.4.3,2 Plants And Yeast
Inositol signalling in plants and yeast remains closely related to that of mammalian 
organisms. Arabidopsis and brewers yeast show evidence of putative homologues to 
the majority of enzymes involved in inositol phosphate metabolism. Some noticeable 
differences have been reported however, including a distinct absence of the signalling 
molecule PIP3 despite genes encoding putative PTEN protein whose preferred 
substrate is PIP3 . They also lack inositol-4-phosphatases and PI-3-kinases but show an 
abundance of inositol 5-phosphatases (reviewed in Mueller-Roeber and Pical 2002). 
Significantly elevated levels of IP6  are observed in plant cells compared to 
mammalian cells, especially seeds, where it may act as a phosphate store.
1.4.4 Effect Of Li* And VPA On Inositol Signalling
In 1989 Berridge et al. put forward the inositol depletion hypothesis suggesting the 
pertinent therapeutic action of lithium in treatment of mood disorders was its 
depletion of the intracellular inositol pool by inhibition of both de novo synthesis and 
recycling of inositol (Berridge et al. 1989). A similar decrease in intracellular inositol 
has been observed following treatment of both rat brain and yeast with VPA 
(O’Donnell et al. 2000; Vaden et al. 2001).
It would now appear that this may be a common mechanism of therapeutic action for 
multiple mood stabilising drugs. The spreading effect of lithium, VPA and CBZ on 
growth cones of dorsal root ganglia neurons may be reversed by addition of either 
extracellular inositol or a PO specific inhibitor, which results in derepression of the 
IPs to IP3 pathway (Williams et al. 2002). The inositol pathway effects are caused by 
interactions of the drugs at a number of steps in the inositol phosphate pathway.
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Lithium affects inositol signaling by inhibition of both IMPase (inositol 
monophosphatase) (Berridge et al. 1982) and IPP (inositol polyphosphatase) (Inhom 
and Majerus 1987). These enzymes catalyze the dephosphorylation of IP to inositol 
and IP2  to IP respectively thus resulting in a decreased intracellular pool of inositol 
(Figure 1-6). VPA depletes intracellular inositol by inhibition of myo-inositol-1- 
phosphate synthase, the enzyme which catalyses the conversion of glucose-6 - 
phosphate to inositol-1 -phosphate in de novo inositol synthesis, in human brain 
homogenates (Shaltiel et al. 2004). This inhibition was not observed in vitro using the 
purified enzyme suggesting inhibition by VPA may be an indirect effect (Ju et al.
2004) (Figure 1-6).
The cellular interactions of CBZ that result in inositol depletion remain to be 
identified. However, CBZ as well as Li+ and VPA treatment of astrocytes at 
therapeutic levels results in a decrease in the SMIT inositol transporter activity and 
mRNA resulting in decreased inositol uptake (Lubrich and van Calker 1999).
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Figure 1-6 Drug Interactions with Inositol Phosphate Pathway
A simplified version of the inositol phosphate pathway showing points of inhibition by the mood 
stabilising drugs Li+, VPA and CBZ.
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1.5 Dictyostelium Discoideum
1.5.1 Model Organism
Dictyostelium discoideum is a species of slime mould first discovered in the 1930s by 
KB Raper (Raper 1935). Dictyostelium is the most commonly studied member of the 
Dictyostelids, used to investigate processes such as chemotaxis, motility (Eichinger et 
al. 1999) and signal transduction (Harwood 2001). The Dictyostelids are closely 
related to the Metazoa utilizing several homologous signal transduction pathways and 
modes of action. In the model of evolution put forward by Baldauf et al. (2000) and 
later by Eichinger et al. (2005), the Dictyostelium Dictyostelidae lineage is thought to 
have diverged before the branching of fungi and animals but after the branching of 
plants.
Dictyostelium are proving to be a valuable research tool, publications in PubMed to 
date number over 6,000 and are rapidly increasing. Dictyostelium is a highly tractable 
organism well suited to laboratory conditions and ideal for biochemical studies. It is 
also a good molecular genetics model for four main reasons; a haploid genome makes 
knockout models relatively straightforward, it is very amenable to transformation and 
overexpression studies, thirdly its complex life cycle allows separation of effects on 
growth and development and finally sequencing of the Dictyostelium discoideum 
genome has been completed providing a wealth of information (Eichinger et al.
2005).
Completion of the genome has enabled identification of a number of Dictyostelium 
genes homologous to human disease genes revealing Dictyostelium to have a higher 
number of human disease orthologues than observed in the yeast S.cerevisae and 
S.pombe, though fewer than D.melanogastor or C.elegans. The Dictyostelium genome
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is approximately 34Mb in size which is just over one hundredth the size of the human 
genome or one sixth that of D.melanogastor. In this small space it fits half as many 
genes as the human genome equalling the number observed in D.melanogastor 
(Eichinger et al. 2005).
The Dictyostelium life cycle of growth, aggregation and differentiation into a 
multicellular organism enables observation of distinct aggregation or developmental 
phenotypes following gene knockouts, protein over-expression, drug treatments or 
varying growth conditions. It also makes possible large scale screening of mutants for 
distinctive phenotypes. The signal transduction pathways involved in this process in 
many cases are homologous to those of mammalian systems including GSK signaling 
(via the Dictyostelium GSK-3 homologue GSKA) (Harwood et al. 1995) and inositol 
signalling as well as signalling via a number of G-proteins.
1.5.2 Amoeboid Cell Growth
Dictyostelium is a social amoeba whose natural habitat is the soil of forest floors. 
Dictyostelium grow and divide as single celled amoeba feeding on bacteria, the strains 
generally used for research (Ax2, 3 or 4) are also able to grow on plates or in 
suspension in nutrient rich media (Axenic Media) in the laboratory.
During amoeboid cell growth cells undergo growth and division independently of one 
another. Cells are able to sense and move towards bacteria by detecting folate levels 
using a G-protein coupled cell surface receptor. The folate receptor signal is 
transduced by the Ga4 subunit {Dictyostelium contain 11 G-protein a-subunits but 
just one p and one y subunit) (Hadwiger et al. 1994). Folate signalling through the 
same receptor also acts to repress expression of the developmental marker discoidinl 
and other early developmental genes (Blusch and Nellen 1994; Salger and Wetterauer 
2000).
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Growing cells also secrete and sense a 6 8 kDa glycoprotein called Pre-Starvation 
Factor (PSF). This factor builds up in the environment allowing cells to detect the cell 
density of their surrounding environment (Clarke et al. 1988). When PSF levels reach 
a threshold cell growth is arrested and cells begin to express car A and acaA, both of 
these are developmental genes encoding cAR-1, extracellular cAMP receptor 1, and 
adenylyl cyclase A (ACA), the enzyme which synthesizes cAMP, respectively 
(Soderbom and Loomis 1998).
The response to PSF is mediated by a protein kinase Yak-A, expression of the gene 
yakA increases throughout cell growth reaching a peak at the start of starvation in 
response to build up of extracellular factors. Yak-A activity is responsible for 
suppression of growth related proteins such as the cysteine protease CprD and 
expression of developmental genes acaA, car A and pka-C encoding the active subunit 
of PKA (Souza et al. 1998). YakA induced expression of acaA and car A is dependent 
on PKA activity (Soderbom and Loomis 1998).
Thus growth arrest and entry to starvation phase may be initiated by a decrease in 
folate and increase in PSF levels in the extracellular environment.
1.5.3 Starvation And Aggregation
The most striking feature of Dictyostelium is their ability to survive starvation by 
developing into a multicellular fruiting body by aggregation of single amoeboid cells. 
This aggregation is stimulated by waves of cAMP that induce the amoeboid cells to 
migrate towards a central point forming a mound of approximately 1X105 cells.
7 .5 .3.1 cAMP Signalling
As cells enter starvation both cAMP synthesis (ACA) and detection (cAR-1) are 
upregulated however, build up of another glycoprotein, conditioned medium factor
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(CMF), is also required to facilitate cAMP signalling (Mehdy and Firtel 1985). 
Secretion of this factor begins as cells enter starvation and builds up in the presence of 
several starving cells, thus allowing cells to wait for a sufficiently large population of 
cells in starvation before beginning aggregation, avoiding formation of small 
ineffective fruiting bodies (Gomer et al. 1991). CMF facilitates cAMP signalling by 
inhibition of Ga2-GTP hydrolysis by a mechanism involving receptor mediated 
activation of G a l, release of G(3y and subsequent activation of phospholipase C 
(Brazill et al. 1998).
The process of aggregation is mediated by a cAMP gradient set up by a single cell at 
the centre of aggregation and relayed by surrounding cells. Single cells are able to 
sense the pulse of cAMP and move towards it as well as releasing cAMP themselves 
to signal to subsequent cells. The pertinent receptor in this process is the cAMP 
receptor cARl; extracellular cAMP is detected at the plasma membrane by cARl, a 
G-protein coupled 7-transmembrane receptor (Klein et al. 1988; Saxe et al. 1988). 
Dictyostelium have four such receptors (cARl-4), which are expressed at different 
stages throughout aggregation and development (Kim et al. 1998). cARl is the first 
cAMP receptor to be expressed and is expressed throughout aggregation.
Waves of cAMP emanating outwards from the centre of aggregation are maintained 
by a self-regulating pathway of cAMP sensing, synthesis and degradation resulting in 
pulses of cAMP. cARl is coupled to the Ga2 subunit (Kumagai et al. 1991), cAMP 
binding results in release of Ga2-GTP and Gpy* This leads to activation of ACA and 
synthesis of intracellular cAMP (Wu et al. 1995), in addition the MAP Kinase, ERK2, 
is also activated by cAMP binding to cARl (Knetsch et al. 1996). One of the actions 
of ERK2 is to inhibit the cytoplasmic phosphodiesterase RegA. RegA degrades 
cAMP, thus this facilitates a build up of intracellular cAMP. Increased levels of
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intracellular cAMP result in activation of the cAMP-dependent protein kinase PKA. 
This enzyme, responsible for inducing expression of early developmental genes, 
completes a feedback loop by inhibiting both ACA and ERK, repressing cAMP 
synthesis and removing inhibition of its breakdown (Laub and Loomis 1998; Maeda 
et al. 2004).
1.5.3.2 Chemotaxis
cARl signalling also brings about a number of other downstream effects including, 
actin polymerisation, cyclic GMP accumulation and activation of PLC the enzyme 
responsible for PIP2  hydrolysis to IP3 and DAG. All of these may play an essential 
role in chemotactic movement (McRobbie and Newell 1984; Europe-Finner and 
Newell 1987).
Dictyostelium are able to sense a gradient of just 2% difference between the front and 
back of the cell and move towards the source of the cAMP. cARl is distributed 
evenly around the cell, not localised to the leading edge (Xiao et al. 1997), instead 
polarisation and directional sensing is mediated by recruitment of the two PI3K 
homologues PI3K1 and PI3K2 to the leading edge in response to cAMP signalling 
(Funamoto et al. 2001).
PIP2  is phosphorylated to PIP3 (phosphatidylinositol (3,4,5)-trisphosphate) by PI3K, 
the reverse reaction resulting in dephosphorylation to PIP2  is controlled by the PTEN 
(phosphatase and tensin homologue) enzyme. Recruitment of PI3K to the leading 
edge results in an increase in PIP3 in this region resulting in recruitment of PH domain 
proteins including; CRAC, an activator of adenylyl cyclase, PKB, a mammalian 
protein kinase B homologue and PhdA, pleckstrin homology domain containing 
protein A (Parent et al. 1998; Funamoto et al. 2001). Both PKB and PhdA are 
essential for normal chemotaxis to occur (Meili et al. 1999). PhdA is thought to be an
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adaptor protein that plays a role in F-actin localisation. Pseudopod formation at the 
leading edge also requires activity of the Arp2/3 protein complex responsible for actin 
polymerisation and branching. Arp 2/3 is controlled by activity of the proteins SCAR 
and WASP (Machesky and Insall 1998), whose activity at the leading edge is 
controlled by the Rho GTPase Raclb (Chung et al. 2000).
In addition pseudopod formation at the sides and back of the cell is repressed by the 
continued presence of PTEN and an absence of PI3K leading to increased PIP2  and a 
lack of PIP3 , as well as a cGMP induced regulation of myosin II filaments (Bosgraaf 
et al. 2 0 0 2 ).
1.5.3.2.1 Role o f inositol signalling
PLC activity is increased over the first 10 hours of starvation when the cells are 
undergoing aggregation and mound formation (Bominaar et al. 1994; Bominaar and 
Van Haastert 1994). Unlike mammals, Dictyostelium has just one PLC enzyme, 
which is similar to the mammalian PLC- 6  isoform (Drayer et al. 1994). In the plc- 
mutant strain IP3 levels are maintained by an alternative pathway whereby the higher 
order inositol phosphate IP5 is dephosphorylated by M IPP at the plasma membrane in 
a Ca2+ dependent manner (Van Dijken et al. 1995). Decreased levels of IP5 are 
observed in this mutant though the higher order inositol phosphates IP6 -IP8 appear 
unaffected (Van Dijken et al. 1997). This pathway is inhibited by PO which blocks 
the dephosphorylation of IP5 to IP3 (Williams et al. 1999).
The use of cAMP derivatives which inhibit PLC activity have shown a clear 
correlation between IP3 levels and chemotaxis (Bominaar and Van Haastert 1993), 
revealing I(1,4,5)P3 plays an integral role in translating this chemical signal within the 
cell. In the presence of cAMP derivatives IP3 levels were not maintained in contrast to 
the pic- mutant. Van Dijken et al. (1997) reported that IP5 dephosphorylation to
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I( 1 ,4 ,5 )P3 by MIPP at the plasma membrane was stimulated by extracellular cAMP. 
Disruption of this stimulation may explain the discrepancies in IP3 levels and 
chemotaxis between cells treated with cAMP derivatives and the pic- mutants. 
Following cAMP binding a rapid accumulation of IP3 has been observed in 
Dictyostelium (Europe-Finner and Newell 1987; Van Haastert et al. 1989). IP3 
releases Ca2+ from intracellular stores and a number of studies report that introduction 
of IP3 or Ca2+ to permeablised cells is able to replicate actin polymerisation and 
cGMP accumulation without signalling through cARl, suggesting these steps are 
downstream of IP3 release (Europe-Finner and Newell 1985, 1986). 
cAMP is also able to stimulate receptor mediated Ca2+ influx via cAR-1, cAR-2 or 
cAR-3 independently of G-protein activation (Milne and Devreotes 1993).
1.5.4 Development Of Multicellular Organism
Following aggregation the mound of cells undergo various stages of differentiation 
and morphogenesis during formation of a multicellular fruiting body (Harwood 2001) 
(Figure 1-7). The Dictyostelium fruiting body consists of spore cells suspended on a 
thin column of highly vacuolised stalk cells, in the wild these spores would be 
dispersed to form new colonies. Differentiation of cells into the different subtypes 
required for a functional fruiting body involves control of differential gene expression 
mediated by cAMP, differentiation inducing factors (DIFs) and intracellular enzymes 
(Berks and Kay 1990; Meima and Schaap 1999).
1.5.4,1 Early Differentiation
Cells begin to differentiate into prespore and three types of prestalk cells (pstA, B and 
O) very early following mound formation. After the mound has formed a tip is 
generated at the top which appears to co-ordinate differentiation of the other cells
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(Williams et al. 1989). The mound elongates behind the tip to form a first finger 
structure that may topple over to form a slug. Differentiation occurs throughout the 
slug and clear regions of pre-spore and pre-stalk cells are defined. The tip of the slug 
contains pstA cells with a small core of pstB cells, these are followed by a layer of 
pstO cells. The final four fifths of the slug consists mainly of prespore cells but may 
include a few isolated pstB cells. In the first finger structure these pstB cells form a 
layer at the base, as the slug moves they are lost but are regenerated before further 
development and go on to form the basal disk (Williams et al. 1989; Harwood 2001).
7 .5 .4.2 cAMP A nd D IF Signalling
Cells secrete cAMP throughout development as well as aggregation and this signal 
plays a key role in differentiation. cAMP signalling via cAR-3 and cAR-4 controls 
activity of the protein kinase GSKA, the Dictyostelium homologue of the human 
enzyme GSK-3. At moderate levels of cAMP cAR-3 stimulation results in activation 
of the protein kinase, Zaphod kinase (ZAK1), which in turn activates GSKA (Kim et 
al. 1999; Plyte et al. 1999). However, at high concentrations of cAMP, cAR-4 is 
stimulated resulting in activation of a protein phosphatase (PTP), which acts to 
downregulate GSKA (Ginsburg and Kimmel 1997; Kim et al. 2002). GSKA activity 
regulates the ratio of prespore cells to pstB cells by suppression of pstB and induction 
of the prespore gene pspA; in the GSKA null mutant a mis-shapen fruiting body with 
an enlarged basal disk and small fruiting body is produced (Harwood et al. 1995). 
Other key molecules in cell fate determination are the differentiation inducing factors, 
DIF1-DIF5. These factors isolated from Dictyostelium are able to induce prestalk cell 
differentiation and repress differentiation of prespore cells (Kay and Jermyn 1983). 
Of the five DIF factors, DIF-1 is the most abundant and is related in structure to DIF- 
2 and DIF-3, synthesis of all three requires the enzyme des-methyl DIF-1 transferase
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(idmtA) (Kay et al. 1983; Morris et al. 1988; Thompson and Kay 2000). DIF-1 is 
synthesised by prespore cells, which show increased levels of dmtA mRNA and 
activity (Kay and Thompson 2001). In a self regulating mechanism DIF-1 acts to 
suppress the prespore cells which produce it, while inducing prestalk cells which in 
turn produce DIF-1 degrading enzymes (Kay 2002). Loss of dmtA expression results 
in a mutant lacking pstO cells but not pstA, which must be induced by an alternative 
signal, DIF-4 and DIF-5 are potential candidates for this role (Thompson and Kay 
2000).
1,5,4.3 Terminal Differentiation
The final step in formation of the mature fruiting body is termed culmination and 
involves terminal differentiation including sporulation of prespore cells, this process 
is controlled by PKA controlled gene expression. cAMP continues to be produced 
throughout development however at later stages ACA is downregulated and an 
alternative adenylyl cyclase ACR is active (Soderbom et al. 1999). Increased PKA 
activity is achieved by downregulation of RegA resulting in increased cAMP due to 
decreased degradation. RegA inhibition is brought about by a decrease in ammonia 
levels and secretion of the sporulation peptide factor SDF-2.
Ammonia activates the histidine kinase DhkC which potentially activates the histidine 
kinase cascade, RdeA and RegA (Singleton et al. 1998; Harwood 2001). SDF-2 
signals via alternative histidine kinases, DhkA and DhkB whose downstream effect is 
inhibition rather than activation of RegA (Wang et al. 1999). Expression of SDF-2 is 
controlled by PKA activity, therefore, PKA activity is further increased by an auto­
stimulatory loop (Anjard et al. 1997). PKA controlled genes involved in terminal 
differentiation include the coat protein SpiA, spiA and the transcription factor 
StalkyA, stkA (Thomason et al. 1999).
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Figure 1-7 Stages of Dictyostelium Development
Diagram depicting the morphological stages of development; a, single cells, b, aggregation, c, 
mound, d, tipped mound, e, first finger, f, slug, g, Mexican hat, h, preculminant and i, mature 
fruiting body. Not to scale.
1.5.5 Effect Of Li+ Treatment
Cell differentiation and morphogenesis may be affected by external factors. For 
example, lithium treatment of wild type cells results in a fruiting body with a large 
base and a very small spore head, or a complete lack of aggregation when 
administered at increased concentrations (Maeda 1970). Peters et al. found that Li+ 
treatment during starvation resulted in an induction of prestalk associated gene 
expression and an inhibition of prespore gene expression, in agreement with the 
previous observations of a small spore head and large base (Peters et al. 1989). This 
effect is mediated by Li+ inhibition of GSKA, the Dictyostelium homologue of GSK- 
3, the same spore head to stalk ratio of patterning is observed in the GSKA null 
mutants as seen with a low dose of Li+ (Harwood et al. 1995). However, the gskA- 
strain remain sensitive to increased concentrations of Li+ revealing an additional 
target of Li+ inhibition.
Loss of PO results in increased intracellular IP3 and enables aggregation to proceed in 
the presence of lOmM Li+ though the gskA- phenotype is maintained (Williams et al. 
1999). This clearly points to inositol signalling as the lithium target at increased Li+ 
concentrations and provides a clear and efficient model with which to study this 
pathway.
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1.6 Aims
The aim of this study is to elucidate the intracellular role of the enzyme prolyl 
oligopeptidase using the model organism Dictyosteleum dicoideum. Special emphasis 
is placed on the role of PO in the context of its ability to confer resistance to a number 
of mood stabilising drugs. This will be approached from a number of directions.
1. To determine the similarity of DpoA to the mammalian enzyme and 
characterise the enzyme activity in order to ascertain its relevance as a model 
for the mammalian PO.
2. To discover if the mood stabilising drugs, in particular lithium, valproic acid 
and carbamazepine elicit any effect directly on PO activity.
3. To identify the localisation of PO within the cell in order to understand its 
intracellular role, this will also give information on potential protein-protein 
interactions.
4 . To elucidate the inhibitory action of PO on M IPP activity, loss of PO results in 
increased IP5/6 to IP3 dephosphorylation, a reaction catalysed in both 
Dictyostelium and mammals by this multiple inositol polyphosphate 
phosphatase.
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2 Materials And Methods
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2.1 Solutions
2.1.1 Chemicals
All standard chemicals were purchased from Sigma Chemical Company unless stated 
otherwise.
2.1.2 Molecular Biology
STET
5% Triton X-100, 50mM Tris-HCl (pH8.0), 50mM EDTA (pH8.0), 8 % Sucrose 
TE
lOmM Tris-HCl ImM EDTA, pH7.5 
0.5X TBE
45mM Tris-HCl, 45mM Boric acid, ImM EDTA, pH 8.3 
Loading Dye (6X)
0.25% Bromophenol blue, 1M Sucrose, filter sterilised, stored at 4°C
2.1.3 Bacterial Growth
LB-(Luria Bertani) Broth Miller, ForMedium™, UK
(10% Tryptone , 5% Yeast Extract, 10% NaCl, pH 7.0) filter sterile 
LB-Agar
IX LB Broth, 15% Agar 
LB-Glycerol
50% LB Broth, 50% Glycerol 
LB-Ampicillin Broth/Agar Plates
LB Broth/Agar Plates + 0.1 mg ml' 1 Ampicillin
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NZY+ Broth
10% Casein Hydrolysate, 5% Yeast Extract (Oxoid), 85mM NaCl, 2M MgC^, 2M 
MgSC>4 , 0.15% Glucose, filter sterile, pH 7.5
2.1.4 Northern Blot Solutions
MOPS Buffer
20mM MOPS (pH 7.0), 5mM Sodium Acetate, ImM EDTA 
RNA Loading Solution
ImM EDTA, 0.4% Bromophenol Blue, 0.4% Xylene Cyanol, 50% Glycerol
ssc
150mMNaCl, 15mM NasCitrate 
Hybridisation Buffer
43% Formamide, 5X SSC, 10X Denhardt’s Solution, 200mM Sodium Phosphate 
buffer (pH 6 .8 ), 200pg ml' 1 Salmon sperm DNA (boiled immediately prior to use), 
0.1% SDS
50X Denhardt’s Solution
1%BSA, l%Ficoll, 1% Polyvinylpyrollidine
2.1.5 Protein Gels
Laemmli Buffer (6X)
75mM Tris-HCl (pH 6 .8 ), 2% SDS, lOOmM DTT, 10% Glycerol, 0.1% Bromophenol 
Blue
Resolving Buffer
1.5M Tris-HCl (pH8 .8 ), 0.4% SDS, filter sterile 
Running Buffer
25mM Tris-HCl, 192mM Glycine, 0.1% SDS
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Transfer Buffer
25mM Tris-HCl, 192mM Glycine, 20% Methanol 
Fixing Solution
0.09% Acetic Acid, 45% Methanol
2.1.6 PO Assays
Homogenisation Buffer
50mM Tris-HCl (pH 7.4), ImM EDTA, ImM DTT, 5pg ml' 1 Aprotinin, ImM 
Benzamidine, lOpg ml' 1 Leupeptin 
Bacterial Lysis Buffer
50mM Potassium Phosphate (pH 7.8), 400mM NaCl, lOOmM KC1, 10% Glycerol, 
0.5% TritonX-100, pH 7.8, store at 4°C 
PO Assay Buffer
50mM HEPES (pH 7.8), ImM EDTA, ImM DTT, 0.25% DMSO, 141pM Z-Gly- 
Pro-pNA.
PO Assay Buffer II
lOOmM HEPES (pH 7.8), ImM EDTA, ImM DTT, 0.25% DMSO, 35.25pM Z-Gly- 
Pro-pNA, (8 .8 , 17.6, 35.25, 70.5, 141 pM Z-Gly-Pro-pNA also used during enzyme 
kinetics and inhibitor studies), KC1 to final ionic strength of 155mM (Beynon 2006). 
PO Assay Buffer II (pH adjustments)
lOOmM Propionate (pH 5-5.5)/MES (pH 5.5-6.5)/HEPES (pH 6.6-8.5)/Tris-HCl (pH 
8.5-9), ImM EDTA, ImM DTT, 0.25% DMSO, 141pM Z-Gly-Pro-pNA, KC1 to final 
ionic strength of 155mM (Beynon 2006), pH adjusted using HC1 or KC1, 
pH Elution Buffer
50mM Sodium Acetate, 300mM NaCl, 10% Glycerol, pH 5.0 (pH- glacial acetic acid)
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2.1.7 MIPP Assays
TEE Buffer
20mM Triethanolamine (pH 6.5), 5.9mM EGTA, 0.5mM EDTA 
MIPP Assay Buffer
IX TEE Buffer, 20mM CaCl2, 50mM LiCl, 200pM IP6
2.1.8 Dictyostelium Cell Culture
Axenic Medium
HL5 Medium with Glucose, Formedium™, UK (14% Peptone, 7% Yeast Extract,
0.5% Na2 HP04> 0.5% KH2 P 04, 13.5% Glucose), 0.5mg ml' 1 Vitamin B12, 0.2mg I' 1
Folic Acid, pH 6.4
Dictyostelium Freezing Medium
95% Horse Serum, 5% DMSO
SM (Sussmans Medium) Agar, Formedium™, UK
(10% Glucose, 10% Peptone, 1% Yeast Extract, 17% Agar, 4mM MgS04, 4mM 
KH2 P 04, 6 mM K2 HP04)
SM Black Agar
IX SM Agar, 5% Charcoal
KK2 (KK2-UCL), Formedium™, UK
(15.5mM KH2 P04, 3.8mM K2 HP04, pH 6.2)
2.1.9 Transformation Solutions
MES-HL5 Medium
0.5% Yeast Extract (Oxoid), 1.0% Bactopeptone (Oxoid), 1.0% Glucose, 6 .6 mM 
MES, pH 7.0-7.1
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Hepes Buffered Saline (HBS)
270mM NaCl, lOmM KC1, 1.2mM Sodium phosphate, 40mM Hepes, 0.2% D- 
glucose, pH 7.05 (use NaOH)
2.1.10 Immunofluorescence Solutions
PBS (Phosphate Buffered Saline)-A, Formedium™, UK
(160mM NaCl, 3mM KC1, 8 mM Na2 HP04> ImM KH2 P 0 4, pH 7.4)
PBST
99.95% PBS, 0.05% Tween20 
PBS/G/S
PBS, 1% Gelatin, 0.2% Saponin
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2.2 Sequence Analysis
2.2.1 Phylogenetic Analysis
Phylogenetic analysis was completed using Mac Vector® software (MacVector Inc, 
Cambridge, UK). Sequences were aligned using the ClustalW method (Thompson et 
al. 1994). Alignment parameters; Matrix = BLOSUM Series, Deletion penalty (open 
gap penalty) = 10, Gap penalty (extension gap penalty) = 0.1, Residue Specific 
Penalties used and Hydrophilic penalties used (hydrophilic residues; GPSNDQEKR) 
(Henikoff and Henikoff 1992). Phylogenetic reconstruction was completed using the 
following parameters; Tree building method = ‘Neighbour joining’, Evolutionary 
distance = Uncorrected ‘p’ method (this represents the proportion of differences 
between the two sequences) (Saitou and Nei 1987).
2.2.2 Definition Of Prolyl Oligopeptidase (PO) Domains
PO sequences were defined as those containing both the PO catalytic domain and p- 
propeller domain.
The catalytic domain was identified by the presence of either of the following protein 
subsequences, underlined amino acids represent residues essential for a positive 
match;
PO catalytic triad
NGGSNGGLLVAA (gap 70-1 lOaa) ADHDDRVVP (gap 25-55aa) AGHGAGK 
(allowed mismatch 8/12, 8/9, 6/7)
PO conserved domain- pfam00326
SFTPNFSVSVASWLNRGGIYAWNGRGGGEYGQKWHSAGTRRLKKNEFNDF 
IAAAEYLGKLGYTSPKRIAIFGGSNGGLL (allowed mismatch 60/80)
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The p-propeller domain was identified following an alignment of the query sequence 
with the (3-propeller conserved domain using the Mac Vector® ClustalW alignment 
function. Alignment parameters; Matrix = BLOSUM Series, Deletion penalty (open 
gap penalty) = 10, Gap penalty (extension gap penalty) = 0.1, Residue Specific 
Penalties used and Hydrophilic penalties used (hydrophilic residues; GPSNDQEKR) 
(Henikoff and Henikoff 1992). Alignments were analysed manually to identify the 
presence of the (3-propeller domain at the N-terminus of the protein. Sequences with a 
similarity score of less than 2 0 % were discarded unless a clear alignment could be 
identified manually, a small number of sequences with similarity scores above 2 0 % 
were also discarded where it was clear by manual inspection that the propeller domain 
was not aligned.
(3-propeller conserved domain- pfam02897
PPTRRDETVVDELHGDWADPYRWLEDDDSPEVLAWVEAENKYTEDFLAQL
KPLREKIFEELTKLIN YDRIS APFRRGG Y Y Y YFRN V GGKN Y S VLCRRP AL STE
GPTEEVLLDPNTLSEDGDFTVAGGGFAFSPDGRLLAYSLSLGGSDWYTIRFRD
IETGEDLPDVLEGVKFSGIVWAPDNTGFFYTRYDEPQRGSTNLPQKVWRHRL
GTPQSQDELVFEEPDDPFYLGAERSRDGKYLFISSGSGTDVNELYVLDLGSEV
PHLPLRKWPREDGVYYYVEHWGDRFYFLTNDGAPNFRLVRVDLNDPSPAD
WKDVIVEHREDVLLESVAVFGNYLVVSYRRDVLSRVRVFDLGSGGVLFEEFL
PGVGSVSSASGEYDSDELFYSFSSFLTPSTLYDLDLDTGERELLKDR
The peptidase domain was taken as sequence from the start of the PO conserved 
domain through to the C-terminus. This sequence fragment was approximately 200 aa 
in size and included the majority of the a/p  hydrolase fold domain. The p-propeller
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domain was taken as the aa region aligned to the P-propeller conserved domain 
sequence.
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2.3 Molecular Biology
2.3.1 Polymerase Chain Reaction (PCR)
PCR Reaction Mix; lOOng Mini-Prep DNA, lp l 5’-primer (lOOpmol pil"1), lp l 3’- 
primer (lOOpmol pi'1) (for primer details see section 2.3.13), 2.5pi dNTPs (200pM 
dATP, dTTP, dCTP, dGTP; Amersham Pharmacia Biotech), 5pi 10X Accubuffer™ 
(Bioline, UK), lp l Accuzyme™ enzyme (2.5U pi'1; Bioline) and ddtUO to 50pl final 
volume. Reactions were set up in 0.2ml thin walled tubes (Anachem, UK).
PCR Program; 95°C for 45seconds- denaturation, followed by 30 cycles of 95°C for 
45seconds, ~56°C (dependent on primer Tm) for 1 minute and 6 8 °C for 5minutes. 
Followed by a final extension step of 6 8 °C for lOminutes and storage at 4°C.
Addition of 3’-Deoxyadenosine (A) Overhang; PCR reaction was incubated at 6 8 °C 
for 10-15minutes following addition of lp l Taq polymerase (2.5U pi'1; Bioline), then 
returned to 4°C.
PCR Equipment; Perkin Elmer PTC-100 thermal cycler.
2.3.2 Restriction Enzyme Digestions
Plasmids were analysed using both single and double restriction digests, fragments 
produced were visualised by agarose gel electrophoresis.
Restriction Digest Mix; 5pi Mini-prep or 0.1-lpg DNA, lp l each restriction 
endonuclease (10 U pi'1), 2pl 10X manufacturers’ buffer, 0.2pl BSA (lOmg ml'1) if 
required according to manufacturers’ instructions and ddfUO to a final volume of 
20pl. Digests were incubated at 37°C for 2hours. All restriction enzymes and buffers 
were obtained from New England Biolabs.
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2.3.3 Agarose Gel Electrophoresis
DNA fragments were visualised by running on a 0.8% agarose gel prepared in 0.5X 
TBE (section 2.1.2). Ethidium bromide was added to 0.5pg ml' 1 to enable 
visualisation of DNA under UV light. DNA in solution was added to loading dye 
(section 2.1.2) at a ratio of 5:1 prior to gel loading. The size marker added was lkb 
DNA Ladder (New England Biolabs).
2.3.4 TOPO Cloning
The dpoA PCR product was cloned into the pBAD TOPO vector according to the 
manufacturer’s instructions then transformed into the chemically competent TOP 10 
E.coli cells, see below. The pBAD TOPO TA Cloning® kit (Invitrogen) includes the 
pBAD TOPO vector linearised complete with 3’ thymidine overhangs and bound to 
topoisomerase enzyme. In the presence of a PCR product with 3’ deoxyadenosine 
overhangs, as added in a template independent manner by Taq polymerase, 
topoisomerase activity results in efficient ligation of the PCR product into the 
linearised vector.
2.3.5 Plasmids
The following plasmid constructs were used in this thesis:
2 .5 .5 ./ pBAD TOPO.DpoA
The Dictyostelium prolyl oligopeptidase gene dpoA was obtained by PCR 
amplification from the cDNA clone DDC47a24 provided by the National Institute of 
Genetics, Mishima 411-8540, Japan (Morio et al. 1998) using the primer pair DpoA- 
Ncol-for and DpoA-XhoI-rev (section 2.3.13). It was cloned into the pBAD TOPO 
TA plasmid (Invitrogen) in frame with C-terminal V5 and His epitope tags. N-
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terminal leader sequence was removed by Ncol digestion and re-ligation. The entire 
length of the gene was sequenced using primers; pBAD Forward, H172-2BREV, 
H172-2B, 172-3-REV, 172-4-REV, 172-5-REV, LisA4forB, 172-5-FOR and LisA 6  
For (section 2.3.13) to confirm the fidelity of the sequence.
2.3.5.2 pTrcHis:Rpo
The pTrcHis plasmid expressing an N-terminal His-tagged rat prolyl oligopeptidase 
(rpo) was a kind gift from Prof T.Takahashi, Hokkaido University, Japan. Expression 
of the tagged Rpo was under the control of the trc promoter (Kimura and Takahashi 
2000).
2.3.5.3 pDXA GFP2
The pDXA GFP2 (Accession No. AF269235) vector contains coding sequence for the 
GFPmut2 variant of the Green fluorescent protein flanked by multiple cloning sites 
allowing incorporation of additional coding sequence to produce either N or C- 
terminal fusion proteins. GFP expression is under the control of the constitutive actin 
promoter act 15 (Manstein et al. 1995). This vector provides G418 resistance and 
contains Ddp2, a cis-acting extrachromosomal replication element. To enable 
extrachromosomal replication pDXA GFP2 must be co-transfected with the pREP 
vector, in the absence of pREP this vector will be maintained via chromosomal 
integration (Levi et al. 2000).
2.3.5.4 pDXA GFP2:DpoA
The promoter and coding regions of dpoA were previously cloned into pDXA GFP2 
by R.Williams in the Harwood lab, such that control of the recombinant DpoA:GFP
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expression is under the dpoA endogenous promoter. For sequence and vector diagram 
see appendices I.III.I and LIII.II.
2.3.5.5 pREP
The pREP vector contains the trans acting Dpd2 open reading frame (ORF) enabling 
extrachromosomal replication of vectors carrying the Dpd2 origin of replication (ori) 
element.
2.3.6 Site-Directed Mutagenesis Of PO Active Site
Active site variants were achieved by site directed mutagenesis of the DNA encoding 
the catalytic triad in both pBAD TOPO:DpoA and pDXA GFP2:DpoA vectors. The 
QuikChange® II Site-Directed Mutagenesis Kit (Stratagene) was used according to 
manufacturer’s instructions.
For the QuikChange® site directed mutagenesis protocol; Primers were designed 
containing point mutations resulting in single amino acid changes at the catalytic 
triad. These primers were then used for amplification of the entire dpoA-containing 
vector using the non-variant mini-prep as a template. The reaction mix was as 
follows; 5pl 10X QuikChange® reaction buffer, 0.2pl pBAD TOPO:DpoA or pDXA 
GFP2:DpoA mini-prep, 1.25pl top-strand primer (lOOng pi'1), 1.25pl bottom-strand 
primer lOOng pi’1), lp l QuikChange® dNTP mix, lp l PfuUltra DNA Polymerase 
(2.5U pi'1) and ddF^O to a final volume of 50pl, set up in a 500pl thin-walled PCR- 
tube. The following PCR programme was used; denaturation of the template vector at 
95°C for 30 seconds then 15 cycles of primer annealing and extension, 95°C for 30 
seconds, 55°C for 90 seconds and 6 8 °C for 20minutes, followed by storage at 4°C. 
Primers used;
Serine (AGU) 609 to Alanine (GCU) variation; DpoA Ser rev and DpoA Ser for.
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Aspartic acid (GAU) 693 to Glycine (GGU) variation; DpoA Asp rev and DpoA Asp 
for.
Histidine (CAU) 730 to Alanine (GCU) variation; DpoA His rev and DpoA His for 
(section 2.2.13).
lpl of Dpnl restriction enzyme (10U pi'1) was added to the reaction and incubated at 
37°C for lhour. Dpnl selectively cleaves methylated DNA and therefore will digest 
the template DNA leaving the newly amplified DNA containing the point mutation. 
The Dpnl treated DNA was transformed into the XL 1-Blue supercompetent cells 
supplied, lpl DNA was added to 50pl of the supercompetent cells in a chilled 14ml 
Falcon tube and incubated on ice for 30minutes. Cells were heat shocked in a 42°C 
water bath for 45 seconds and returned to ice for 2minutes.
NZY+ broth (section 2.1.3) (0.5ml) heated to 45°C was added to the cells and 
incubated for lhour at 37°C and 250rpm before being split between two LB- 
ampicillin agar plates (section 2.1.3) and grown over night. Individual colonies were 
picked and analysed by mini-prep and sequencing to confirm vector identity and 
presence of the point mutation.
2.3.7 Transformation Of Bacteria
TOPIO™ chemically competent Escherichia coli (Invitrogen) were transformed as per 
the manufacturer’s instructions. lOpl and 50pl of transformed cells were then spread 
onto LB agar (section 2.1.3) plates containing lOOpg ml' 1 ampicillin. Single 
transformed colonies were picked using a sterile pipette tip and inoculated into 5ml 
LB (section 2.1.3) also containing lOOpg ml' 1 ampicillin. Cultures were shaken at 
250rpm and 37°C in a 20ml tube, then analysed by mini-prep and restriction digests.
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Following positive identification, bacterial stocks of correct clones were produced by 
addition of 0.75ml of overnight culture to 0.75ml LB-Glycerol (section 2.1.3). 
Bacterial Stocks were stored at -80°C.
2.3.8 Mini-Prep Of Bacterial Plasmids
Two different methods were used for small-scale plasmid preparations; The Rapid 
Boiling Method (Harwood 1996) was used for screening transformed colonies to 
identify correct clones while the Ultraclean™ 6  Minute Mini Plasmid Prep Kit™, Mo 
Bio Laboratories Inc kit was used for preparations used for DNA sequencing and 
other applications.
2.3.8.1 Rapid Boiling Method
1.5ml of plasmid-containing E.coli were centrifuged at 12,000g for lminute in a 
benchtop centrifuge and the medium removed. The pellet was vortexed and the cells 
lysed in 200pl STET (section 2.1.2) containing lmg ml' 1 lysozyme then placed in 
boiling water for exactly 45seconds. The lysate was then centrifuged at 12,000g for 
lOminutes resulting in formation of a loose white pellet of bacterial genomic DNA 
and protein precipitate, this pellet was removed from the supernatant using a sterile 
loop. 200(li1 of isopropanol was added to the supernatant in order to precipitate the 
remaining plasmid DNA, which was pelleted by centrifugation at 12,000g for 
5minutes. The pellet was washed in lOOpl of 70% ethanol, air-dried for lOminutes 
and resuspended in lOOpl TE (section 2.1.2). This method results in yields of l-5pg 
of plasmid DNA.
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2.3.8.2 Ultraclean ™ 6 Minute M ini Plasmid Prep Kit ™
The Mo Bio mini-prep kit uses the alkaline lysis method and a silica spin filter to bind 
plasmid DNA.
Ultraclean™ 6  Minute Mini Plasmid Prep Kit™ Mo Bio Laboratories, Inc. method 
summary; 2ml of Plasmid-containing E.coli were centrifuged at 12,000g for 1 minute 
and the medium removed, all spin steps were carried out using a benchtop centrifuge. 
The cell pellet was resuspended in 50|xl solution 1 (Tris-HCl, EDTA, RNase A) by 
vortexing. Cells were lysed by addition of lOOpl solution 2 (SDS, NaOH, pH 12) 
followed by gentle inversion. 325p,l of solution 3 (Potassium Acetate, binding salt) 
was added resulting in co-precipitation of proteins, chromosomal DNA and other cell 
debris with SDS and potassium acetate. Cell debris was removed by centrifugation at 
10,000g for 1 minute. Supernatant containing plasmid DNA was decanted into a spin 
filter and centrifuged for 1 minute. Plasmid DNA was bound to the white silica 
membrane, any other impurities passed through the membrane into the collection tube 
and were discarded. Bound DNA was washed with 300pl solution 4 (Tris-HCl, NaCl, 
+50% ethanol) before being eluted with 50pl of solution 5 (lOmM Tris-HCl), DNA 
was released from the silica membrane due to the absence of any salt in this final 
solution. This method resulted in rescue of 5-10pg of plasmid DNA.
2.3.9 Maxi-Prep Of Bacterial Plasmids
Plasmid maxi-preps were carried out when large-scale amounts of DNA plasmid were 
required, e.g. for Dictyostelium transformations. Plasmid maxi preps were carried out 
using the QIAGEN HiSpeed Plasmid Maxi Kit (Qiagen) according to manufacturer’s 
instructions. This kit is also based on the alkaline lysis method. In brief: 250ml 
overnight cultures of plasmid containing E.coli were harvested by centrifugation at
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4,000g for 20minutes at 4°C in a Rotanta 460R centrifuge (Hettich Zentrifugen). The 
cell pellet was resuspended in 10ml buffer PI (50mM Tris-HCl, pH 8.0, lOmM 
EDTA, lOOfxg ml' 1 RNAseA), cells were lysed by addition of 10ml solution P2 
(200nM NaOH, 1% SDS) and cell debris, genomic DNA and proteins precipitated by 
addition of 10ml chilled buffer P3 (3M Potassium Acetate, pH 5.5). Precipitate was 
removed by passing the solution through a Qiafilter Maxi Cartridge into a 50ml falcon 
tube. A Qiagen-tip 500 containing anion-exchange resin was equilibriated by 
application of 10ml buffer QBT (750mM NaCl, 50mM MOPS, pH7.0, 15% 
isopropanol, 0.15% Triton-XlOO), then lysate was passed through the resin by 
gravity-flow. The resin was washed twice with 30ml buffer QC (1M NaCl, 50mM 
MOPS, pH 7.0, 50% isopropanol) to remove any impurities then DNA was eluted 
from the resin in 15ml buffer QF (1.25M NaCl, 50mM Tris-HCl, pH 8.5, 15% 
isopropanol). DNA was precipitated by addition of 10.5ml isopropanol and collected 
by centrifugation at 10,000g for 30minutes at 4°C. The DNA pellet was washed with 
5ml 70% ethanol, re-centrifuged and left to air-dry before being dissolved in 350pl 
TE (section 2.1.2).
2.3.10 Sequencing Of Plasmid DNA
DNA was sequenced by MWG Biotech UK Ltd. or The Functional Genomics 
Laboratory, Birmingham University. Both were provided with DNA template and 
primers according to the service provider’s requirements. Raw sequence data were 
returned in a format compatible with analysis using Lasergene, DNAStar™ software 
or MacVactor® software.
2.3.11 Expression Of PO In Bacteria
2 .3.11.1 Rpo Expression
Expression of the tagged Rpo from the pTrcHis:Rpo vector is under the control of the 
trc promoter. Expression of tagged Rpo was induced by addition of 0.5mM IPTG to 
exponentially growing bacterial cultures for 2 0 hours.
2.3.11.2 DpoA Expression
Expression of the tagged DpoA from the pBAD TOPO:DpoA vector is under the 
control of the araBAD promoter. Expression of tagged DpoA was induced by 
addition of 0.05% L-arabinose to exponentially growing bacterial cultures for 4 hours. 
Following induction 1-1.5ml cell pellets were collected by centrifugation at maximum 
speed in a microcentrifuge. Cell pellets were resuspended in Bacterial Lysis Buffer 
(section 2.1.6) for PO activity assays and PO purification or in Laemmli Buffer 
(section 2.1.5) for western blot analysis to confirm presence of recombinant protein 
(see sections 2.6.5 and 2.6.2).
2.3.12 Northern Blot Detection Of PO Expression
2.3.12.1 RNA Preparation
Total RNA was isolated from cells using the High Pure RNA Isolation Kit (Roche) 
according to the manufacturer’s instructions. 1X106 cells in 200pi PBS (section 
2.1.10) were lysed with 400pi lysis buffer (4.5M guanidine hydrochloride, 50mM 
Tris-HCl, 30% Triton-XlOO, pH 6 .6 ). The sample was then applied to a glass fibre 
fleece, which binds nucleic acids in the presence of chaotropic salts, under binding 
conditions optimised for RNA rather than DNA. The glass fibre fleece was then
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incubated at room temperature with 90pl DNase I in incubation buffer (1M NaCl, 
20mM Tris-HCl, lOmM MnCL, pH 7.0), then washed with wash buffers I (5M 
guanidin hydrochloride, 20mM Tris-HCl, 38% ethanol, pH 6.6) and II (20mM NaCl, 
2mM Tris-HCl, 50% ethanol, pH 7.5). RNA was eluted from the filter in 50pl 
nuclease free, sterile, H2 O.
2.3.12.2 Probe Preparation
Probes were prepared from PCR products for both PO (primers 172-4-REV and 
H172-2C) and the control gene Ig7 (primers RT-Ig7-F2 AND RT-Ig7-R2) (section 
2.3.13). PCR products were labelled with [a-32P]dATP using the Megaprime DNA 
labelling kit (Amersham Pharmacia Biotech). The 5pi of DNA was boiled for 
5minutes together with 5pi primer mix (random nonamer primers in aqueous solution) 
and 16pl ddH20 then 4pl each of dCTP, dGTP and dTTP, 5pi radiolabelled [a- 
32P]dATP, 5pl of 10X Reaction Buffer and 2pl of enzyme (1U pi'1 DNA Polymerase 
I Klenow fragment) were added and the reaction incubated at 37°C for 30minutes. 
The probe was then purified on a Microspin™ S-400 HR column (Amersham 
Pharmacia Biotech), to remove any unincorporated nucleotides.
2.3.12.3 Northern Blot
RNA Samples were prepared in IX MOPS Buffer (section 2.1.4), 200mM 
formaldehyde, 50% formamide and 10% RNA Loading Buffer (section 2.1.4), 
denatured for 15minutes at 60°C and cooled on ice. RNA (5pg lane'1) was run on a 
1% agarose gel containing IX MOPS Buffer, 650mM formaldehyde and 0.17 pg ml'1 
ethidium bromide. The gel was run in IX MOPS Buffer for 3.5hours at 105volts. 
RNA was visualised briefly under UV light before transferring to ddH20 for 
lOminutes. RNA was transferred onto Hybond N nylon membrane (Amersham
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Pharmacia Biotech) by capillary transfer in 10X SSC then UV cross-linked to the 
membrane using a Stratalinker (Stratagene).
The filter was then incubated in 30ml of Hybridisation Buffer (section 2.1.4) for 2 
hours at 42°C. The radioactive probe was denatured by boiling for 5minutes and 
cooled immediately on ice before being added to 10ml Hybridisation Buffer, the 
Hybridisation Buffer on the filter was replaced by Hybridisation Buffer with probe 
and incubated at 42°C overnight. The filter was washed to remove unbound probe at 
65°C for 15minutes twice with 2X SSC +0.1% SDS and twice with 0.5X SSC+0.1% 
SDS. After washing the filter was sealed in plastic and exposed to a phosphorimaging 
screen (K-Screen, Kodak) then real time images were obtained using a BioRad 
phosphorimager.
To re-probe filters with a second probe the filter was stripped by washing in boiling
0.1% SDS twice for 5minutes each. The filter was then incubated for a further 2hours 
in Hybridisation Buffer at 42°C, probed and visualised as before.
2.3.13 Oligonucleotides
All oligonucleotides used in this thesis were ordered from MWG or Sigma-Genosys. 
Oligonucleotides were supplied lypholised and resuspended in ddH20 at lOOpM.
Name Sequence (5’-3’) Tm (°C)
DpoA-NcoI-for AG AT AAAAT ACC AT GG AATTT AATT ACCC 
AG
60.2
DpoA-XhoI-rev TT AATTT AAAAACTCGAGAAAATTT AATT 
TAAC
55.8
pBAD Forward AT GCC AT AGC ATTTTT AT CC
H172-2BREV AAT G ATTTT AAACT CC AT GT ACC 43.0
H172-2B AAAT C ATTT GT AAT CT C AAAG AG 63.0
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H172-2C ATTT AG AAG AT C A AC AAT C ACC AG 55.9
172-3-REV GATT AAT CT ATT G A AT GGT GC AG 55.3
172-4-REV AT AT AAT AAGTT ACCG AT GGT G 52.8
172-5-REV T GCC AAGCTTT ACC AT ACT C ACC 60.6
LisA4forB ACC AT CGGT AACTT ATT AT AT GG 55.3
172-5-FOR GCCGCTGAATATTTGATAAAGG 56.5
LisA 6 For G ACC AT GAT GAT CGT GT C ATT CC 60.6
DpoA Ser rev GATCAGGACGTTGATTTGAAATTGCACCC 65
ATT AAC A AACC ACC ATT AGC ACC AC C 
DpoA Ser for GGT GGT GCT AAT GGT GGTTTGTT AATGGG 65
T GC AATTT C AAAT C AACGT CCT GAT C 
DpoA Asp rev GC AGG AAT G AC ACG AT C ACC AT GGT C AC 68
C AGT AC AAAGC
DpoA Asp for GCTTT GT ACT GGTG ACC AT GGT G ATCGTG 68
TCATTCCTGC
DpoA His rev GC ACC AG C AC C AG AAT CTTT AT C A ACT CT 65
AATT AAAAGT GG AGT AT C AAC 
DpoA His for GTT GAT ACT CC ACTTTT AATT AG AGTT G A 65
T AAAG ATT CT GGT GCT GGT GC 
RT-Ig7-F2 GT ACTT AAACCG AC ACT GGTT AATT G 57.1
RT-Ig7-R2 CGCT ACCTT AGG ACCGTC AT AGTT AC 64.8
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2.4 Cell Biology
2.4.1 Dictyostelium Cell Culture
Dictyostelium were grown vegetatively at 22°C in Axenic Medium (section 2.1.8) 
with 0.1 mg ml'1 streptomycin sulphate additional selection was added as appropriate 
to transformed and knockout cell lines. All transformed cell lines were grown in the 
presence of 20-80pg ml'1 Geneticin (G418). All knockout cell lines, such as the PO 
null LisA cells (Williams et al. 1999), were grown in the presence of lOpg ml'1 
Blasticidin.
Cells were grown in 9cm cell culture dishes (Falcon) or in shaking suspension in glass 
flasks. Cultures were maintained between 2 X 104 and 2 X 106 cells ml"1. For long­
term storage of cell lines, cells were resuspended in Dictyostelium Freezing Medium 
(section 2.1.8) at 107 cells ml'1 then frozen at -80°C in 500pl aliquots in cryovials 
(Nunc), which were subsequently transferred to liquid nitrogen storage. Cells were 
restored from long-term storage by scraping a small amount of frozen cell suspension 
onto a SM Agar plate (section 2.1.8) already spread with the bacteria Klebsiella 
pneumoniae. These plates were grown at 22 °C until there were sufficient numbers of 
Dictyostelium to inoculate an axenic medium culture.
2.4.2 Dictyostelium Transformation Using The Calcium 
Phosphate Method
Cells were plated into a 9cm cell culture dish at 1 X 106 cells ml'1 and media replaced 
by 10ml MES-HL5 Medium (section 2.1.9). Cells were left in MES-HL5 Medium for 
2-3hours before addition of DNA in HBS (section 2.1.9). 12pg plasmid DNA was 
prepared in 0.6ml HBS with 2M CaCfe per plate to be transformed and left for
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25minutes at room temperature before addition to cells. DNA/HBS/CaCb was added 
to the cells and left for 4hours. Medium was then replaced with 2ml HBS-Glycerol 
(HBS + 15% glycerol) for 2minutes at room temperature then subsequently replaced 
with 10ml Axenic Medium (section 2.1.8) + streptomycin sulphate (Strep). Cells were 
left overnight then the medium was replaced with fresh Axenic Medium 
supplemented with 20pg ml'1 G418 and 1% heat killed E.coli. Medium was then 
replaced every 2-3 days with fresh Axenic Medium containing Strep and G418 only 
until appearance of colonies. Colonies were picked using a pipette into a 24 well plate 
and the G418 concentration was gradually increased to 80pg ml'1. Transformed cell 
lines were maintained and stored as described in section 2.4.1. 
pDXA GFP2:DpoA was transformed in the absence of the trans acting 
extrachromosomal replication vector pREP in order to create stable colonies. Large 
variations within populations were observed in the presence of pREP due to variable 
plasmid replication or partitioning (Levi et al. 2000). However, in studies of active 
site variants, Dictyostelium were co-transformed with pREP and pDXA GFP2:DpoA 
(variant or un-mutated) in order to produce larger amounts of enzyme for activity 
assay and an improved transformation efficiency.
2.4.3 Timecourse Of In Vivo PO Inhibition
Dictyostelium cells were grown overnight in shaking suspension in FM Minimal 
Medium (Formedium™, UK). Cells were then set up at 3 X106 cells ml'1 and 9.9ml 
flask'1 in fresh FM Minimal Medium. lOOpl of Z-Pro-Prolinal (Bachem) (130mM 
stock resulting in 1.3mM final concentration) or lOOpl of DMSO carrier control were 
added to the flasks of cells. Two 500pl aliquots were taken from the cell cultures 
immediately after addition of the inhibitor or control and then at 30minutes, lhour and
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3hours after treatment. One aliquot was immediately centrifuged to harvest cells for 
PO activity assay as described in section 2.6.5, the other aliquot was immediately 
added to lOOpl of ice cold trichloroacetic acid (TCA) and assayed for IP3 content as 
described in section 2.6.10.
2.4.4 Dictyostelium Development
96 well plates were set up with 180pl SM Black Agar (section 2.1.8) per well. For 
observing the effects of drugs on Dictyostelium development, 5 pi of 38X drug stock 
or carrier control was added to the well prior to the molten agar. Cells growing at 
approximately log phase (1-2 X 106 cells ml'1) in shaking suspension were centrifuged 
at 2000rpm for 2minutes in a CentraMP4 centrifuge (International Equipment 
Company) and resuspended in an overnight culture of Klebsiella pneumoniae at 1 X 
106 Dictyostelium cells ml"1. 5pi of the K.pneumoniae!Dictyostelium combination was 
added per well. Plates were observed regularly until the appearance of fruiting bodies 
in control wells (carrier control, wild type (Ax2) cells). Wells were photographed 
using a Canon PC 1089 digital camera attached to a Zeiss Stemi SV6 stereo zoom 
dissecting microscope.
2.4.5 Mammalian Cell Culture
The human lymphoblastoid cell line, GC12139, is of human B-cell origin 
immortalised with Epstein Barr Virus (ECACC). Cells were maintained between 
3X105 and 2X106 cells per ml in RPMI 1640 medium (2mM Glutamine, 10% FCS, 
1% Pen-Strep-Neo*) (PerBio Science) at 37°C and 5% CO2 in T25 Nunc cell culture 
flasks. Cells were prepared for long-term storage in RPMI 1640, 20% FBS, 10% 
DMSO at 2-4X106 cells ml"1, 750pl aliquots were added to 2ml cryovials (Nunc). 
Vials were frozen slowly to -80°C before transfer to liquid nitrogen storage. Cells
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were revived from frozen by rapid defrosting at 37°C followed by addition to 10ml of 
RPMI 1640 medium. The cell suspension was then centrifuged at 2500rpm at 4°C for 
lOminutes, the cell pellet was resuspended in 10ml pre-warmed fresh medium 
resulting in removal of DMSO from freezing media. (*=100X Penicillin (SOOOUml1)- 
Streptomycin (5mg ml ^-Neomycin (lOmg ml'1) solution, Sigma)
2.4.6 In Vivo Effect Of VP A And Analogues
lml of lymphoblastoid cells (GC12139) at 1X106 cells ml"1 grown in RPMI 1640 
were added per well of a 24 well cell culture plate (Falcon). Wells were treated 
overnight by addition of lOpl of 100X Stock of VP A, Valpromide or Octanoic acid to 
final concentrations of 0.1 mM, 0.5mM, ImM, 3mM and lOmM or lOpl of Ethanol 
carrier control. Each well was also treated overnight with lp l of 1000X stock of 
S I7092 to final concentrations of 1.3nM, 13nM and 130nM or lp l of DMSO carrier 
control. Following drug treatment, cells were transferred to Eppendorf tubes and 
assayed for PO activity as described in section 2.6.5.
2.4.7 Cell Viability Assay
50pl of lymphoblastoid cell suspension was combined with 50pl of 0.4% Trypan Blue 
(Sigma). Viable (bright cells) and non-viable cells (stained blue) were counted using a 
NeuBauer haemocytometer; 100-150 cells were counted per sample. Trypan blue is a 
vital dye, the chromophore is negatively charged and does not enter the cell unless the 
membrane is damaged. Therefore, cells that exclude the dye are viable (Freshney 
1987).
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2.5 Immunofluorescence
2.5.1 Fluorescence Of Live Cells
A greased small rubber O-ring was placed on a coverslip. Cells from a confluent plate 
(~2 X 106 cells ml'1) were diluted 1 in 3 in KK2 (section 2.1.8) and plated onto 
coverslips in a large (lOOpl) droplet within the rubber ring. Cells were left to adhere 
for approximately 20minutes. Medium was removed and replaced with KK2  3 times 
for 15minutes each. Excess KK2 was removed leaving the cells covered by a small 
droplet of KK2 . The coverslip and rubber ring were then inverted onto a glass slide 
carefully to avoid any disruption of the KK2  meniscus. Cells were observed 
immediately using a Zeiss Axioskop Compound Microscope with a 40X objective; 
both bright field and fluorescent images were captured.
2.5.2 Fixing And Staining Dictyostelium Cells
Glass coverslips were treated with 10% poly-L-lysine for at least 2hours then rinsed 
twice in distilled water before adding cells. Cells from a confluent plate (~2 X 106 
cells ml'1) were diluted 1 in 2 in Axenic Medium (section 2.1.8) and plated onto 
coverslips. Cells were left to adhere for at least 2hours. Medium was removed and 
replaced with KK2 (section 2.1.8) 3 times for 15minutes each. KK2  was replaced with 
3.5% paraformaldehyde in PBS (section 2.1.10) and left for 20minutes. Cells were 
washed 3 times with PBS each wash was left on for 5 minutes. Cells were then treated 
with 15mM glycine in PBS twice for lOminutes each then washed again in PBS for 3 
times 5minutes. PBS was replaced with PBS 1% gelatin 0.2% saponin (PBS/G/S) 3 
times, the final PBS/G/S wash was left on for 20minutes. The primary antibody was 
diluted in PBS/G/S, the coverslip was inverted onto the antibody (approx. 400pl) on
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parafilm and left for lhour at room temperature. The primary antibody was followed 
with five 2minute washes in PBS/G/S before the coverslip was incubated in the 
secondary antibody (also diluted in 400pi PBS/G/S per slide) for 30minutes at room 
temperature. Slides were washed 4 times for 2minutes in PBS/G/S followed by a final 
20minute wash. Finally DAPI stain (lpg  ml'1 in PBS) was added for 15minutes. 
Slides were washed 3 times for 5minutes in PBS before being rinsed in distilled water 
and mounted onto glass slides using Vectashield® liquid mountant (Vectorlabs). 
Slides were sealed using nail varnish before viewing.
2.5.3 Immunofluorescence Of Inhibitor Treated Cells
Cells were plated at 5 X 105 cells m l'1 in a 9cm dish lined with poly-L-lysine treated 
cover slips. Cells were treated with 1.3mM Z-Pro-Prolinal (Bachem) overnight then 
fixed and stained as described above.
2.5.4 Immunofluorescence Of Polarised Cells
Cells were polarised using the Lab-Tek® Chamber Slide™ System chamber slides 
(Nunc). Slides were treated with 10% poly-L-lysine for at least 2hours then rinsed 
with ddFLO. One end of the chamber was filled with 0.75ml of 1% LM (Low Melting 
point) agarose in KK2 (section 2.1.8) containing 20nM cAMP.
Cells were grown in shaking suspension in Axenic Medium (section 2.1.8). Cells in 
log-phase growth were harvested, washed twice in KK2  then resuspended in KK2  at 5 
X 106 cells ml'1. 10ml of cells in KK2  was added to a 50ml flask and returned to the 
shaker. Cells were sensitised to cAMP signalling by being pulsed with lOOnM cAMP 
(50pl of a 2mM stock) at 6minute intervals using a Watson Marlow 505 Di Pump for 
five hours. After five hours, an aliquot of the pulsed cells was taken and diluted 1:4 
with vigorous pipetting to break up any cell clumps. lOOp.1 of diluted cells were
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pipetted in to the slide chamber in 2 thin lines parallel to the end containing the agar 
block. Cells were left to adhere to the slide for lOminutes. An additional 650pl of 
KK2 was added, cAMP from the agar block diffused into the KK2 in the chamber 
creating a cAMP gradient at an appropriate concentration for cell motility (Vamum 
and Soil 1984). Cells were left to polarise for twenty minutes.
Cells were fixed by replacing KK2 with 6% paraformaldehyde in PBS (section 2.1.10) 
for 20minutes; the increased paraformaldehyde concentration is necessary to allow for 
diffusion into the agar block. Cells were then washed three times with PBS. The agar 
block and the chamber were removed from the slide which was then stained and 
mounted as described above.
2.5.5 Antibodies Used
Primary Antibodies:
Detection of microtubules; anti-a-Tubulin (Mouse IgGl isotype, Sigma) was used at 
a 1:400 dilution.
Detection of endoplasmic reticulum; anti-Dd-PDI antibody 221-64-1 raised in mice 
against the C-terminus of Dictyostelium Protein Disulfide Isomerase, an endoplasmic 
reticulum marker, (Monnat et al. 1997) (kind gift from Prof. M. Maniak) was used at 
a dilution of 1:3.
Secondary Antibody:
Texas Red® goat anti-mouse IgG (Invitrogen) was used at a dilution of 1:1000.
2.5.6 Imaging
Fixed and stained cells were visualised using a DM600B or DMIRE2 (inverted) 
microscope together with a Leica TCS SP2 confocal microscope. Images were 
recorded using Leica Confocal Software (LCS). A Z-series of confocal images was
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taken through each cell using the 63X objective. These cell ‘slices’ were compiled 
into 3D images or maximum projections using the LCS software.
For GFP imaging argon ion laser excitation was used at 488nm, emission was 
recorded at 500-560nm. For DAPI imaging blue diode laser excitation was used at 
405nm, emission was recorded at 415-480nm. For Texas Red® imaging He/Ne laser 
excitation was used at 543nm, emission was recorded at 595-705nm
2-107
2.6 Biochemistry
2.6.1 Protein Separation
Prior to western blot or silver stain analysis, proteins in cell extracts or other samples 
were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS- 
PAGE). Samples were prepared by addition of Laemmli Buffer (section 2.1.5). Cell 
pellets were resuspended in 10-30% of the original culture volume, samples from 
purification or MACs column steps (section 2.6.9) were mixed at a ratio of 1:1 with 
Laemmli Buffer. 10-15 pi of sample was loaded per well, 5 pi of the size marker 
SeeBlue® Pre-Stained Standard (Invitrogen) was loaded alongside samples to 
measure protein size.
Two SDS-PAGE methods were followed;
1. 7.5% Acrylamide gels (25% Protogel acrylamide (30% acrylamide:0.8% 
methylene bisacrylamide), 25% Resolving Buffer (section 2.1.5), 0.03% 
APS, 0.1% TEMED) poured between two glass plates, were run in 
Running Buffer (section 2.1.5) at lOOVolts for 1-2 hours until the leading 
edge had progressed at least two-thirds the length of the gel.
2. NuPAGE® Novex Bis-Tris Gels (Invitrogen) were run in NuPAGE® 
MES SDS Running Buffer (Invitrogen) at 200Volts for 40minutes.
After electrophoresis was complete, gels for western blot analysis were equilibrated in 
Transfer Buffer (section 2.1.5) while gels for silver stain analysis were transferred to 
Fixing Solution (section 2.1.5).
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2.6.2 Western Blot Analysis
Protein was transferred from the gel to a nitrocellulose filter (Hybond C+™ 
nitrocellulose membrane, Amersham Pharmacia Biotech) using a semi-dry blotting 
unit (BioRad). The membrane and gel were placed between six layers of 3MM paper 
soaked in Transfer Buffer (section 2.1.5) and subjected to 20Volts for 48minutes. The 
membrane was blocked by soaking in PBST+5% Marvel® milk powder (section 
2.1.10) at room temperature for 1 hour, then incubated in primary antibody in PBST 
at room temperature for 1 hour. If required the membrane was washed in PBST five 
times for five minutes each and incubated in secondary antibody in PBST at room 
temperature for 1 hour. The membrane was then given five 5minute washes in PBST 
before a 5minute incubation in chemi-luminescence reagent (Supersignal™, Pierce 
and Warringer Ltd) to detect the HRP-conjugated antibody (primary or secondary). 
Bands were visualised by exposure to Biomax film (Kodak), which was developed in 
an Optimax X-Ray Film Processor (Scientific Laboratory Supplies).
The following antibodies were used:
Primary antibodies;
Anti-V5:HRP (Invitrogen) was used at a 1:5000 dilution. Anti-6XHis:HRP (Clontech) 
was used at a 1:5000 dilution. Anti-a-Tubulin (Mouse IgGl isotype, Sigma) was 
used at a 1:400 dilution. Anti-GFP (Mouse IgG, Roche) was used at a 1:10000 
dilution.
Secondary antibodies;
Anti-Mouse IgG:HRP , developed in goat (Sigma) was used at a 1:10000 dilution.
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2.6.3 Silver Staining
Gels were taken from Fixing Solution (section 2.1.5) for silver staining using the 
Sterling™ Rapid Silver Stain Kit (National Diagnostics). Gels were fixed further in 
Sterling fixative for 5minutes before washing for twice 15minutes in ddH2O+0.1% 
Tween20. Gels were then immersed in staining solution and observed for the 
appearance of black/brown bands revealing the proteins present. When desired 
intensity was reached the gel was incubated in 5% acetic acid to stop the reaction. A 
permanent record was taken by photographing the gel before or after gel drying.
2.6.4 PO Purification
150ml E.coli containing either pTrcHis:Rpo or pBAD TOPO:DpoA bacterial cultures 
were grown overnight then induced as described in section 2.3.11. Following 
induction cells were harvested by centrifugation at 9,000g at 4°C for 5minutes in 
50ml aliquots, cell pellets were resuspended in 8ml Bacterial Lysis Buffer (section
2.1.6). Cells were lysed by sonication. Cell suspensions were subjected to three 
lOsecond bursts at Amplitude 30 using a vibra-cell™ ultrasonic processor (Sonics and 
Materials Inc.) and rested on ice for at least 30seconds between bursts. Cell debris 
was removed by centrifugation at 10,000g at 4°C for 30minutes.
All subsequent steps were carried out at 4°C. Supernatant containing PO was loaded 
onto a medium width FPLC column packed with 2ml Talon® metal affinity resin 
slurry (BD Biosciences) (1ml total beads) and equilibrated with Bacterial Lysis 
Buffer. The FPLC (pump P-500, controller LCC-501 Plus, motor valve MV-7, optical 
unit UV-1, Pharmacia Biotech) was run at a speed of 0.5ml min'1. Following loading 
of supernatant onto the His-binding column, the column was washed with Bacterial 
Lysis Buffer for a further 20minutes. At this point the buffer entering the column was
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switched from 100% Bacterial Lysis Buffer to 100% pH Elution Buffer (section 2.1.6) 
and fraction collection began. 0.5ml fractions were collected every minute for 
30minutes. Samples were taken from the supernatant prior to purification, from the 
flowthrough and from each fraction for analysis by silver stain as described in section 
2.6.3. 3pl of each sample was assayed for PO activity and protein concentration was 
also determined as described in section 2.6.5.
This method resulted in a clear peak of activity eluting from the Talon™ column, all 
fractions which cleaved more than 3pmoles of Z-Gly-Pro-pNA during the 90minute 
assay time were pooled to produce a standard stock of purified enzyme. Stock enzyme 
was stored in lOOpl aliquots at -20°C.
2.6.5 PO Activity Assay
2.6.5.1 Cell Extract Preparation
Dictyostelium or lymphoblastoid cells were pelleted and washed in KK2  (section 
2.1.8) or PBS (section 2.1.10) respectively then resuspended in Homogenisation 
Buffer (section 2.1.6) to give 2X108 cells ml'1. For bacterial cells expressing 
recombinant PO, 1.5ml of induced overnight bacterial culture was pelleted and 
resuspended in 500pl of Bacterial Lysis Buffer. Cells were lysed by sonication, cell 
suspensions were subjected to three 5 second bursts at Amplitude 30 and rested on ice 
for at least 30 seconds between bursts. Cell debris was removed by centrifugation at 
10,000 g at 4°C for 30minutes. Supernatant containing PO was collected and kept at 
4°C for up to 24hours. For measurement of PO activity the volume of cell extract 
containing 2.5pg total protein was added per assay.
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2.6.5.2 Measurement O f Protein Concentration
Protein concentration of cell extracts or purification fractions was determined using 
BioRad Protein Assay Dye Reagent (BioRad Laboratories). This reagent changes 
colour on contact with protein and is based on the dye binding method of Bradford 
(Bradford 1976). Assays were set up in 96 well flat-bottomed plates (Nunc), 2pi of 
sample was added to 198pl BioRad Assay Dye Reagent and absorbance at 595nm was 
measured on a BioRad microplate reader (model 3550). Protein concentration was 
calculated from a standard curve produced from BSA samples with concentrations 
from 0.25 to lmg ml'1.
2.6.5.3 PO Assay I
All samples were assayed in a final volume of 60pl PO Assay Buffer I (section 2.1.6) 
in a 96 well plate, the sample and PO Assay Buffer were incubated at 37°C for 
90minutes. Samples were set up in duplicate in the presence and absence of enzyme 
substrate Z-Gly-Pro-pNA (Bachem). PO cleavage of the substrate Z-Gly-Pro-pNA 
results in the release of p-nitroaniline (pNA). Production of this chemical was 
observed by measurement of absorbance at 405nm using a BioRad microplate reader 
(model 3550). The difference between absorbance in the presence and absence of 
substrate was calculated and converted into moles of pNA produced (or moles of 
substrate cleaved) using a standard curve of absorbance of 60 pi of pNA standards 
from 5 to 200pM.
2.6.5.4 PO Assay II; Enzyme Kinetics
Activity was measured using the fluorescent substrate Z-Gly-Pro-AMC (Z-Gly-Pro-7- 
amido-4-methylcoumarin). Cleavage of Z-Gly-Pro-AMC results in release of 7-
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amino-4-methylcoumarin (AMC), detected by fluorescence at excitation 351nm, 
emission 430nm. This substrate is similar to Z-Gly-Pro-pNA however the pNA 
moiety has been replaced by AMC. Release of 7-amino-4-methylcoumarin was 
measured using a FLUOstar OPTIMA luminometer (BMG labtechnologies) with 
excitation and emission filters of 355nm and 460nm respectively. Use of this machine 
enables a higher accuracy of detection as well as taking readings under temperature- 
controlled conditions.
A set of standards of known concentrations of AMC were included on the plate to be 
read. This enabled conversion of fluorescence readings to concentration of reaction 
product. The standards were also used to set the maximum gain of the luminometer. 
In each experiment 90% maximum gain was set using a standard concentration of 
AMC equal to approximately 15% the assay substrate concentration thus increasing 
sensitivity of readings in the range before significant substrate depletion occurs.
The activity assays were incubated in the luminometer at 25°C and the increase in 
fluorescence measured at lOminute intervals.
Assays were carried out in lOOmM HEPES buffer at pH 7.8 (PO Assay buffer II, 
section 2.1.6). A pH profile of PO activity between pH 5 and pH 8.5 confirmed pH 
7.8 to be in the range of optimal PO activity. Enzyme activity, v, was taken as the 
initial rate of AMC production observed between 0 and 20minutes. PO activity was 
assayed across a range of Z-Gly-Pro-AMC concentrations from 2.2 to 141 pM. The 
Km and Vmax of DpoA and Rpo were calculated using Michaelis-Menten kinetics by 
Prism® software (GraphPad Prism 4.0a).
2.6.6 Determination Of Inhibition Constants
PO assays were carried out as described in section 2.6.5.4 above using 1X10'5U 
purified recombinant DpoA or Rpo. Specific inhibitors S I7092 and Z-Pro-Prolinal or
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carrier controls were added to PO Assay Buffer II (section 2.1.6) prior to incubation at 
25°C. S I7092 (kindly provided by Dr F Lamour, Institut de Recherches 
Internationales Servier, Courbevoie, France) was dissolved in DMSO and added at a 
range of final concentrations from 0.1 to InM. Z-Pro-Prolinal (Bachem) was 
dissolved in DMSO and added to a range of final concentrations from 1 to lOpM.
PO activity was measured across a range of substrate concentrations (8.8, 17.6, 35.3 
and 70.5pM) at each inhibitor concentration. Inhibition constants were calculated 
using Prism® software (GraphPad Prism 4.0a) as described in chapter 3 section 3.2.4. 
Values of Kj for Z-Pro-Prolinal were calculated using Michaelis-Menten kinetics and 
for SI7092 using tight-binding kinetics as described by Henderson (1972), both were 
calculated using Prism® software.
2.6.7 pH Profile Of PO Activity
To assay PO activity across a range of pH values, 4 different buffers were used 
(Propionate pH 5-5.5, MES pH 5.5-6.5, HEPES pH 6.6-8.5, Tris-HCl pH 8.5-9, see 
section 2.1.6). Each buffer was used at an assay concentration of lOOmM brought to 
the required pH using HC1 or KOH. The ionic strength of all buffers was maintained 
at 155mM (physiological ionic strength) using KC1 as calculated using the buffer 
calculator created by Rob Beynon at The University of Liverpool (Beynon 2006). 
Ionic strength of a solution can be measured using the following equation (Equation 
2- 1);
Equation 2-1
I<= = '/2 IC bZb2
Ic = ionic strength, Cb = concentration of salt in buffer, Zb = valency of salt.
Purified recombinant PO activity (1X10'5U assay'1) was assayed as described in 
section 2.6.5.3.
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2.6.8 Inhibition Studies Of Mood Stabilising Drugs
PO assays were carried out as described above (section 2.6.5.4) using 1X10'5U 
purified recombinant DpoA or Rpo. LiCl, CBZ, VPA or carrier controls were added 
to sample and PO Assay Buffer II (section 2.1.6) prior to incubation at 25°C. All three 
drugs were added at several times their therapeutic concentration, LiCl (therapeutic 
concentration 1.5mM) was added at 40pM, 200pM, ImM, 5mM and 25mM, CBZ 
(therapeutic concentration 75pM) was added at 4pM, 20pM, lOOpM, 500pM and 
ImM, VPA (therapeutic concentration 0.6mM) was added at lOpM, 48pM, 240pM, 
1.2mM and 6mM.
2.6.8.1 Effects O f VPA And Analogues
Further activity assays were set up in assay buffers representing a range of pH as in 
section 2.6.7 with addition of VPA, Valpromide or Octanoic acid to a final 
concentration of 6mM, or a carrier control. All compounds were dissolved in MeOH.
2.6.9 Isolation Of DpoA:GFP Using Magnetic Columns
The GFP tagged Dictyostelium PO was isolated from cell extracts using the 
pMACS™ Epitope Tag Protein Isolation Kit (Miltenyi Biotec).
A confluent 10ml plate of Dictyostelium cells were pelleted and washed in KK2  
(section 2.1.8) then resuspended in 1ml of Homogenisation Buffer (section 2.1.6). 
Cells were lysed by sonication, cell suspensions were subjected to three 5second 
bursts at Amplitude 30 and rested on ice for at least 30seconds between bursts. Cell 
debris was removed by centrifugation at 10,000 g at 4°C for 30minutes, supernatant 
was added to 50pl of Anti-GFP MicroBeads and incubated for at least 30minutes at 
4°C.
2-115
The p Column was placed into the magnetic field of the pMACS Separator and 
prepared by addition of 200pl of Homogenisation Buffer +1% Triton-XlOO. The 
labelled cell lysate was applied to the column and the flow through collected. The 
column was then washed four times with 200pl Homogenisation Buffer followed by 
lOOpl pi of wash buffer 2 (20mM Tris-HCl, pH 7.5), all wash buffers were also 
collected for analysis.
2.6.9.1 Isolation O f DpoA Binding Proteins
The p Column was prepared, loaded and washed as described above, following the 
two washes (Homogenisation Buffer and wash buffer 2), the bound GFP-tagged 
protein along with any specifically-bound proteins were eluted. Bound proteins were 
incubated with 20pl of pre-warmed (95°C) elution buffer (50mM Tris-HCl pH6.8, 
50mM DTT, 1% SDS, ImM EDTA, 0.005% bromophenol blue, 10% glycerol) for 
5minutes followed by elution from the column in 50pl of the warmed elution buffer. 
The MicroBeads were then eluted by removing the p Column from the magnetic field 
and washing with 200pl of wash buffer 2. The elution buffer was applied directly onto 
an SDS-PAGE gel for western and silver stain analysis as described in section 2.6.1-3. 
All other samples were combined with Laemmli Buffer (section 2.1.5) at a 3:1 ratio 
before gel loading.
2.6.9.2 PO Activity Assay
The p Column was prepared, loaded and washed as described above. Following wash 
buffer 2 the column was washed again with lOOpl of PO Assay Buffer (section 2.1.6). 
A further 25 pi (column capacity) of PO Assay Buffer was added, lp l of sealing 
solution was added to prevent evaporation and the column incubated at 37°C for
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90minutes. An aliquot of the cell lysate before addition of Anti-GFP MicroBeads and 
the column flowthrough were also assayed for PO activity as described in section 
2.6.5. The PO Assay on the column was eluted directly into a 96 well plate by 
addition of 60pl of PO Assay Buffer, and activity measured as described above 
(section 2.6.5.3).
2.6.10 IP3 Assay
IP3 concentrations were determined using the Inositol-1,4,5-Trisphosphate [ H] 
Radioreceptor Assay Kit (PerkinElmer Life Sciences, Inc). This kit contains a 
membrane preparation containing the IP3 receptor bound to the radiolabelled ligand 
[3 H]IP3 (tracer). Sample IP3 concentration is determined by measurement of the 
amount of radiolabelled ligand displaced by the unlabelled IP3 present in the sample. 
Samples were prepared by addition of 0.2 volumes of 100% trichloroacetic acid 
solution. The sample/TCA solution was vortexed vigorously and incubated for 
15minutes on ice before being centrifuged at 13,000 g for 1 minute in a benchtop 
microfuge. The supernatant was kept for IP3 analysis. TCA was removed from the 
sample by addition of TCTFE (l,l,2-Trichloro-l,2,2-trifluoroethane):trioctylamine 
(3:1 ratio) at a ratio of 2:1 with the sample/TCA solution. The mixture was vortexed 
for 15 seconds then left to allow phase separation. The top, aqueous, layer containing 
the IP3 was removed and placed on ice.
A working receptor tracer solution was prepared on the day of the assay by dilution of 
the concentrated receptor preparation/tracer in Assay buffer (0.05% sodium azide, 
5mM EDTA, 5mM EGTA, 50mM sodium TAPS buffer, pH 8 .6 ) at a ratio of 1:15. 
400pl of working receptor/tracer solution was added to lOOpl of sample in a minitube 
on ice. All samples were assayed in duplicate. lOOpl aliquots of a series of IP3
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dilutions made up in ddthO (for MIPP assays) or FM Minimal Medium 
(ForMedium™, UK) (for Dictyostelium cell extracts) were also set up in minitubes 
with receptor/tracer solution as well as two minitubes containing lOOpl blanking 
solution to measure non-specific binding and two counting vials containing 
receptor/tracer solution alone to measure total counts.
All tubes were vortexed for 3-4seconds then incubated for one hour at 4°C. Tubes 
were centrifuged in their racks at 3000g for 20minutes at 4°C in a Rotanta 460R 
centrifuge (Hettich Zentrifugen) and supernatant decanted. The pellets were 
resuspended in 50pl of 0.15M sodium hydroxide by vortexing for 3seconds, 
incubating at room temperature for lOminutes and vortexing for a further 5seconds. 
The membrane suspension was then transferred to a counting vial by pipetting. 4ml of 
Ecolite (+)™ Liquid Scintillation Fluid (MP Biomedicals) was added to each vial, 
including the total counts vial, and mixed by inversion and vortexing. Counts per 
minute (CPM) were measured using a TriCarb 2800TR scintillation counter 
(PerkinElmer), with Quantasmart software, each vial was counted for 5minutes.
To calculate moles of IP3 present in each sample, the average non-specific binding 
CPM was subtracted from the CPM for all other samples, then the percent of 
radiolabelled ligand bound was calculated for each standard and sample using the 
total counts CPM. The concentration of IP3 present in each sample was taken from a 
standard curve created by plotting percentage of radiolabelled ligand bound against 
concentration of the IP3 dilutions.
2.6.11 MIPP Activity Assay
To measure the effects of DpoA on MIPP activity, membrane fractions from a MIPP 
over-expressor cell line (developed in the Harwood lab by Jason King) were used.
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Cells were grown in Axenic Medium (section 2.1.8) in shaking culture, cell pellets 
were harvested, washed in KK2 (section 2.1.8) and pellets frozen on dry ice. Pellets 
were then defrosted and resuspended at 2X108 cells ml*1 in TEE Buffer (section
2.1.7). Cells were lysed by being passed through a Nucleopore® filter (5pm pore 
size) directly into a pre-chilled ultracentrifuge tube (Beckman). The cell suspension 
was spun at 39,000rpm for 30minutes at 4°C in a Beckmann Optima™ TLX 
ultracentrifuge, rotor TLS-55. Supernatant was discarded and the pellet resuspended 
in the original volume of TEE Buffer. Protein concentration was calculated by 
Bradford assay as described in section 2.6.5.2.
Cell extracts were incubated for 30minutes at room temperature with and without 
purified recombinant DpoA (see section 2.6.4) and Z-Pro-Prolinal. The incubation 
mixture contained; lOpl MIPP0EX Pellet fraction, lOpl Purified recombinant DpoA 
(~3mU) or pH Elution Buffer (section 2.1.6), 29.5pl TEE Buffer, 0.5pl Z-Pro-Prolinal 
(to final concentration of 1.3mM) or DMSO. The MIPP assay was started by addition 
of 50pl of MIPP Assay Buffer (section 2.1.7) containing 200pM IP6. The solution 
was mixed by pipetting and 50pl was immediately removed then added to lOpl TCA 
on ice; this was the time 0 sample.
The remaining 50pl of reaction was incubated at room temperature for 15minutes 
before addition of lOpl ice cold TCA. 440pl ddHiO was added to all samples, which 
were then vortexed for 15seconds and centrifuged 13,000g for 1 minute in a 
microcentrifuge. The supernatant was transferred to a fresh tube and TCA extraction 
was carried out as described above (section 2.6.10). Samples were further diluted 1:2 
in ddH20 before IP3 was assayed as described (section 2.6.10). M IPP activity was 
determined by the increase in IP3 from time 0 to the 15minute timepoint. IP3 is 
produced by M IPP mediated dephosphorylation of IP6 in the assay buffer.
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3 Biochemistry Of DpoA
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3.1 Introduction
3.1.1 Serine Protease Family
The serine protease family is a large family of proteases whose common feature is a 
catalytic triad, His-Asp-Ser, in which the Ser residue is responsible for nucleophilic 
attack. This family can by sub-divided into the chymotrypsin, subtilisin and serine 
carboxypeptidases (clans SA, SB and SC respectively) (Rawlings and Barrett 1993). 
The Prolyl Oligopeptidase family (family S9) is a sub-group of the serine 
carboxypeptidase family and contains prolyl oligopeptidase (the family namesake), 
dipeptidyl peptidase IV (DPPIV), acylaminoacyl peptidase (AP), oligopeptidase B 
(OB) and prolyl endopeptidase like A (PREPL A). While these enzymes do not all 
specifically cleave at a proline residue, all preferentially cleave short oligopeptides 
and show clear sequence homology around the active site.
Prolyl oligopeptidase is particularly similar at sequence level to oligopeptidase B and 
the 3D structure of oligopeptidase B was modelled using PO as a template (Gerczei et 
al. 2000). Both PO and OB are formed from a catalytic domain containing the active 
site and a (3-propeller domain. Other enzymes in the family which also have a 13- 
propeller domain are acylaminoacyl peptidase (7-bladed) and dipeptidyl peptidase IV 
(8-bladed) (Polgar 2002; Bartlam et al. 2004). In contrast to prolyl oligopeptidase and 
oligopeptidase B, which both operate as monomers, acylaminoacyl peptidase, 
dipeptidyl peptidase IV and prolyl endopeptidase like A form dimeric structures. 
Because of the similarity within this family it is important to confirm the identity of 
DpoA, which based on sequence analysis and limited biochemistry has been 
considered to be a prolyl oligopeptidase homologue, as a prolyl oligopeptidase rather 
than any other S9 family enzyme.
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3.1.2 AIM
This chapter aims to determine the relevance of DpoA as a model for the mammalian 
enzyme, using a more detailed sequence analysis, enzyme kinetics and mutagenesis.
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3.2 Results
3.2.1 DpoA Is A Characteristic Prolyl Oligopeptidase
In order to determine the relationship of DpoA and the mammalian prolyl 
oligopeptidase, protein sequence comparison of the prolyl oligopeptidase family was 
carried out.
3.2.1.1 Obtaining Prolyl Oligopeptidase (S9) Family Sequences
The first step was to identify and download all PO family protein sequences. In order 
to form a reliable picture the maximum number of sequences were included. Initially 
sequences from Dictyostelium and other species were downloaded from the NCBI 
Entrez database via the MacVector™ sequence analysis program. A search for any 
sequences with the enzyme name present in the title enabled identification not only of 
all named proteins but also sequences identified as potential, putative, proteins 
homologous to each specific enzyme and fragments of each specific enzyme. 
Searches carried out for ‘prolyl oligopeptidase’ ‘prolyl endopeptidase’ ‘oligopeptidase 
B’ ‘dipeptidyl peptidase’ and ‘acylaminoacyl peptidase’ identified a total of 763 
sequences (prolyl oligopeptidase 169, prolyl endopeptidase 127, oligopeptidase B 45, 
dipeptidyl peptidase 351, acylaminoacyl peptidase 71). The sequences identified in 
the ‘prolyl endopeptidase’ search include a very small number of sequences encoding 
prolyl endopeptidase like A (PREPL A). PREPL A was only recently identified as a 
novel member of the prolyl oligopeptidase family (Szeltner et al. 2005) and very few 
protein sequences have been elucidated. Sequences were annotated with species 
name, enzyme name and accession number (full species names are listed in appendix 
I.I).
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Alignments of multiple sequences belonging to one species were carried out for each 
enzyme and any duplicate sequences removed from the analysis. All protein sequence 
fragments (less than lOOaa) were also removed from the analysis. This decreased the 
sequence total to 326 (prolyl oligopeptidase/endopeptidase 111, oligopeptidase B 22, 
dipeptidyl peptidase 157, acylaminoacyl peptidase 36).
3.2.1.2 Prolyl Oligopeptidase Family Alignment
Analysis of the phylogenetic tree of the entire PO family was carried out by 
completing a ClustalW alignment followed by neighbour joining method of tree 
construction using a distance matrix of uncorrected p-values. This analysis shows 
clear multi-species clusters for each enzyme. This is indicative of the sequence 
conservation between homologous enzymes from different species and illustrates that 
there are distinct differences between the enzymes despite the structural similarity 
throughout the family (See Figure 3-1).
Best tree analysis of the prolyl oligopeptidase family phylogeny revealed a clear 
grouping of the mammalian sequences within each enzyme cluster. Dictyostelium PO 
did group together with the mammalian PO sequences, however, it showed a greater 
divergence from the mammalian enzyme than that of the plant A.thaliana and the fruit 
fly D.melanogaster. Bacterial PO sequences clustered closely with one another and 
showed a weaker association with the eukaryote PO sequences (Figure 3-1).
The oligopeptidase B sequences show an association with those for PO as would be 
expected by their similar structure, a similar relatedness is observed for acylaminoacyl 
peptidase and dipeptidyl peptidase IV.
PREPL has been identified in humans as well as a number of other mammals it shows 
closest similarity to the oligopeptidase B enzymes and only a very weak similarity to 
the mammalian prolyl oligopeptidase (Szeltner et al. 2005). As expected, this
3-124
alignment also resulted in clustering of PREPL sequences (just one sequence shown) 
with OB. Despite conservation of the catalytic triad no substrates have yet been 
identified for PREPL and it is unable to hydrolyse substrates of PO or OB (Martens et 
al. 2006). Interest in this potential enzyme is largely due to observation that PREPL is 
deleted in a population of patients suffering the congenital disorder ‘the hypotonia- 
cystinuria syndrome’ (Jaeken et al. 2006).
A very small number of sequences annotated as PO appeared to be displaced as they 
were distributed throughout the phylogeny; a number of these were placed in groups 
with dipeptidyl peptidase IV and acylaminoacylpeptidase however the large majority 
were among those sequences later discarded as not representing true PO (see later) 
(Figure 3-1).
Dictyostelium also express proteins homologous to oligopeptidase B, 2 acylaminoacyl 
peptidases and a dipeptidyl peptidase all of which associate with their respective 
enzyme clusters. No PREPL sequence has been detected to date in Dictyostelium.
In this case the best tree diagram appears to represent a reliable picture of the PO 
phylogeny as it is largely supported by the bootstrap tree. Bootstrap significance is 
weakest around the AP family suggesting it must contain greatest divergence (See 
Figure 3-1).
Bootstrap analysis of the phylogenetic tree involves re-sampling of groups of 
sequences within the complete data set and recording the frequency with which 
sequences are placed together, the standard bootstrap resampling frequency of 1000X 
was used. This provides evidence of significance of the clusters identified. In this 
software any branches with a bootstrap value of below 50 are ‘collapsed’.
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Figure 3-1 Prolyl Oligopeptidase Family Phylogeny.
This tree shows a scaled down phylogenetic tree containing representative sequences from the complete 
phylogeny. Enzymes are named in the format; species name-enzyme abbreviation-accession number (DP 
Dipeptidyl peptidase, OB Oligopeptidase B, PO Prolyl Oligopeptidase and AP Acylaminoacylpeptidase). 
Branches to the left represent Best Tree Analysis, those to the right represent Bootstrap analysis. Mammalian 
and Dictyostelium PO sequences are highlighted in red.
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3.2.1.3 Closer Analysis O f Prolyl Oligopeptidase Sequences
All PO sequences identified were analysed to identify their active domain and 13- 
propeller domain (section 2.2.2). A number of PO sequences in the database did not 
contain both PO catalytic domain and p-propeller. These sequences were removed 
from the next analysis leaving a total of 54 PO sequences.
3.2.1.4 Phylogeny O f The Active Site Domain
Phylogenetic analysis of the peptidase domain revealed three significant clusters, two 
of which contain mainly bacterial sequences and one which contains the majority of 
eukaryotic sequences (See Figure 3-2). Plant sequences were present in both the 
eukaryotic and bacterial clusters. Within the eukaryotic cluster the mammalian 
sequences were closely grouped as were those of the plants A.thaliana and O.sativa as 
well as the parasites T.cruzi and T.brucei. DpoA showed a similar closeness to the 
human PO in the presence of all available PO sequences as that seen with a limited 
number of sequences by Venalainen et al. (2004a).
3.2.1.5 Similarity O f DpoA And Mammalian PO Active Sites
An alignment of the peptidase domains of DpoA, Human PO, Rat PO (Rpo), and 
Drosophila PO illustrates the high degree of sequence similarity across the catalytic 
domain, including the N-terminal fragment. The catalytic triad are absolutely 
conserved throughout the different species (Figure 3-3 B). Also well conserved are 
the five residues lining the SI pocket responsible for binding the proline residue, 
F476, V580, W595, Y599 and V644, and residues Y473 and N555 (numbering for 
human PO) of the oxyanion binding site.
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As well as the surrounding sequence homology, the catalytic triad is positioned at a 
similar distance from the C-terminus of each of the proteins (Figure 3-3 A and B). 
One clear difference observed in the Drosophila sequence is additional amino acids at 
the N-terminus. This may affect the active site as the N-terminal fragment is 
responsible for two a-helices and two strands of the (3-sheet structure of the a/(3- 
hydrolase fold, alternatively this region may be cleaved to produce the active enzyme.
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Figure 3-2 PO Active Site Phylogeny.
Phylogenetic analysis of the catalytic domain of all available PO sequences in the Entrez database. Branches to 
the left represent the best tree analysis of the sequences and show phylogenetic distance (p-values), those to the 
right represent Bootstrap analysis compiled of 1000 repeats, these branches are labelled with confidence levels. 
Both human and Dictyostelium PO are present in the cluster outlined in red.
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Figure 3-3 Full Length and Active Site Alignment.
A. Schematic of Full Length Protein Alignment of Mammalian, Dictyostelium and Drosophila PO. Regions shaded in 
green represent the PO conserved domain, red the (3-propeller domain and grey sequence similarity outside of the specific 
conserved domains. Unshaded regions represent areas of poor sequence similarityy between the proteins. B. Sequence 
alignment of the a/(J hydrolase fold domain. Salient residues are marked; ★ = active site residues, o = oxyanion binding site, 
•  = proline binding pocket. Homologous and similar amino acid residues as defined by MacVector® using the ClustalW 
grouping method are shaded grey.
3.2.1.6 Phylogeny O f /3-propeller Domain
The (3-propeller domain of DpoA retains its association to the mammalian cluster 
however its phylogenetic distance (p-value) is almost 0.40 compared with less than 
0.25 observed for the active site. 0.40 is also greater than that observed for the full 
length protein. A p-value of 0.1 may be considered as a difference of ~10% between 
two proteins (Figure 3-4). In the schematic protein alignment (Figure 3-3 A) it is clear 
that DpoA contains additional sequence in the (3-propeller domain compared with the 
mammalian enzyme, this may account for the increased divergence observed between 
the Dictyostelium and mammalian full length enzyme sequences. The (3-propeller 
domain is central to controlling the entry of substrates to the active site of PO and has 
been shown to be involved in protein-protein interactions in other enzymes (Jenne and 
Stanley 1987; Neer and Smith 1996). Therefore, alterations to the (3-propeller have the 
potential to affect substrate-specific interactions as well as intracellular interactions.
3.2 .1 .7Differences Between DpoA And Mammalian ^-propeller 
Domains
An alignment of the complete protein sequence o f the human, rat, Dictyostelium and 
Drosophila enzymes revealed additional sequence present within the Dictyostelium (3- 
propeller domain compared to that of the mammalian and fly enzymes. However, 
sequence similarity was conserved in the regions either side of the additional 
sequence (Figure 3-3 A).
In order to determine the significance of this insertion, the (3-propeller domain was 
considered in terms of the seven individual blades; each of which is a four stranded (3- 
sheet. An insertion in the loop between two blades would be expected to have a much
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smaller impact on the shape of the domain than one in the centre of a (3-sheet. The 
Dictyostelium (3-propeller domain was modelled on the structure described by Fulop 
et al. using a secondary structure prediction program and crystal structure analysis 
(Fulop et al. 1998). According to this model, the Dictyostelium enzyme has additional 
amino acids in between the 3rd and 4th strands of both the 1st and 2nd blades (Figure 
3-5 and Figure 1-2). It is difficult to predict the effect of these amino acids, however, 
their position towards the outside of the propeller domain may allow them to form 
loops without affecting the (3-sheet.
The hydrophilic loop between the 2nd and 3rd strands of blade 3, which interacts with 
the catalytic domain by hydrogen bonding, is also conserved in the Dictyostelium 
enzyme (Figure 3-5).
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Figure 3-4 (5-Propeller Phylogeny.
Phylogenetic analysis of the P-propeller domain of all available PO sequences in the Entrez database. Branches 
to the left represent the best tree analysis of the sequences and show phylogenetic distance (p-values), those to 
the right represent Bootstrap analysis compiled of 1000 repeats, these branches are labelled with confidence 
levels. Both human and Dictyostelium PO are present in the cluster outlined in red.
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Figure 3-5 p-Propeller Alignment.
Alignment of the amino acid sequences of the (3-pro >eller domains of the mammalian, Dictyostelium 
and Drosophila enzymes. The sequence is divided int > the seven individual (3-sheets forming the seven 
blades. Each {3-strand is outlined in red, the hydrop lilic loop involved in interdomain interaction is 
underlined by a double black line. Homologous t id similar amino acid residues as defined by 
MacVector® using the ClustalW grouping method are shaded grey.
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3.2.2 Expression And Purification Of DpoA And Rpo
3.2.2.1 Cloning DpoA
The Dictyostelium prolyl oligopeptidase gene dpoA was obtained by PCR 
amplification from the Japanese cDNA clone DDC47a24. The complete 2283bp open 
reading frame was inserted into the pBAD TOPO TA plasmid in frame with C- 
terminal V5 and His epitope tags. The entire length of the gene was sequenced to 
confirm the sequence agreed with that in the database and ensure the absence of any 
nonsense or missense point mutations introduced during amplification. Expression of 
the tagged DpoA was under the control of the arabinose promoter (See Appendix 0). 
The pTrcHis plasmid expressing an N-terminal His-tagged rat prolyl oligopeptidase 
(rpo) was a kind gift from Prof T.Takahashi, Hokkaido University, Japan. Expression 
of the tagged Rpo was under the control of the trc promoter (Kimura and Takahashi 
2000).
Both plasmids were transformed into E.coli TOP 10 cells.
3.2.2.2 Expression O f  Active Prolyl Oligopeptidase
Expression of both recombinant enzymes was induced in the bacterial cells by 
addition of L-arabinose (DpoA) or IPTG (Rpo). Expression of both recombinant 
proteins was confirmed by western blotting, which revealed a strong induction of both 
the rat and Dictyostelium enzymes (Figure 3-6 A). The calculated molecular mass of 
the recombinant DpoA is 90kDa which is in clear agreement with the observed band. 
The band observed for the recombinant Rpo also correlates with the molecular mass 
of 75kDa reported by Kimura and Takahashi (Kimura and Takahashi 2000).
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Enzyme activity assays of total cell extract following induction of cells transformed 
with plasmid encoding the recombinant protein or empty plasmid confirmed the 
activity of the recombinant protein. Enzyme activity was measured by the appearance 
of the yellow-coloured p-nitroaniline, which is released from the substrate Z-Gly-Pro- 
pNA following cleavage after the proline residue (Figure 3-6 B). Activity is recorded 
in enzyme units (U); one enzyme unit (1 U) is defined as the amount of enzyme 
required to produce 1 pmole of product per minute.
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Figure 3-6 Expression of Active Tagged DpoA and Rpo
A. Induction of Active Tagged DpoA and Rpo. Western blot of lOpl cell extract from bacteria 
transformed with pBAD TOPO;DpoA uninduced, a, or induced with L-arabinose, b, and 
pTrcHis;Rpo uninduced, c, or induced with IPTG, d. Western blot probed using anti-V5:HRP 
antibody, a&b or anti-6X:HRP antibody, c&d. B. Activity of Expressed enzyme. PO activity in cell 
extracts of bacterial cells transformed with plasmid expressing the tagged enzyme compared with 
bacterial cells transformed with empty plasmid. pBAD TOPO plasmid containing cells were induced 
with L-arabinose, pTrcHis plasmid containing cells were induced with IPTG. PO activity was 
assayed in HEPES buffer using the substrate Z-Gly-Pro-pNA. Values are mean of two repeats done 
in duplicate ± SEM.
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3.2.2.3 Purification O f Recombinant Prolyl Oligopeptidase
The recombinant enzymes were both purified using Talon™ metal affinity resin. The 
enzyme was bound by interaction between the His tag and the cobalt beads then 
eluted after extensive washing using a pH gradient (see Materials and Methods 
section 2.6.4). The Talon™ beads were packed into a column set up for FPLC. The 
fractions collected during the pH elution were tested for the presence of PO by 
assaying the enzyme activity. Analysis of the fraction showing the maximum activity 
(the peak fraction) alongside the total extract and flow through (i.e. unbound extract) 
showed increased purity of the recombinant enzyme (Figure 3-7 A and B).
Silver staining of proteins present in the cell extract, flow through and peak fraction 
suggests the majority of contaminating proteins have been removed during washing of 
the column and illustrates the relative purity of the recombinant enzyme (Figure 3-7 C 
and D).
Specific enzyme activity is greatly increased in the peak fraction compared to both the 
complete cell extract and the flow through, suggesting a 100-200 fold purification of 
the enzyme. This figure may be an over or under estimate of the true purification 
factor if any inhibitory or stimulatory factors have been removed.
Presence of a significant amount of enzyme activity in the flow through indicates that 
the Talon™ column was saturated with enzyme enabling some to pass through 
without binding (Figure 3-7 & Table 3-1). This helps to minimise non-specific 
binding and binding of naturally His-rich proteins, which should be present at much 
lower concentrations than the induced recombinant protein.
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Figure 3-7 Purification of Tagged Enzyme
A & B. Activity of Purified Enzyme. E.coli expressing tagged DpoA, A and Rpo, B. PO 
activity of bacterial cell extracts before loading onto Talon™ beads, flowthrough following 
binding to Talon™ beads and peak fraction eluted from beads. PO activity was measured in 
HEPES buffer (pH 7.8) using the substrate Z-Gly-Pro-pNA. C & D. Purification of the 
Tagged Enzyme. Silver stain of purified DpoA, C and Rpo, D. Silver stain of protein content in 
bacterial cell extract expressing tagged PO columns a and d, flow through following binding of 
enzyme to Talon™ beads columns b and e and eluted fraction containing maximum PO activity 
columns c and f. Arrow indicates the position of the tagged enzyme.
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Table 3-1 Purification of Tagged PO Using Talon™ Beads.
Enzyme Fraction Purification factor*
DpoA Whole extract 1
Flow through 0.67
Peak elution 197
Rpo Whole extract 1
Flow through 0.78
Peak elution 117
♦Purification factor=Fold increase in enzyme units, U (pmoles pNA produced per min) per mg protein.
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3.2.3 Activity Of DpoA
3.2.3.1 PO Enzyme Assay
All further enzyme assays were completed using a stock of purified recombinant 
enzyme produced by pooling the eluted fractions containing significant enzyme 
activity (see Materials and Methods section 2.5.4).
Initial assays were carried out using DpoA across a pH range from 5.0 to 9.0, using 
lOOmM Propionate, MES, HEPES and Tris-HCl buffers all at an ionic strength of 
154mM (physiological ionic strength). Activity was measured by cleavage of the 
substrate Z-Gly-Pro-AMC at a temperature of 25°C. Appearance of the fluorescent 
product, 7-amino-4-methylcoumarin (AMC), was monitored at 10 minute intervals 
(Figure 3-8).
The pH profile revealed a clear peak of activity around pH 8 and very little variation 
in enzyme activity when measured in the different buffers at the same pH. PO activity 
assays were subsequently carried out in HEPES buffer at pH 7.8. A pH of 7.8 was 
used in PO activity assays when DpoA activity was first reported (Williams et al. 
1999), this pH is within the range of optimal PO activity and close to physiological 
pH (7.4) of both mammalian and Dictyostelium cells (Martin et al. 1987).
A curve of best fit was added to the pH profile data produced using the equation, pH 
optimum (Equation 3-1) (Rob John, personal communication).
Equation 3-1
V = Kma,/(((l+10'pKal)/10'pH)+(10pH/10‘’’Ka2))
A curve of best fit was achieved with the parameters Vmca 0.238pM m in 1, pKai 8.93 
and pKa2 7.68.
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Figure 3-8 Effect of pH on DpoA Activity.
DpoA activity was measured at pH 5.0 to 9.0 in lOOmM Propionate ■, MES A, HEPES ▼ or Tris- 
HCl^ buffer at 25°C. All buffers were maintained at an ionic strength of 154mM and contained 
141 pM PO substrate, Z-Gly-Pro-AMC. v represents the initial rate measured between 0 and 20 
minutes. Points represent an average of three repeats ± standard deviation. Curve of best fit produced 
using equation; pH optimum.
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DpoA activity was assayed across a range of substrate concentrations from 2.2 to 
140pM. These activity assays were incubated in the luminometer at 25°C and the 
increase in fluorescence measured at 10 minute intervals (Figure 3-9 A & B)
Enzyme velocity, v (pM/min), was calculated for each substrate concentration at 
every time point where appearance of product was in a linear range and product 
represented less than 20% of the substrate. Values plotted represent average v at each 
substrate concentration ± standard deviation, [S] = substrate concentration, (Figure 
3-9 C).
Values for Km and Vmax were calculated by Prism® software using the Michaelis- 
Menten equation (Equation 3-2).
Equation 3-2
v = ^ * [ S ] / ( t f * + [ S ] )
Results are given plus and minus standard error.
K m =  31 ±1.5 pM
Vmax = 0.175 ± 0.003 pM/min.
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Figure 3-9 DpoA Enzyme Activity.
A & B, DpoA activity was assayed in lOOmM HEPES buffer (pH 7.8) at 25°C across a range of 
substrate (Z-Gly-Pro-AMC) concentrations 141pM ■ , 70.5pM A, 35.3pM ▼, 17.6pM ♦ ,  8 .8pM 
•  , 4.4pM □ 5 2.2pM A. Appearance of the fluorescent product AMC was measured at 10 minute 
intervals. Points represent an average of three repeats ± standard deviation. Graph B shows the points 
on graph A indicated by a dashed box at an increased magnification.
C, v (pM/min) was calculated for each substrate concentration at every time point where appearance of 
product was in a linear range and product represented less than 20% of the substrate. Values plotted 
represent average v at each substrate concentration ± standard deviation.
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3.2.3,2 Mammalian PO Shows Similar Kinetics To DpoA
A pH profile of purified recombinant Rat PO (Rpo) activity from pH 5.0 to 9.0 was 
measured as described above. The mammalian enzyme showed a very similar peak in 
activity around pH 8.0 to that seen with the Dictyostelium enzyme (Figure 3-10). A 
curve of best fit was produced using the equation pH optimum (Equation 3-1), with 
the parameters Vmax 0.25 lpM  min'1, pKai 9.54 and pKa2 7.59.
Rpo activity was also assayed across a range of substrate concentrations from 2.2 to 
140pM as described for DpoA (Figure 3-11 A & B).
Again the enzyme velocity, v (pM/min), was calculated for each substrate 
concentration at every time point where appearance of product was in a linear range 
and product represented less than 20% of the substrate. The data points plotted 
represent average v at each substrate concentration ± standard deviation (Figure 3-11 
C).
Values of Km and Vmax for Rpo calculated by Prism® software using the Michaelis- 
Menten equation (Equation 3-2) were very similar to the A^and Vmax of DpoA.
Results are given plus and minus standard error.
Km = 36 ±3.3 pM
Vmax = 0.210 ± 0.007 pM /min.
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Figure 3-10 Effect of pH on Rpo Activity.
Rpo activity was measured at pH 5.0 to 9.0 in lOOmM Propionate ■ , MES A, HEPES ▼ or Tris- 
HC1 ♦  buffer at 25°C. All buffers were maintained at an ionic strength of 154mM and contained 
141 pM PO substrate, Z-Gly-Pro-AMC. v represents the initial rate measured between 0 and 20 
minutes. Points represent an average of three repeats ± standard deviation. Curve of best fit produced 
using equation pH optimum.
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Figure 3-11 Rpo Enzyme Activity.
A & B, Rpo activity was assayed in lOOmM HEPES buffer (pH 7.8) at 25°C across a range of substrate 
(Z-Gly-Pro-AMC) concentrations 141p,M ■ , 70.5pM A, 35.3pM ▼, 17.6p,M ♦ ,  8 .8p,M • ,  4.4p.M 
□ , 2.2pM A. Appearance of the fluorescent product AMC was measured at 10 minute intervals. 
Points represent an average of three repeats ± standard deviation. Graph B shows the points on graph A 
indicated by a dashed box at an increased scale.
C, v (p.M/min) was calculated for each substrate concentration at every time point where appearance of 
product was in a linear range and product represented less than 20% of the substrate. Values plotted 
represent average v at each substrate concentration ± standard deviation.
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3 ,2 .33  The Active Site Triad A re Required For DpoA Activity
The identity of the active triad identified by sequence alignment in the Dictyostelium 
PO was tested by observation of enzyme activity following mutation of these three 
amino acids. Site-directed mutagenesis was used on the pBAD TOPO;DpoA vector to 
produce plasmids encoding 3 mutant versions of the recombinant DpoA; S609A, 
D693G and H730A each of which lacks one member of the putative catalytic Ser- 
Asp-His triad respectively. The mutagenesis was confirmed by sequencing and 
mutant DpoA was expressed in TOP 10 cells as before. Expression of the mutant 
protein was induced using L-arabinose and presence of the tagged protein was 
confirmed by western blotting (Figure 3-12 A).
Enzyme assay results using the total cell extract revealed a total loss of Z-Gly-Pro- 
pNA hydrolysing activity in the absence of any one of the catalytic triad amino acids, 
supporting a role for these amino acids (Figure 3-12 B). It suggests that all three 
residues are required for enzyme activity however it is also possible that the loss of 
enzyme activity was a result of protein mis-folding caused by the mutations,
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Figure 3-12 Induction and Activity of M utant DpoA
A. Induction of Mutant, Tagged DpoA. Western blot of bacterial cells expressing tagged DpoA 
mutated at the catalytic triad; no mutation, lanes a&b, H730A, lanes c&d, D693G, lanes e&f and S609A, 
lanes g&h. Bacterial extracts were taken before, a,c,e&g and after, b,d,f&h, induction of protein 
expression with L-arabinose. Western probed using anti-V5:HRP Ab. B. Activity of Mutant Protein. 
PO activity assays of bacterial cell extracts expressing tagged DpoA containing mutations in the catalytic 
triad. Cell extracts were prepared with and without L-arabinose induction. PO activity was assayed in 
HEPES buffer using substrate Z-Gly-Pro-pNA. Results are average of two repeats done in duplicate ± 
standard deviation
3-149
3.2.4 Inhibition Of DpoA By Two Specific Inhibitors
Enzyme activity was measured in the presence of the PO specific inhibitors S I7092 
and Z-Pro-Prolinal. Activity was measured in lOOmM HEPES buffer (pH 7.8), at a 
substrate concentration close to Km (35.25pM) and an assay time of 20 minutes. The 
same amount of recombinant enzyme, 1X1 O'5 U, as used in previous assays (Figure 
3-9 and Figure 3-11) was added per 60pl assay.
3.2.4.1 Inhibition By S I 7092
PO activity was measured in the presence of S I7092 from 0.1-InM. An inhibition 
curve of v/vo against inhibitor concentration, [SI7092] was plotted: v = observed 
enzyme activity, vo = enzyme activity in absence of inhibitor (Figure 3-13 A). A curve 
was fitted to these data using Equation 3-3;
Equation 3-3
v/vo = (KM+[S])/(KM(\+[lVKi )+[S])
This is derived from the Michaelis-Menten model of inhibition described by Equation 
3-4 ([I] = inhibitor concentration);
Equation 3-4
v = ( U S ] )  / ( X a , ( 1 + [ I ] / X ; ) + [S])
The observed data show a systematic diversion from the curve fit using this model. 
This can be illustrated more clearly by a plot of the residuals i.e. the difference 
between the experimental points and the theoretical points predicted by the curve fit 
by Equation 3-3 (Figure 3-13 B). This shows a clear pattern of diversion rather than 
random deviation from the model.
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Figure 3-13 Inhibition of DpoA by S17092; Michaelis-Menten Model.
A. 1X1 O'5 U DpoA enzyme activity was assayed in a final volume of 60pl HEPES buffer (pH 7.8) at 
25°C, in the presence of inhibitor SI7092 at concentrations from 0.1 to InM. The reaction rate v (pM 
increase in product (AMC) m in1) was measured at 20 minutes, v0 = v when [I] = 0. The Michaelis- 
Menten model of inhibition was used to fit a curve to these data. B. A plot of the residuals i.e. 
difference between the observed data and data points given by the Michaelis-Menten model.
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3.2.4.2 Tight Binding Inhibition By S I 7092
Inhibition as modelled using the Michaelis-Menten model assumes that the free 
concentration of inhibitor is not significantly reduced by formation of the enzyme- 
inhibitor complex. This assumption is not true in the case of tight binding inhibition 
where the enzyme-inhibitor complex may represent a significant amount of the total 
inhibitor concentration. S I7092 has previously been described as a potent and long 
lasting inhibitor (Portevin et al. 1996). It is shown here that S I7092 inhibition of PO 
is consistent with that of a tight binding inhibitor.
Low concentrations of inhibitor (nanomolar range) were needed to produce the 
inhibition observed, therefore, an equation derived for tight-binding inhibition was 
used to fit the same data. Derivation of this more complex equation (Equation 3-5) 
takes into account the depletion of free inhibitor concentration by formation of the 
enzyme-inhibitor complex (Henderson 1972). The Henderson equation for 
competitive inhibition;
Equation 3-5
[I]/(l-v/v0)=  E o+ K ({[S \+ K m)IK m) v0/ v
E0 = total enzyme concentration. The Henderson equation can be rearranged to be 
given in terms of v/vo (Equation 3-6).
Equation 3-6
v/v<,=(-([I]-E0+(([S]+/rM)/A:M)*A-,)+V(([I]-E0+(([S]+^„)/^„)*A:,)2+
4*e0*(([S]+a:„)/a:„)*a:,))/(2*e0)
Known values for [S] (35.25pM) and previously calculated values Km (30.8pM) were 
included in the equation before the curve was fitted using Prism software.
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The curve representing tight binding inhibition provides a much better representation 
of the inhibition data observed in the presence of S17092 (Figure 3-14 A). A plot of 
the residuals from this model indicates small non-systematic deviation from the tight 
binding model (Figure 3-14 B).
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Figure 3-14 Inhibition of DpoA by S17092; Tight Binding Model.
A. 1X10'5 U DpoA enzyme activity was assayed in a final volume of 60ptl HEPES buffer (pH 7.8) at 
25°C, in the presence of inhibitor SI7092 at concentrations from 0.1 to InM. The reaction rate v (pM 
increase in product (AMC) min'1) was measured between 0 and 20 minutes, v0 = v when [I] = 0. The 
tight binding model o f inhibition was used to fit a curve to these data. B. A plot of the residuals i.e. 
difference between the observed data and data points given by the tight binding model.
3-154
The model of tight binding inhibition also calculates the concentration of enzyme 
present in the assay. This figure can be more accurately calculated at higher enzyme 
concentrations. When E0  is significantly greater than the concentration of a tight 
binding inhibitor, a linear relationship is observed between [I] and v from which the 
enzyme concentration may be extrapolated (Henderson 1972). This may be illustrated 
by theoretical tight binding curves showing increasing concentrations of enzyme 
(Figure 3-15).
Because of assay limitations it was not possible to increase the concentration of 
enzyme above four times (4X1 O' 5 U enzyme activity) that of the normal assay because 
of the enzyme volume that would need to be added to the assay. At four times enzyme 
concentration the assay remained in the linear range, product always represented less 
than 20% of the total substrate concentration. A curve fitted to these data using the 
tight binding inhibition equation (Equation 3-6) by Prism® software returned a value 
for the total active enzyme concentration (Ec) of 0.58 ±0.04nM (Figure 3-16 A). From 
this it is possible to estimate the total active enzyme concentration for all assays 
containing 1X10’5U enzyme activity to be 0.15nM
The accuracy of any model is increased by replacing as many variables as possible 
with known values. The calculated value for [Ec] and Km were entered into the tight 
binding equation before values for Kt were calculated, again using Prism® software, at 
4 different substrate concentrations (Figure 3-16 B).
The average value returned for the Kt of S I7092 was 58pM, indicating S I7092 is a 
very efficient inhibitor of Dpo (Table 3-2).
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Figure 3-15 Effect Of Enzyme Concentration On Tight Binding Inhibition
Family of theoretical curves illustrating effect o f increased enzyme concentration. Curves generated 
using the tight binding inhibition equation (See Equation). 150 points were calculated at inhibitor 
concentration [I] values ranging from 0.0 to 10.0. [S] = KM, Kt =0.07, A. Ec=6 , B. Eo=0.6, C. Eo=0.06.
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Figure 3-16 Inhibition Of DpoA By S17092.
A. 4X10‘5 U , ■ , and 1X1 O'5 U, ▼, DpoA enzyme activity were assayed in a final volume of 60pl 
HEPES buffer (pH 7.8) at 25°C, in the presence of inhibitor SI7092 at concentrations ranging from 0.1 
to 4nM. The reaction rate v (pM increase in product (AMC) min"1) was measured between 0 and 20 
minutes: Vo = v when [I] = 0. The tight binding model of inhibition was used to fit a curve to these data 
and estimate the concentration of total active enzyme. B. SI7092 inhibition was measured across a 
range of substrate ,Z-Gly-Pro-AMC, concentrations, ■ 70.5 pM, ▼ 35.25pM, •  17.6pM, A  8 .8pM. 
1X10'5 U DpoA enxyme activity added per assay. Results represent mean ± standard deviation.
Table 3-2 Kt of S17092 for DpoA
Substrate (Z-Gly-Pro-AMC) Concentration In Assay
(pM)
Ki
(pM)
70.5 77 ±3.0
35.25 56 ±1.4
17.6 48 ±1.8
8.8 50 ±2.0
Average value of Kt 58
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3.2.4.3 Inhibition By Z-Pro-Prolinal
PO activity was measured in the presence of Z-Pro-Prolinal from 1-lOpM. An 
inhibition curve of v/vo against inhibitor concentration, [Z-Pro-Prolinal] was plotted. 
The inhibition of DpoA by Z-Pro-Prolinal required a concentration of inhibitor in the 
micromolar range, compared to the nanomolar range observed for S I7092, indicating 
this inhibitor is not exhibiting tight binding inhibition (Figure 3-17 A). A curve was 
fitted to these data using the Michaelis-Menten model of inhibition (Equation 3-3). 
The inhibition curve was repeated across a range of substrate concentrations (70.5, 
35.25, 17.6 and 8 .8 pM) and the values for AT, calculated using Prism® (Figure 3-17 
B). An average AT, of 1.70pM was calculated for DpoA inhibition by Z-Pro-Prolinal 
(Table 3-3).
3-159
0.0 I i ■ ■ i
0.0 2.5 5.0 7.5 10.0
[Z-Pro-Prolinal] (pM)
1.0
!  0.5
0.0
10.05.0 7.52.50.0
[Z-Pro-Prolinal] (p,M)
Figure 3-17 Inhibition of DpoA by Z-Pro-Prolinal
A. 1X10'5 U DpoA enzyme activity was assayed in a final volume of 60|xl HEPES buffer (pH 7.8) at 
25°C, in the presence of inhibitor Z-Pro-Prolinal at concentrations from 1 to 10pM. The reaction rate v 
(p,M increase in product (AMC) min'1) was measured between 0 and 20 minutes, v0 = v when [I] = 0. 
The Michaelis-Menten model of inhibition was used to fit a curve to these data. B. Z-Pro-Prolinal 
inhibition was measured across a range of substrate ,Z-Gly-Pro-AMC, concentrations, ■ 70.5pM, ▼ 
35.25p.M, •  17.6p,M, A  8 .8p.M. Data represent mean ± standard deviation.
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Table 3-3 Kt Of Z-Pro-Prolinal For DpoA
Substrate (Z-Gly-Pro-AMC) Concentration In Assay
(HM)
Ki
(pM)
70.5 1.66±0.07
35.25 1.42±0.06
17.6 1.43±0.07
8 . 8 2.28±o.21
Average value of Ki 1.7
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3.2.5 Inhibition Of Rpo By PO Specific Inhibitors
Enzyme activity of the mammalian enzyme, Rpo, was measured in the presence of the 
PO specific inhibitors S I7092 and Z-Pro-Prolinal under the same conditions as the 
Dictyostelium enzyme (See 3.2.4). Activity was measured in lOOmM HEPES buffer 
(pH 7.8), at a substrate concentration close to Km (35.25pM). 1X10' 5 U recombinant 
enzyme was added per 60pl assay.
S I7092 inhibition of Rpo again showed deviation from the Michaelis-Menten model 
as observed previously for the Dictyostelium enzyme (section 3.2.4.2) (data not 
shown). Therefore, tight binding kinetics were also used to calculate the X, for 
S I7092 with the mammalian enzyme.
The total active enzyme concentration in the assay was calculated from an S I7092 
inhibition curve in the presence of 4X1 O' 5 U enzyme activity using the tight binding 
inhibition model (Equation 3-6) (Figure 3-18 A). This model calculated the 
concentration of 4X10 ' 5 U enzyme activity in 60pl to be 0.72 ±0.l4nM active enzyme. 
From this it is estimated that the enzyme concentration, E0, per assay containing 
1X10 ' 5 U Rpo enzyme activity is 0.18 nM. This value along with the previously 
calculated Km of 36.1pM were included in the tight binding model equation to 
calculate the X, of SI 7092 for Rpo.
Rpo activity was measured in the presence of S I7092 at concentrations from 0.1-InM 
at three different substrate concentrations (70.5, 35.25 and 17.6pM) (Figure 3-18 B) 
(Table 3-4). The values calculated for X, under these conditions result in an average X, 
of 134nM.
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Figure 3-18 Inhibition Of Rpo By SI7092.
A. 4X1 O'5 U , ■ , Rpo enzyme activity was assayed in a final volume of 60pl HEPES buffer (pH 7.8) at 
25°C, in the presence of inhibitor SI7092 at concentrations ranging from 0.1 to 4nM. The reaction rate 
v (pM increase in product (AMC) m in1) was measured between 0 and 20 minutes, v0 = v when [I] = 0. 
The tight binding model of inhibition was used to fit a curve to these data and estimate the 
concentration of total active enzyme. B. SI7092 inhibition was measured across a range of substrate, 
Z-Gly-Pro-AMC, concentrations, ■ 70.5pM, ▼ 35.25p.M, •  17.6pM. 1X10'5 U Rpo enzyme activity 
added per assay. Results represent mean ± standard deviation.
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Table 3-4 Kt of S17092 Calculated For Rpo
Substrate (Z^Gly-Pro-AMC) Concentration In Assay K
(pM) (pM)
70.5 139 ±7
35.25 110 ±3
17.6 153 ±7
Average value of Ki 134
Rpo activity was also measured in the presence of Z-Pro-Prolinal at concentrations of 
1-lOpM (Figure 3-19). The Kt of Z-Pro-Prolinal for Rpo was calculated using the 
Michaelis-Menten model of inhibition (Equation 3-3) at four different substrate 
concentrations ranging from 2 to 0.25 times Km (70.5, 35.25, 17.6 and 8 .8 pM). The 
values for Kt were calculated using Prism®, an average K  of 3pM was calculated for 
Rpo inhibition by Z-Pro-Prolinal (Table 3-5).
Table 3-5 Ki Of Z-Pro-Prolinal For Rpo
Substrate (Z-Gly-Pro-AMC) Concentration In Assay
(pM)
Ki
(pM)
70.5 3.6 ±0.15
35.25 3.2 ±0 . 1 2
17.6 2.8 ±0.09
8 . 8 3.3 ±0.18
Average value of Ki 3
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Figure 3-19 Inhibition of Rpo by Z-Pro-Prolinal
1X10'5 U Rpo enzyme activity was assayed in a final volume of 60pl HEPES buffer (pH 7.8) at 25°C, 
in the presence o f inhibitor Z-Pro-Prolinal at concentrations from 1 to lOpM. The reaction rate v (pM 
increase in product (AMC) min'1) was measured at 20 minutes, vo = v when [I] = 0. Inhibition was 
measured across a range of substrate, Z-Gly-Pro-AMC, concentrations, ■ 70.5pM, ▼ 35.25pM, •  
17.6pM, A  8.8pM. The Michaelis-Menten model of inhibition was used to fit a curve to these data. 
Data represent mean ± standard deviation.
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3.2.6 Inhibition Of Rpo Resembles That Of DpoA
S I7092 has a picomolar Ki of 58pM and 134pM for the Dictyostelium and rat 
enzymes respectively. These values are lower than those previously reported which 
include a AT, of InM in enzyme purified from human brain and IC50 of 1.3nM for 
enzyme purified from rat brain (Portevin et al. 1996; Barelli et al. 1999)
K s  in the micromolar range were calculated for Z-Pro-prolinal indicating it is a less 
efficient inhibitor than S I7092. Z-Pro-prolinal shows a Kj o f 1.7pM and 3pM for the 
Dictyostelium and rat enzymes. This compares well with the previously reported Kt of 
1.15pM for the Dictyostelium enzyme in cell extract (Williams et al. 1999) and is 
within 10-fold of the IC50 of 0.13pM for the purified human platelet PO (Goossens et 
al. 1997).
The Dictyostelium and mammalian enzymes also showed similar specific activity, 
1X10' 5 U of enzyme activity in 60pl was calculated to be produced by 0.15nM 
Dictyostelium or 0.18nM Rat enzyme.
The similarity of the Dictyostelium and rat enzymes supports the sequence alignment 
results suggesting similar amino acid composition around the active triad and 
substrate binding regions. Comparison of these results with those observed by other 
groups using non-recombinant enzyme purified from animal tissue gives confidence 
that the V5-His epitope tag is not interfering significantly with the structure of the 
active site.
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3.3 Discussion
This chapter presents a study of the biochemical properties of the Dictyostelium PO in 
comparison to a mammalian enzyme.
Phylogenetic analyses have grouped DpoA with other PO enzymes within the prolyl 
oligopeptidase family, consisting of PO, OB, DPP and AP, within this group DpoA 
was placed in the same cluster as the mammalian enzymes. Complete phylogeny of 
the prolyl oligopeptidase family has illustrated that all family members are distinct 
despite sharing characteristic structural features and catalytic triad order.
A previous study also showed distinct clustering of the different sequences of a single 
enzyme following evolutionary analysis of the peptidase domains of a limited 
selection of the prolyl oligopeptidase family (Venalainen et al. 2004a). In this case a 
small number of enzyme sequences were selected based on a blast search using the 
mammalian enzyme. Here it is shown that the specific enzyme clusters are maintained 
when all available sequences are included.
Subsequence analysis (alignments of PO active site and (3-propeller conserved 
sequences) has enabled separation of true prolyl oligopeptidases from mis-identified 
sequences. The latter may in fact belong to alternative groups of the prolyl 
oligopeptidase family. Further phylogenetic analyses clearly illustrate the similarity 
between functional domains of these enzymes.
A number of tree building methods are available. In this example a ClustalW 
alignment was carried out using the blosum series of distance matrices. The blosum 
series represents a range of matrices which are based on amino acid pairs in blocks of 
aligned protein segments, these matrices compare favourably with previous methods 
based on accepted mutations in closely related groups (Henikoff and Henikoff 1992). 
The series of matrices contains a number of matrices whose suitability varies with the
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degree of divergence between the sequences to be analysed, the ClustalW allows the 
correct matrix to be employed at the correct point in the alignment. ClustalW also 
weights results for each region of sequence allowing alternate weighting of runs of 
hydrophilic amino acids which often represent more flexible regions (Thompson et al.
1994). A phylogenetic tree of this alignment was constructed using the neighbour 
joining method, a progressive method, therefore any mistakes introduced early on in 
the tree construction may be maintained. However, a number of studies have found 
this an efficient method when compared with alternatives such as maximum 
likelihood and maximum parsimony (Saitou and Nei 1987; Tateno et al. 1994).
I have been able to establish good confidence in the reliability of this method by 
calculating the bootstrap tree. Bootstrap analysis is based on multiple resampling of 
the data to provide confidence levels for identified relationships, the usefulness of this 
analysis is widely accepted however a number of studies criticise bootstrapping for 
frequently underestimating confidence values (Sitnikova et al. 1995; Price et al. 2005) 
While this does not affect its usefulness in confirming identified relationships, more 
tenuous relationships should not be dismissed on the basis of bootstrapping alone.
In the case of the (3-propeller domain, the observed phylogenetic differences are larger 
than those seen between the active site sequences. The explanation for this may be 
that the absolute sequence, other than those residues in close proximity to the active 
site, is less critical as long as the correct structure is maintained. Therefore this 
domain can accept evolutionary amino acid substitutions, which may represent 
adaptation to specific environmental conditions, for example the archaea 
H.marismortui the proteins of which tend to contain negatively charged amino acids 
on the protein surface to allow it to cope with its highly saline environment. The 13- 
propeller domain may also be involved in protein-protein interactions. It is reasonable
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to presume that the outer amino-acids may vary depending on the structure of any 
binding partners.
In contrast, the catalytic domain is involved in substrate binding and activity for 
which specificity may be essential. In this case, similarity would be expected between 
sequences encoding enzymes showing the same specificity regardless of the 
organism.
3.3.1 Active Site Sequence And Structure
The sequence and structure at the active site of prolyl oligopeptidase play an essential 
role in both substrate specificity and enzyme activity. The Ser-Asp-His order of the 
catalytic triad is unique to the SC clan of serine proteases, however, throughout the 
entire serine protease family nucleophilic attack of the substrate is mediated by the 
serine hydroxyl group and stabilised by the aspartic acid and histidine residues via 
proton transfer and formation of hydrogen bonds.
A specific binding pocket (the SI binding pocket) accommodates the substrate proline 
residue while the backbone amide group of Asn555 (human PO numbering) and the 
OH group of Tyr 473 (also known as the oxyanion binding hole) forms hydrogen- 
bonds with the oxyanion of the proline residue, thus providing substrate stereo- 
specificity. A hydrogen bond is also formed between a nitrogen atom of the catalytic 
triad histidine and the first amino acid following the proline residue (the P I’ position). 
A number of hydrogen bonds and hydrophobic interactions also occur from positions 
P4 through to P2’ however it is the interactions directly surrounding the proline 
residue which confer the majority of the observed enzyme specificity.
The essential nature of the catalytic triad is illustrated by an apparent loss or severe 
decrease of activity following substitution of S609, D693 or H730 for a small neutral 
amino acid (alanine or glycine). Previously, Szeltner found the effect of Asp variants
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D641N and D641A of the pig PO depended greatly on the substrate leaving group, the 
stronger the bond to be broken the greater the effect of the variant on enzyme activity. 
They also reported that the Asp variant did not affect binding of substrate to the 
enzyme implicating a role purely in hydrolysis of the bond to be cleaved (Szeltner et 
al. 2 0 0 2 ).
A similar situation has been observed in other serine proteases. Site-directed 
mutagenesis of the catalytic triad of trypsin found that while only the Ser mutant 
resulted in a total loss of enzyme activity, substitution of either His or Asp decreased 
enzyme activity to between 0.04 and 0.0004% of wild type (Corey and Craik 1992). 
His substitution also results in severe reduction in subtilisin activity (Carter and Wells 
1987).
3.3.2 p-Propeller Domain
Access to the active site of PO is controlled by a 7-bladed p-propeller domain, formed 
from seven 4-stranded anti-parallel (3-sheets arranged around a central tunnel. 
Whether the substrate enters the active site via the central tunnel or through a gap 
between the two domains has been a matter of contention: it is currently thought that 
the latter is true (Fulop et al. 1998; Szeltner et al. 2004; Juhasz et al. 2005).
|3-propeller domains are present in a number of proteins, other than the prolyl 
oligopeptidase family of proteases, where they play a role in protein-protein 
interactions and enzyme co-factor binding (Jenne and Stanley 1987; Faber et al. 1995; 
Neer and Smith 1996). The amino acid sequence of different ^-propeller domains can 
be very varied, however, conservation of the propeller structure and residues involved 
in interactions with surrounding molecules is vital to their function.
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This is also the case for PO. Inter-domain hydrophilic interactions and salt-bridge 
formation between the (3-propeller and the catalytic domain play a significant role in 
enzyme activity (Shan et al. 2005). This interaction is likely to require a degree of 
flexibility as mutations introducing a disulphide link between the two domains 
resulted in a loss of enzyme activity (Szeltner et al. 2004; Juhasz et al. 2005). 
(3-propeller domain alignments have revealed the presence of additional amino acid 
residues in the DpoA (3-propeller domain which can be mapped to the loop between 
the third and fourth anti-parallel strands of the 1st and 2nd blades. It is relevant to 
discover the positioning of these additional regions within the entire protein, any 
protrusion towards the catalytic domain could affect specific interdomain interactions 
with potential to improve or inhibit substrate access to the active site. According to 
the crystal structure of PO described by Fulop et al. both of the extended loops are 
positioned on the outer side of the protein pointing away from the active domain 
(Fulop et al. 1998). This positioning is very unlikely to interfere with the structure or 
activity of PO however it is this domain of the (3-propeller that is responsible for 
protein-protein interactions in other (3-propeller proteins (Wall et al. 1995; Neer and 
Smith 1996). This raises the possibility that the additional residues may play a role in 
any intracellular protein-protein interactions of DpoA. Future studies on any binding 
partners of the (3-propeller domain and the role, if any, of these residues in that 
interaction may provide a valuable insight into the endogenous function of PO.
3.3.3 PO Activity
Both Rpo and DpoA showed a clear peak in activity around pH 8.0 when assayed 
across a pH range from 5 to 9. This is consistent with an enzyme whose activity is 
dependent on the ionisation state of a residue to allow activity.
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Previous studies of PO activity across a pH range reported a sigmoidal distribution of 
activity. This distribution was attributed to activity of two forms of the enzyme, one 
of which is predominant at low pH (below pH 6 .1-6.9) and one which is predominant 
at higher pH (above pH 6 .1-6.9) (Polgar 1991b).
Deuterium oxide studies (a ‘heavy’ water molecule which slows acylation and 
deacylation reactions by interfering with acid base catalysis) on enzyme activity have 
shown an effect only on the low pH form of the enzyme resulting in the conclusion 
that this relies on an acid/ base catalysis to mediate formation and decomposition of 
the tetrahedral intermediate. It is thought that the rate-limiting step of hydrolysis by 
the high pH form relies on a conformational change (Polgar 1991b). In this study the 
low pH PO activity was not observed, the physiological relevance of a low pH form is 
questionable as it would not be expected to occur under normal intracellular 
conditions.
A curve of best fit to the pH data observed, was achieved using values for pKa2 of 
around 7.5 and pKai of around 9. This suggests an ionisation event around 7.5 that is 
required for enzyme activity. This is consistent with the estimated pK of the His 
residue at the active site of serine proteases of 7.0 (Polgar 1991b) or 6.25 for the His 
residue in porcine PO (Fulop et al. 2001) and the hypothesis of Polgar (1991a) that 
this imidazole side chain must be deprotonated for ion transfer, essential for enzyme 
activity, to occur.
At pH 7.8 both the mammalian and Dictyostelium enzymes show similar kinetics for 
cleavage of the fluorigenic substrate Z-Gly-Pro-AMC. Under these conditions the two 
enzymes have a very similar KM, 30pM (DpoA) and 36pM (Rpo), and Vmax, 0.18pM 
min" 1 (DpoA) and 0.2 lpM  min ' 1 (Rpo). These values are in agreement with the
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previously reported Km of Z-Gly-Pro-AMC of 20±3pM and 30±3pM for purified 
porcine PO and porcine brain homogenate respectively (Venalainen et al. 2002).
3.3.4 PO Specific Inhibition
The association of PO with a number of neurological disorders has led to discovery 
and development of numerous specific and non-specific inhibitors (see introduction 
Table 1-1). Several have been identified in plant and fungal extracts however a large 
number have been developed synthetically, largely due to interest in their potential as 
treatments.
S I7092 and Z-Pro-prolinal are both potent, specific inhibitors which interact with 
prolyl oligopeptidase at the active site and substrate binding sites. Both are reportedly 
specific for PO in mammalian cells. Z-Pro-prolinal is commonly used in the study of 
PO activity. It is based on a Pro-Pro dipeptide structure thus mimicking the substrate 
and binding in the SI proline binding pocket of the enzyme (Figure 3-20) (Wilk and 
Orlowski 1983). The aldehyde moiety of the prolinal forms a hemiacetal adduct with 
the active site serine (Kahyaoglu et al. 1997a). Wilk and Orlowski (1983) found that 
Z-Pro-prolinal was unable to inhibit a number of other proteases at 150 times the Ki 
observed for PO.
S I7092 also capitalises on the SI proline-binding pocket and was developed around 
the same basic structure, of two heterocycles and an N-terminal side chain, as Z-Pro- 
prolinal (Figure 3-20). In this case the efficiency of inhibition has been improved by 
substitution of the central proline residue, which binds the S2 specificity pocket, with 
non-natural amino acid PHI containing a perhydroindole group. It also has a 2- 
phenylcyclopropyl group N-terminal side chain and a thiazolidine in place of the 2nd 
heterocycle bound at position SI (Portevin et al. 1996).
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Figure 3-20 PO Inhibitors.
Chemical structures of the PO specific inhibitors Z-Pro-L-Prolinal and SI7092.
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A number of studies have examined the best structures at each of these three positions 
in order to produce an efficient and specific inhibitor.
S17092 shows strong PO specificity with concentrations up to 5000 fold that of the AT, 
of PO inhibition having no effect on a number of enzymes including; elastase, 
aminopeptidase B, dipepitidyl peptidase IV, aminopeptidase M and the 
coagulation/fibrinolysis cascade components thrombin, plasmin, factor Xa, kallikrein, 
activated protein C and trypsin (Portevin et al. 1996; Barelli et al. 1999).
Both of these inhibitors rely on interaction with the S3 hydrophobic pocket as well as 
the S2 and SI specificity pockets. Any changes in the catalytic domain, especially 
around the substrate binding site have potential to affect the inhibition constants 
achieved by these compounds.
Despite the differences in sequence between DpoA and the mammalian enzyme the 
enzyme kinetics appear very similar. DpoA also shows similar Ki values to Rpo for 
both of the specific inhibitors Z-Pro-prolinal and S I7092 supporting their suitability 
for further in vivo and in vitro studies of DpoA. Taken together the enzyme kinetics 
and inhibition constants indicate that the substrate binding site and surrounding 
environment of DpoA and Rpo are very similar.
S I7092 is a potent specific inhibitor of the human PO enzyme (Barelli et al. 1999). A 
comparison of the fit o f the Michaelis-Menton model of non-tight binding competitive 
inhibition and the model of tight binding inhibition with the DpoA SI 7092 inhibition 
curve revealed the tight binding model to be a much more accurate fit to the observed 
data. Both DpoA and Rpo were inhibited by S I7092 at picomolar concentrations with 
a calculated AT, of 56±l.4pM (DpoA) and 110±3pM (Rpo).
Z-Pro-prolinal only inhibited both enzymes at pmolar concentrations. Following 
estimates of enzyme concentrations of 0.15nM and 0.18nM respectively for DpoA
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and Rpo it may be assumed that Z-Pro-prolinal is not a tight binding inhibitor. For the 
Michaelis-Menten inhibition model to hold true EJKt must be less than 0.01 
(Henderson 1972). This assumption is met for Z-Pro-prolinal inhibition of DpoA and 
Rpo, therefore this model was used to calculate Kp of 1.42±0.06jjiM (DpoA) and 
3.2±0.l2pM (RpoA) for these two enzymes.
Both the tight binding and Michaelis-Menten equation used to model enzyme 
inhibition are specific to competitive inhibition (Henderson 1972; Comish-Bowden 
2001). Observation that, using these models, inhibition curves carried out at differing 
substrate concentrations returned a consistent value for the inhibition constant, Kit is 
in agreement with the model of competitive rather than un-competitive or non­
competitive inhibition.
3.3.5 Summary
• Following sequence analysis PO family enzymes from bacteria, mammals and 
plants were found to cluster in to distinct enzyme groups.
• DpoA shows close homology to the mammalian enzyme especially in the 
catalytic domain where the active residues are absolutely conserved.
• The Dictyostelium PO homologue also shares similar enzyme kinetics (KM and 
Vmax) and specific inhibition (Ki) by Z-Pro-prolinal and S I7092 with the 
mammalian (rat) enzyme.
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4 Effect Of Mood Stabilising Drugs On PO
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4.1 Introduction
4.1.1 Bipolar Disorder And Mood Stabilising Drugs
Bipolar Disorder is a mood disorder defined by cycling between periods of depression 
and mania often interspersed with periods of normal behaviour. This disorder affects 
up to 1% of the population and carries a high risk of suicide (NIMH 2001). Treatment 
for Bipolar Disorder can be complex, a number of drugs are currently available which 
may be given exclusively or in combination, the majority of these carry numerous 
unwanted side effects.
Lithium, an alkali metal element, has been used to treat Bipolar Disorder for well over 
a century, however, the therapeutically relevant molecular target of this treatment 
remains uncertain. Uncertainty also prevails over the relevant targets of other 
regularly prescribed mood stabilising drugs.
Identification of a common mechanism of action for lithium, valproic acid and 
carbamazepine (all mood stabilising drugs) in inositol depletion suggests a possible 
therapeutic mechanism (Williams et al. 2002). Each of these compounds has multiple, 
varied targets within the cell. However, when used to treat explanted rat dorsal root 
ganglion neurons all three drugs resulted in increased numbers of spread growth cones 
and a smaller proportion of collapsed growth cones implying at least one common 
target. In all three cases this effect was reversed following combined treatment with 
extracellular myo-inositol. These observations strongly implicated inositol depletion 
as a common therapeutic mechanism.
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4.1.2 Inositol Depletion Hypothesis
Intracellular levels of inositol and the second messenger, ip3 , are controlled by; 
recycling of inositol phosphates, de-novo synthesis of inositol, dephosphorylation of 
higher order inositol phosphates and import of extracellular inositol. Li, VPA and 
CBZ deplete inositol by acting at different points in inositol synthesis and recycling 
(Figure 1-6). Lithium is a potent inhibitor of IPP and IMPase; enzymes responsible 
for dephosphorylation of IP2 to IP and IP to inositol (Berridge et al. 1982; Inhom and 
Majerus 1987). While VPA inhibits Inositol-1-Phosphate Synthase, an enzyme 
involved in de novo synthesis of inositol by conversion of glucose-6 -phosphate to 
inositol-1-phosphate (Shaltiel et al. 2004). The mechanism of CBZ depletion of 
inositol is not yet characterised.
4.1.3 Role Of Prolyl Oligopeptidase In Inositol Signalling
Prolyl Oligopeptidase was first identified in Dictyostelium following a lOmM lithium 
screen for resistance mutants. Loss of DpoA conferred lithium resistance on 
Dictyostelium aggregation (Williams et al. 1999).
Following the onset of starvation, single cell amoebae Dictyostelium aggregate to 
form mounds, which eventually undergo cell differentiation and develop into a 
fruiting body. The process of aggregation is mediated by a cAMP gradient set up by a 
single cell at the centre of the mound, and relayed by surrounding cells. The receptor 
involved in this process is the cAMP receptor cARl, a G-protein coupled 7- 
transmembrane receptor whose downstream effects include; actin polymerisation, 
cyclic GMP accumulation and activation of PLC, the enzyme responsible for PIP2 
breakdown to IP3 and DAG, all of which may play an essential role in chemotactic 
movement (Parent and Devreotes 1996). Following cAMP binding a rapid
4-179
accumulation of IP3 has been observed in Dictyostelium (Europe-Finner and Newell 
1987; Van Haastert et al. 1989). IP3 releases Ca2+ from intracellular stores and a 
number of studies report that introduction of IP3 or Ca2+ to permeabilised cells is able 
to replicate actin polymerisation and cGMP accumulation without signalling through 
cARl suggesting these steps are downstream of IP3 release. This implies an essential 
role for inositol signalling in Dictyostelium aggregation (Europe-Finner and Newell 
1985, 1986). The essential role of Ca2+ in chemotaxis is questioned by a mutant 
lacking IplA, the IP3 receptor responsible for rapid Ca2 +entry. The absence of cAMP 
stimulated Ca2+ entry to the cell does not appear to affect normal chemotaxis of 
Dictyostelium (Traynor et al. 2000).
In addition, loss of Phospholipase C activity in the PLC null mutant does not affect 
Dictyostelium chemotaxis as might be expected (Drayer et al. 1994). In this mutant 
IP3 levels are maintained at an almost normal level by dephosphorylation of higher 
order inositol phosphates (IP5 and IP4) by the enzyme M IPP. This may account for the 
unaltered chemotaxis and developmental phenotype observed (Van Dijken et al.
1995).
PO activity plays a role in regulation of inositol levels by inhibiting MIPP mediated 
dephosphorylation of IP5 to IP3 . Dictyostelium mutants lacking PO show increased 
breakdown of IP5 to IP3 , treatment of wild type Dictyostelium with the specific PO 
inhibitor Z-Pro-Prolinal also results in an increase of IP3 (Williams et al. 1999). 
Levels of IP3 are also increased in mammalian astroglioma cells by treatment with PO 
inhibitors or transfection with an antisense vector against PO (Schulz et al. 2002). 
Inhibition of PO is able to reverse inositol depletion by derepression of the IP5 to IP3 
pathway thus replenishing IP3 , and subsequently inositol, levels by dephosphorylation 
of higher order inositol phosphates. This is evident in the ability of PO inhibition to
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reverse effects of Li+, VPA and CBZ attributed to inositol depletion. Li+, VPA and 
CBZ induced spreading of neural growth cones is reversed by addition of PO 
inhibitors (Williams et al. 2002), similarily addition of PO inhibitors may reverse 
autophagy induced by any of these three drugs (Sarkar et al. 2005), both of these 
effects are also reversed by addition of inositol. Dictyostelium mutants lacking DpoA 
are able to aggregate in the presence of Li+ or VPA, while wild type amoebae are 
unable to aggregate due to an inability to chemotax towards a cAMP gradient 
(Williams et al. 1999; Williams et al. 2002).
4.1.4 VPA Interaction With Prolyl Oligopeptidase
A direct interaction between Li+, VPA or CBZ and PO would not be expected, if one 
did exist it would be expected that these drugs activate PO. Surprisingly, a recent 
report suggests that VPA acts as a PO inhibitor. Cheng et al. (2005) reported 
significant, mixed, inhibition of recombinant porcine and human PO activity at ImM 
VPA, close to the therapeutic levels of 0.3-0.7mM.
VPA is a saturated branched short chain fatty acid, it is possible to hypothesise that 
the carboxylic group and side chain will be integral to any inhibition of PO.
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4.1.5 AIM
This section aims to determine the direct effects, if any, of a number of mood 
stabilising drugs on PO. It will also further investigate the apparent inhibition of PO 
by VPA and determine any intracellular effect of this inhibition.
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4.2 Results
4.2.1 Mood Stabilising Drugs Do Not Act Through PO
Loss of PO activity results in resistance to the mood stabilising drugs LiCl, VPA and 
CBZ. Therefore it is expected that any direct effects of these compounds on PO would 
result in an increase in PO activity. Purified recombinant DpoA and Rpo were both 
assayed in the presence of LiCl, VPA or CBZ at a range of concentrations 
representing from 0.1 up to at least 10 times the therapeutic concentration of each of 
the drugs. Activity was measured against purified enzyme with a carrier control (H2 O 
for VPA and LiCL and EtOH for CBZ, NaCl was also added as a salt control for 
LiCl,) (Figure 4-1).
None of the mood stabilisers LiCl, VPA and CBZ had any direct effect on PO enzyme 
activity within the therapeutic range. However, at approximately 10 times therapeutic 
concentration CBZ treatment resulted in a significant decrease in Rpo but not DpoA 
activity. A significant decrease in both Rpo and DpoA was also observed at 10 times 
therapeutic concentration of VPA (6mM).
Inhibition of PO by VPA has previously been described by Cheng et al. (2005) who 
report an 80% decrease in PO activity at 6mM VPA as well as a significant decrease 
at therapeutic concentrations. This is a much larger decrease than that observed in this 
study. At 6mM VPA PO activity is decreased by just 32% (Rpo) and 28% (DpoA) 
respectively while no significant decrease is observed at therapeutic concentrations.
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Figure 4-1 Effect of Mood Stabilising Drugs on PO Activity.
Activity of purified recombinant DpoA and Rpo, was assayed in the presence of the three mood 
stabilising drugs; LiCl, VPA and CBZ across a range of drug concentrations. Assays were carried out 
in lOOmM HEPES buffer (pH 7.8) using the fluorigenic substrate Z-Gly*Pro-AMC at 25°C. The 
therapeutic dose concentration for each drug is marked on the graph by a dashed line. Results are the 
average of two repeats done in duplicate ± standard deviation.
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4.2.2 VPA Inhibition Of Purified PO
The difference in VPA inhibition observed by Cheng et al. (2005) to that reported in 
this study could be accounted for by the use of a different assay pH. Cheng et al. 
observed the 80% inhibition of PO activity by VPA (6mM) in assay buffer adjusted to 
pH 7 and pH 7.2 whereas in this study a buffer adjusted to pH 7.8 was used. It has 
been shown previously in this study (section 3.2.3) that a change in pH from 7 to 8 
may have a significant effect on enzyme activity. The PO activity assay using 
recombinant DpoA and Rpo was repeated at pH 7.0, 7.5 and 8.0 in the presence of 
6mM VPA or a MeOH carrier control (Figure 4-2).
At pH 7.5 and 8.0 VPA inhibited both DpoA and Rpo by 25-30%. At pH 7.0 DpoA 
was inhibited to a lesser extent (20%) while Rpo showed no significant inhibition. 
The effect of VPA inhibition appears to increase in line with suggested ionisation of 
the histidine imidazole ring. It may be the case that this de-protonation is necessary 
for the inhibitory effect of VPA.
VPA is known to inhibit a number of other enzyme targets, including histone 
deacetalase (Gottlicher et al. 2001; Phiel et al. 2001), inositol-1-phosphate synthase 
(Shaltiel et al. 2004) and microsomal epoxide hydrolase (Spiegelstein et al. 2000). 
Investigation of the method of inhibition of these targets used VPA analogues to 
determine the significance of the carbon chain shape, including the side chain and the 
role of the carboxylic acid group, revealing the differing importance of the backbone 
structure and acid moiety depending on the target.
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Figure 4-2 VPA Inhibition Of PO Activity Between pH 7 And pH 8.
Activity of purified recombinant DpoA, A, and Rpo, B, was assayed in lOOmM HEPES buffer between 
pH 7 and 8 using the fluorigenic substrate Z-Gly-Pro-AMC at 25°C. Assays were carried out in the 
presence of 6mM VPA, A , or carrier control (MeOH), • .  Results are the average of at least 3 repeats 
± standard deviation. Significant differences (p<0.05) between activity in the presence of VPA, 
compared with carrier control is indicated by * .
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Figure 4-3 Structure of VPA and Analogues
Stick diagram of VPA (C8Hi60 2) and analogues including amide derivative, Valpromide 
(C8Hi7NO) and unbranched isomer, Octanoic acid (C8Hi602).
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VPA analogues were used to determine if VPA inhibition of PO required specific 
interactions with the branched carbon backbone or the acid group. Valpromide (VPM) 
(CgHnNO) is a VPA analogue in which the carboxylic acid moiety has been replaced 
by an amide group, octanoic acid (C8H 1 6O2 ) is an unbranched carboxylic acid with the 
same molecular formula as VPA (Figure 4-3).
Activity of recombinant DpoA and Rpo was measured in the presence of 6mM VPM 
or 6mM octanoic acid across the pH range from 7.0-8.0 (Figure 4-4). Inhibition of 
both DpoA and Rpo by VPM closely resembled that observed in the presence of 
VPA. VPM, as VPA, did not inhibit either enzyme at pH 7.0 but showed significant 
inhibition at pH 7.5 (32%, DpoA and 26%, Rpo) and pH 8.0 (26%, DpoA and 22% 
Rpo).
The same pattern of inhibition was not observed following addition of 6mM octanoic 
acid. This acid showed significant inhibition of both enzymes at pH 7.0 and pH 7.5. 
Inhibition of the mammalian enzyme, Rpo, (62% and 46% at pH 7 and 7.5) by this 
unbranched carboxylic acid was greater than that seen for the Dictyostelium enzyme 
(48% and 22% at pH 7 and 7.5). These observations imply that while the branched 
structure is more important at higher pH conditions the acid group may also play a 
role in inhibition at lower pH, especially in the case of the mammalian enzyme. 
Human blood pH is strictly maintained at 7.4, the intracellular pH of human cells is 
close to this value but may vary dramatically within different cellular compartments 
(approximately 5.0 in lysosomes). The cytosolic pH of Dictyostelium is also estimated 
to be 7.4 ±0.2 (Martin et al. 1987). At pH 7.5, close to the physiological pH of 7.4 
both the branched amide, VPM, and the unbranched carboxylic acid, octanoic acid, 
show significant inhibition of PO activity.
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As changes of just pH 0.5 clearly affect PO activity it is of note that pH of the buffers 
was not altered by addition of 6mM VPA, VPM or octanoic acid, therefore the 
inhibitory effects observed are not simply a result of altered pH (data not shown).
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Figure 4-4 Effect Of pH On Inhibition Of PO Activity By VPA And Analogues.
Activity of purified recombinant DpoA and Rpo was assayed in 1 OOmM HEPES buffer between pH 7 
and 8 using the fluorigenic substrate Z-Gly-Pro-AMC at 25°C. Assays were carried out in the presence 
of 6mM VPA, A, VPM, ▼, Octanoic acid, ♦  or carrier control (MeOH), •  . Results are the average 
of at least 3 repeats ± standard deviation. Significant differences between activity in the presence of 
VPA, VPM or Octanoic acid compared with carrier control is indicated by * or **.
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4.2.3 VPA Inhibition Of Cellular PO
VPA is able to inhibit purified recombinant PO activity. For PO to be a potential 
intracellular target of VPA it is important to determine if this inhibition occurs in vivo. 
The effect of VPA on intracellular PO activity was measured using the human 
lymphoblastoid cell line GC12139. Lymphoblast cells have been used previously in 
studies of in vivo inositol levels and found to mirror inositol levels in the frontal 
cortex of the brain (Belmaker et al. 2002). This suggests they show a similar pattern 
of inositol signalling as that observed in the brain, making them a useful model for 
studying the effects of mood stabilising drugs at the cellular level.
Lymphoblast cells growing in culture medium were treated overnight with increasing 
concentrations of VPA and analogues, VPM and octanoic acid. Cells were counted in 
the presence of Trypan blue to determine the effect of these compounds on cell 
viability. Following treatment with lOmM VPA, VPM or octanoic acid extensive cell 
death was observed. Treatment with 3mM resulted in a reduced amount of cell death 
caused by VPA and octanoic acid while VPM no longer had a noticeable effect on 
cell viability (Figure 4-5). The effect of the three compounds on cellular PO levels 
was subsequently measured up to a maximum concentration of 3mM. The possibility 
of these compounds to act in an additive way in combination with conventional PO 
inhibitors was determined by dual treatment of lymphoblast cells with VPA, VPM or 
octanoic acid and S I7092.
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Figure 4-5 Lymphoblast Viability in Presence of VPA and Analogues
Lymphoblastoid cells in culture were treated overnight (16 hours) with VPA, VPM or Octanoic acid. 
Viable cells were determined by counting cells using a haemocytometer following addition of Trypan 
Blue. Results are average of 2-3 repeats, error bars represent the range of the repeats.
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Figure 4-6 Intracellular Effect of VPA and Analogues
Lymphoblastoid cells in culture were treated overnight with VPA, graph A, VPM, graph B or Octanoic acid, 
graph C plus specific inhibitor SI7092 or MeOH control. Following treatment cell extracts were taken and 
measured for PO activity. Results are average of three repeats done in duplicate ±SEM.
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SI7092 has a dose independent pharmacological index of oral bioavailability of 0.7 
indicating it is a membrane permeable drug. This is reflected in complete inhibition of 
intracellular PO activity following HEK293 cell treatment with just 30nM S I7092 
(Barelli et al. 1999). VPA also shows rapid uptake following oral dosing with 
maximal serum levels observed after 1-4 hours. VPA has an estimated half-life of up 
to 16 hours in vivo, indicating it is not rapidly broken down within the cell.
At 0.5mM, within the therapeutic range of VPA, none of the compounds showed 
significant inhibition of PO activity (using students t-test and a cut off value of 
p<0.05). VPA showed a small yet significant inhibition of PO activity at 
concentrations of 1 and 3mM (12% and 15% respectively). At these concentrations 
octanoic acid also showed PO inhibition almost 2 fold greater than that of VPA 
(Figure 4-6 A&C). It is possible that the decrease in PO activity in the presence of 
either of these two compounds is an effect of cell death rather than specific inhibition, 
treatment with both VPA and octanoic acid results in an increase in cell death. The 
effect of both acids was lost in the presence of specific PO inhibitor SI 7092 at 1.3nM 
(50% inhibition of PO). S I7092 treatment had no effect on cell viability (data not 
shown).
VPM also shows a small (16%) but significant decrease in PO activity yet no cell 
toxicity at 3mM, VPM inhibition is maintained in the presence of 1.3nM S I7092 
showing significant (p<0.05) inhibition at both 1 and 3mM (Figure 4-6 B).
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4.2.4 VPA Enhances Not Inhibits LiCI Effect On Cellular 
Processes
Lithium treatment of Dictyostelium prevents aggregation due to modulation of inositol 
signalling, this effect is avoided by the lisA mutant lacking DpoA (Williams et al. 
1999). VPA also prevents aggregation of wild type cells, again by modulation of 
inositol signalling, but does not prevent aggregation in the lisA mutant (Williams et 
al. 2002). Treatment with a PO inhibitor would be expected to attenuate Li+ inhibition 
of aggregation. VPA does not act as a PO inhibitor to dampen the effect of lithium, 
but, increases lithium sensitivity preventing aggregation at lower LiCI concentrations. 
Dictyostelium were grown on agar plates containing 3mM VPA, VPM or Octanoic 
acid and increasing concentrations from 2-12mM of LiCI or NaCl control. In the 
presence of VPA a LiCI concentration of just 4mM was sufficient to prevent 
aggregation, Dictyostelium aggregation in the absence of any other compound was 
inhibited only at concentrations above 8mM, (Figure 4-7), NaCl did not affect 
Dictyostelium aggregation or development at any concentration (data not shown). 
VPA alone did not prevent aggregation but inhibited normal development of the 
fruiting body, this may be attributed to inhibition of alternative VPA targets.
Any PO inhibitory activity of VPM or octanoic acid is insufficient to have an effect 
on aggregation in the presence of LiCI, aggregation was affected to the same degree 
as that of Dictyostelium grown in the presence of LiCI alone. Neither VPM nor 
octanoic acid enhanced the effect of LiCI or showed any developmental defects. This 
implies that neither compound is able to target inositol-1-phosphate synthase, 
responsible for the inositol depletion effect of VPA (Shaltiel et al. 2004) or other VPA 
targets (possibly histone deacetylase or microsomal epoxide hydrolase) responsible 
for developmental defects.
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Figure 4-7 Dictyostelium  Development in the Presence of VPA or Analogues
Development o f Dictyostelium on agar supplemented with VPA (D,E,F), VPM (G,HJ), Octanoic acid (J,K,L) 
or MeOH (A,B,C) as well as 4mM (B,E,H,K), or lOmM (C,FJ,L) LiCI or NaCl salt control (A,D,G,J) was 
observed and photographed using a Zeiss stereo zoom dissecting microscope. Pictures are representative o f 3- 
4 repeats.
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4.3 Discussion
Initial results indicate that PO activity is not directly modulated by therapeutic 
concentration of mood stabilising drugs Li+, VPA and CBZ. However, it has become 
evident that when considering PO activity and inhibition a small change in 
environmental conditions may have a significant effect on the behaviour of this 
enzyme.
4.3.1 VPA Inhibition Of PO Is pH Dependent
Assays of both the mammalian and Dictyostelium PO enzyme revealed little or no 
inhibition by VPA at pH 7.0 and inhibition of between 25 and 30% at pH 7.5 and 8.0. 
VPA inhibition may be dependent on the ionisation state of the enzyme, it is of note 
that the imidazole ring of the active site histidine is proposed to be deprotonated in 
this pH range. A similar inhibition was observed using the amide derivative of VPA, 
VPM, suggesting the effect of VPA on PO is not dependant on the carboxylic acid 
group. The unbranched VPA analogue octanoic acid was also able to inhibit PO 
activity at pH7.5 and 7.0 so the acid effect on the inhibition cannot be discounted.
PO inhibition by carboxylic acids has been reported previously by Park et al. (2006) 
who observed an inhibitory effect of a number of fatty acids. In their study it was 
concluded that the inhibition was dependant on the presence of a number of double 
bonds and the COOH moiety, no inhibition was observed with saturated fatty acids. 
Octanoic acid and VPA are shorter chain fatty acids than those previously tested 
therefore, I propose they may be able to overcome any steric effects preventing their 
longer, unsaturated family members from interacting with the binding site of the 
enzyme.
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Studies of specific PO inhibitors often include a carbon chain ending in an aromatic 
ring that is able to enter the hydrophobic S3 pocket. Portevin et al. show the 
importance of side chain chirality and an optimum side chain length of (CH2 )3 , they 
also report that saturated side chain analogs were 2 fold less effective inhibitors than 
their unsaturated counterparts (Portevin et al. 1996). This is reminiscent of the 
situation in fatty acid inhibition and may support a steric effect in access to the S3 
pocket.
A number of PO inhibitors, including Z-Pro-Prolinal and JTP-4819 (Table 1-1), 
contain a hydroxyl group on the proline binding the PI position at the catalytic site. 
However, to my knowledge no inhibitors have been shown containing a carboxylic 
acid moiety in this domain, though the oxyanion binding site would be an obvious 
choice for binding of the carboxyl oxygen. If VPA, octanoic acid or VPM are 
interacting with PO at the active site, future studies may involve linking these 
compounds to a PO targeting peptide at both the S3 and S1 binding position.
The carboxylic acid domain of VPA is also not essential for the VPA inhibitory effect 
on human microsomal epoxide hydrolase (mEH) (Spiegelstein et al. 2000). mEH is an 
important metabolic enzyme responsible for hydrolysis of epoxides to their 
corresponding trans-dihydrodiols and is also a target for VPA inhibition. A study of 
the effect of both amide and acid VPA derivatives on mEH activity revealed 
inhibition requirements were limited to 8+ carbon atoms, including two saturated 
aliphatic alkyl side chains attached to the carbonyl. The presence of a carboxylic acid 
group was not necessary, in fact the compounds containing the amide moiety proved 
the more potent inhibitors (Spiegelstein et al. 2000). A similar study looking at the 
inhibition of another VPA target, the histone deacetylases (HDACs), revealed that 
while introduction of a double bond (to produce 2- or 4-ene VPA) was tolerated,
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HD AC inhibition was severely depleted by amide substitution or structural alterations 
(Eyal et al. 2005).
From our observations using the VPA analogues VPM and octanoic acid it is not 
possible to differentiate between the importance of the branched structure or the 
carboxylic acid group for inhibition of PO activity.
4.3.2 In Vivo Effect Of VPA
The effect of VPA on endogenous human PO activity in lymphoblasts was 
complicated by the effect of VPA on cell viability. Both VPA and its unbranched 
analogue, octanoic acid, decrease cell viability by 12 and 19% respectively when 
added at 3mM. Eyal et al (2005) have also reported a decrease in cell viability (of 
67%) in the presence of 2mM VPA using SW620 and 1106mel cells, but less than 
20% in the presence of VPM.
In our assay, at 3mM both VPA and octanoic acid decreased lymphoblast PO activity 
by 16% and 39% respectively. At this concentration the decrease in cell viability must 
be considered and may account for a significant proportion of the lost PO activity. 
However, this raises the question of why this inhibition is lost in the presence of 
specific inhibitor S I7092 when both compounds show the same effect on cell viability 
in the presence and absence of S I7092 (data not shown).
Intracellular cytosolic pH of mammalian cells is tightly maintained at 7.4. Addition of 
acid or basic solutions to cells may alter intracellular pH (pH*) only very transiently 
(5-10) minutes (Salvi et al. 2002) therefore it is unlikely that VPA or its analogues 
will affect pH*. It is of note that cytosolic pH is decreased in apoptotic cells (Nilsson 
et al. 2003), as cell viability decreases decreased cytosolic pH may allow increased 
PO inhibition by octanoic acid.
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The amide derivative of VPA, VPM, also showed a significant (p<0.05) decrease in 
PO activity, 17% decrease at 3mM, this is of particular interest as this compound did 
not have a significant effect on cell viability. As VPM only inhibits purified PO 
activity above pH 7.0 it is expected that VPM preferentially inhibits the de-protonated 
form of PO. VPM’s inhibitory effect was also maintained in the presence of 50% PO 
inhibition by S I7092,
Several studies have illustrated the ability of specific PO inhibitors to reverse the 
inositol depletion effects of LiCI. One of these effects is the inhibition of 
Dictyostelium aggregation, which is avoided in the mutant lacking DpoA. Neither 
VPA nor its analogues were able to overcome lithium inhibition of aggregation at 
3mM, and VPA itself amplified the inhibition. This may merely imply an insufficient 
inhibition of PO for an effect to be seen, however, at increased concentrations of all 
three compounds normal cell viability was severely impaired (data not shown). 
Neither VPM nor octanoic acid amplified the LiCI inhibition of aggregation. Other 
VPA targets have been closely examined for structural requirements of inhibition, this 
has not been undertaken specifically for inositol-1-phosphate synthase, thought to be 
the VPA target responsible for its inositol depletion properties (Shaltiel et al. 2004). 
However, structural requirements of inositol depletion have been reported to be the 
presence of a carboxylic acid group as well as specific enantiomorphism (Eickholt et 
al. 2005; Shimshoni et al. 2007). I would not expect either of the above VPA 
analogues to affect inositol-1-phosphate synthase activity.
4.3.3 Summary
• Purified PO activity is not affected by therapeutic concentrations of mood 
stabilisers
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The inhibitory effect of VPA and its analogues on prolyl oligopeptidase is pH 
dependant.
In vivo inhibition of PO by VPA is very slight and may be masked by the 
negative effect of VPA on cell viability.
5 Cellular Role Of PO
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5.1 Introduction
A considerable amount of information is available on the PO enzyme structure, 
sequence, kinetics and inhibitors, some of which have even reached clinical trials. 
However, the true function of PO within the cell remains unresolved.
5.1.1 Potential Intracellular Functions Of PO
Prolyl Oligopeptidase is able to cleave small peptides following a proline residue, 
many bioactive peptides fall under this description and have proved, in vitro, to be 
effective substrates for PO. This has resulted in PO activity being linked to a number 
of different cellular processes, though it remains unclear whether all of these peptides 
are cleaved by PO in vivo.
PO may play a role in neuropeptide degradation. PO inhibition may result in 
neuroprotection (Checler et al. 1986b; Lew et al. 1994; Shishido et al. 1999a) and 
improvements in memory loss in both patients with cognitive memory disorders and 
animal models of amnesia (Yoshimoto et al. 1987; Toide et al. 1995a; Morain et al. 
2000; Morain et al. 2002). PO also cleaves a number of bioactive peptides involved in 
osmoregulation, and altered PO levels are observed in rats following excessive salt or 
water treatments (Ferrario and Iyer 1998; Irazusta et al. 2001).
A function for PO involving less specific peptide cleavage has been suggested in 
general proteolysis. Constant protein turnover is central to healthy cellular 
metabolism, the presence of a proline residue within a peptide can protect against 
degradation by a number of general proteases. Thus, proteases specifically able to 
cleave proline-containing peptides are essential. Decreased PO levels have been 
observed at times of cell differentiation and cell stress both of which are associated
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with altered levels of proteolysis (Pratt et al. 1989; Tsukahara et al. 1990b; Tsukahara 
et al. 1991a).
PO activity is also implicated in a number of cellular processes not obviously 
connected to cleavage of small peptides. The most prominent of these is its role in 
inositol signalling by inhibition of breakdown of higher order inositol phosphates to 
the second messenger IP3 (Williams et al. 1999; Schulz et al. 2002). Another is POs 
potential role in DNA synthesis and therefore cell proliferation as observed in Swiss 
3T3 and embryonic insect cells (Ohtuski et al. 1997; Ishino et al. 1998). Also, more 
recently, a role for PO in protein secretion has been identified. Inhibition of PO results 
in detection of increased overall protein secretion as well as an increase in secretion of 
P-amyloid peptides associated with Alzheimer’s Disease (Rossner et al. 2005; Schulz 
et al. 2005).
Elevated mammalian PO levels have been associated with a number of inflammatory 
and autoimmune conditions (Cunningham and O’Connor 1997; Kakegawa et al. 2004; 
Seo et al. 2006). Bacterial PO is thought to be secreted from the bacterial cell and play 
a key role in infection by cleavage of the hosts extracellular matrix (Santana et al. 
1997; Grellier et al. 2001; Bastos et al. 2005).
5.1.2 Localisation Of PO
Prolyl Oligopeptidase is a largely cytosolic enzyme, as has been observed in a number 
of mammalian tissues and in Dictyostelium cells (Goossens et al. 1995; Williams et al. 
1999). A small proportion of cellular PO activity, between 10 and 30%, is associated 
with the particulate fraction rather than the soluble fraction (Dresdner et al. 1982; 
Agirregoitia et al. 2005). Reports of a membrane associated form of PO, which is 
largely removed following stringent washing suggests PO is interacting with other 
membrane bound proteins rather than integrated into the membrane (Lew et al. 1994).
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The presence of PO within the nucleus has been observed in Swiss 3T3 cells and 
cultured insect cells, in both cases nuclear PO was present only in restricted regions of 
the nucleus while remaining distributed throughout the cytoplasm. Under certain 
conditions PO in cultured insect cells appeared to localise solely to the nucleus 
(Ohtuski et al. 1997; Ishino et al. 1998). In contrast, Schulz et al. have reported PO 
localisation to the perinuclear region and microtubules close to the nucleus, but 
excluded from the nucleus itself, in human glial and neuronal cell lines (Schulz et al. 
2005).
Secretion of PO has been observed but only in bacteria (Chevallier et al. 1992; 
Kabashima et al. 1998), parasites (Bastos et al. 2005) and fungi (Yoshimoto et al. 
1988; Sattar et al. 1990). PO is not secreted from mammalian or Dictyostelium cells 
(Williams et al. 1999; Schulz et al. 2005). This is at odds with reports detailing serum 
PO levels in relation to a number of disorders (Maes et al. 1995). Studies of PO levels 
in different tissues have reported PO activity in serum to be orders of magnitude less 
than that observed in other tissues (Agirregoitia et al. 2005). This activity may be 
accounted for by lysis of cells in the bloodstream, it is also reported that at least 60% 
of apparent PO activity observed in serum may be the result of ZIP activity (an 
enzyme showing similar specificity to PO) (Breen et al. 2004).
5.1.3 Inositol Signalling And PO Function
Inositol signalling is involved in a diverse array of cellular processes, therefore, any 
changes which affect these signalling pathways have the potential to bring about a 
number of effects.
PO inhibition of dephosphorylation of IP6/IP5 to IP3 affects the levels of these higher 
order inositol phosphates as well as intracellular levels of IP3 . Therefore, as well as
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affecting IP3 mediated Ca2+ release and any downstream signalling events, a change 
in PO activity may affect downstream pathways of IP6 , IP5 and IP4 .
The ratio of IP6  to IP4/IP5 affects gene expression by negative (IP6) and positive 
(IP4/IP5) regulation of chromatin remodelling factors (Shen et al. 2003; Steger et al. 
2003). IP6  is also essential for efficient mRNA export from the nucleus in yeast cells 
(York et al. 1999). Additionally, both IP4 and IP6  are able to inhibit endocytosis by 
interaction with proteins involved in clathrin coated pit formation (Palczewski et al. 
1991; Gaidarov et al. 1996; Milano et al. 2006).
The enzyme, Multiple Inositol Polyphosphate Phosphatase (MIPP), dephosphorylates 
IP6 , IP5 and IP4  in both mammalian and Dictyostelium cells (Nogimori et al. 1991; 
Van Dijken et al. 1995). The mammalian enzyme is located largely in the rough and 
smooth endoplasmic reticulum (Ali et al. 1993; Craxton et al. 1995), while the 
Dictyostelium homologue is reportedly located at the inner face of the plasma 
membrane rather than the ER (Van Dijken et al. 1997).
5.1.4 AIM
This chapter will examine the cellular role of PO by establishing the intracellular 
localisation of this enzyme within Dictyostelium. It will also clarify the method by 
which PO is able to inhibit MIPP activity and thus affect inositol phosphate levels.
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5.2 Results
5.2.1 Transfection Of Dictyostelium With GFP-Tagged DpoA
Wild type, Ax2, Dictyostelium discoideum were transfected with the pDXA- 
GFP2:DpoA vector, encoding a GFP tagged DpoA controlled by its endogenous 
promoter. Positive clones were identified by G418 resistance and maintained in high 
levels of G418 (100mg/l) to ensure sufficient expression for detection of fluorescence 
(for vector diagram and sequence see appendix I.III).
Transcription of the tagged DpoA was confirmed by Northern blot analysis of RNA 
extracted from two separate clones, RNA from untransformed Ax2 cells and LisA, the 
PO null cell line, were included as a control. Use of a PO specific probe revealed the 
presence of RNA encoding the endogenous DpoA, which was absent from LisA cells, 
and the presence of a larger DpoA RNA band in the transformed cells representing 
that encoding the tagged enzyme (Figure 5-1). The Northern blot was stripped and 
reprobed against Ig7, this gene encodes a microsomal rRNA subunit and is regularly 
used as a loading control.
Protein expression was then confirmed by visualisation of the tagged protein using a 
Zeiss Axioskop fluorescence microscope. Comparison of bright field and fluorescence 
pictures reveals the cells transformed with the tagged enzyme are clearly fluorescent 
while untransformed cells were not (Figure 5-2 images A-F). Subsequent 
transformation of LisA cells with the same vector was confirmed in the same way 
(Figure 5-2 images G-L).
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Figure 5-1 Expression of DpoA:GFP in Dictyostelium
A Northern blot was performed on Dictyostelium cell extracts (prepared from growing cells). Cell 
extracts were prepared from Ax2 (wild type) cells, a, LisA (PO null) cells, b and DpoA:GFP 
transfected Ax2 cells from two individual colonies, c and d. The blot was probed with a DpoA 
specific probe, A then stripped and re probed with an Ig7 specific probe as a loading control, B (for 
hybridisation conditions see Materials and Methods 2.3.12).
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Figure 5-2 Visualisation of DpoA:GFP
Live Dictyostelium cells in KK2 media were captured using both bright field, pictures 
A,C,E,GJ,K and fluorescence, pictures B,D,F,H,J,L microscopy to identify cells expressing 
GFP tagged enzyme. Untransformed Ax2, A,B and LisA, G,H cells did not fluoresce while both 
Ax2, pictures C,D,E,F and LisA, pictures I,J,K,L cells expressing DpoA:GFP clearly 
fluoresced. Pictures are representative of total population.
20pM
It has been established previously that the PO enzyme containing the V5 tag retains 
enzyme activity (see section 3.2.2), the GFP tag also allows enzyme activity. Cell 
extracts were taken from transformed and untransformed Ax2 and LisA cells and 
assayed for PO activity using the substrate Z-Gly-Pro-pNA.
These assays revealed that DpoA:GFP expression resulted in an approximately 50% 
increase in PO activity in Ax2 cells (Figure 5-3). As expected PO activity was 
completely absent from the LisA cells. Importantly this also indicates the absence of 
any other enzyme showing a similar substrate specificity from Dictyostelium. 
DpoA:GFP expression in LisA cells returned PO activity levels to that seen in wild 
type cells.
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Ax2 (wild type)  LisA (DpoA Ax2 DpoA:GFP Ax2 DpoA:GFP LisA DpoA:GFP LisA DpoA:GFP 
null) ( d o n e l )  (clone2) ( d o n e l )  ( do ne 2 )
Figure 5-3 Activity of GFP Tagged DpoA in Dictyostelium Cell Extracts
Cell extracts of untransformed Ax2 and LisA cells and cells transformed with the GFP tagged DpoA 
expressing vector pDXA-GFP2:DpoA were incubated with the PO substrate Z-GIy-Pro-pNA PO activity 
was measured by the appearance of the product pNA (see materials and methods 2.6.5). Results are average 
of two repeats done in duplicate ± standard deviation.
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5.2.2 DpoA:GFP Is Distributed Throughout The Entire Cell
The localisation of PO within the cell may provide a clue to its cellular role and aid 
our understanding of this enigmatic enzyme. A number of reports have placed PO in 
the cytosol of the cell, others report some nuclear localisation or localisation to the 
particulate fraction or specific cell structures. In this study the localisation of a GFP 
tagged DpoA in fixed Dictyostelium cells has been observed using confocal 
microscopy.
A Z-series of images taken through the cell enabled a 3D image of the PO distribution 
to be formed. When viewed directly as a stack of images (Figure 5-4 images A & E), 
distribution appears increased around the centre of the cell and at the plasma 
membrane. However, rotation of the 3D image reveals that the increased volume of 
GFP at the centre of the cell may be attributed to the ‘fried egg’ shape of the cell. 
Enriched fluorescence around the plasma membrane may also be accounted for by 
the shape of the cell, a side view reveals membrane protrusions pointing upwards at 
the edge of the cell (Figure 5-4 images C & G). These images reveal PO to be 
distributed evenly throughout both the cytoplasm and nucleus.
Ax2 (wild type) Dictyostelium cells either; untransformed, expressing DpoA:GFP or 
expressing un-attached GFP were stained using DAPI to confirm presence of PO 
within the nucleus. Observation of single, unstacked confocal pictures of 
Dictyostelium expressing DpoA:GFP revealed a rather granular, slightly wispy 
distribution throughout the entire cell. Co-staining with DAPI showed a clear 
presence of DpoArGFP, showing the same granular distribution, throughout the 
nucleus (Figure 5-5).
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Figure 5-4 3D Projection Showing Cellular D istribution of DpoArGFP
A Z-series o f confocal images taken through Ax2 and LisA cells expressing DpoA:GFP were stacked 
together to produce a 3D image o f the distribution o f the tagged enzyme throughout the cell (see 
materials and methods 2.5.6). Pictures A-D show rotation o f a single Ax2 cell around 180° while 
pictures E-H show the 180° rotation o f a LisA cell. Both pictures are representative o f all fluorescent 
cells observed.
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Comparison of cells expressing DpoA:GFP with those expressing unattached GFP 
showed clear differences in cellular distribution (Figure 5-5). GFP alone showed a 
much more even distribution throughout the cytoplasm, it did not show the grainy 
distribution observed with DpoA:GFP. Another clear difference is the exclusion of 
GFP from vesicles present throughout the cell, this is not seen with the tagged protein 
suggesting the DpoA:GFP is able to freely enter these vesicles. This also implies 
distribution of DpoA:GFP is not governed by the GFP tag.
Subsequently the presence of DpoA:GFP was observed alongside staining of the 
endoplasmic reticulum. Several reports of PO activity in the particulate, non-soluble 
fraction of the cell suggest PO may be present within or associated with the ER or 
other cellular structures. Staining of the endoplasmic reticulum was achieved using a 
monoclonal antibody, mAb 221-64-1, against the ER marker Protein Disulphide 
Isomerase (PDI).
This antibody was a kind gift from Prof. M.Maniak, it targets the C-terminus of the 
PDI protein and is similar to mAb 221-135-2 described previously by Monnat et al. 
and used subsequently as an ER marker (Monnat et al. 1997; Williams et al. 1999). 
Cell staining using the anti-PDI l°Ab followed by a Texas Red conjugated secondary 
revealed a membranous structure within the cell. This was similar to that previously 
reported by Monnat using both anti-PDI Abs and a GFP:HDEL protein chimera 
containing GFP and the ER retention signal sequence HDEL (Monnat et al. 1997).
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Figure 5-6 Comparison of DpoA:GFP Distribution with ER M arker
DpoA:GFP transformed, F-K, GFP transformed, L-Q and untransformed, A-E, Ax2 cells were stained with an anti- 
PDI l°antibody followed by a Texas Red conjugated 2°antibody to identify the endoplasmic reticulum (see 
materials and methods 2.5). No l°antibody was added in pictures, B,E,H,K,N &Q to identify any background signal.
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DpoA:GFP did not specifically co-localise with the ER marker though the two stains 
did overlap in some regions (Figure 5-6). PO is not distributed throughout the entire 
ER but may show some localised association. In the cells expressing GFP alone the 
ER stain showed a clear lack of co-localisation with the vesicles excluding GFP. The 
size and position of these vesicles indicates they may represent endosomes or 
lysosomes.
5.2.3 Protein-Protein Interactions Of PO
The protein sequence of both mammalian and Dictyostelium prolyl oligopeptidase 
does not contain a classical nuclear, vesicular, plasma membrane or ER localisation 
signal, therefore, it is presumed that any significant intracellular localisation must be 
mediated by interaction with other proteins.
A number of other (3-propeller domain proteins interact with other proteins via the top 
surface of the ^-propeller domain (Jenne and Stanley 1987; Neer and Smith 1996). 
This region may, therefore, play an important part in the cellular localisation of PO. 
To date other than the peptides cleaved by PO the only protein-protein interaction 
described for PO is binding of a-tubulin. PO has been reported to bind cx-tubulin in 
the same region as the binding site for microtubule-associated proteins (MAPs) 
(Schulz et al. 2005).
Tubulin forms an important structural component of the cell and a-tubulin staining 
reveals a network of fibres spread throughout the cytosol of the cell. This structure is 
best appreciated by viewing the maximum projection picture, built by stacking a 
confocal Z-series taken through the cell (Figure 5-7).
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It is quite clear that DpoA:GFP and a-tubulin are not co-localised however this 
cannot discount an interaction between them, especially as the staining and GFP 
protein do overlap (Figure 5-7). The binding of a-tubulin to DpoA was further tested 
by investigating any interaction between these two proteins in extracellular extracts. 
Dictyostelium cell extracts were taken from Ax2 cells expressing DpoA:GFP or 
unattached GFP. These extracts were incubated with magnetic beads conjugated to 
antiGFP antibodies and applied to a pMACs separation column. Any GFP tagged 
proteins and associated proteins are bound by magnetic force. A weak wash (20mM 
Tris-HCl, pH 7.5) is used to remove any unbound proteins while disrupting specific 
protein-protein interactions as little as possible. Following this a more stringent 
elution (50mM Tris-HCl pH6 .8 , 50mM DTT, 1% SDS, ImM EDTA, 0.005% 
bromophenol blue, 10% glycerol) was used to remove the GFP proteins from the 
beads. An aliquot of the original cell extract along with the wash, eluted fraction and 
bead slurry was analysed by western blot for the presence of DpoA:GFP, GFP and a - 
tubulin.
Western blot analysis showed both DpoA:GFP and GFP clearly bound to the beads on 
the column and were only partly removed following the elution step as a proportion 
remained bound to the beads (Figure 5-8 B). a-Tubulin was not present in the column 
flow-through or preliminary wash however nor was it eluted along with DpoA. a - 
tubulin was only detected in the fraction containing the bead slurry, this indicates that 
a-tubulin may form a non-specific interaction with the antiGFP beads. It is not 
thought that its retention on the column is indicative of any interaction with PO as it 
remains bound following DpoA:GFP elution. In addition a-tubulin was also retained 
on the column in the absence of DpoA. The band identified by the a-tubulin antibody 
is smaller than expected (around 30 kDa rather than 51 kDa) suggesting the tubulin
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has degraded. This may be caused by the stringent wash conditions or during removal 
of beads from the column.
This result does not give a definitive result but suggests that in our hands a-tubulin 
does not show specific interaction with DpoA.
A silver stain of the eluted fractions was also carried out, DpoA:GFP, GFP and a - 
tubulin were all visible in their respective fractions (Figure 5-8 A). Interestingly a 
number of bands were also visible representing proteins which apparently co-eluted 
with DpoA:GFP yet are absent from the GFP elution fraction. These bands (indicated 
by stars, Figure 5-8 A) may represent additional proteins that interact with DpoA.
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Figure 5-7 DpoA Does Not Co-Localise with a-Tubulin
Growing cells were fixed and stained with a l°antibody against a-tubulin followed by a Texas Red conjugated 2°antibody. A 
series of Z-sections were taken through each cell and stacked to form a maximum projection picture of the tubulin through the 
depth of the cell (see materials and methods 2.5). Images from two cells of Ax2 untransformed, A-G, expressing DpoA:GFP, H-N 
or expressing GFP, O-U are representative of all cells observed. A maximum projection of the GFP fluorescence was only 
:ompleted for one cell of each type. 5-220
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Figure 5-8 Protein-Protein Interaction of DpoA and a-Tubulin
A. Silver Stain of Proteins retained by DpoA:GFP on a GFP Binding Column. Cell extracts of DpoA:GFP, a-e, and 
GFP, f-j, expressing cells were incubated with GFP binding beads before being loaded onto a magnetic column. 
Unbound proteins were washed out in the flowthrough, a & f, and washes, b-c & g-h before elution of GFP proteins, d & 
i followed by release of the beads from the column, e & j. Bands representing DpoA:GFP, GFP and a-tubulin are 
indicated by arrows, stars indicate bands co-eluted with DpoA:GFP which were not observed with GFP alone. B&C. 
Western Blot of GFP Binding Column Eluates. Cell Extracts as for silver stain, A. DpoA:GFP, a-f, GFP, g-1, 
flowthrough, a & g, washes 1-3, b-d & h-j, elution, e & k, beads, f  & 1. Blot B was probed using anti-GFP-HRP 
antibody, blot C was probed using anti-a-tubulin l°antibody followed by anti-mouse-HRP 2°antibody.
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5.2.4 Localisation Of PO Is Not Dependent On Activity
Cells expressing DpoA:GFP were grown in the presence of the specific PO inhibitor 
Z-Pro-Prolinal at 130mM before being fixed for confocal microscopy. No change in 
the distribution of DpoA was observed, indicating that enzyme localisation 
throughout the cell including entry to the nucleus and any potential vesicular 
localisation is independent of enzyme activity (Figure 5-9 images C-D).
The localisation of PO also appears to remain unchanged during development. 
Dictyostelium cells in suspension were pulsed with cAMP for 5 hours then placed in a 
cAMP gradient. The cells migrate towards the higher concentration of cAMP 
mimicking aggregation of cells during mound formation. Confocal images of cells 
chemotaxing along a cAMP gradient clearly show the cells elongated with a leading 
edge pushing out at the front, however, DpoA:GFP remains evenly distributed 
throughout the moving cell (Figure 5-9 images E-F).
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Figure 5-9 PO Localisation is Independent of Activity or Development
Confocal images of cells grown in the presence, C-D and absence A-B of the PO specific inhibitor 
Pro-Prolinal, or grown in suspension, pulsed with cAMP for 5 hours and placed in a cAMP gradient, E- 
Cells were prepared as described in sections 2.5.3 and 2.5.4.
5.2.5 Mechanism Of PO Inhibition Of MIPP
5.2.5.1 Timecourse O f M IPP Inhibition
Inhibition of PO results in derepression of IP5 dephosphorylation to IP3 , this reaction 
is catalysed by the enzyme Multiple Inositol Polyphosphate Phosphatase (MIPP) 
(Nogimori et al. 1991; Craxton et al. 1995). The mechanism by which PO is able to 
inhibit MIPP activity is not known. Direct cleavage of MIPP may be unlikely because 
of its size, MIPP activity could therefore be affected by a regulatory peptide. 
Alternatively PO could affect gene expression or protein synthesis of this enzyme.
In order to clarify the pathway from PO to M IPP inhibition a timecourse was 
investigated to determine any delay between inhibition of PO and activation of M IPP. 
PO specific inhibitor Z-Pro-Prolinal was added to Dictyostelium cells grown in 
culture, aliquots of cells were taken directly after addition of inhibitor and at 
subsequent time points. PO activity and IP3 levels in cell samples were measured. 
Following addition of Z-Pro-Prolinal, PO inhibition was immediate (6 second time 
point) and maintained for over an hour. PO activity was decreased to less than 20% of 
that seen in control cells and did not increase in samples taken up to an hour after 
inhibitor treatment (Figure 5-10).
IP3 levels were significantly higher in treated cells than those in control cells 
30minutes after addition of PO inhibitor, indicating PO inhibitors are able to de­
repress M IPP activity in under half an hour (Figure 5-11). This short time-course 
makes it unlikely that PO is acting via alteration of gene expression.
A steady increase in IP3 was observed throughout the assay. As the assay progressed, 
levels of IP3 in both treated and untreated cell cultures increased. This may be due to 
secretion of IP3 into the cell culture media rather than an increase in intracellular IP3.
5-224
■  Z-Pro-prolinal
■  DMSO Control
Time from Addition of Inhibitor (m in u tes)
Figure 5-10 Time-course of PO Inhibition by Z-Pro-Prolinal
PO activity in cell extracts taken at lOminute intervals from growing cells following treatment with 
Z-Pro-Prolinal or DMSO, carrier control. Results are mean of 3 biological repeats done in duplicate 
±SEM
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Figure 5-11 Time-course of Cellular IP3 Changes Following Z-Pro-Prolinal Treatment
IP3 level in cell extracts taken at 30minute intervals from growing cells following treatment with Z-Pro-Prolinal 
or DMSO, carrier control. Results are mean of at least 3 biological repeats done in duplicate ±SEM
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This increase in IP3 was also observed in the absence of DMSO eliminating the 
possibility of a DMSO effect (data not shown).
5.2.5.2 Interaction O f  PO A n d M IPP
The conclusion that PO inhibition of MIPP is not mediated via gene expression is 
supported by the observation that recombinant DpoA is able to inhibit MIPP activity 
in the particulate fraction of cell extracts (Figure 5-12). To measure MIPP activity the 
particulate fraction of cell extracts was incubated with IP6 , production of IP3 was then 
measured using the Inositol-1,4,5-Trisphosphate [3 H] Radioreceptor Assay (see 
Materials and methods, PerkinElmer Life Sciences). MIPP is able to dephosphorylate 
IP6 , IP5 and IP4  to produce IP3 (Nogimori et al. 1991; Van Dijken et al. 1995). A 
direct effect of DpoA on MIPP activity was detected by pre-incubation of the 
particulate fraction, containing MIPP, with purified recombinant DpoA with and 
without Z-Pro-Prolinal.
Pre-incubation of MIPP with recombinant DpoA resulted in a significant decrease in 
MIPP activity, approximately 50%, compared with pre-incubation with buffer only. 
No decrease in activity was observed when MIPP was pre-incubated with both 
recombinant DpoA and its specific inhibitor (Figure 5-12).
This implies PO inhibition o f MIPP activity is mediated by a direct interaction 
between PO and MIPP or via an intermediate protein or peptide present within the 
particulate fraction. This raises the question, could PO be able to cleave some proteins 
as well as small peptides and could PO potentially be acting directly on MIPP itself?
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Figure 5-12 Direct Inhibition of MIPP by Recombinant DpoA
The particulate cell fraction containing MIPP A was incubated with and without purified recombinant 
DpoA in the presence of Z-Pro-Prolinal or DMSO. MIPP A activity was then assayed by addition of 
IP6 followed by measurement of breakdown to IP3. Results are average of at least 3 repeats done in 
duplicate ±SEM
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Figure 5-13 Protein Sequence of Dictyostelium MIPP A (EAL64744)
Potential Prolyl Oligopeptidase cleavage sites are identified by numbered boxes around four residues with 
the bond to be cleaved at the centre. Box 7 identifies the site most likely to be a true cleavage site.
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The preferred cleavage site of PO is the carboxyl bond of a proline residue adjacent to 
a hydrophobic residue. PO is also able to cleave after an alanine residue, though with 
lower efficiency, under certain conditions (Sharma and Ortwerth 1994). Inspection of 
the protein sequence for Dictyostelium MIPP A (Accession No. EAL64744) identified 
seven potential PO cleavage sites within 100 residues of either end of the protein 
(Figure 5-13).
Six of these were proline residues, the seventh an alanine residue. Of these seven, five 
conformed to the Pro(Ala)-X motif where X is a hydrophobic residue (Figure 5-13 
box 1,2,3,4,7). Cleavage of peptides by PO is reported to be restricted to sites within 
4-5 residues of the peptide terminus therefore the only strong possibility as a cleavage 
site for PO is that outlined in box 7 Figure 5-13. Cleavage at this point would remove 
the three residues LIQ from the C-terminus of MIPP A.
5.2.6 Inactive DpoA Does Not Act As A Dominant Negative
The same active site mutations as introduced to the V5-tagged DpoA expressed in 
bacteria, were introduced to the GFP tagged DpoA in the Dictyostelium expression 
vector pDXA (Appendix I.III). Again, this was done using Quickchange mutagenesis 
and confirmed by sequencing of the vector. Both Ax2 and LisA cells were 
transformed with each of the mutants H730A, D693G and S609A, clones were 
selected using G418 and positive colonies confirmed by observation of fluorescence. 
Activity of the GFP tagged mutants was measured following isolation on GFP 
binding magnetic columns. PO assays were carried out in the columns containing the 
bound GFP protein, the assay buffer was eluted into a 96 well plate, following 
completion, for spectrophotometric analysis as normal. The unbound cell extract (data 
not shown) and the flowthrough, were also assayed for PO activity (Figure 5-14).
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Figure 5-14 Activity of Mutant DpoA:GFP
Cell extracts were taken from wild type (WT) Ax2 and LisA cells as well as Ax2 and LisA cells expressing 
unaltered DpoA:GFP or DpoA:GFP containing the mutations H730A, D693G or S609A. These extracts 
were incubated with anti-GFP antibodies conjugated to magnetic beads and applied to a magnetic column. 
Flow-through, and GFP proteins bound to the columns were both assayed for PO activity.
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As expected PO activity was observed in the unbound extract of all Ax2 cells as well 
as LisA cells expressing the wild type DpoA.GFP. Columns were loaded to saturation 
so some recombinant enzyme activity was present in the flowthrough. Also as 
expected, PO activity was observed bound to the columns in the cells expressing wild 
type DpoA:GFP. Very little or no activity was observed bound to the columns 
containing extracts from cells expressing S609A or D693G mutants or the respective 
flowthroughs when expressed in LisA cells.
Rather unexpectedly the H730A mutant retained its PO activity, this was not the case 
for the V5 tagged DpoA H730A mutant previously expressed in bacteria. The major 
difference between these two proteins is the C-terminal tag. The H730 residue is very 
close to the beginning of the tag sequence therefore its positioning may potentially be 
distorted by the presence of the tag. The GFP peptide is considerably larger than that 
of the V5 epitope tag so may have a greater effect on the context of the His residue at 
the active site
These mutants were observed to determine if they would behave as a dominant 
negative and show a similar insensitivity to LiCl as the LisA DpoA null mutants. 
Cells were plated out on agar containing increasing concentrations of LiCl or NaCl as 
a salt control.
Rather than acting as a dominant negative the mutant DpoA:GFP protein appears to 
increase sensitivity; aggregation of Dictyostelium expressing the mutant enzymes was 
inhibited at 5mM LiCl while both the untransformed cells and cells expressing the 
non-mutant tagged enzyme retained the ability to aggregate (Figure 5-15). 
Dictyostelium expressing the wild type DpoA:GFP showed a slight increased 
sensitivity to LiCl by showing inhibition of aggregation at a lower LiCl concentration 
than the untransformed cells (data not shown).
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Figure 5-15 Sensitivity of Mutant DpoA Transformed Dictyostelium to LiCl
Ax2 cells expressing H730A, D693G or S609A mutant DpoA:GFP were allowed to develop in the 
presence of LiCl or NaCl salt control (see materials and methods 2 .4 .4).
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5.3 Discussion
The cellular function of PO has been linked to a diverse array of processes. By 
studying intracellular localisation of this enzyme as well as specific enzyme 
interactions, it is possible to suggest potential mechanisms responsible for some of 
these effects.
5.3.1 Localisation Of DpoA; Indication Of PO Function
Confocal images of Dictyostelium cells expressing GFP tagged DpoA have revealed a 
diffuse localisation throughout the cell. Noticeably, DpoA:GFP was not excluded 
from intracellular vesicles that clearly excluded GFP alone. Distribution and size of 
these vesicles suggests they may represent endosomes or lysosomes. This conflicts 
with western blot analysis of different cellular fractions by Williams et al. (1999) 
which showed DpoA to be absent from the vesicular fraction. The potential presence 
of PO activity within these vesicles is interesting when considered in connection with 
the proposed existence of two pH forms of the enzyme (Polgar 1991a).
The high pH form of PO is active under physiological conditions, the vesicular 
localisation may propose a function of the low pH form as the pH within lysosomes is 
considerably lower than that of the cytoplasm. If PO is in fact functional within 
lysosomes (pH5) or late endosomes (pH5-6), it supports a previously proposed role in 
general proteolysis (Pratt et al. 1989; Tsukahara et al. 1991a; Tsukahara et al. 1991b). 
PO may be important for cells to be able to degrade and recycle peptides containing 
proline residues.
Staining of DpoA:GFP cells with DAPI revealed the presence of PO within the 
nucleus. Previous reports of nuclear PO have proposed a role in DNA synthesis 
(Ohtuski et al. 1997; Ishino et al. 1998). Another possibility is that of a nuclear
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inositol signalling function. Although MIPP is reportedly localised to the endoplasmic 
reticulum or plasma membrane, a potential nuclear function is suggested by 
observation of the effect of ratio of IP6 to IP4 /IP5 in chromatin remodelling and gene 
expression (Shen et al. 2003; Steger et al. 2003). In Dictyostelium, changes in PO or 
MIPP activity are able to affect levels of gene expression of a number of enzymes in 
the inositol pathway (personal communication M.Keim and J.King).
The presence of DpoA within the nucleus is not dependent on enzyme activity, 
distribution was not affected by the presence of Z-Pro-Prolinal. There was also no 
change during chemotaxis, nuclear distribution was not decreased or accentuated. 
Ohtsuki et al. (1997) reported a decrease in nuclear PO accompanied by an increase in 
cytosolic PO following changes in cell culture conditions of insect embryonic cells. 
No such effects have been observed in Dictyostelium cells during aggregation or PO 
inhibition however, many other conditions may affect DpoA. Observation of DpoA 
localisation under different cellular conditions may yet reveal changes in its position 
within the cell.
PO distribution at the plasma membrane, the suggested localisation of MIPP in 
Dictyostelium, was not observed. There was also no apparent co-localisation of 
DpoA:GFP with the ER marker PDI as shown previously by Williams et al. (1999).
PO has been implicated in a number of functions that are localised to specific 
intracellular structures, for example gene expression and protein secretion. However, 
in this study even distribution of PO throughout the cytoplasm and nucleus is 
observed. This suggests that either PO acts sufficiently upstream in the signalling 
pathway that it does not localise to effecter proteins or, PO is able to play specific 
roles, by cleaving different substrates, in the different cellular compartments without 
increased localisation to these regions.
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In order to completely discount the effect of the GFP tag on localisation of DpoA 
within the cell it would be necessary to carry out immunofluorescence studies of 
endogenous DpoA in untransformed cells. Unfortunately two DpoA antibodies raised 
against peptide fragments of the enzyme have proved ineffective.
5.3.2 Effects Of DpoA Mediated By Inositol Signalling
Previous reports have linked a loss of PO activity to increased vesicular transport and 
an increase in total protein secretion as well as a specific increase in secretion of 13- 
amyloid (protein involved in plaque formation observed in Alzheimer’s Disease) 
(Rossner et al. 2005; Schulz et al. 2005).
A function for PO in intracellular transport and peptide secretion would provide an 
alternative explanation to a number of contradictory hypotheses about the role of this 
enzyme. Numerous groups have reported an increase in a variety of neuropeptides 
including Substance P, a-MSH (Bellemere et al. 2003) and TRH (Shinoda et al. 1995) 
following PO inhibition. The current theory is that inhibition of PO results in a 
decrease in degradation of these peptides, this is slightly contentious as there is 
mounting evidence of the cytosolic, non-secreted localisation implying PO would not 
come in to contact with these peptides in vivo. Another explanation may be increased 
secretion of neuropeptides resulting from removal of the repressive effect of PO on 
vesicle trafficking and secretion. While these neuropeptides are clear substrates of PO 
in vitro, a significant number of enzymes are expressed in vivo which may result in 
the same cleavage.
These results have not identified PO localisation to the microtubules as previously 
observed (Schulz et al. 2005), however, this does not discount the role of PO in this 
process. It is possible that the effect of PO on vesicle trafficking and secretion is also 
mediated by the effect of PO on inositol phosphate levels. Inhibition of PO results in
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increased dephosphorylation of IP6 , IPs and IP4. Both IP6  and IP4 are able to bind a 
number of proteins involved in vesicle trafficking resulting in inhibition of 
endocytosis and vesicle recycling (Palczewski et al. 1991; Voglmaier et al. 1992; 
Gaidarov et al. 1996; Milano et al. 2006).
Inositol pyrophosphate IP7 also shows a negative effect on clathrin coat formation, by 
binding proteins involved in assembly including AP-3 (Ye et al. 1995), and vesicle 
trafficking (Fleischer et al. 1994; Ali et al. 1995). While no change in pyrophosphate 
levels has been reported following inhibition of PO, it is known that in mammalian 
cells up to 50% of the IP6  pool goes through cycles of phosphorylation and 
dephosphorylation to IP7 and IPs every hour (Menniti et al. 1993). Therefore, an 
increase in IP6  breakdown has the potential to cause a knock-on effect to the levels of 
these compounds.
5.3.3 Specific Intracellular Interactions
Other proteins containing a (3-propeller domain are able to form protein-protein 
interactions via the top surface of the propeller (e.g. interactions of both hemopexin 
and vitronectin with cellular receptors and binding of G(3 to the a  and y subunits 
(Jenne and Stanley 1987; Neer and Smith 1996)). This domain provides a potential 
site for PO to interact with other intracellular proteins. PO is present throughout the 
cytoplasm, nucleus and potentially a number of intracellular vesicles and able to 
influence a number of cellular functions. Specific protein interactions may be 
important in targeting PO to a particular localisation or particular signalling pathway. 
Silver stain analysis of proteins bound by DpoA:GFP trapped in a GFP binding 
column revealed a number of proteins retained in the presence of DpoA:GFP but not 
GFP alone. These results showing potential DpoA-binding proteins highlight an
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exciting progression, perhaps using yeast-2 -hybrid methods, for work on this enzyme 
however, this is beyond the scope of this particular investigation.
The addition of PO inhibitors resulting in increased IP3 levels has been well 
documented (Williams et al. 1999; Schulz et al. 2002). Increased IP3 is the result of 
increased dephosphorylation of higher order inositol phosphates, a reaction catalysed 
by the enzyme M IPP. Time course and activity studies have enabled further insight 
into how PO may act to inhibit M IPP activity. M IPP is not an obvious target for 
cleavage by PO, whose activity is reportedly restricted to peptides of less than 30 
amino acids. This restriction has been proposed to be due to the presence of secondary 
structures in larger peptides preventing access to the active site, therefore, PO is 
potentially also able to cleave unstructured regions at the N or C-terminus of a larger 
protein.
MIPP activity was increased within 30 minutes of PO inhibition making it unlikely 
that the effect of PO is mediated by changes in gene expression. In fact a much more 
direct interaction between these two enzymes is highly likely, addition of purified 
DpoA is able to inhibit MIPP activity in a cell extract particulate fraction. Three 
possible scenarios of MIPP inhibition by PO are proposed; cleavage of MIPP itself, 
peptide cleavage to create an inhibitory peptide or cleavage of a stimulatory peptide. 
Despite the size restriction preventing MIPP cleavage by PO a potential PO cleavage 
site is present at the C-terminus of the enzyme.
5.3.4 Effect Of Catalytically Inactive DpoA
In contrast to the V5 tagged DpoA the H730A mutant of DpoAiGFP retained its 
ability to hydrolyse Z-Gly-Pro-pNA. The only difference between these two 
recombinant enzymes is the C-terminal tag, suggesting the presence of the larger GFP 
tag may distort the last member of the catalytic triad or the area around it such that
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another residue may compensate for the loss of His. The literature contains a number 
of examples where the mutated amino acid may be compensated for; Corey et al. 
(1992) found that the function of the mutated Asp residue in trypsin may be replaced 
by the introduction of a nearby acidic residue.
A number of mechanisms have been proposed to explain the activity of the catalytic 
triad in the prolyl oligopeptidase family enzymes. These include models of charge 
relay, hydrogen bond formation and the existence of two active diads rather than a 
single active triad (Polgar and Halasz 1982; Liao et al. 1992). The role of the histidine 
residue is that o f a proton acceptor, stabilising the active serine residue and the 
tetrahedral intermediate (Polgar and Bender 1969). During catalysis the His imidazole 
ring gains a proton in the transition state and is stabilised by Asp.
The exact position of the His residue is flexible. Carter and Wells (1987) reported 
site-directed mutagenesis of the catalytic His residue in subtilisin can be partially 
compensated by substrate assisted catalysis, His at the P2 position of the substrate is 
able to compensate for the missing catalytic residue. The Gly residue in our synthetic 
substrate would not act in this way, however, it is possible another residue close to the 
active site would. In a small subset of serine proteases (Sedolisins SB, S53) the His 
residue function is in fact carried out by a glutamic acid residue whose carboxyl group 
is able to accept a proton from serine (Polgar 2005).
The region surrounding the catalytic triad of DpoA, 30 aa upstream of Ser to 30 aa 
downstream of His, contains 26 possible proton acceptors; 7 His, 13 Asp and 6  Glu 
residues, of which 4 His, 8  Asp and 2 Glu residues lie outside of predicted secondary 
structures while a further 2 His residues are at the terminus of a-helices (Fulop et al. 
1998). If the active site is slightly distorted by the presence of the GFP tag one of 
these residues may be able to align close to the active site and compensate to a certain
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extent for the loss of the catalytic His. A structural model of the active site of DpoA 
was created using the Swiss Model application using the X-ray crystal structure of the 
porcine enzyme, lh2w, as a template. In this structure it appears that three of these 
possible proton acceptors, Glu742, Asp 632 and Asp 694 are in the vicinity of the 
active and have the potential to compensate for loss of the His residue (Figure 5-16). 
Further mutagenesis studies would be required to determine if this was the case. 
Surprisingly, following development in the presence of LiCl the transformants 
containing the mutant DpoA:GFP did not behave as a dominant negative, instead 
aggregation was hypersensitive to the presence of lithium as would be expected in a 
transformant showing over-expression of the active enzyme. Hypersensitivity to LiCl 
of Dictyostelium expressing the mutant enzymes may indicate that although mutant 
PO is no longer able to cleave its target it can still bind it, thus sequestering it from its 
appropriate role. This is consistent with a model whereby PO is cleaving either MIPP 
directly or a stimulatory peptide rather than creating an inhibitory peptide.
The transformant expressing active DpoA:GFP was also hypersensitive to Lithium 
treatment but to a slightly lesser extent than those expressing the mutant versions. No 
difference in hypersensitivity was observed between the active H730A mutant and the 
inactive S609A and D693G mutants suggesting activity of the His mutant may not be 
maintained in the cell. The role of the catalytic triad become much more important in 
cleavage of a stronger peptide bond rather than an activated substrate (Corey and 
Craik 1992). Szeltner et al. (2002) also found that stabilisation of the transition state 
during catalysis was less important for activity if the substrate contained a good 
leaving group such that only a weak bond was being cleaved. This may account for 
the ability of the His mutant to cleave Z-Gly-Pro-pNA but show the same phenotype 
as the other mutants.
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Figure 5-16. Potential Proton Acceptors close to the active site
Ribbon representation of the structure of the Dictyostelium PO, DpoA, as modelled by SwissModel 
using prolyl oligopeptidase from porcine brain, accession no. Ih2w, as a template. Images were 
produced using MacPyMol software. Only the catalytic domain is represented in this image. Active site 
residues are shown by purple stick structures (Ser609, Asp693 and His730). The 26 possible proton 
acceptors, which may compensate for the loss of the catalytic His, in the region surrounding the 
catalytic triad of DpoA, 30 aa upstream of Ser to 30 aa downstream of His, are highlighted in orange. 
Stick structures are shown (in orange) for three of these possible proton acceptors, Glu742, Asp 632 
and Asp 694, which may be close to the active site. Also highlighted, are the proline binding residues 
(light blue) and the oxyanion binding residues (dark blue).
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Catalytically inactive DpoA mutants may prove valuable for identification of the in 
vivo target of this enzyme. Rioli and co-workers describe a method using catalytically 
inactive enzymes to identify endogenous substrates present in crude peptide extracts 
from animal tissues, followed by isolation and sequencing of peptides identified (Rioli 
et al. 2003). Using this method they were able to describe a number of novel peptide 
substrates for the enzymes; Endopeptidase 24.15, Neurolysin and Angiotensin- 
converting enzyme. This method may provide a highly feasible route to identification 
of the elusive PO substrates.
5.3.5 Summary
• PO is distributed throughout the cytoplasm and nucleus of the cell.
• Potential, unidentified, DpoA interacting proteins have been detected, 
however, a previously reported interaction with a-tubulin has not been 
reproduced.
• DpoA is able to inhibit MIPP A in an isolated particulate fraction implying a 
direct mechanism of inhibition.
• Mutant studies of inactive enzyme are consistent with a model of PO cleavage 
of MIPP or a MIPP stimulatory peptide.
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6 Discussion
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6.1 Introduction
PO was first identified in 1971 as an oxytocin degrading enzyme (Walter et al. 1971). 
More than 30 years on and the true intracellular targets and functions of prolyl 
oligopeptidase are still not fully understood. In this study, sequence analysis, 
biochemical kinetics and cell biology have been used to study this enzyme in order to 
further understand its function as well as its potential as a therapeutic target.
6-244
6.2 Dictyostelium Provides A Good Model For Inositol 
Phosphate Signalling
Since its first discovery in the 1930s Dictyostelium discoideum has enjoyed an ever- 
increasing popularity as a model organism (Raper 1935), not least because of its 
single celled amoeboid growth, division and chemotaxis followed by cellular 
differentiation and development to form a multicellular organism. Studies using this 
organism have enabled insights into our understanding of some important biological 
processes including chemoattractant sensing, cell movement, and signal transduction 
(Harwood 2001).
Identification of the PO homologue, DpoA, in Dictyostelium and its role in inositol 
signalling adds weight to the argument for use of this organism to study the inositol 
phosphate pathway. This pathway is central to cell function and while Dictyostelium 
shows some differences to mammalian cells in its inositol phosphate chemistry, 
inositol phosphate signalling and the enzymes involved are highly conserved in this 
organism (van Haastert and van Dijken 1997).
Sequence analysis of the prolyl oligopeptidase enzyme across a number of species 
from the three different kingdoms has revealed a number of points. A striking 
observation was that a number of database sequences annotated as PO showed closer 
phylogenetic relatedness to other members of the Prolyl Oligopeptidase (S9) family 
than to PO suggesting they may be mis-annotated. The majority of these protein 
sequences lacked regions of homology to either the p-propeller or the catalytic 
domain. It may be the case that these sequences could be more accurately annotated 
as DPPIV, OB or AP, this observation highlights the essential nature of detailed 
sequence analysis on database sequences.
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The prolyl oligopeptidase sequence is conserved across Eukaryotes, Bacteria and 
Archaea. Within the Prolyl Oligopeptidase phylogeny the Eukaryotes form a separate 
cluster from the Bacterial and Archaea proteins. DpoA, present in the eukaryote 
cluster, surprisingly shows a greater evolutionary distance from the mammalian 
enzyme than the plant {O.saliva and A.thaliana) or parasitic (T.cruzi and T.brucei) 
enzymes. Despite this evolutionary distance the more detailed sequence analysis 
shows a very high sequence homology around the active site and (3-propeller domain, 
site directed mutagenesis has confirmed both the identity and necessity of the residues 
of the catalytic triad.
The use of the Dictyostelium homologue as a model for the mammalian enzyme is 
further supported by biochemical analysis of activity of recombinant DpoA and Rpo 
against the PO specific substrate Z-Gly-Pro-AMC. Enzyme kinetics studies revealed a 
similar Km and Vmax for both enzymes as well as very similar inhibition profiles in the 
presence of the specific PO inhibitors Z-Pro-prolinal and SI 7092.
The mechanism by which PO is able to control dephosphorylation of higher order 
inositol phosphates is currently under investigation. The similarity of DpoA to the 
mammalian enzyme makes Dictyostelium an ideal model for further understanding 
how this complex pathway is controlled. Dictyostelium may prove a more suitable 
choice than a number of other model organisms, the enzyme annotated as PO in the 
nematode C.elegans was one of those lacking the (3-propeller domain while yeast 
completely lack PO. The two commonly used model organisms D.melanogastor and 
D.rerio contain PO sequences showing a closer relatedness to the mammalian enzyme 
than that of Dictyostelium. However, preliminary studies indicate that the recombinant 
D.melanogaster PO expressed in bacteria does not hydrolyse the PO specific substrate 
Z-Gly-Pro-pNA (unpublished data). In addition, while D.rerio PO may represent a
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closer model of the mammalian enzyme, this organism is much harder to maintain and 
manipulate in a laboratory environment.
The two plant enzymes also show good homology to the mammalian enzyme. 
Signalling in these organisms may be complicated by identification of multiple PO 
homologues, some showing a closer homology to the bacterial enzyme and some the 
mammalian enzyme.
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6.3 Understanding Of Inositol Pathways In Mood Disorders
Changes in inositol signalling, inositol or inositol phosphate levels have been 
reported in a number of mood disorders and other neurological disorders including 
Bipolar Disorder (Berridge et al. 1989), Schizophrenia (Shimon et al. 1998) and 
Down’s Syndrome (Berry et al. 1999; Beacher et al. 2005). These represent complex 
disorders with both genetic and environmental causes. The underlying cause of most 
mood disorders remains poorly understood and treatment requires a combination of 
drugs, some with potentially serious side effects, and careful dose control (Burt and 
Rasgon 2004; Freeman and Freeman 2006; Young and Newham 2006). 
Understanding of signal transduction pathways potentially underlying these disorders 
may aid identification of more relevant and specific therapeutic targets.
One common treatment for Bipolar Disorder, valproic acid (VPA), is also used to 
treat epilepsy and migraines. The effects of VPA in Bipolar treatment are thought to 
be mediated by its effect on inositol-1 -phosphate synthase resulting in inositol 
depletion; LiCl, another BD treatment, also causes inositol depletion though by 
inhibition of IMPase (Berridge et al. 1982; Inhom and Majerus 1987; Shaltiel et al. 
2004). A recent report by Cheng et al. (2005) identified an inhibitory effect of VPA 
on PO and proposed a model in which VPA is able to control inositol levels by acting 
on different parts of the pathway to both deplete and increase inositol. This suggests a 
mechanism to control both manic and depressive episodes, which may be related to 
increased and decreased inositol levels in bipolar patients.
In this study using recombinant His-tagged DpoA and Rpo (the Dictyostelium and rat 
prolyl oligopeptidase homologues) VPA inhibition was observed but to a much lesser 
extent than previously reported (Cheng et al. 2005). Effects of VPA analogues 
valpromide (VPM) and octanoic acid on PO activity indicate that both the carboxylic
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acid domain and the branched structure may play a role in PO inhibition. At pH 7.5 
both the unbranched carboxylic acid, octanoic acid, and the VPA amide derivative, 
valpromide, are able to inhibit recombinant DpoA and Rpo.
Physiological pH of mammalian cells, blood and cerebral spinal fluid (CSF) is around 
pH 7.4 and very little variation in pH is observed. At this pH either the carboxylic 
acid domain, the branched structure or both may be important for PO inhibition. To 
examine the effect of VPA in vivo, lymphoblast cells were treated overnight with 
VPA or its analogues. A small yet significant decrease in activity was observed in the 
presence of VPM. A small but significant inhibition of PO was also observed 
following treatment with VPA or octanoic acid, both of these treatments also led to a 
decrease in cell viability, therefore it is possible that the decrease in PO activity is a 
result of cell stress rather than direct inhibition.
The model proposed by Cheng et al. (2005) of altered functions of VPA during 
periods of mania compared with periods of depression could potentially be explained 
by the pH dependency of VPA inhibition of PO. This is an intriguing idea as small 
decreases in brain intracellular pH (changes of less than pH 0.1) have been associated 
with bipolar disorder (Kato et al. 1998; Hamakawa et al. 2004). Even more 
intriguingly a mitochondrial DNA polymorphism has been associated with Bipolar 
Disorder, Alzheimers Disease and Parkinson Disease, cells containing this 
polymorphism showed decreased mitochondrial matrix pH (approximately pH 0.1) 
and increased intracellular Ca2+ signalling (Kazuno et al. 2006); VPA has recently 
been reported to decrease Ca2+ levels only in cells containing this polymorphism 
(Kazuno et al. 2007).
VPM was able to inhibit recombinant PO at a physiological pH, this ability was 
maintained in vivo, VPM was able to demonstrate small yet significant PO inhibition
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in lymphoblast cells without affecting cell viability. However, this inhibition was not 
sufficient to provide any visible lithium resistance when applied to developing 
Dictyostelium.
These results combined with a previous inhibitor study of unsaturated fatty acids on 
PO (Park et al. 2006), enable the suggestion that the important structural requirements 
for PO inhibition are the presence of one or more double bonds, a branched or a 
relatively short carbon chain and, at low pH, a carboxylic acid group. Other reports on 
the essential structural requirements for inhibition of alternative targets of VPA 
showed differing importance of the branched structure and the carboxylic acid 
(Spiegelstein et al. 2000; Eyal et al. 2005). These differences may be key in 
separating desired therapeutic effects of VPA from those causing unwanted side 
effects.
The structure required for VPA inhibition of inositol-1-phosphate synthase may prove 
valuable in future treatment of mood disorders. Studies of VPA derivatives have 
found the main structural requirement for inositol depletion to be the presence of a 
carboxylic acid group. The side chain length and branching appeared less important, 
however, inositol depletion was enantiomer specific suggesting a stereo-specific 
interaction is involved (Eickholt et al. 2005; Shimshoni et al. 2007). These reported 
essential structural requirements for inositol depletion differ from the potential 
requirements for PO inhibition, therefore, it may be possible to separate these two 
opposing effects of VPA on inositol signalling.
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6.4 Cellular Interactions Of PO
The importance of non-inositol phosphate signalling roles of PO should not be 
overlooked. As is evident from phylogenetic analysis, a large number of bacterial POs 
that show strong similarity to the mammalian enzyme have been identified. Bacteria 
do not contain inositol polyphosphates therefore, the role of PO in these organisms is 
exclusively un-related to MIPP signalling. Elucidation of these roles may be aided by 
identification o f PO binding partners or intracellular substrates.
PO does not contain a nuclear localisation signal or other targeting sequences. It is 
therefore expected that PO is able to interact with other proteins within the cytoplasm 
to facilitate nuclear localisation, entry to vesicles or even transient localisation to the 
plasma membrane or ER to interact with MIPP. The presence of PO within 
intracellular vesicles is supported by observation of a GFP tagged DpoA. This protein 
is localised throughout the cytoplasm while GFP alone showed clear exclusion from a 
number of small intracellular vesicles. Additionally, up to 30% of PO in the cell may 
be present in the particulate fraction (Agirregoitia et al. 2005). If this is true it 
suggests the existence of two separate pools of PO, which may be carrying out 
different functions. This is an interesting proposition as PO has been linked to varied 
biological functions.
To date the only protein reported to bind to PO other than peptide substrates is a - 
tubulin (Schulz et al. 2005). In this study I have been unable to replicate this 
interaction, however, very preliminary data indicates PO may bind a number of other 
proteins. Further research is needed to identify binding partners of this enzyme, an 
ideal step would be to complete yeast-2-hybrid studies. It will also be important to 
determine if  any interactions identified in Dictyostelium also occur with the 
mammalian enzyme.
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A final question, which has not been addressed in this study, is the upstream control 
of PO. PO levels and localisation are altered in response to different cell stresses 
indicating this enzyme is under specific control (Pratt et al. 1989; Tsukahara et al. 
1990b; Sharma and Ortwerth 1994; Ohtsuki et al. 1997). In Dictyostelium cells 
localisation was not affected by addition of inhibitors, nor did it change during 
chemotaxis. A previous report describes an endogenous inhibitor for PO (Salers 
1994), identification of proteins interacting with PO should identify any intracellular 
inhibitors. To determine if PO expression rather than activity is altered during 
different cell stress conditions, gene expression and promoter studies may be needed.
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6.5 Potential Direct MIPP inhibition By PO
Loss of PO is known to result in increased MIPP activity. I propose that PO inhibition 
of MIPP is mediated by either direct cleavage of MIPP by PO or PO cleavage of a 
MIPP stimulatory peptide present in the particulate fraction.
Following PO inhibition M IPP activity, as measured by accumulation of IP3, is 
increased in less than 30 minutes. In addition, purified PO is able to decrease M IPP  
activity when added to the particulate fraction of cell extracts. This rapid downstream 
effect as well as the ability to interact in the absence of whole cells indicates a 
relatively direct interaction between PO and M IPP. Three models to fit this pathway 
include (a) PO cleavage of M IPP itself, (b) cleavage of a stimulatory peptide or (c) 
cleavage of an additional protein or peptide to release an inhibitory peptide (Figure 
6- 1).
Localisation of these enzymes does not disagree with these models, MIPP is localised 
within the endoplasmic reticulum or potentially at the plasma membrane (Ali et al. 
1993; Craxton et al. 1995; Van Dijken et al. 1997). The action of MIPP within the cell 
is to dephosphorylate higher order inositol phosphates to produce IP3. These IPs are 
involved in a number of signalling pathways occurring within the cytoplasm however 
the ratio of IP6  to IP5 and IP4 also affects gene expression, by activation and inhibition 
of chromatin remodelling complexes (Shen et al. 2003; Steger et al. 2003), therefore 
MIPP may also play a nuclear role.
PO’s presence throughout the cytosol may indicate that it is unlikely to come into 
contact with MIPP. However, reports showing PO in the particulate fraction 
(Dresdner et al. 1982; Agirregoitia et al. 2005) and observation of the DpoA:GFP 
localisation within the nucleus as well as avoiding vesicle exclusion, indicates that at 
least a proportion of cellular PO may be able to access MIPP.
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(a )
ACTIVE
(b)
ACTIVE
Presence of active PO
INACTIVE INACTIVE
Presence of inactive PO variant
INACTIVE INACTIVE
(C)
ACTIVE
INACTIVE
ACTIVE
Figure 6-1 Potential Models of PO Inhibition of MIPP
I propose three possible models of MIPP inhibition by PO; (a) PO cleavage of MIPP itself, (b) cleavage of a 
stimulatory peptide or (c) cleavage of an additional peptide to release an inhibitory peptide. Only models (a) 
and (b) agree with observations of over-expression of the inactive PO variant in Dictyostelium.
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Further studies are required to determine if the PO inhibition of MIPP reported here is 
conserved when the enzymes are present at physiological levels. Under the conditions 
of the assay, MIPP over expresser cell extracts and purified DpoA, both PO and MIPP 
were present at arbitrary levels.
Mutagenesis studies have revealed that loss of any of the catalytic triad residues 
results in a loss of peptidase activity. Growth of Dictyostelium in the presence of LiCl 
results in inhibition of aggregation mediated by inositol depletion. While a loss of 
DpoA attenuates this inhibtion by increasing cellular IP3, transformation with the 
inactive DpoA mutant does not confer LiCl resistance indicating that it does not act as 
a dominant negative. The inactive DpoA mutant results in LiCl hypersensitivity as is 
observed in Dictyostelium transformed with a fully functional DpoA. This may 
indicate that the variants are able to cleave the intracellular substrate despite not 
acting on the PO specific substrate Z-Gly-Pro-pNA. A more likely scenario is that the 
variants are still able to bind the endogenous substrate at the active site but unable to 
cleave or easily release the substrate, resulting in sequestration of the substrate. This 
result fits with models (a) and (b) but would not fit with model (c) of production of an 
inhibitory peptide (Figure 6-1).
A distinction between these two models may be determined by isolation of MIPP and 
western blot analysis to detect any cleavage of this enzyme. Our laboratory has 
recently acquired an antibody raised against MIPP, characterisation of this enzyme to 
determine specificity and efficiency is currently ongoing therefore this question may 
be answered in the very near future.
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6.6 Summary
Prolyl Oligopeptidase has been identified in archaea, bacteria and eukaryotes and is 
highly conserved between different species. In this study both phylogenetic and 
biochemical analysis have revealed the Dictyostelium PO homologue, DpoA, to be 
similar to the mammalian enzyme. While much work is still required to understand 
this enzyme fully Dictyostelium appears to be a highly suitable model for studying 
this pathway.
Inhibition of PO is able to reverse the action of a number of mood stabilising drugs by 
reversing their inositol depletion effect. This does not appear to involve direct 
interaction between the drugs and PO. However, in contrast to this an inhibitory effect 
of VPA on PO has been observed in vitro at physiological pH. This inhibition may be 
dependent on the presence of a carboxylic acid domain and a short or branched carbon 
backbone. The negative effect of VPA on cell viability leaves its inhibitory effect in 
vivo unclear.
Identification of PO binding proteins including its intracellular substrate and any 
regulatory peptides or proteins may prove integral to understanding the cellular role of 
PO. Initial results from isolation of the GFP tagged enzyme indicate the presence of 
potential PO binding partners. Further research using the peptidase dead mutants 
described in this study to identify in vivo targets of this enzyme has the potential to 
finally throw some light on this mysterious protein.
Finally, following observation of a time-course of enzyme activity inhibition in vivo 
as well as in vitro enzyme assays and mutant enzyme over expression, I have 
proposed three models to explain PO inhibition of MIPP activity.
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I Appendices
i
I.I Species List
Archaea Euryarchaeota Halobacteria Haloarcula marismortui
Thermococci Pyrococcus furiosus
Thermoplasmata Thermoplasma volcanium 
Picrophilus torridus
Bacteria Actinobacteria Actinobacteria (class) Corynebacterium glutamicum 
Mycobacterium tuberculosis 
Corynebacterium diphtheriae
Bacteroidetes/Chlorobi group Bacteroidetes Flavobacterium 
meningosepticum 
Elizabethkingia meningoseptica
Cyanobacteria Gloeobacteria Gloeobacter violaceus
Nostocales Nostoc sp
Dei n oc occu s-Thermu s Deinococci Deinococcus radiodurans
Firmicutes Bacilli Bacillus cereus 
Streptococcus pneumoniae 
Streptococcus mutans 
Streptococcus pyogenes
Planctomycetes Planctomycetacia Rhodopirellula baltica
Proteobacteria Alphaproteobacteria Erythrobacter litoralis 
Rickettsia typhi 
Gluconobacter oxydans 
Caulobacter crescentus 
Novosphingobium capsulatum
Betaproteobacteria Chromobacterium violaceum 
Burkholderia pseudomallei
Bdellovibrionaceae Bdellovibrio bacteriovorus
Cystobacterineae Myxococcus xanthus
Gammaproteobacteria Xanthomonas axonopodis 
Xanthomonas oryzae 
Shewanella oneidensis 
Idiomarina loihiensis 
Aeromonas punctata 
Aeromonas hydrophila 
Vibrio parahaemolyticus 
Vibrio fischeri 
Photorhabdus luminescens 
Salmonella enterica 
Escherichia coli 
Coxiella burnetii
Spirochaetes Spirochaetes (class) Treponema denticola
Eukaryota Euglenozoa Kinetoplastida Trypanosoma cruzi 
Trypanosoma brucei
Fungi/Metazoa group Fungi Aspergillus fumigatus 
Trichophyton rubrum
Metazoa Drosophila melanogaster 
Danio rerio 
Mus musculus 
Rattus Norvegicus 
Bos Taurus 
Sus scrofa 
Homo sapiens 
Pan troglodytes 
Caenorhabditis elegans
Mycetozoa Dictyosteliida Dictyostelium discoideum
Viridiplantae Streptophyta Arabidopsis thaliana 
Oryza sativa
ii
I.II pBAD TOPO: DpoA 
I.II.I Vector Diagram
R ibosom e bind ing  s i te
A rab i n o se
pBAD TOPO TA:DpoA 
63 7 1  bp
Features
4-276 Arabinose promoter
329-332 Ribosome binding site
346-2718 DpoA:V5His
4262-4935 pBR322 origin
3258-4117 Ampicillin resistance gene 
6345-5466 AraC
III
I.II.II Sequence
S e q u e n c e  R a n g e :  1 t o  6 3 7 1
> A r a b i n o s e _ p r o m o t e r
| 10 20  30 40 50 60 70 80
j * * * * * * * * * * * * * * * *
AAGAAACCAATTGTCCATATTGCATCAGACATTGCCGTCACTGCGTCTTTTACTGGCTCTTCTCGCTAACCAAACCGGTA
TTCTTTGGTTAACAGGTATAACGTAGTCTGTAACGGCAGTGACGCAGAAAATGACCGAGAAGAGCGATTGGTTTGGCCAT
90 100  110  120  130 140 150 160
* * * * * * * * * * * * * * * *
ACCCCGCTTATTAAAAGCATTCTGTAACAAAGCGGGACCAAAGCCATGACAAAAACGCGTAACAAAAGTGTCTATAATCA
TGGGGCGAATAATTTTCGTAAGACATTGTTTCGCCCTGGTTTCGGTACTGTTTTTGCGCATTGTTTTCACAGATATTAGT
> p B A D _ F o rw a rd _ _ p rim in g _ s  i t e
17 0  18 0  19 0  20 0  21 0  22 0  23 0  2 4 0
* * * * * * * * * | * * * * * * *
CGGCAGAAAAGTCCACATTGATTATTTGCACGGCGTCACACTTTGCTATGCCATAGCATTTTTATCCATAAGATTAGCGG
GCCGTCTTTTCAGGTGTAACTAATAAACGTGCCGCAGTGTGAAACGATACGGTATCGTAAAAATAGGTATTCTAATCGCC
2 5 0  2 6 0  2 7 0  2 8 0  2 90  300  31 0  3 2 0
* * * * * * * * * * * * * * * *
ATCCTACCTGACGCTTTTTATCGCAACTCTCTACTGTTTCTCCATACCCGTTTTTTTGGGCTAGAAATAATTTTGTTTAA
TAGGATGGACTGCGAAAAATAGCGTTGAGAGATGACAAAGAGGTATGGGCAAAAAAACCCGATCTTTATTAAAACAAATT
> D p o A _ m u t_ fo r
> R ib o s o m e _ b i n d in g _ s  i t e > D p o A - N c o I - f o r
3 3 0  3 4 0  | 3 5 0  36 0  37 0  38 0  3 9 0  4 0 0
* * * ! * *  * * * * * * * * *  *
CTTTAAGAAGGAGATATACATACCCATGGAATTTAATTACCCAGAAACAAGAAGAGATGATTCTGTTTTTGATATATTTA
GAAATTCTTCCTCTATATGTATGGGTACCTTAAATTAATGGGTCTTTGTTCTTCTCTACTAAGACAAAAACTATATAAAT
M E F N Y P E T R R D D S V F D I F >
DPOA + TAG >
4 1 0  4 2 0  4 3 0  440  45 0  4 6 0  4 7 0  4 8 0
* * * * * * * * * * * * * * * *
AATCAACAGAAAAAGGAAGTGTTAAAGTTTATGATCCATATCGTCATTTAGAAGATCAACAATCACCAAGAACAAAGAAA
TTAGTTGTCTTTTTCCTTCACAATTTCAAATACTAGGTATAGCAGTAAATCTTCTAGTTGTTAGTGGTTCTTGTTTCTTT
K S T E K G S V K V Y D P Y R H L E D Q Q S P R T K K >
DPOA + TAG >
4 9 0  5 0 0  5 1 0  520  53 0  5 4 0  5 5 0  5 6 0
* * * * * * * * * * * * * * * *
TGGGTTGATGAAGAAAATAAAATTACAAGATCATTTTTAGATCAAGATAATACAAGTGAAAAGATTTCAAATGAAATTAT
ACCCAACTACTTCTTTTATTTTAATGTTCTAGTAAAAATCTAGTTCTATTATGTTCACTTTTCTAAAGTTTACTTTAATA
W V D E E N K I T R S F L D Q D N T S E K I S N E I M >
DPOA + TAG >
IV
5 70  58 0  59 0  60 0  6 1 0  6 20  6 3 0  64 0
* * * * * * * * * * * * * * * *
GAAAATGTTAAATTTTGAAAGATTTGATTGGTTTAGAAGAAGAGGTTCAAAATTATTCTTTTCAAGAAATCCAAATACAT 
CTTTTACAATTTAAAACTTTCTAAACTAACCAAATCTTCTTCTCCAAGTTTTAATAAGAAAAGTTCTTTAGGTTTATGTA 
K M L N F E R F D W F R R R G S K L F F S R N P N T >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG  >
6 5 0  6 60  670  68 0  6 90  70 0  71 0  7 2 0
* * * * * * * * * * * * * * * *
TAAATCAAAATATAATTTATTTGATTGATATTGATCAAATTTCAATTAGTAAAGATGGTAAATCAAGTGCAAAAGGATTT 
ATTTAGTTTTATATTAAATAAACTAACTATAACTAGTTTAAAGTTAATCATTTCTACCATTTAGTTCACGTTTTCCTAAA 
L N Q N I I Y L I D I D Q I S I S K D G K S S A K G F >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
7 3 0  7 40  750  760  77 0  7 8 0  7 90  80 0
* * * * * * * * * * * * * * * *
GAAAATGCAATTGAATTCTTAAATCCAAACACTTATTCAAAAGATGGTACATGGAGTTTAAAATCATTTGTAATCTCAAA 
CTTTTACGTTAACTTAAGAATTTAGGTTTGTGAATAAGTTTTCTACCATGTACCTCAAATTTTAGTAAACATTAGAGTTT 
E N A I E F L N P N T Y S K D G T W S L K S F V I S K >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
8 1 0  8 2 0  830  840 85 0  8 60  8 7 0  8 8 0
* * * * * * * * * * * * * * * *
GAGTGGTGATCATGTTTGTTTTAGTTATTCAAAGGCAGGTTCTGATTGGGAAGAGATTGCAGTAAAGAAAATTATAACAA 
CTCACCACTAGTACAAACAAAATCAATAAGTTTCCGTCCAAGACTAACCCTTCTCTAACGTCATTTCTTTTAATATTGTT 
S G D H V C F S Y S K A G S D W E E I A V K K I I T >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
8 9 0  90 0  910  920 9 30  94 0  9 5 0  9 6 0
* * * * * * * * * * * * * * * *
CTAATGAGTTAAAGACAAATAAGGATGATGAAGAGGAGAAAGAAGATTTAAAAAAGAAGAATTGTTTACATTATGCAGTT 
GATTACTCAATTTCTGTTTATTCCTACTACTTCTCCTCTTTCTTCTAAATTTTTTCTTCTTAACAAATGTAATACGTCAA 
T N E L K T N K D D E E E K E D L K K K N C L H Y A V >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
9 7 0  9 80  99 0  1000  1 0 1 0  1 0 2 0  1 0 3 0  1 0 4 0
* * * * * * * * * * * * * * * *
GTGGATCTACCAGATTCAATAAATTGGTGTAAATTTACTTCGATTAAATGGGATGAGAATGAGACTGGTTTCATCTATAA 
CACCTAGATGGTCTAAGTTATTTAACCACATTTAAATGAAGCTAATTTACCCTACTCTTACTCTGACCAAAGTAGATATT 
V D L P D S I N W C K F T S I K W D E N E T G F I Y N >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
1 0 5 0  1 0 6 0  1 0 7 0  108 0  1 0 9 0  1 1 0 0  1 1 1 0  1 1 2 0
* * * * * * * * * * * * * * * *
TCGATATCCAAAACCGGAAAAAGTATCCGATGATGATAAAGGCACTGAAACCGACACCAACTTGAATAATAAAGTTTATT 
AGCTATAGGTTTTGGCCTTTTTCATAGGCTACTACTATTTCCGTGACTTTGGCTGTGGTTGAACTTATTATTTCAAATAA 
R Y P K P E K V S D D D K G T E T D T N L N N K V Y >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
1 1 3 0  1 1 4 0  1150  1160  1 1 7 0  1 1 8 0  1 1 9 0  1 2 0 0
* * * * * * * * * * * * * * * *
ATCATAAATTAGGTGATGCCAATGAGTCGTTTGATAGAGTGGTTTTCGAATGTCCAGAGAACCCACAATGGATATTTGGT
V
TAGTATTTAATCCACTACGGTTACTCAGCAAACTATCTCACCAAAAGCTTACAGGTCTCTTGGGTGTTACCTATAAACCA 
Y H K L G D A N E S F D R V V F E C P E N P Q W I F G >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG  >
1 2 1 0  1 2 2 0  123 0  1240  1 2 5 0  1 2 6 0  1 2 7 0  1 2 8 0
* * * * * * * * * * * * * * * *
ACTGAGTTCTCTCATGACCATAGCTCTTTGTTTATCAGCGCTTTCAGGGACTGCAATGTTGAGCATAATCTATATGTAAT 
TGACTCAAGAGAGTACTGGTATCGAGAAACAAATAGTCGCGAAAGTCCCTGACGTTACAACTCGTATTAGATATACATTA 
T E F S H D H S S L F I S A F R D C N V E H N L Y V I >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
1 2 9 0  1 3 0 0  1310  1 3 2 0  13 3 0  1 3 4 0  1 3 5 0  1 3 6 0
* * * * * * * * * * * * * * * *
TAGAAATTTCCAAGAGGCAATTGCAAATAAATCAGCCTTTAAAGTCGAGGCCCTCATAGATAATTTCGATGCTTGTTATT 
ATCTTTAAAGGTTCTCCGTTAACGTTTATTTAGTCGGAAATTTCAGCTCCGGGAGTATCTATTAAAGCTACGAACAATAA 
R N F Q E A I A N K S A F K V E A L I D N F D A C Y >  
 DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
1 3 7 0  1 3 8 0  1390  1400  1 4 1 0  1 4 2 0  1 4 3 0  1 4 4 0
* * * * * * * * * * * * * * * *
ATTATATTACAAATACTAAACAAGGTGAATATTTCTTTTTAACCAATTTATCTGCACCATTCAATAGATTAATCTCAATT 
TAATATAATGTTTATGATTTGTTCCACTTATAAAGAAAAATTGGTTAAATAGACGTGGTAAGTTATCTAATTAGAGTTAA 
Y Y I T N T K Q G E Y F F L T N L S A P F N R L I S I >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
1 4 5 0  1 4 6 0  1470 148 0  1 4 9 0  1 5 0 0  1 5 1 0  1 5 2 0
* * * * * * * * * * * * * * * *
CAATTGAATGATGATCAACCAATCGTACCAAATTCAAAGAGTAAATTAGAATTTAAAGAGATCATTCCAGAGAAAGACTA 
GTTAACTTACTACTAGTTGGTTAGCATGGTTTAAGTTTCTCATTTAATCTTAAATTTCTCTAGTAAGGTCTCTTTCTGAT 
Q L N D D Q P I V P N S K S K L E F K E I I P E K D Y >  
 DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
1 5 3 0  1 5 4 0  1550  156 0  1 5 7 0  1 5 8 0  1 5 9 0  1 6 0 0
* * * * * * * * * * * * * * *  *
TGTATTGGAATCGGTTAGTCGTTCCTCTCCAGAGAAATTCTACGTTTCCTATCAAAAACATGTTCAAGATATCATTGAAG 
ACATAACCTTAGCCAATCAGCAAGGAGAGGTCTCTTTAAGATGCAAAGGATAGTTTTTGTACAAGTTCTATAGTAACTTC 
V L E S V S R S S P E K F Y V S Y Q K H V Q D I I E >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
1 6 1 0  1 6 2 0  1630  164 0  1 6 5 0  1 6 6 0  1 6 7 0  1 6 8 0
* * * * * * * * * * * * * * * *
TATATGATTTCAATGGTAAATATTTAAAGGATATTAAATTACCAGGCCCTGGAAGTGCTTCATTATCAGCCACTGAGTAT 
ATATACTAAAGTTACCATTTATAAATTTCCTATAATTTAATGGTCCGGGACCTTCACGAAGTAATAGTCGGTGACTCATA 
V Y D F N G K Y L K D I K L P G P G S A S L S A T E Y >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
1 6 9 0  1 7 0 0  1710  172 0  1 7 3 0  1 7 4 0  1 7 5 0  1 7 6 0
* * * * * * * * * * * * * * * *
CATGATCATATCTTTATAAACTTTTCAAATTTAGTTTCACCATCGGTAACTTATTATATGGATTCAAAGAATGATGAATT
GTACTAGTATAGAAATATTTGAAAAGTTTAAATCAAAGTGGTAGCCATTGAATAATATACCTAAGTTTCTTACTACTTAA
H D H I F I N F S N L V S P S V T Y Y M D S K N D E L >
DPOA + TAG >
VI
1 7 7 0  1 7 8 0  179 0  180 0  1 8 1 0  1 8 2 0  1 8 3 0  1 8 4 0
* * * * * * * * * * * * * * * *
GTTACTCTTTAAAGAACCACACATTGAAGGCTTCAAATCATCAGATTATGAATGTAAACAAGTCTTTTATGAATCTCCAA 
CAATGAGAAATTTCTTGGTGTGTAACTTCCGAAGTTTAGTAGTCTAATACTTACATTTGTTCAGAAAATACTTAGAGGTT 
L L F K E P H I E G F K S S D Y E C K Q V F Y E S P >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
1 8 5 0  1 8 6 0  1870  188 0  18 9 0  190 0  1 9 1 0  1 9 2 0
* * * * * * * * * * * * * * * *
AGGATAAAACAAAGATTCCAATGTTTATAGCCTATAAGAAGACCACAGATATCACCAGTGGTAATGCTCCAACCTATATG 
TCCTATTTTGTTTCTAAGGTTACAAATATCGGATATTCTTCTGGTGTCTATAGTGGTCACCATTACGAGGTTGGATATAC 
K D K T K I P M F I A Y K K T T D I T S G N A P T Y M >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA +_ TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
1 9 3 0  1 9 4 0  1950  196 0  197 0  1 9 8 0  1 9 9 0  2 0 0 0
* * * * * * * * * * * * * * * *
ACTGGTTATGGTGGTTTCAATATCTCTTACACTCAATCATTCTCAATTAGAAATATTTACTTTTTAAATAAATTCAATGG 
TGACCAATACCACCAAAGTTATAGAGAATGTGAGTTAGTAAGAGTTAATCTTTATAAATGAAAAATTTATTTAAGTTACC 
T G Y G G F N I S Y T Q S F S I R N I Y F L N K F N G >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA +_ TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
2 0 1 0  2 0 2 0  2 0 3 0  2 0 4 0  2 0 5 0  2 0 6 0  2 0 7 0  2 0 8 0
* * * * * * * * * * * * * * * *
TATCTTTGTAATTGCAAACATTAGAGGTGGTGGTGAGTATGGTAAAGCTTGGCATGAGGCTGGTTCAAAAAAGAATAAGC 
ATAGAAACATTAACGTTTGTAATCTCCACCACCACTCATACCATTTCGAACCGTACTCCGACCAAGTTTTTTCTTATTCG 
I F V I A N I R G G G E Y G K A W H E A G S K K N K >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
> 1 7 2 -5 -F O R
2 0 9 0  2 1 0 0  2 1 1 0  2 1 2 0  2 1 3 0  2 1 4 0  2 1 5 0  2 1 6 0
* * * * * | * * * * * * *  * * * * 
AAAATTGCTTTGATGATTTTATTGGTGCCGCTGAATATTTGATAAAGGAAAACTATACAAACCCAAACCAATTGGCCGTA 
TTTTAACGAAACTACTAAAATAACCACGGCGACTTATAAACTATTTCCTTTTGATATGTTTGGGTTTGGTTAACCGGCAT 
Q N C F D D F I G A A E Y L I K E N Y T N P N Q L A V >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
> A c t i v e _ s i t e _ s e r e i n e
2 1 7 0  2 1 8 0  2 1 9 0  2 2 0 0  2 2 1 0  2 2 2 0  2 2 3 0  2 2 4 0
* * * * * * * * * * * * * * * *
AGAGGTGGTAGTAATGGTGGTTTGTTAATGGGTGCAATTTCAAATCAACGTCCTGATCTATTTAAATGTGTTGTAGCAGA 
TCTCCACCATCATTACCACCAAACAATTACCCACGTTAAAGTTTAGTTGCAGGACTAGATAAATTTACACAACATCGTCT 
R G G S N G G L L M G A I S N Q R P D L F K C V V A D >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
2 2 5 0  2 2 6 0  22 7 0  2 2 8 0  2 2 9 0  2 3 0 0  2 3 1 0  2 3 2 0
* * * * * * * * * * * * * * * *
CGTTGGTGTTATGGATATGCTAAGATTCCATCTTCATACTATCGGTAGTAATTGGGTCTCTGATTATGGTAGAAGTGATA
GCAACCACAATACCTATACGATTCTAAGGTAGAAGTATGATAGCCATCATTAACCCAGAGACTAATACCATCTTCACTAT
V G V M D M L R F H L H T I G S N W V S D Y G R S D >
VII
DPOA + TAG >
2 3 3 0  2 3 4 0  2 3 5 0  2 3 6 0  2 3 7 0  2 3 8 0  2 3 9 0  2 4 0 0
* * * * * * * * * * * * * * * *
ATCCTGATGATTTTGAAGTACTCATTAAATATTCTCCTCTAAATAATGTCCCCAAGGATTCAAATCCATATCCATCAATT 
TAGGACTACTAAAACTTCATGAGTAATTTATAAGAGGAGATTTATTACAGGGGTTCCTAAGTTTAGGTATAGGTAGTTAA 
N P D D F E V L I K Y S P L N N V P K D S N P Y P S I >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
>Ac t  i  v e _ s  i  t e _ A s p a r t  i c _ a c  i  d
2 4 1 0  2 4 2 0  | 2 4 3 0  2 4 4 0  2 4 5 0  2 4 6 0  2 4 7 0  2 4 8 0
*  *  *  * | * *  *  *  *  *  *  *  *  *  *  *  
ATGCTTTGTACTGGTGACCATGATGATCGTGTCATTCCTGCTCACTCTTATAAATTCATCTCTGAATTACAATATCAACT
TACGAAACATGACCACTGGTACTACTAGCACAGTAAGGACGAGTGAGAATATTTAAGTAGAGACTTAATGTTATAGTTGA
M L C T G D H D D R V I P A H S Y K F I S E L Q Y Q L >
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
> A c t i v e _ s i t e _ H i s t i d i n e
2 4 9 0  2 5 0 0  2 5 1 0  2 5 2 0  2 5 3 0  | 2 5 4 0  2 5 5 0  2 5 6 0
* * * * * * * * * * | * * * * *  *
TGGTAAAAAAGTTGATACTCCACTTTTAATTAGAGTTGATAAAGATTCTGGTCATGGTGCTGGTAAAGGTTTATCCAAAC 
ACCATTTTTTCAACTATGAGGTGAAAATTAATCTCAACTATTTCTAAGACCAGTACCACGACCATTTCCAAATAGGTTTG 
G K K V D T P L L I R V D K D S G H G A G K G L S K >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
> D p o A _ m u t_ re v
> D p o A - X h o I- r e v _
i
2 5 7 0  2 5 8 0  2 5 9 0  2 6 0 0  2 6 1 0 1 2 6 2 0  2 6 3 0  2 6 4 0
* * * * * * * * * * | * * * * *  *
CAAATAATGAAATAGCTGATATCTTTAATTTCTTTTCAAAAGTTTTAAATGTTAAATTAAATTTTCTCGACCATGGCGAG 
GTTTATTACTTTATCGACTATAGAAATTAAAGAAAAGTTTTCAAAATTTACAATTTAATTTAAAAGAGCTGGTACCGCTC 
P N N E I A D I F N F F S K V L N V K L N F L D H G E >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
2 6 5 0  2 6 6 0  2 6 7 0  2 6 8 0  2 6 9 0  2 7 0 0  2 7 1 0  2 7 2 0
* * * * * * * * * * * * * * * *
CTTGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGCGTACCGGTCATCATCACCATCACCATTGAGT
GAACTTCCATTCGGATAGGGATTGGGAGAGGAGCCAGAGCTAAGATGCGCATGGCCAGTAGTAGTGGTAGTGGTAACTCA
L E G K P I P N P L L G L D S T R T G H H H H H H * >
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA + TAG _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ V5 EPITOPE_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
 PO L Y H IST ID I >
> p B A D _ R e v e r s e _ p r im in g _ s  i t e
2 7 3 0  2 7 4 0  2 7 5 0  2 7 6 0  2 7 7 0  2 7 8 0  2 7 9 0  2 8 0 0
* * * * * * * * * * * * * * * *
TTAAACGGTCTCCAGCTTGGCTGTTTTGGCGGATGAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAG
VIII
AATTTGCCAGAGGTCGAACCGACAAAACCGCCTACTCTCTTCTAAAAGTCGGACTATGTCTAATTTAGTCTTGCGTCTTC
> r r n B _ T l _ a n d _ T 2 _ t r a n s c r i p t i o n _ t e r m i n a t o r s
2 8 1 0  2 8 2 0  2 8 3 0  2 8 4 0  2 8 5 0  2 8 6 0  2 8 7 0  2 8 8 0
* * * * * * * * * * * * * * * *
CGGTCTGATAAAACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCAGAAGTGAAAC
GCCAGACTATTTTGTCTTAAACGGACCGCCGTCATCGCGCCACCAGGGTGGACTGGGGTACGGCTTGAGTCTTCACTTTG
2 8 9 0  2 9 0 0  2 9 1 0  2 9 2 0  2 9 3 0  2 9 4 0  2 9 5 0  2 9 6 0
* * * * * * * * * * * * * * * *
GCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTAGGGAACTGCCAGGCATCAAATAAAACGAAAGGCTCA
CGGCATCGCGGCTACCATCACACCCCAGAGGGGTACGCTCTCATCCCTTGACGGTCCGTAGTTTATTTTGCTTTCCGAGT
2 9 7 0  2 9 8 0  2 9 9 0  3 0 0 0  3 0 1 0  3 0 2 0  3 0 3 0  3 0 4 0
* * * * * * * * * * * * * * * *
GTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGGTGAACGCTCTCCTGAGTAGGACAAATCCGCCGGGAGCGG
CAGCTTTCTGACCCGGAAAGCAAAATAGACAACAAACAGCCACTTGCGAGAGGACTCATCCTGTTTAGGCGGCCCTCGCC
3 0 5 0  3 0 6 0  3 0 7 0  3 0 8 0  3 0 9 0  3 1 0 0  3 1 1 0  3 1 2 0
* * * * * * * * * * * * * * * *
ATTTGAACGTTGCGAAGCAACGGCCCGGAGGGTGGCGGGCAGGACGCCCGCCATAAACTGCCAGGCATCAAATTAAGCAG
TAAACTTGCAACGCTTCGTTGCCGGGCCTCCCACCGCCCGTCCTGCGGGCGGTATTTGACGGTCCGTAGTTTAATTCGTC
3 1 3 0  3 1 4 0  3 1 5 0  3 1 6 0  3 1 7 0  3 1 8 0  3 1 9 0  3 2 0 0
* * * * * * * * * * * * * * * *
AAGGCCATCCTGACGGATGGCCTTTTTGCGTTTCTACAAACTCTTTTTGTTTATTTTTCTAAATACATTCAAATATGTAT
TTCCGGTAGGACTGCCTACCGGAAAAACGCAAAGATGTTTGAGAAAAACAAATAAAAAGATTTATGTAAGTTTATACATA
3 2 1 0  3 2 2 0  3 2 3 0  3 2 4 0  3 2 5 0  3 2 6 0  3 2 7 0  3 2 8 0
* * * * * * * * * * * * * * * *
CCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGT
GGCGAGTACTCTGTTATTGGGACTATTTACGAAGTTATTATAACTTTTTCCTTCTCATACTCATAAGTTGTAAAGGCACA
M S I Q H F R V >  
 A M PIC IL LIN  R E S IS  >
3 2 9 0  3 3 0 0  3 3 1 0  3 3 2 0  3 3 3 0  3 3 4 0  3 3 5 0  3 3 6 0
* * * * * * * * * * * * * * * *
CGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTG
GCGGGAATAAGGGAAAAAACGCCGTAAAACGGAAGGACAAAAACGAGTGGGTCTTTGCGACCACTTTCATTTTCTACGAC
A L I P F F A A F C L P V F A H P E T L V K V K D A >
A M PICILLIN RESISTANCE GENE >
3 3 7 0  3 3 8 0  339 0  3 4 0 0  3 4 1 0  3 4 2 0  3 4 3 0  3 4 4 0
* * * * * * * * * * * * * * * *
AAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAA 
TTCTAGTCAACCCACGTGCTCACCCAATGTAGCTTGACCTAGAGTTGTCGCCATTCTAGGAACTCTCAAAAGCGGGGCTT 
E D Q L G A R V G Y I E L D L N S G K I L E S F R P E >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ AM PICILLIN RESISTANCE GENE_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
3 4 5 0  3 4 6 0  3 4 7 0  3 4 8 0  3 4 9 0  3 5 0 0  3 5 1 0  3 5 2 0
IX
GAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCA
CTTGCAAAAGGTTACTACTCGTGAAAATTTCAAGACGATACACCGCGCCATAATAGGGCACAACTGCGGCCCGTTCTCGT
E R F P M M S T F K V L L C G A V L S R V D A G Q E Q >
A M PICILLIN  RESISTANCE GENE >
3 5 3 0  3 5 4 0  3 5 5 0  3 5 6 0  3 5 7 0  3 5 8 0  3 5 9 0  3 6 0 0
* * * * * * * * * * * * * * * *
ACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCA 
TGAGCCAGCGGCGTATGTGATAAGAGTCTTACTGAACCAACTCATGAGTGGTCAGTGTCTTTTCGTAGAATGCCTACCGT 
L G R R I H Y S Q N D L V E Y S P V T E K H L T D G >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ A M PICILLIN RESISTANCE GENE_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
3 6 1 0  3 6 2 0  3 6 3 0  3 6 4 0  3 6 5 0  3 6 6 0  3 6 7 0  3 6 8 0
* * * * * * * * * * * * * * * *
TGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGA 
ACTGTCATTCTCTTAATACGTCACGACGGTATTGGTACTCACTATTGTGACGCCGGTTGAATGAAGACTGTTGCTAGCCT 
M T V R E L C S A A I T M S D N T A A N L L L T T I G >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ A M PICILLIN RESISTANCE GENE_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
3 6 9 0  3 7 0 0  3 7 1 0  3 7 2 0  3 7 3 0  3 7 4 0  3 7 5 0  3 7 6 0
* * * * * * * * * * * * * * * *
GGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAA 
CCTGGCTTCCTCGATTGGCGAAAAAACGTGTTGTACCCCCTAGTACATTGAGCGGAACTAGCAACCCTTGGCCTCGACTT 
G P K E L T A F L H N M G D H V T R L D R W E P E L N >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ AM PICILLIN  RESISTANCE GENE_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
3 7 7 0  3 7 8 0  3 7 9 0  3 8 0 0  3 8 1 0  3 8 2 0  3 8 3 0  3 8 4 0
* * * * * * * * * * * * * * * *
TGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCG 
ACTTCGGTATGGTTTGCTGCTCGCACTGTGGTGCTACGGACATCGTTACCGTTGTTGCAACGCGTTTGATAATTGACCGC 
E A I P N D E R D T T M P V A M A T T L R K L L T G >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ AM PICILLIN RESISTANCE__ GENE_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
3 8 5 0  3 8 6 0  3 8 7 0  3 8 8 0  3 8 9 0  3 9 0 0  3 9 1 0  3 9 2 0
* * * * * * * * * * * * * * * *
AACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCG 
TTGATGAATGAGATCGAAGGGCCGTTGTTAATTATCTGACCTACCTCCGCCTATTTCAACGTCCTGGTGAAGACGCGAGC 
E L L T L A S R Q Q L I D W M E A D K V A G P L L R S >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  AM PICILLIN RESISTANCE GENE >
3 9 3 0  3 9 4 0  3 9 5 0  3 9 6 0  3 9 7 0  3 9 8 0  3 9 9 0  4 0 0 0
* * * * * * * * * * * * * * * *
GCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGG 
CGGGAAGGCCGACCGACCAAATAACGACTATTTAGACCTCGGCCACTCGCACCCAGAGCGCCATAGTAACGTCGTGACCC 
A L P A G W F I A D K S G A G E R G S R G I I A A L G >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ AM PICILLIN RESISTANCE GENE_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
4 0 1 0  4 0 2 0  4 0 3 0  4 0 4 0  4 0 5 0  4 0 6 0  4 0 7 0  4 0 8 0
* * * * * * * * * * * * * * * *
GCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGA
CGGTCTACCATTCGGGAGGGCATAGCATCAATAGATGTGCTGCCCCTCAGTCCGTTGATACCTACTTGCTTTATCTGTCT
P D G K P S R I V V I Y T T G S Q A T M D E R N R Q >
X
A M PICILLIN  RESISTANCE GENE
4 0 9 0  4 1 0 0  4 1 1 0  4 1 2 0  4 1 3 0  4 1 4 0  4 1 5 0  4 1 6 0
* * * * * * * * * * * * * * * *
TCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTA
AGCGACTCTATCCACGGAGTGACTAATTCGTAACCATTGACAGTCTGGTTCAAATGAGTATATATGAAATCTAACTAAAT
I A E I G A S L I K H W X >
 A M PIC ILLIN  RESISTANCE GENE >
4 1 7 0  4 1 8 0  4 1 9 0  4 2 0 0  4 2 1 0  4 2 2 0  4 2 3 0  4 2 4 0
* * * * * * * * * * * * * * * *
AAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTT
TTTGAAGTAAAAATTAAATTTTCCTAGATCCACTTCTAGGAAAAACTATTAGAGTACTGGTTTTAGGGAATTGCACTCAA
> p B R 3 2 2 _ o r ig in
4 2 5 0  4 2 6 0  | 4 2 7 0  4 2 8 0  4 2 9 0  4 3 0 0  4 3 1 0  4 3 2 0
* * * * | * * * * * * * * * * *  *
TTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCT 
AAGCAAGGTGACTCGCAGTCTGGGGCATCTTTTCTAGTTTCCTAGAAGAACTCTAGGAAAAAAAGACGCGCATTAGACGA
4 3 3 0  4 3 4 0  4 3 5 0  4 3 6 0  4 3 7 0  4 3 8 0  4 3 9 0  4 4 0 0
* * * * * * * * * * * * * * * *
GCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTA
CGAACGTTTGTTTTTTTGGTGGCGATGGTCGCCACCAAACAAACGGCCTAGTTCTCGATGGTTGAGAAAAAGGCTTCCAT
4 4 1 0  4 4 2 0  4 4 3 0  4 4 4 0  4 4 5 0  4 4 6 0  4 4 7 0  4 4 8 0
* * * * * * * * * * * * * * * *
ACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGT
TGACCGAAGTCGTCTCGCGTCTATGGTTTATGACAGGAAGATCACATCGGCATCAATCCGGTGGTGAAGTTCTTGAGACA
4 4 9 0  4 5 0 0  4 5 1 0  4 5 2 0  4 5 3 0  4 5 4 0  4 5 5 0  4 5 6 0
* * * * * * * * * * * * * * *  *
AGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGT
TCGTGGCGGATGTATGGAGCGAGACGATTAGGACAATGGTCACCGACGACGGTCACCGCTATTCAGCACAGAATGGCCCA
4 5 7 0  4 5 8 0  4 5 9 0  4 6 0 0  4 6 1 0  4 6 2 0  4 6 3 0  4 6 4 0
* * * * * * * * * * * * * * * *
TGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAG
ACCTGAGTTCTGCTATCAATGGCCTATTCCGCGTCGCCAGCCCGACTTGCCCCCCAAGCACGTGTGTCGGGTCGAACCTC
4 6 5 0  4 6 6 0  4 6 7 0  4 6 8 0  4 6 9 0  4 7 0 0  4 7 1 0  4 7 2 0
* * * * * * * * * * * * * * * *
CGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGA
GCTTGCTGGATGTGGCTTGACTCTATGGATGTCGCACTCGATACTCTTTCGCGGTGCGAAGGGCTTCCCTCTTTCCGCCT
4 7 3 0  4 7 4 0  4 7 5 0  4 7 6 0  4 7 7 0  4 7 8 0  4 7 9 0  4 8 0 0
* * * * * * * * * * * * * * * *
CAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATA
GTCCATAGGCCATTCGCCGTCCCAGCCTTGTCCTCTCGCGTGCTCCCTCGAAGGTCCCCCTTTGCGGACCATAGAAATAT
4 8 1 0  4 8 2 0  4 8 3 0  4 8 4 0  4 8 5 0  4 8 6 0  4 8 7 0  4 8 8 0
XI
* * * * * * * * * * * * * * * *
GTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAAC
CAGGACAGCCCAAAGCGGTGGAGACTGAACTCGCAGCTAAAAACACTACGAGCAGTCCCCCCGCCTCGGATACCTTTTTG
4 8 9 0  4 9 0 0  4 9 1 0  4 9 2 0  4 9 3 0  4 9 4 0  4 9 5 0  4 9 6 0
* * * * * * * * * * * * * * * *
GCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGA
CGGTCGTTGCGCCGGAAAAATGCCAAGGACCGGAAAACGACCGGAAAACGAGTGTACAAGAAAGGACGCAATAGGGGACT
4 9 7 0  4 9 8 0  4 9 9 0  5 0 0 0  5 0 1 0  5 0 2 0  5 0 3 0  5 0 4 0
* * * * * * * * * * * * * * * *
TTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAG
AAGACACCTATTGGCATAATGGCGGAAACTCACTCGACTATGGCGAGCGGCGTCGGCTTGCTGGCTCGCGTCGCTCAGTC
5 0 5 0  5 0 6 0  5 0 7 0  5 0 8 0  5 0 9 0  5 1 0 0  5 1 1 0  5 1 2 0
* * * * * * * * * * * * * * * *
TGAGCGAGGAAGCGGAAGAGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATATGGTGC
ACTCGCTCCTTCGCCTTCTCGCGGACTACGCCATAAAAGAGGAATGCGTAGACACGCCATAAAGTGTGGCGTATACCACG
5 1 3 0  5 1 4 0  5 1 5 0  5 1 6 0  5 1 7 0  5 1 8 0  5 1 9 0  5 2 0 0
* * * * * * * * * * * * * * * *
ACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATACACTCCGCTATCGCTACGTGACTGGGTCATGGCT
TGAGAGTCATGTTAGACGAGACTACGGCGTATCAATTCGGTCATATGTGAGGCGATAGCGATGCACTGACCCAGTACCGA
5 2 1 0  5 2 2 0  5 2 3 0  5 2 4 0  5 2 5 0  5 2 6 0  5 2 7 0  5 2 8 0
* * * * * * * * * * * * * * * *
GCGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGT
CGCGGGGCTGTGGGCGGTTGTGGGCGACTGCGCGGGACTGCCCGAACAGACGAGGGCCGTAGGCGAATGTCTGTTCGACA
5 2 9 0  5 3 0 0  5 3 1 0  5 3 2 0  5 3 3 0  5 3 4 0  5 3 5 0  5 3 6 0
* * * * * * * * * * * * * * * *
GACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGGCAGCAGATCAATTCGCGCG
CTGGCAGAGGCCCTCGACGTACACAGTCTCCAAAAGTGGCAGTAGTGGCTTTGCGCGCTCCGTCGTCTAGTTAAGCGCGC
5 3 7 0  5 3 8 0  5 3 9 0  5 4 0 0  5 4 1 0  5 4 2 0  5 4 3 0  5 4 4 0
* * * * * * * * * * * * * * * *
CGAAGGCGAAGCGGCATGCATAATGTGCCTGTCAAATGGACGAAGCAGGGATTCTGCAAACCCTATGCTACTCCGTCAAG
GCTTCCGCTTCGCCGTACGTATTACACGGACAGTTTACCTGCTTCGTCCCTAAGACGTTTGGGATACGATGAGGCAGTTC
5 4 5 0  5 4 6 0  5 4 7 0  5 4 8 0  5 4 9 0  5 5 0 0  5 5 1 0  5 5 2 0
* * * * * * * * * * * * * * * *
CCGTCAATTGTCTGATTCGTTACCAATTATGACAACTTGACGGCTACATCATTCACTTTTTCTTCACAACCGGCACGGAA
GGCAGTTAACAGACTAAGCAATGGTTAATACTGTTGAACTGCCGATGTAGTAAGTGAAAAAGAAGTGTTGGCCGTGCCTT
< * S L K V A V D N V K E E C G A R F  
<_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ARAC_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
5 5 3 0  5 5 4 0  5 5 5 0  5 5 6 0  5 5 7 0  5 5 8 0  5 5 9 0  5 6 0 0
* * * * * * * * * * * * * * * *
CTCGCTCGGGCTGGCCCCGGTGCATTTTTTAAATACCCGCGAGAAATAGAGTTGATCGTCAAAACCAACATTGCGACCGA 
GAGCGAGCCCGACCGGGGCCACGTAAAAAATTTATGGGCGCTCTTTATCTCAACTAGCAGTTTTGGTTGTAACGCTGGCT 
< E S P S A G T C K K F V R S F Y L Q D D F G V N R G V  
<____  ARAC
XII
5 6 1 0  5 6 2 0  5 6 3 0  5 6 4 0  5 6 5 0  5 6 6 0  5 6 7 0  5 6 8 0
* * * * * * * * * * * * * * * *
CGGTGGCGATAGGCATCCGGGTGGTGCTCAAAAGCAGCTTCGCCTGGCTGATACGTTGGTCCTCGCGCCAGCTTAAGACG
GCCACCGCTATCCGTAGGCCCACCACGAGTTTTCGTCGAAGCGGACCGACTATGCAACCAGGAGCGCGGTCGAATTCTGC
< T A I P M R T T S L L L K A Q S I R Q D E R W S L V
 <_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ARAC_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
5 6 9 0  5 7 0 0  5 7 1 0  5 7 2 0  5 7 3 0  5 7 4 0  5 7 5 0  5 7 6 0
* * * * * * * * * * * * * * * *
CTAATCCCTAACTGCTGGCGGAAAAGATGTGACAGACGCGACGGCGACAAGCAAACATGCTGTGCGACGCTGGCGATATC
GATTAGGGATTGACGACCGCCTTTTCTACACTGTCTGCGCTGCCGCTGTTCGTTTGTACGACACGCTGCGACCGCTATAG
< S I G L Q Q R F L H S L R S P S L C V H Q A V S A I D
 <_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ARAC_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
5 7 7 0  5 7 8 0  5 7 9 0  5 8 0 0  5 8 1 0  5 8 2 0  5 8 3 0  5 8 4 0
* * * * * * * * * * * * * * * *
AAAATTGCTGTCTGCCAGGTGATCGCTGATGTACTGACAAGCCTCGCGTACCCGATTATCCATCGGTGGATGGAGCGACT
TTTTAACGACAGACGGTCCACTAGCGACTACATGACTGTTCGGAGCGCATGGGCTAATAGGTAGCCACCTACCTCGCTGA
< F N S D A L H D S I Y Q C A E R V R N D M P P H L S E
 <_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ARAC_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
5 8 5 0  5 8 6 0  5 8 7 0  5 8 8 0  5 8 9 0  5 9 0 0  5 9 1 0  5 9 2 0
* * * * * * * * * * * * * * * *
CGTTAATCGCTTCCATGCGCCGCAGTAACAATTGCTCAAGCAGATTTATCGCCAGCAGCTCCGAATAGCGCCCTTCCCCT
GCAATTAGCGAAGGTACGCGGCGTCATTGTTAACGAGTTCGTCTAAATAGCGGTCGTCGAGGCTTATCGCGGGAAGGGGA
< N I A E M R R L L L Q E L L N I A L L E S Y R G E G
 <_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ARAC_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
5 9 3 0  5 9 4 0  5 9 5 0  5 9 6 0  5 9 7 0  5 9 8 0  5 9 9 0  6 0 0 0
* * * * * * * * * * * * * * * *
TGCCCGGCGTTAATGATTTGCCCAAACAGGTCGCTGAAATGCGGCTGGTGCGCTTCATCCGGGCGAAAGAACCCCGTATT
ACGGGCCGCAATTACTAAACGGGTTTGTCCAGCGACTTTACGCCGACCACGCGAAGTAGGCCCGCTTTCTTGGGGCATAA
< Q G A N I I Q G F L D S F H P Q H A E D P R F F G T N
 <_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ARAC_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
6 0 1 0  6 0 2 0  6 0 3 0  6 0 4 0  6 0 5 0  6 0 6 0  6 0 7 0  6 0 8 0
* * * * * * * * * * * * * * * *
GGCAAATATTGACGGCCAGTTAAGCCATTCATGCCAGTAGGCGCGCGGACGAAAGTAAACCCACTGGTGATACCATTCGC
CCGTTTATAACTGCCGGTCAATTCGGTAAGTACGGTCATCCGCGCGCCTGCTTTCATTTGGGTGACCACTATGGTAAGCG
< A F I S P W N L W E H W Y A R P R F Y V W Q H Y W E R
 <_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ARAC_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
6 0 9 0  6 1 0 0  611 0  6 1 2 0  6 1 3 0  6 1 4 0  6 1 5 0  6 1 6 0
* * * * * * * * * * * * * * * *
GAGCCTCCGGATGACGACCGTAGTGATGAATCTCTCCTGGCGGGAACAGCAAAATATCACCCGGTCGGCAAACAAATTCT
CTCGGAGGCCTACTGCTGGCATCACTACTTAGAGAGGACCGCCCTTGTCGTTTTATAGTGGGCCAGCCGTTTGTTTAAGA
< A E P H R G Y H H I E G P P F L L I D G P R C V F E
 <_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ARAC_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
6 1 7 0  6 1 8 0  6 1 9 0  6 2 0 0  6 2 1 0  6 2 2 0  6 2 3 0  6 2 4 0
XIII
CGTCCCTGATTTTTCACCACCCCCTGACCGCGAATGGTGAGATTGAGAATATAACCTTTCATTCCCAGCGGTCGGTCGAT
GCAGGGACTAAAAAGTGGTGGGGGACTGGCGCTTACCACTCTAACTCTTATATTGGAAAGTAAGGGTCGCCAGCCAGCTA
< R G Q N K V V G Q G R I T L N L I Y G K M G L P R D I
 <_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ARAC_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
6 2 5 0  6 2 6 0  6 2 7 0  6 2 8 0  6 2 9 0  6 3 0 0  6 3 1 0  6 3 2 0
* * * * * * * * * * * * * * * *
AAAAAAATCGAGATAACCGTTGGCCTCAATCGGCGTTAAACCCGCCACCAGATGGGCATTAAACGAGTATCCCGGCAGCA
TTTTTTTAGCTCTATTGGCAACCGGAGTTAGCCGCAATTTGGGCGGTGGTCTACCCGTAATTTGCTCATAGGGCCGTCGT
< F F D L Y G N A E I P T L G A V L H A N F S Y G P L L
 <_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ARAC_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
6 3 3 0  6 3 4 0  6 3 5 0  6 3 6 0  6 3 7 0
* * * * * * * * * *
GGGGATCATTTTGCGCTTCAGCCATACTTTTCATACTCCCGCCATTCAGAG
CCCCTAGTAAAACGCGAAGTCGGTATGAAAAGTATGAGGGCGGTAAGTCTC
< P D N Q A E A M
< ARAC
XIV
I.III pDXA GFP2: DpoA  
I.III.I Vector Diagram
c-myc
0453bp
Features
1616-786
4299-3439
5106-5694
6067-7353
7353-10430
Neomycin Phosphotransferase 
Ampicillin Resistance 
Ddpl
DpoA Promoter 
DpoA:GFP
XV
I.III.II Sequence
S e q u e n c e  R a n g e :  1 t o  104 5 3
10 20 30 40 50 60 70 80
* * * * * * * * * * * * * * * *
AATTCAAGTTTTACCATAAAATAAAAAAAAAAAATAAAAAAAAACAAATCCAATTGTTTTTATATTAAATAATTAAAATA
TTAAGTTCAAAATGGTATTTTATTTTTTTTTTTTATTTTTTTTTGTTTAGGTTAACAAAAATATAATTTATTAATTTTAT
90  100 110 120 130 140 150 160
* * * * * * * * * * * * * * * *
AATGTAACTATAACTATAAATATAATAATATATACTTATATATACTAACTCTATTTCTTTTTTTTTTTTTTTTTTTTAGA
TTACATTGATATTGATATTTATATTATTATATATGAATATATATGATTGAGATAAAGAAAAAAAAAAAAAAAAAAAATCT
1 70 180 190 2 0 0  21 0  22 0  23 0  2 4 0
* * * * * * * * * * * * * * * *
TTTAATAAAAAATTTTATTTATTTTTAAATTCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCTAAACTAAATATTTG
AAATTATTTTTTAAAATAAATAAAAATTTAAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGATTTGATTTATAAAC
2 5 0  260  270  28 0  2 9 0  3 0 0  31 0  3 2 0
* * * * * * * * * * * * * * * *
GTATAAATTTAAATTATACTAGTTGAAACAAAGTTTGATACACCACATGTATTCTTTCCTCTTCTTAAATAAATGTATCC
CATATTTAAATTTAATATGATCAACTTTGTTTCAAACTATGTGGTGTACATAAGAAAGGAGAAGAATTTATTTACATAGG
3 3 0  3 40  35 0  36 0  3 7 0  3 8 0  3 9 0  4 0 0
* * * * * * * * * * * * * * * *
TTGTTCTCCCCAACTTTTTTTTTTTTTTAACAAAATTAATTATTAGTAAACTAAATTATTATTTTTTTTATTATTATTAT
AACAAGAGGGGTTGAAAAAAAAAAAAAATTGTTTTAATTAATAATCATTTGATTTAATAATAAAAAAAATAATAATAATA
4 1 0  42 0  430  4 40  4 5 0  46 0  4 7 0  4 8 0
* * * * * * * * * * * * * * * *
TTTAAAATTTAAAATACTTACTCTGCACCCCAAGAATTGATCCCAAAGCGGCCATCGTGCCTCCCCACTCCTGCAGTTCG
AAATTTTAAATTTTATGAATGAGACGTGGGGTTCTTAACTAGGGTTTCGCCGGTAGCACGGAGGGGTGAGGACGTCAAGC
4 9 0  500  510  5 2 0  5 3 0  5 4 0  5 5 0  5 6 0
* * * * * * * * * * * * * * * *
GGGGCATGGATGCGCGGATAGCCGCTGCTGGTTTCCTGGATGCCGACGGATTTGCACTGCCGGTAGAACTCCGCGAGGTC
CCCCGTACCTACGCGCCTATCGGCGACGACCAAAGGACCTACGGCTGCCTAAACGTGACGGCCATCTTGAGGCGCTCCAG
5 7 0  58 0  590  600  6 1 0  6 2 0  6 3 0  6 4 0
* * * * * * * * * * * * * * * *
GTCCAGCCTCAGGCAGCAGCTGAACCAACTCGCGAGGGGATCGAGCCCGGGCCGGGTGGGCGAAGAACTCCAGCATGAGA
CAGGTCGGAGTCCGTCGTCGACTTGGTTGAGCGCTCCCCTAGCTCGGGCCCGGCCCACCCGCTTCTTGAGGTCGTACTCT
6 5 0  66 0  670  680 690  7 0 0  7 1 0  72 0
* * * * * * * * * * * * * * * *
TCCCCGCGCTGGAGGATCATCCAGCCGGCGTCCCGGAAAACGATTCCGAAGCCCAACCTTTCATAGAAGGCGGCGGTGGA
AGGGGCGCGACCTCCTAGTAGGTCGGCCGCAGGGCCTTTTGCTAAGGCTTCGGGTTGGAAAGTATCTTCCGCCGCCACCT
7 3 0  740  750  760  77 0  7 8 0  7 9 0  80 0
* * * * * * * * * * * * * * * *
ATCGAAATCTCGTGATGGCAGGTTGGGCGTCGCTTGGTCGGTCATTTCGAACCCCAGAGTCCCGCTCAGAAGAACTCGTC
XVI
TAGCTTTAGAGCACTACCGTCCAACCCGCAGCGAACCAGCCAGTAAAGCTTGGGGTCTCAGGGCGAGTCTTCTTGAGCAG
<* F F E D 
< NEOMYCIN
8 10  820 8 30  840  85 0  8 60  87 0  8 8 0
* * * * * * * * * * * * * * * *
AAGAAGGCGATAGAAGGCGATGCGCTGCGAATCGGGAGCGGCGATACCGTAAAGCACGAGGAAGCGGTCAGCCCATTCGC
TTCTTCCGCTATCTTCCGCTACGCGACGCTTAGCCCTCGCCGCTATGGCATTTCGTGCTCCTTCGCCAGTCGGGTAAGCG
< L L R Y F A I R Q S D P A A I G Y L V L F R D A W E G
 <_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ NEOMYCIN PHOSPHOTRANSFERASE_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
8 9 0  900 910  920  93 0  940  9 50  96 0
* * * * * * * * * * * * * * * *
CGCCAAGCTCTTCAGCAATATCACGGGTAGCCAACGCTATGTCCTGATAGCGGTCCGCCACACCCAGCCGGCCACAGTCG
GCGGTTCGAGAAGTCGTTATAGTGCCCATCGGTTGCGATACAGGACTATCGCCAGGCGGTGTGGGTCGGCCGGTGTCAGC
< G L E E A I D R T A L A I D Q Y R D A V G L R G C D
 <_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ NEOMYCIN PHOSPHOTRANSFERASE _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
9 70  980 990  10 0 0  10 1 0  102 0  10 3 0  1 0 4 0
* * * * * * * * * * * * * * * *
ATGAATCCAGAAAAGCGGCCATTTTCCACCATGATATTCGGCAAGCAGGCATCGCCATGGGTCACGACGAGATCCTCGCC
TACTTAGGTCTTTTCGCCGGTAAAAGGTGGTACTATAAGCCGTTCGTCCGTAGCGGTACCCAGTGCTGCTCTAGGAGCGG
< I F G S F R G N E V M I N P L C A D G H T V V L D E G
 <_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ NEOMYCIN PHOSPHOTRANSFERASE _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
1 0 5 0  106 0  107 0  108 0  1 0 9 0  110 0  1 1 1 0  1 1 2 0
* * * * * * * * * * * * * * * *
GTCGGGCATGCGCGCCTTGAGCCTGGCGAACAGTTCGGCTGGCGCGAGCCCCTGATGCTCTTCGTCCAGATCATCCTGAT
CAGCCCGTACGCGCGGAACTCGGACCGCTTGTCAAGCCGACCGCGCTCGGGGACTACGAGAAGCAGGTCTAGTAGGACTA
< D P M R A K L R A F L E A P A L G Q H E E D L D D Q D
 <_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ NEOMYCIN PHOSPHOTRANSFERASE _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
1 1 3 0  11 4 0  115 0  116 0  1 1 7 0  11 8 0  1 1 9 0  1 2 0 0
* * * * * * * * * * * * * * * *
CGACAAGACCGGCTTCCATCCGAGTACGTGCTCGCTCGATGCGATGTTTCGCTTGGTGGTCGAATGGGCAGGTAGCCGGA
GCTGTTCTGGCCGAAGGTAGGCTCATGCACGAGCGAGCTACGCTACAAAGCGAACCACCAGCTTACCCGTCCATCGGCCT
< V L G A E M R T R A R E I R H K A Q H D F P C T A P
 <_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ NEOMYCIN PHOSPHOTRANSFERASE _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
1 2 1 0  12 2 0  1230  124 0  125 0  1 2 6 0  1 2 7 0  1 2 8 0
* * * * * * * * * * * * * * * *
TCAAGCGTATGCAGCCGCCGCATTGCATCAGCCATGATGGATACTTTCTCGGCAGGAGCAAGGTGAGATGACAGGAGATC
AGTTCGCATACGTCGGCGGCGTAACGTAGTCGGTACTACCTATGAAAGAGCCGTCCTCGTTCCACTCTACTGTCCTCTAG
< D L T H L R R M A D A M I S V K E A P A L H S S L L D
 <_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ NEOMYCIN PHOSPHOTRANSFERASE _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
1 2 9 0  1 3 0 0  1310  1320  1 3 3 0  1 3 4 0  1 3 5 0  1 3 6 0
* * * * * * * * * * * * * * * *
CTGCCCCGGCACTTCGCCCAATAGCAGCCAGTCCCTTCCCGCTTCAGTGACAACGTCGAGCACAGCTGCGCAAGGAACGC
GACGGGGCCGTGAAGCGGGTTATCGTCGGTCAGGGAAGGGCGAAGTCACTGTTGCAGCTCGTGTCGACGCGTTCCTTGCG
< Q G P V E G L L L W D R G A E T V V D L V A A C P V G
 <_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ NEOMYCIN PHOSPHOTRANSFERASE _ _ _ _ _ _ _
XVII
1 3 7 0  1 3 8 0  1 3 9 0  140 0  14 1 0  1 4 2 0  1 4 3 0  1 4 4 0
* * * * * * * * * * * * * * * *
CCGTCGTGGCCAGCCACGATAGCCGCGCTGCCTCGTCCTGCAGTTCATTCAGGGCACCGGACAGGTCGGTCTTGACAAAA
GGCAGCACCGGTCGGTGCTATCGGCGCGACGGAGCAGGACGTCAAGTAAGTCCCGTGGCCTGTCCAGCCAGAACTGTTTT
< T T A L W S L R A A E D Q L E N L A G S L D T K V F
 <_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ NEOMYCIN PHOSPHOTRANSFERASE _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
1 4 5 0  1460  147 0  1 4 8 0  1 4 9 0  150 0  1 5 1 0  1 5 2 0
* * * * * * * * * * * * * * * *
AGAACCGGGCGCCCCTGCGCTGACAGCCGGAACACGGCGGCATCAGAGCAGCCGATTGTCTGTTGTGCCCAGTCATAGCC
TCTTGGCCCGCGGGGACGCGACTGTCGGCCTTGTGCCGCCGTAGTCTCGTCGGCTAACAGACAACACGGGTCAGTATCGG
< L V P R G Q A S L R F V A A D S C G I T Q Q A W D Y G
 <_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ NEOMYCIN PHOSPHOTRANSFERASE _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
1 5 3 0  154 0  1550  1 5 6 0  157 0  1 5 8 0  15 9 0  1 6 0 0
* * * * * * * * * * * * * * * *
GAATAGCCTCTCCACCCAAGCGGCCGGAGAACCTGCGTGCAATCCATCTTGTTCAATCATGCGAAACGATCCAGCTTGAA
CTTATCGGAGAGGTGGGTTCGCCGGCCTCTTGGACGCACGTTAGGTAGAACAAGTTAGTACGCTTTGCTAGGTCGAACTT
< F L R E V W A A P S G A H L G D Q E I M R F S G A Q V
 <_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ NEOMYCIN PHOSPHOTRANSFERASE _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
1 6 1 0  1620  16 3 0  164 0  165 0  1 6 6 0  167 0  1 6 8 0
* * * * * * * * * * * * * * * *
CATCTTCTCCGTCCATTTTATATTATATTTATTTATTTGATTATTTTTTTGAATTAATTAAAAAAAAAAAAAAAATTTCA 
GTAGAAGAGGCAGGTAAAATATAATATAAATAAATAAACTAATAAAAAAACTTAATTAATTTTTTTTTTTTTTTTAAAGT 
<D E G D M
 < NEOMYCIN _ _ _ _
1 6 9 0  170 0  171 0  172 0  17 3 0  17 4 0  1 7 5 0  1 7 6 0
* * * * * * * * * * * * * * * *
TTTTATAATCTCAGAAACCTCAAAAAAAAAAAAATAAAAAATAAAAAATATAAAAAAATAAAAATAAAATCCCAATTTTA
AAAATATTAGAGTCTTTGGAGTTTTTTTTTTTTTATTTTTTATTTTTTATATTTTTTTATTTTTATTTTAGGGTTAAAAT
1 7 7 0  1 7 8 0  17 9 0  1 8 0 0  1 8 1 0  1 8 2 0  1 8 3 0  1 8 4 0
* * * * * * * * * * * * * * * *
AAGCGAAAAACCACCCATGGTTTGAAAATTTCAATCAATTTCAAATAACTTTACTTAACTTTTAACTTTAAGCTGGTCAC
TTCGCTTTTTGGTGGGTACCAAACTTTTAAAGTTAGTTAAAGTTTATTGAAATGAATTGAAAATTGAAATTCGACCAGTG
1 8 5 0  1 8 6 0  1870  188 0  1 8 9 0  1 9 0 0  1 9 1 0  1 9 2 0
* * * * * * * * * * * * * * * *
TTGGTTTCCTTGTTTGGAAAAAAAAAANTACCATGACTAAACTTTAAATCTATTTTTTTTTTATAATTATTATTTTTCAT
AACCAAAGGAACAAACCTTTTTTTTTTNATGGTACTGATTTGAAATTTAGATAAAAAAAAAATATTAATAATAAAAAGTA
1 9 3 0  1 9 4 0  195 0  19 6 0  1 9 7 0  1 9 8 0  1 9 9 0  2 0 0 0
* * * * * * * * * * * * * * * *
ACTCTTTTTTTTTTATATAAAATATCCATCATTATCTTCAAAATAAAAAAATAATTACAAAAAGTGAATAATAATTAAAT
TGAGAAAAAAAAAATATATTTTATAGGTAGTAATAGAAGTTTTATTTTTTTATTAATGTTTTTCACTTATTATTAATTTA
2 0 1 0  2 0 2 0  2 0 3 0  2 0 4 0  2 0 5 0  2 0 6 0  2 0 7 0  2 0 8 0
* * * * * * * * * * * * * * * *
AATTAATAAACCTTTACACTTTTTTTTTTCTTTTTACAGTTTTTATATTTATTTTAATTTTATTATTTTGCGCAACTTTG
XVIII
TTAATTATTTGGAAATGTGAAAAAAAAAAGAAAAATGTCAAAAATATAAATAAAATTAAAATAATAAAACGCGTTGAAAC
2 0 9 0  2 1 0 0  2 1 1 0  2 1 2 0  2 1 3 0  2 1 4 0  2 1 5 0  2 1 6 0
* * * * * * * * * * * * * * * *
AAAAAATAAAAAAGATAAAGTTTTTATAAATATCTATCAAAAAAGATATCGTTGTTGATTGATTATTTTGGATAATTTTT
TTTTTTATTTTTTCTATTTCAAAAATATTTATAGATAGTTTTTTCTATAGCAACAACTAACTAATAAAACCTATTAAAAA
2 1 7 0  2 1 8 0  2 1 9 0  2 2 0 0  2 2 1 0  2 2 2 0  2 2 3 0  2 2 4 0
* * * * * * * * * * * * * * * *
CTTTAAATTGGGGCAAATCTGTAATTTTCAGATTAATAAGATTTTTCCTTTTTATTTTTCTTTTTACTTTTTGTAATTTT
GAAATTTAACCCCGTTTAGACATTAAAAGTCTAATTATTCTAAAAAGGAAAAATAAAAAGAAAAATGAAAAACATTAAAA
2 2 5 0  2 2 6 0  22 7 0  2 2 8 0  2 2 9 0  2 3 0 0  2 3 1 0  2 3 2 0
* * * * * * * * * * * * * * * *
TAAAAATAAACCTCTGAATTAATTCGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATT
ATTTTTATTTGGAGACTTAATTAAGCCGCATTAGTACCAGTATCGACAAAGGACACACTTTAACAATAGGCGAGTGTTAA
2 3 3 0  2 3 4 0  2 3 5 0  2 3 6 0  2 3 7 0  2 3 8 0  2 3 9 0  2 4 0 0
* * * * * * * * * * * * * * * *
CCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTT
GGTGTGTTGTATGCTCGGCCTTCGTATTTCACATTTCGGACCCCACGGATTACTCACTCGATTGAGTGTAATTAACGCAA
2 4 1 0  2 4 2 0  2 4 3 0  2 4 4 0  2 4 5 0  2 4 6 0  2 4 7 0  2 4 8 0
* * * * * * * * * * * * * * * *
GCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCG
CGCGAGTGACGGGCGAAAGGTCAGCCCTTTGGACAGCACGGTCGACGTAATTACTTAGCCGGTTGCGCGCCCCTCTCCGC
2 4 9 0  2 5 0 0  2 5 1 0  2 5 2 0  2 5 3 0  2 5 4 0  2 5 5 0  2 5 6 0
* * * * * * * * * * * * * * * *
GTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCA
CAAACGCATAACCCGCGAGAAGGCGAAGGAGCGAGTGACTGAGCGACGCGAGCCAGCAAGCCGACGCCGCTCGCCATAGT
2 5 7 0  2 5 8 0  2 5 9 0  2 6 0 0  2 6 1 0  2 6 2 0  2 6 3 0  2 6 4 0
* * * * * * * * * * * * * * * *
GCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCA
CGAGTGAGTTTCCGCCATTATGCCAATAGGTGTCTTAGTCCCCTATTGCGTCCTTTCTTGTACACTCGTTTTCCGGTCGT
2 6 5 0  2 6 6 0  2 6 7 0  2 6 8 0  2 6 9 0  2 7 0 0  2 7 1 0  2 7 2 0
* * * * * * * * * * * * * * * *
AAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATC
TTTCCGGTCCTTGGCATTTTTCCGGCGCAACGACCGCAAAAAGGTATCCGAGGCGGGGGGACTGCTCGTAGTGTTTTTAG
2 7 3 0  2 7 4 0  2 7 5 0  2 7 6 0  2 7 7 0  2 7 8 0  2 7 9 0  2 8 0 0
* * * * * * * * * * * * * * * *
GACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGC
CTGCGAGTTCAGTCTCCACCGCTTTGGGCTGTCCTGATATTTCTATGGTCCGCAAAGGGGGACCTTCGAGGGAGCACGCG
2 8 1 0  2 8 2 0  2 8 3 0  2 8 4 0  2 8 5 0  2 8 6 0  2 8 7 0  2 8 8 0
* * * * * * * * * * * * * * * *
TCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTC
AGAGGACAAGGCTGGGACGGCGAATGGCCTATGGACAGGCGGAAAGAGGGAAGCCCTTCGCACCGCGAAAGAGTTACGAG
X IX
2 8 9 0  2 9 0 0  2 9 1 0  2 9 2 0  2 9 3 0  2 9 4 0  2 9 5 0  2 9 6 0
* * * * * * * * *  * * * * * *  *
ACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGGTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACC
TGCGACATCCATAGAGTCAAGCCACATCCAGCAAGCCAGGTTCGACCCGACACACGTGCTTGGGGGGCAAGTCGGGCTGG
2 9 7 0  2 9 8 0  2 9 9 0  3 0 0 0  3 0 1 0  3 0 2 0  3 0 3 0  3 0 4 0
* * * * * * * * * * * * * * * *
GCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGT
CGACGCGGAATAGGCCATTGATAGCAGAACTCAGGTTGGGCCATTCTGTGCTGAATAGCGGTGACCGTCGTCGGTGACCA
3 0 5 0  3 0 6 0  3 0 7 0  3 0 8 0  3 0 9 0  3 1 0 0  3 1 1 0  3 1 2 0
* * * * * * * * * * * * * * * *
AACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAG
TTGTCCTAATCGTCTCGCTCCATACATCCGCCACGATGTCTCAAGAACTTCACCACCGGATTGATGCCGATGTGATCTTC
3 1 3 0  3 1 4 0  3 1 5 0  3 1 6 0  3 1 7 0  3 1 8 0  3 1 9 0  3 2 0 0
* * * * * * * * * * * * * * * *
GACACTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAA
CTGTGATAAACCATAGACGCGAGACGACTTCGGTCAATGGAAGCCTTTTTCTCAACCATCGAGAACTAGGCCGTTTGTTT
3 2 1 0  3 2 2 0  3 2 3 0  3 2 4 0  3 2 5 0  3 2 6 0  3 2 7 0  3 2 8 0
* * * * * * * * * * * * * * * *
CCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTG
GGTGGCGACCATCGCCACCAAAAAAACAAACGTTCGTCGTCTAATGCGCGTCTTTTTTTCCTAGAGTTCTTCTAGGAAAC
3 2 9 0  3 3 0 0  3 3 1 0  3 3 2 0  3 3 3 0  3 3 4 0  3 3 5 0  3 3 6 0
* * * * * * * * * * * * * * * *
ATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGAT
TAGAAAAGATGCCCCAGACTGCGAGTCACCTTGCTTTTGAGTGCAATTCCCTAAAACCAGTACTCTAATAGTTTTTCCTA
3 3 7 0  3 3 8 0  3 3 9 0  3 4 0 0  3 4 1 0  3 4 2 0  3 4 3 0  3 4 4 0
* * * * * * * * * * * * * * * *
CTTCACCTAGATCCTTTTAAATTAAAATGAAGTATTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTT
GAAGTGGATCTAGGAAAATTTAATTTTACTTCATAAATTTAGTTAGATTTCATATATACTCATTTGAACCAGACTGTCAA
<*
<__
3 4 5 0  3 4 6 0  3 4 7 0  3 4 8 0  3 4 9 0  3 5 0 0  3 5 1 0  3 5 2 0
* * * * * * * * * * * * * * * *
ACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTG 
TGGTTACGAATTAGTCACTCCGTGGATAGAGTCGCTAGACAGATAAAGCAAGTAGGTATCAACGGACTGAGGGGCAGCAC 
< W H K I L S A G I E A I Q R N R E D M T A Q S G T T  
< A M PICILLIN  RESISTANCE
3 5 3 0  3 5 4 0  3 5 5 0  3 5 6 0  3 5 7 0  3 5 8 0  3 5 9 0  3 6 0 0
* * * * * * * * * * * * * * * *
TAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCC 
ATCTATTGATGCTATGCCCTCCCGAATGGTAGACCGGGGTCACGACGTTACTATGGCGCTCTGGGTGCGAGTGGCCGAGG 
< Y I V V I R S P K G D P G L A A I I G R S G R E G A G  
< A M PICILLIN  RESISTANCE_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
3 6 1 0  3 6 2 0  3 6 3 0  3 6 4 0  3 6 5 0  3 6 6 0  3 6 7 0  3 6 8 0
X X
* * * * * * * * * * * * * * * *
AGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGT
TCTAAATAGTCGTTATTTGGTCGGTCGGCCTTCCCGGCTCGCGTCTTCACCAGGACGTTGAAATAGGCGGAGGTAGGTCA
< S K D A I F W G A P L A S R L L P G A V K D A E M W D
 < A M PIC ILLIN  RESISTANCE_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
3 6 9 0  3 7 0 0  3 7 1 0  3 7 2 0  3 7 3 0  3 7 4 0  3 7 5 0  3 7 6 0
* * * * * * * * * * * * * * * *
CTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGC
GATAATTAACAACGGCCCTTCGATCTCATTCATCAAGCGGTCAATTATCAAACGCGTTGCAACAACGGTAACGATGTCCG
< I L Q Q R S A L T L L E G T L L K R L T T A M A V P
 < A M PIC ILLIN  RESISTANCE_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
3 7 7 0  3 7 8 0  3 7 9 0  3 8 0 0  3 8 1 0  3 8 2 0  3 8 3 0  3 8 4 0
* * * * * * * * * * * * * * * *
ATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCC
TAGCACCACAGTGCGAGCAGCAAACCATACCGAAGTAAGTCGAGGCCAAGGGTTGCTAGTTCCGCTCAATGTACTAGGGG
< M T T D R E D N P I A E N L E P E W R D L R T V H D G
 < A M PICILLIN  RESISTANCE_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
3 8 5 0  3 8 6 0  3 8 7 0  3 8 8 0  3 8 9 0  3 9 0 0  3 9 1 0  3 9 2 0
* * * * * * * * * * * * * * * *
CATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCA
GTACAACACGTTTTTTCGCCAATCGAGGAAGCCAGGAGGCTAGCAACAGTCTTCATTCAACCGGCGTCACAATAGTGAGT
< M N H L F A T L E K P G G I T T L L L N A A T N D S M
 < A M PIC ILLIN  RESISTANCE_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
3 9 3 0  3 9 4 0  3 9 5 0  3 9 6 0  3 9 7 0  3 9 8 0  3 9 9 0  4 0 0 0
* * * * * * * * * * * * * * * *
TGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACC
ACCAATACCGTCGTGACGTATTAAGAGAATGACAGTACGGTAGGCATTCTACGAAAAGACACTGACCACTCATGAGTTGG
< T I A A S C L E R V T M G D T L H K E T V P S Y E V
 < A M PICILLIN  RESISTANCE_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
4 0 1 0  4 0 2 0  4 0 3 0  4 0 4 0  4 0 5 0  4 0 6 0  4 0 7 0  4 0 8 0
* * * * * * * * * * * * * * * *
AAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAG
TTCAGTAAGACTCTTATCACATACGCCGCTGGCTCAACGAGAACGGGCCGCAGTTATGCCCTATTATGGCGCGGTGTATC
< L D N Q S Y H I R R G L Q E Q G A D I R S L V A G C L
 < A M PICILLIN RESISTANCE_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
4 0 9 0  4 1 0 0  4 1 1 0  4 1 2 0  4 1 3 0  4 1 4 0  4 1 5 0  4 1 6 0
* * * * * * * * * * * * * * * *
CAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCA
GTCTTGAAATTTTCACGAGTAGTAACCTTTTGCAAGAAGCCCCGCTTTTGAGAGTTCCTAGAATGGCGACAACTCTAGGT
< L V K F T S M M P F R E E P R F S E L I K G S N L D L
 < A M PICILLIN RESISTANCE_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
4 1 7 0  4 1 8 0  4 1 9 0  4 2 0 0  4 2 1 0  4 2 2 0  4 2 3 0  4 2 4 0
* * * * * * * * * * * * * * * *
GTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACA
CAAGCTACATTGGGTGAGCACGTGGGTTGACTAGAAGTCGTAGAAAATGAAAGTGGTCGCAAAGACCCACTCGTTTTTGT
XXI
< E I Y G V R A G L Q D E A D K V K V L T E P H A F V  
< A M PICILLIN  RESISTANCE
4 2 5 0  4 2 6 0  4 2 7 0  4 2 8 0  4 2 9 0  4 3 0 0  4 3 1 0  4 3 2 0
* * * * * * * * * * * * * * * *
GGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTA 
CCTTCCGTTTTACGGCGTTTTTTCCCTTATTCCCGCTGTGCCTTTACAACTTATGAGTATGAGAAGGAAAAAGTTATAAT 
< P L C F A A F F P I L A V R F H Q I S M  
<_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ AM PICILLIN_ RESISTANCE_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
4 3 3 0  4 3 4 0  4 3 5 0  4 3 6 0  4 3 7 0  4 3 8 0  4 3 9 0  4 4 0 0
* * * * * * * * * * * * * * * *
TTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTC
AACTTCGTAAATAGTCCCAATAACAGAGTACTCGCCTATGTATAAACTTACATAAATCTTTTTATTTGTTTATCCCCAAG
4 4 1 0  4 4 2 0  4 4 3 0  4 4 4 0  4 4 5 0  4 4 6 0  4 4 7 0  4 4 8 0
* * * * * * * * * * * * * * * *
CGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGT
GCGCGTGTAAAGGGGCTTTTCACGGTGGACTGCAGATTCTTTGGTAATAATAGTACTGTAATTGGATATTTTTATCCGCA
4 4 9 0  4 5 0 0  4 5 1 0  4 5 2 0  4 5 3 0  4 5 4 0  4 5 5 0  4 5 6 0
* * * * * * * * * * * * * * * *
ATCACGAGGCCCTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCAC
TAGTGCTCCGGGAAAGCAGAGCGCGCAAAGCCACTACTGCCACTTTTGGAGACTGTGTACGTCGAGGGCCTCTGCCAGTG
4 5 7 0  4 5 8 0  4 5 9 0  4 6 0 0  4 6 1 0  4 6 2 0  4 6 3 0  4 6 4 0
* * * * * * * * * * * * * * * *
AGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGC
TCGAACAGACATTCGCCTACGGCCCTCGTCTGTTCGGGCAGTCCCGCGCAGTCGCCCACAACCGCCCACAGCCCCGACCG
4 6 5 0  4 6 6 0  4 6 7 0  4 6 8 0  4 6 9 0  4 7 0 0  4 7 1 0  4 7 2 0
* * * * * * * * * * * * * * * *
TTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGA
AATTGATACGCCGTAGTCTCGTCTAACATGACTCTCACGTGGTATACGCCACACTTTATGGCGTGTCTACGCATTCCTCT
4 7 3 0  4 7 4 0  475 0  4 7 6 0  4 7 7 0  4 7 8 0  4 7 9 0  4 8 0 0
* * * * * * * * * * * * * * * *
AAATACCGCATCAGGCAATTCCAACATCCAATAAATCATACAGGCAAGGCAAAGAATTAGCAAAATTAAGCAATAAAGCC
TTTATGGCGTAGTCCGTTAAGGTTGTAGGTTATTTAGTATGTCCGTTCCGTTTCTTAATCGTTTTAATTCGTTATTTCGG
4 8 1 0  4 8 2 0  4 8 3 0  4 8 4 0  4 8 5 0  4 8 6 0  4 8 7 0  4 8 8 0
* * * * * * * * * * * * * * * *
TCAGAGCATAAAGCTAAATCGGTTGTACCAAAAACATTATGACCCTGTAATACTTTTGCGGGAGAAGCCTTTATTTCAAC
AGTCTCGTATTTCGATTTAGCCAACATGGTTTTTGTAATACTGGGACATTATGAAAACGCCCTCTTCGGAAATAAAGTTG
4 8 9 0  4 9 0 0  4 9 1 0  4 9 2 0  4 9 3 0  4 9 4 0  4 9 5 0  4 9 6 0
* * * * * * * * * * * * * * * *
GCAAGGATAAAAATTTTTAGAACCCTCATATATTTTAAATGCAATGCCTGAGTAATGTGTAGGTAAAGATTCAAACGGGT
CGTTCCTATTTTTAAAAATCTTGGGAGTATATAAAATTTACGTTACGGACTCATTACACATCCATTTCTAAGTTTGCCCA
4 9 7 0  4 9 8 0  4 9 9 0  5 0 0 0  5 0 1 0  5 0 2 0  5 0 3 0  5 0 4 0
XXII
GAGAAAGGCCGGAGACAGTCAAATCACCATCAATATGATATTCAACCGTTCTAGCTGATAAATTCATGCCGGAGAGGGTA
CTCTTTCCGGCCTCTGTCAGTTTAGTGGTAGTTATACTATAAGTTGGCAAGATCGACTATTTAAGTACGGCCTCTCCCAT
> D d p l
5 0 5 0  5 0 6 0  5 0 7 0  5 0 8 0  5 0 9 0  5 1 0 0  | 5 1 1 0  5 1 2 0
* *
GCTATTTTTGAGAGGTCTACAAAGGCTATCAGGTCATTGCCTGAGAGTCTGGAGCAAACAAGAGAATCGATTTATTTTTA
CGATAAAAACTCTCCAGATGTTTCCGATAGTCCAGTAACGGACTCTCAGACCTCGTTTGTTCTCTTAGCTAAATAAAAAT
5 1 3 0  5 1 4 0  5 1 5 0  5 1 6 0  5 1 7 0  5 1 8 0  5 1 9 0  5 2 0 0
* * * * * * * * * * * * * * * *
TATCTATCTAAAAAAAAACTAGGAAAAATGAATGTCATCAAATAGTATTTTAACATTTTTTTTTTTTTTAAAAAAAAAGT
ATAGATAGATTTTTTTTTGATCCTTTTTACTTACAGTAGTTTATCATAAAATTGTAAAAAAAAAAAAAATTTTTTTTTCA
5 2 1 0  5 2 2 0  5 2 3 0  5 2 4 0  5 2 5 0  5 2 6 0  5 2 7 0  5 2 8 0
* * * * * * * * * * * * * * * *
GTCATGACAAAAAAAAAAAAGTGTCATGACAAAAAAAAAAAAAAAAAAGAGGGGAAAGTAATTATAACTAGGTTTTTTTA
CAGTACTGTTTTTTTTTTTTCACAGTACTGTTTTTTTTTTTTTTTTTTCTCCCCTTTCATTAATATTGATCCAAAAAAAT
5 2 9 0  5 3 0 0  5 3 1 0  5 3 2 0  5 3 3 0  5 3 4 0  5 3 5 0  5 3 6 0
* * * * * * * * * * * * * * * *
TAATTTTTACATATTTGTTAATAACTTTTAATTTTGAATCATATGATATTACATCGTCCCGTTGAAAAAAAAAAAAAAAA
ATTAAAAATGTATAAACAATTATTGAAAATTAAAACTTAGTATACTATAATGTAGCAGGGCAACTTTTTTTTTTTTTTTT
5 3 7 0  5 3 8 0  5 3 9 0  5 4 0 0  5 4 1 0  5 4 2 0  5 4 3 0  5 4 4 0
* * * * * * * * * * * * * * * *
TTTTTTTCa a a CATTTTCATTTTTTAAAAAATGATATAAAATTTTAAACTAAACTATTTTATTAAATACAAACATATAAC
AAAAAAAGTTTGTAAAAGTAAAAAATTTTTTACTATATTTTAAAATTTGATTTGATAAAATAATTTATGTTTGTATATTG
5 4 5 0  5 4 6 0  54 7 0  5 4 8 0  5 4 9 0  5 5 0 0  5 5 1 0  5 5 2 0
* * * * * * * * * * * * * * * *
TTTATCTTCAATTTTTTTGGTTTATACATATTTATGTTCGTACTGAAGTATAGATCTTATTACTAAAGTTTCAAAAGTTT
AAATAGAAGTTAAAAAAACCAAATATGTATAAATACAAGCATGACTTCATATCTAGAATAATGATTTCAAAGTTTTCAAA
5 5 3 0  5 5 4 0  5 5 5 0  5 5 6 0  5 5 7 0  5 5 8 0  5 5 9 0  5 6 0 0
* * * * * * * * * * * * * * * *
TAAAAAAAATTAAAGGTAAATATATAACTTTCTGTTTTTTTCAATTCTGTCATGACAAAAAAAAAAAAGTGTCATGACAA
ATTTTTTTTAATTTCCATTTATATATTGAAAGACAAAAAAAGTTAAGACAGTACTGTTTTTTTTTTTTCACAGTACTGTT
5 6 1 0  5 6 2 0  5 6 3 0  5 6 4 0  5 6 5 0  5 6 6 0  5 6 7 0  5 6 8 0
* * * * * * * * * * * * * * * *
AAAAAAAAAAAAAAAAAATTTTCTTCAATAGGTATTGAAATGACCTCCGTTTTTAATAAAAAGTATATATTTGTGCTCGT
TTTTTTTTTTTTTTTTTTAAAAGAAGTTATCCATAACTTTACTGGAGGCAAAAATTATTTTTCATATATAAACACGAGCA
5 6 9 0  5 7 0 0  5 7 1 0  5 7 2 0  5 7 3 0  5 7 4 0  5 7 5 0  5 7 6 0
* * * * * * * * * * * * * * * *
CTAGGATCTACTAGTGTCGACTAGATAAAAAAAATTTTTATTTATTTTTATTATTTTGAATTAAATAGATTACAAATGAT
GATCCTAGATGATCACAGCTGATCTATTTTTTTTAAAAATAAATAAAAATAATAAAACTTAATTTATCTAATGTTTACTA
5 7 7 0  5 7 8 0  5 7 9 0  5 8 0 0  5 8 1 0  5 8 2 0  5 8 3 0  5 8 4 0
XXIII
TACAAATTAATTAATCCCATCAAATCTTTAAAAAAAAAAATGGTTTAAAAAAACTTGGGTTGGTTAATTATTATTTGAAA
ATGTTTAATTAATTAGGGTAGTTTAGAAATTTTTTTTTTTACCAAATTTTTTTGAACCCAACCAATTAATAATAAACTTT
5 8 5 0  5 8 6 0  5 8 7 0  5 8 8 0  5 8 9 0  5 9 0 0  5 9 1 0  5 9 2 0
* * * * * * * * * * * * * * * *
ATTTTAAAACCCAAATTAAAAAAAAAAAATGGGATTCAAAAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TAAAATTTTGGGTTTAATTTTTTTTTTTTACCCTAAGTTTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
5 9 3 0  5 9 4 0  5 9 5 0  5 9 6 0  5 9 7 0  5 9 8 0  5 9 9 0  6 0 0 0
* * * * * * * * * * * * * * * *
TTTTTTTTCAGATTGCATAAAAAGATTTTTTTTTTTTTTTTTTCTTATTTCTTAAAACAAATAAATTAAATTAAATAAAA
AAAAAAAAGTCTAACGTATTTTTCTAAAAAAAAAAAAAAAAAAGAATAAAGAATTTTGTTTATTTAATTTAATTTATTTT
> D poA _P r onto t e r
6 0 1 0  6 0 2 0  6 0 3 0  6 0 4 0  6 0 5 0  6 0 6 0  60 7 0  6 0 8 0
* * * * * * * * * * * * * | * * *
AATAAAAATCAGATCCAAGCTTAAAAAATGCATCATCATCATCATCATCATCATGATATCGGTACCATCGATGTAGCTCC
TTATTTTTAGTCTAGGTTCGAATTTTTTACGTAGTAGTAGTAGTAGTAGTAGTACTATAGCCATGGTAGCTACATCGAGG
6 0 9 0  6 1 0 0  6 1 1 0  6 1 2 0  6 1 3 0  6 1 4 0  6 1 5 0  6 1 6 0
* * * * * *  * * * * * * * * * *
ATTCATCGTTTCATTATGTGATGGTCTCAAAGATACCCAATACGATATCAAATTGTTATGTCATTTAATGATCATTCGTT
TAAGTAGCAAAGTAATACACTACCAGAGTTTCTATGGGTTATGCTATAGTTTAACAATACAGTAAATTACTAGTAAGCAA
6 1 7 0  6 1 8 0  6 1 9 0  6 2 0 0  6 2 1 0  6 2 2 0  62 3 0  6 2 4 0
* * * * * * * * * * * * * * * *
TAGCAAACTCAAATGGTGCTGCTCTCCTCGAAAATATTACTCTCCTCCTTGAACCACTTCGTGTTATTCTCATGACTAAA
ATCGTTTGAGTTTACCACGACGAGAGGAGCTTTTATAATGAGAGGAGGAACTTGGTGAAGCACAATAAGAGTACTGATTT
6 2 5 0  6 2 6 0  6 2 7 0  6 2 8 0  6 2 9 0  6 3 0 0  63 1 0  6 3 2 0
* * * * * * * *  * * * * * * * *
GTAAATGAAACCGCTGTTAAACAACAAATCGAACGTAATGAAGAATGTATTCGTTCAGCTTTACGTGCTGTCGCTTCCAT
CATTTACTTTGGCGACAATTTGTTGTTTAGCTTGCATTACTTCTTACATAAGCAAGTCGAAATGCACGACAGCGAAGGTA
6 3 3 0  6 3 4 0  6 3 5 0  6 3 6 0  6 3 7 0  6 3 8 0  6 3 9 0  6 4 0 0
* * * * * * * * * * * * * * * *
CTCTAGAATTCCAAATAGTGATAGTATCGTTAAATTTGAAGAATTTGTTAAAAATACAATTCGTACAACTCCATTAGCTG
GAGATCTTAAGGTTTATCACTATCATAGCAATTTAAACTTCTTAAACAATTTTTATGTTAAGCATGTTGAGGTAATCGAC
6 4 1 0  6 4 2 0  6 4 3 0  6 4 4 0  6 4 5 0  6 4 6 0  6 4 7 0  6 4 8 0
* * * * * * * * * * * * * * * *
CTCAATTTAATTCAATTTTATCTGAAGATACAATGTCAAATCAAGATTCAATGGATACTTCAAATTAAAAAAAAAAAAAT
GAGTTAAATTAAGTTAAAATAGACTTCTATGTTACAGTTTAGTTCTAAGTTACCTATGAAGTTTAATTTTTTTTTTTTTA
6 4 9 0  6 5 0 0  6 5 1 0  6 5 2 0  6 5 3 0  6 5 4 0  65 5 0  6 5 6 0
* * * * * * * * * * * * * * * *
TTAAAAAAAAAAAATAATAATTTTTGTTACCATAATATATACATATAAATAAAATTAAAATAAAAATATAAAAACAAATA
MTTTTTTTTTTTTATTATTAAAAACAATGGTATTATATATGTATATTTATTTTAATTTTATTTTTATATTTTTGTTTAT
6 5 7 0  6 5 8 0  6 5 9 0  6 6 0 0  6 6 1 0  6 6 2 0  66 3 0  6 6 4 0
XX IV
AAATTATATTTATAAAAAAAAAAAAATTAAAAAAAATATTATATAATACATATTTATAATTATTTCTTTTTTTATTTACC
TTTAATATAAATATTTTTTTTTTTTTAATTTTTTTTATAATATATTATGTATAAATATTAATAAAGAAAAAAATAAATGG
6 6 5 0  6 6 6 0  6 6 7 0  6 6 8 0  6 6 9 0  6 7 0 0  6 7 1 0  6 7 2 0
* * * * * * * * * * * * * * * *
AAAACCTCCTTTACAAGATGGTGATTTATCATCATCAACATTGATTTTTGTTTGATTATTTTTTTTCCATTGAGTTGGAG
TTTTGGAGGAAATGTTCTACCACTAAATAGTAGTAGTTGTAACTAAAAACAAACTAATAAAAAAAAGGTAACTCAACCTC
6 7 3 0  6 7 4 0  6 7 5 0  6 7 6 0  6 7 7 0  6 7 8 0  6 7 9 0  6 8 0 0
* * * * * * * * * * * * * * * *
TTCTTGATGTTATACTTAATGCATGTATTTTACCATTTCCAATAAAATTTTTTAAAATTTCATTTACTAATCTGTGTTGT
AAGAACTACAATATGAATTACGTACATAAAATGGTAAAGGTTATTTTAAAAAATTTTAAAGTAAATGATTAGACACAACA
6 8 1 0  6 8 2 0  6 8 3 0  6 8 4 0  6 8 5 0  6 8 6 0  6 8 7 0  6 8 8 0
* * * * * * * * * * * * * * * *
TCAATCATTGATAAAGTTTCAAATTTTTCAGAAACAATTTTAACTTTAAAATGTGATTCAGATCCTTTTGGTACATTATG
AGTTAGTAACTATTTCAAAGTTTAAAAAGTCTTTGTTAAAATTGAAATTTTACACTAAGTCTAGGAAAACCATGTAATAC
6 8 9 0  6 9 0 0  6 9 1 0  6 9 2 0  6 9 3 0  6 9 4 0  6 9 5 0  6 9 6 0
* * * * * * * * * * * *  * * * *
CATATAACTTTCATTTATAATTTCTAAATTTATTGGATTTAATTCTTTTGTTAATAATTCTTTAATTTCATTTTCAATTG
GTATATTGAAAGTAAATATTAAAGATTTAAATAACCTAAATTAAGAAAACAATTATTAAGAAATTAAAGTAAAAGTTAAC
6 9 7 0  6 9 8 0  6 9 9 0  7 0 0 0  7 0 1 0  7 0 2 0  7 0 3 0  7 0 4 0
* * * * * * * * * * * * * * * *
GTCCTATTGTTGTCATTTTTTTTTTTAATTAAATTTGACTTTTTTGAAAAGGTGATTATGTGGTATTTATAGAATATGTG
CAGGATAACAACAGTAAAAAAAAAAATTAATTTAAACTGAAAAAACTTTTCCACTAATACACCATAAATATCTTATACAC
7 0 5 0  7 0 6 0  7 0 7 0  7 0 8 0  7 0 9 0  7 1 0 0  7 1 1 0  7 1 2 0
* * * * * * * * * * * *  *  *  * *
TGTGTGGTTGGATAAATGTGTTTTTTTTTTTTGTTTTATTTTTTTTTATTTTAATTTTTGACTTTTTTTTTTTTTTTTTT
ACACACCAACCTATTTACACAAAAAAAAAAAACAAAATAAAAAAAAATAAAATTAAAAACTGAAAAAAAAAAAAAAAAAA
7 1 3 0  7 1 4 0  7 1 5 0  7 1 6 0  7 1 7 0  7 1 8 0  7 1 9 0  7 2 0 0
* * * * * * * * * * * * * * * *
TTTTTTTTATGATCATTTTGTGATTTTCTACTTTTAATTTATTTTTTTTTTTTAAATTTTTAATTTTTTTAATTTTTTTT
AAAAAAAATACTAGTAAAACACTAAAAGATGAAAATTAAATAAAAAAAAAAAATTTAAAAATTAAAAAAATTAAAAAAAA
7 2 1 0  7 2 2 0  7 2 3 0  7 2 4 0  7 2 5 0  7 2 6 0  7 2 7 0  7 2 8 0
* * * * * * * * * * * * * * * *
TTTTAATTATTAATATGATTAAAATTTTTTCAACAAAACAGTTTTTTAATATTACCACTACAAAACAATTTTTTAATATT
AAAATTAATAATTATACTAATTTTAAAAAAGTTGTTTTGTCAAAAAATTATAATGGTGATGTTTTGTTAAAAAATTATAA
7 2 9 0  7 3 0 0  7 3 1 0  7 3 2 0  7 3 3 0  7 3 4 0  7 3 5 0  7 3 6 0
* * * * * * * * * * * * * * * *
ATAACAATTTCGAAACCTTTAAACAATTATCATCAATATTTTTCAACAACAACAATAATAGATAAAAATAAAATGAAATT
TATTGTTAAAGCTTTGGAAATTTGTTAATAGTAGTTATAAAAAGTTGTTGTTGTTATTATCTATTTTTATTTTACTTTAA
M K F>
 >
7 3 7 0  7 3 8 0  7 3 9 0  7 4 0 0  7 4 1 0  7 4 2 0  7 4 3 0  7 4 4 0
X X V
TAATTACCCAGAAACAAGAAGAGATGATTCTGTTTTTGATATATTTAAATCAACAGAAAAAGGAAGTGTTAAAGTTTATG 
ATTAATGGGTCTTTGTTCTTCTCTACTAAGACAAAAACTATATAAATTTAGTTGTCTTTTTCCTTCACAATTTCAAATAC 
N Y P E T R R D D S V F D I F K S T E K G S V K V Y >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
7 4 5 0  7 4 6 0  7 4 7 0  7 4 8 0  7 4 9 0  7 5 0 0  7 5 1 0  7 5 2 0
* * * * * * * * * * * * * * * *
ATCCATATCGTCATTTAGAAGATCAACAATCACCAGAAACAAAGAAATGGGTTGATGAAGAAAATAAAATTACAAGATCA 
TAGGTATAGCAGTAAATCTTCTAGTTGTTAGTGGTCTTTGTTTCTTTACCCAACTACTTCTTTTATTTTAATGTTCTAGT 
D P Y R H L E D Q Q S P E T K K W V D E E N K I T R S >  
 DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
7 5 3 0  7 5 4 0  7 5 5 0  7 5 6 0  7 5 7 0  7 5 8 0  7 5 9 0  7 6 0 0
* * * * * * * * * * * * * * * *
TTTTTAGATCAAGATAATACAAGTGAAAAGATTTCAAATGAAATTATGAAAATGTTAAATTTTGAAAGATTTGATTGGTT 
AAAAATCTAGTTCTATTATGTTCACTTTTCTAAAGTTTACTTTAATACTTTTACAATTTAAAACTTTCTAAACTAACCAA 
F L D Q D N T S E K I S N E I M K M L N F E R F D W F >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
7 6 1 0  7 6 2 0  7 6 3 0  7 6 4 0  7 6 5 0  7 6 6 0  7 6 7 0  7 6 8 0
* * * * * * * * * * * * * * * *
TAGAAGAAGAGGTTCAAAATTATTCTTTTCAAGAAATCCAAATACATTAAATCAAAATATAATTTATTTGATTGATATTG 
ATCTTCTTCTCCAAGTTTTAATAAGAAAAGTTCTTTAGGTTTATGTAATTTAGTTTTATATTAAATAAACTAACTATAAC 
R R R G S K L F F S R N P N T L N Q N I  I  Y L I  D I>  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
7 6 9 0  7 7 0 0  7 7 1 0  7 7 2 0  7 7 3 0  7 7 4 0  7 7 5 0  7 7 6 0
* * * * * * * * * * * * * * * *
ATCAAATTTCAATTAGTAAAGATGGTAAATCAAGTGCAAAAGGATTTGAAAATGCAATTGAATTCTTAAATCCAAACACT 
TAGTTTAAAGTTAATCATTTCTACCATTTAGTTCACGTTTTCCTAAACTTTTACGTTAACTTAAGAATTTAGGTTTGTGA 
D Q I S I S K D G K S S A K G F E N A I E F L N P N T >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
7 7 7 0  7 7 8 0  7 7 9 0  7 8 0 0  7 8 1 0  7 8 2 0  7 8 3 0  7 8 4 0
* * * * * * * * * * * * * * * *
TATTCAAAAGATGGTACATGGAGTTTAAAATCATTTGTAATCTCAAAGAGTGGTGATCATGTTTGTTTTAGTTATTCAAA 
ATAAGTTTTCTACCATGTACCTCAAATTTTAGTAAACATTAGAGTTTCTCACCACTAGTACAAACAAAATCAATAAGTTT 
Y S K D G T W S L K S F V I S K S G D H V C F S Y S K >  
 DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
7 8 5 0  7 8 6 0  78 7 0  7 8 8 0  7 8 9 0  7 9 0 0  7 9 1 0  7 9 2 0
* * * * * * * * * * * * * * * *
GGCAGGTTCTGATTGGGAAGAGATTGCAGTAAAGAAAATTATAACAACTAATGAGTTAAAGACAAATAAGGATGATGAAG 
CCGTCCAAGACTAACCCTTCTCTAACGTCATTTCTTTTAATATTGTTGATTACTCAATTTCTGTTTATTCCTACTACTTC 
A G S D W E E I A V K K I I T T N E L K T N K D D E >  
 DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
7 9 3 0  7 9 4 0  7 9 5 0  7 9 6 0  7 9 7 0  7 9 8 0  7 9 9 0  8 0 0 0
* * * * * * * * * * * * * * * *
AGGAGAAAGAAGATTTAAAAAAGAAGAATTGTTTACATTATGCAGTTGTGGATCTACCAGATTCAATAAATTGGTGTAAA
TCCTCTTTCTTCTAAATTTTTTCTTCTTAACAAATGTAATACGTCAACACCTAGATGGTCTAAGTTATTTAACCACATTT
E E K E D L K K K N C L H Y A V V D L P D S I N W C K >
X XV I
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  >
8 0 1 0  8 0 2 0  8 0 3 0  8 0 4 0  8 0 5 0  8 0 6 0  8 0 7 0  8 0 8 0
* * * * * * * * * * * * * * * *
TTTACTTCGATTAAATGGGATGAGAATGAGACTGGTTTCATCTATAATCGATATCCAAAACCGGAAAAAGTATCCGATGA 
AAATGAAGCTAATTTACCCTACTCTTACTCTGACCAAAGTAGATATTAGCTATAGGTTTTGGCCTTTTTCATAGGCTACT 
F T S I K W D E N E T G F I Y N R Y P K P E K V S D D >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
8 0 9 0  8 1 0 0  8 1 1 0  8 1 2 0  8 1 3 0  8 1 4 0  8 1 5 0  8 1 6 0
* * * * * * * * * * * * * * * *
TGATAAAGGCACTGAAACCGACACCAACTTGAATAATAAAGTTTATTATCATAAATTAGGTGATGCCAATGAGTCGTTTG 
ACTATTTCCGTGACTTTGGCTGTGGTTGAACTTATTATTTCAAATAATAGTATTTAATCCACTACGGTTACTCAGCAAAC 
D K G T E T D T N L N N K V Y Y H K L G D A N E S F >  
 DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
8 1 7 0  8 1 8 0  8 1 9 0  8 2 0 0  8 2 1 0  8 2 2 0  8 2 3 0  8 2 4 0
* * * * * * * * * * * * * * * *
ATAGAGTGGTTTTCGAATGTCCAGAGAACCCACAATGGATATTTGGTACTGAGTTCTCTCATGACCATAGCTCTTTGTTT 
TATCTCACCAAAAGCTTACAGGTCTCTTGGGTGTTACCTATAAACCATGACTCAAGAGAGTACTGGTATCGAGAAACAAA 
D R V V F E C P E N P Q W I F G T E F S H D H S S L F >  
 DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
8 2 5 0  8 2 6 0  8 2 7 0  8 2 8 0  8 2 9 0  8 3 0 0  8 3 1 0  8 3 2 0
* * * * * * * * * * * * * * * *
ATCAGCGCTTTCAGGGACTGCAATGTTGAGCATAATCTATATGTAATTAGAAATTTCCAAGAGGCAATTGCAAATAAATC 
TAGTCGCGAAAGTCCCTGACGTTACAACTCGTATTAGATATACATTAATCTTTAAAGGTTCTCCGTTAACGTTTATTTAG 
I S A F R D C N V E H N L Y V I R N F Q E A I A N K S >  
 DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
8 3 3 0  8 3 4 0  8 3 5 0  8 3 6 0  8 3 7 0  8 3 8 0  8 3 9 0  8 4 0 0
* * * * * * * * * * * * * * * *
AGCCTTTAAAGTCGAGGCCCTCATAGATAATTTCGATGCTTGTTATTATTATATTACAAATACTAAACAAGGTGAATATT 
TCGGAAATTTCAGCTCCGGGAGTATCTATTAAAGCTACGAACAATAATAATATAATGTTTATGATTTGTTCCACTTATAA 
A F K V E A L I D N F D A C Y Y Y I T N T K Q G E Y >  
 DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
8 4 1 0  8 4 2 0  8 4 3 0  8 4 4 0  8 4 5 0  8 4 6 0  8 4 7 0  8 4 8 0
* * * * * * * * * * * * * * * *
TCTTTTTAACCAATTTATCTGCACCATTCAATAGATTAATCTCAATTCAATTGAATGATGATCAACCAATCGTACCAAAT 
AGAAAAATTGGTTAAATAGACGTGGTAAGTTATCTAATTAGAGTTAAGTTAACTTACTACTAGTTGGTTAGCATGGTTTA 
F F L T N L S A P F N R L I S I Q L N D D Q P I V P N >  
 DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
8 4 9 0  8 5 0 0  8 5 1 0  8 5 2 0  8 5 3 0  8 5 4 0  8 5 5 0  8 5 6 0
* * * * * * * * * * * * * * * *
TCAAAGAGTAAATTAGAGTTTAAAGAGATCATTCCAGAGAAAGACTATGTATTGGAATCGGTTAGTCGTTCCTCTCAAGA 
AGTTTCTCATTTAATCTCAAATTTCTCTAGTAAGGTCTCTTTCTGATACATAACCTTAGCCAATCAGCAAGGAGAGTTCT 
S K S K L E F K E I I P E K D Y V L E S V S R S S Q E >  
 DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
8 5 7 0  8 5 8 0  8 5 9 0  8 6 0 0  8 6 1 0  8 6 2 0  8 6 3 0  8 6 4 0
XXVII
GAAATTCTACGTTTCCTATCAAAAACATGTTCAAGATATCATTGAAGTATATGATTTCAATGGTAAATATTTAAAGGATA 
CTTTAAGATGCAAAGGATAGTTTTTGTACAAGTTCTATAGTAACTTCATATACTAAAGTTACCATTTATAAATTTCCTAT 
K F Y V S Y Q K H V Q D I I E V Y D F N G K Y L K D >  
 DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
8 6 5 0  8 6 6 0  8 6 7 0  8 6 8 0  8 6 9 0  8 7 0 0  8 7 1 0  8 7 2 0
* * * * * * * * * * * * * * * *
TTAAATTACCAGGCCCTGGAAGTGCTTCATTATCAGCCACTGAGTATCATGATCATATCTTTATAAACTTTTCAAATTTA 
AATTTAATGGTCCGGGACCTTCACGAAGTAATAGTCGGTGACTCATAGTACTAGTATAGAAATATTTGAAAAGTTTAAAT 
I K L P G P G S A S L S A T E Y H D H I F I N F S N L >  
 DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
8 7 3 0  8 7 4 0  8 7 5 0  8 7 6 0  8 7 7 0  8 7 8 0  8 7 9 0  8 8 0 0
* * * * * * * * * * * * * * * *
GTTTCACCATCGGTAACTTATTATATGGATTCAAAGAATGATGAATTGTTACTCTTTAAAGAACCACACATTGAAGGCTT 
CAAAGTGGTAGCCATTGAATAATATACCTAAGTTTCTTACTACTTAACAATGAGAAATTTCTTGGTGTGTAACTTCCGAA 
V S P S V T Y Y M D S K N D E L L L F K E P H I E G F >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
8 8 1 0  8 8 2 0  8 8 3 0  8 8 4 0  8 8 5 0  8 8 6 0  8 8 7 0  8 8 8 0
* * * * * * * * * * * * * * * *
CAAATCATCAGATTATGAATGTAAACAAGTCTTTTATGAATCTCCAAAGGATAAAACAAAGATTCCAATGTTTATAGCCT 
GTTTAGTAGTCTAATACTTACATTTGTTCAGAAAATACTTAGAGGTTTCCTATTTTGTTTCTAAGGTTACAAATATCGGA 
K S S D Y E C K Q V F Y E S P K D K T K I P M F I A >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
8 8 9 0  8 9 0 0  8 9 1 0  8 9 2 0  8 9 3 0  8 9 4 0  8 9 5 0  8 9 6 0
* * * * * * * * * * * * * * * *
ATAAGAAGACCACAGATATCACCAGTGGTAATGCTCCAACCTATATGACTGGTTATGGTGGTTTCAATATCTCTTACACT 
TATTCTTCTGGTGTCTATAGTGGTCACCATTACGAGGTTGGATATACTGACCAATACCACCAAAGTTATAGAGAATGTGA 
Y K K T T D I T S G N A P T Y M T G Y G G F N I S Y T >  
 DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
8 9 7 0  8 9 8 0  8 9 9 0  9 0 0 0  9 0 1 0  9 0 2 0  9 0 3 0  9 0 4 0
* * * * * * * * * * * *  * *  *  *
CAATCATTCTCAATTAGAAATATTTACTTTTTAAATAAATTCAATGGTATCTTTGTAATTGCAAACATTAGAGGTGGTGG 
GTTAGTAAGAGTTAATCTTTATAAATGAAAAATTTATTTAAGTTACCATAGAAACATTAACGTTTGTAATCTCCACCACC 
Q S F S I R N I Y F L N K F N G I F V I A N I R G G G >  
 DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
9 0 5 0  9 0 6 0  9 0 7 0  9 0 8 0  9 0 9 0  9 1 0 0  9 1 1 0  9 1 2 0
* * * * * * * * * * * * * * * *
TGAGTATGGTAAAGCTTGGCATGAGGCTGGTTCAAAAAAGAATAAGCAAAATTGCTTTGATGATTTTATTGGTGCCGCTG 
ACTCATACCATTTCGAACCGTACTCCGACCAAGTTTTTTCTTATTCGTTTTAACGAAACTACTAAAATAACCACGGCGAC 
E Y G K A W H E A G S K K N K Q N C F D D F I G A A >  
 DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
9 1 3 0  9 1 4 0  9 1 5 0  9 1 6 0  9 1 7 0  9 1 8 0  9 1 9 0  9 2 0 0
* * * * * * * * * * * * * * * *
AATATTTGATAAAGGAAAACTATACAAACCAAAACAAATTGGCCGTAAGAGGTGGTAGTAATGGTGGTTTGTTAATGGGT
TTATAAACTATTTCCTTTTGATATGTTTGGTTTTGTTTAACCGGCATTCTCCACCATCATTACCACCAAACAATTACCCA
XXVIII
E Y L I K E N Y T N Q N K L A V R G G S N G G L L M G >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
9 2 1 0  9 2 2 0  9 2 3 0  9 2 4 0  9 2 5 0  9 2 6 0  9 2 7 0  9 2 8 0
* * * * * * * * * * * * * * * *
GCAATTTCAAATCAACGTCCTGATCTATTTAAATGTGTTGTAGCAGACGTTGGTGTTATGGATATGCTAAGATTCCATCT 
CGTTAAAGTTTAGTTGCAGGACTAGATAAATTTACACAACATCGTCTGCAACCACAATACCTATACGATTCTAAGGTAGA 
A I S N Q R P D L F K C V V A D V G V M D M L R F H L >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
9 2 9 0  9 3 0 0  9 3 1 0  9 3 2 0  9 3 3 0  9 3 4 0  9 3 5 0  9 3 6 0
* * * * * * * * * * * * * * * *
TCATACTATCGGTAGTAATTGGGTCTCTGATTATGGTAGAAGTGATAATCCTGATGATTTTGATGTACTCATTAAATATT 
AGTATGATAGCCATCATTAACCCAGAGACTAATACCATCTTCACTATTAGGACTACTAAAACTACATGAGTAATTTATAA 
H T I G S N W V S D Y G R S D N P D D F D V L I K Y >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
9 3 7 0  9 3 8 0  9 3 9 0  9 4 0 0  9 4 1 0  9 4 2 0  9 4 3 0  9 4 4 0
* * * * * * * * * * * * * * * *
CTCCTCTAAATAATGTCCCAAAGGATTCAAATCAATATCCATCAATTATGCTTTGTACTGGTGACCATGATGATCGTGTC 
GAGGAGATTTATTACAGGGTTTCCTAAGTTTAGTTATAGGTAGTTAATACGAAACATGACCACTGGTACTACTAGCACAG 
S P L N N V P K D S N Q Y P S I M L C T G D H D D R V >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
9 4 5 0  9 4 6 0  9 4 7 0  9 4 8 0  9 4 9 0  9 5 0 0  9 5 1 0  9 5 2 0
* * * * * * * * * * * * * * * *
ATTCCTGCTCACTCTTATAAATTCATCTCTGAATTACAATATCAACTTGGTAAAAAAGTTGATACTCCACTTTTAATTAG 
TAAGGACGAGTGAGAATATTTAAGTAGAGACTTAATGTTATAGTTGAACCATTTTTTCAACTATGAGGTGAAAATTAATC 
I P A H S Y K F I S E L Q Y Q L G K K V D T P L L I R >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: G F P _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
9 5 3 0  9 5 4 0  9 5 5 0  9 5 6 0  9 5 7 0  9 5 8 0  9 5 9 0  9 6 0 0
* * * * * * * * * * * * * * * *
AGTTGATAAAGATTCTGGTCATGGTGCTGGTAAAGGTTTATCAAAACAAAATAATGAAATAGCTGATATCTTTAATTTCT 
TCAACTATTTCTAAGACCAGTACCACGACCATTTCCAAATAGTTTTGTTTTATTACTTTATCGACTATAGAAATTAAAGA 
V D K D S G H G A G K G L S K Q N N E I A D I F N F >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
9 6 1 0  9 6 2 0  9 6 3 0  9 6 4 0  9 6 5 0  9 6 6 0  9 6 7 0  9 6 8 0
* * * * * * * * * * * * * * * *
TTTCAAAAGTTTTAAATGTTAAATTAAATTTTGGTACCATGCCCATGAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTC
AAAGTTTTCAAAATTTACAATTTAATTTAAAACCATGGTACGGGTACTCATTTCCTCTTCTTGAAAAGTGACCTCAACAG
F S K V L N V K L N F G T M P M S K G E E L F T G V V >
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
GFP >
9 6 9 0  9 7 0 0  9 7 1 0  9 7 2 0  9 7 3 0  9 7 4 0  9 7 5 0  9 7 6 0
* * * * * * * *  * * * * * * * *
CCAATTCTTGTTGAATTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGATGCAACATA
GGTTAAGAACAACTTAATCTACCACTACAATTACCCGTGTTTAAAAGACAGTCACCTCTCCCACTTCCACTACGTTGTAT
P I L V E L D G D V N G H K F S V S G E G E G D A T Y >
DPOA:GFP >
X X IX
 _______________________________________GFP___________________________________________>
9 7 7 0  9 7 8 0  9 7 9 0  9 8 0 0  9 8 1 0  9 8 2 0  9 8 3 0  9 8 4 0
* * * * * * * * * * * * * * * *
CGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTTTCGCGT
GCCTTTTGAATGGGAATTTAAATAAACGTGATGACCTTTTGATGGACAAGGTACCGGTTGTGAACAGTGATGAAAGCGCA
G K L T L K F I C T T G K L P V P W P T L V T T F A >
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
9 8 5 0  9 8 6 0  9 8 7 0  9 8 8 0  9 8 9 0  9 9 0 0  9 9 1 0  9 9 2 0
* * * * * * * * * * * * * * * *
ATGGTCTTCAATGCTTTGCGAGATACCCAGATCATATGAAACAGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTAT
TACCAGAAGTTACGAAACGCTCTATGGGTCTAGTATACTTTGTCGTACTGAAAAAGTTCTCACGGTACGGGCTTCCAATA
Y G L Q C F A R Y P D H M K Q H D F F K S A M P E G Y >
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
> g fp _ 2 _ F O R
T "
9 9 3 0  9 9 4 0  9 9 5 0  9 9 6 0  9 9 7 0  998 0  9 9 9 0  1 0 0 0 0
* * * * * * * * * * * * * * * *
GTACAGGAAAGAACTATATTTTTCAAAGATGACGGGAACTACAAGACACGTGCTGAAGTCAAGTTTGAAGGTGATACCCT
CATGTCCTTTCTTGATATAAAAAGTTTCTACTGCCCTTGATGTTCTGTGCACGACTTCAGTTCAAACTTCCACTATGGGA
V Q E R T I F F K D D G N Y K T R A E V K F E G D T L >
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
GFP >
< g fp _ 2 _ R E v
1 0 0 1 0  1 0 0 2 0  1 0 0 3 0  1 0 0 4 0  1 0 0 5 0  1 0 0 6 0  1 0 0 7 0  1 0 0 8 0
* * * * * * * * * * *  *  * | *  *  *  
TGTTAATAGAATCGAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTTGGACACAAATTGGAATACAACTATA
ACAATTATCTTAGCTCAATTTTCCATAACTAAAATTTCTTCTACCTTTGTAAGAACCTGTGTTTAACCTTATGTTGATAT
V N R I E L K G I D F K E D G N I L G H K L E Y N Y >
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _    GFP >
1 0 0 9 0  1 0 1 0 0  1 0 1 1 0  1 0 1 2 0  1 0 1 3 0  1 0 1 4 0  1 0 1 5 0  1 0 1 6 0
* * * * * * * * * * * * * * * *
ACTCACACAATGTATACATCATGGCAGACAAACAAAAGAATGGAATCAAAGTTAACTTCAAAATTAGACACAACATTGAA
TGAGTGTGTTACATATGTAGTACCGTCTGTTTGTTTTCTTACCTTAGTTTCAATTGAAGTTTTAATCTGTGTTGTAACTT
N S H N V Y I M A D K Q K N G I K V N F K I R H N I E >
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
1 0 1 7 0  1 0 1 8 0  1 0 1 9 0  1 0 2 0 0  1 0 2 1 0  1 0 2 2 0  1 0 2 3 0  1 0 2 4 0
* * * * * * * *  * * * * * * * *
GATGGAAGCGTTCAACTAGCAGACCATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCA 
CTACCTTCGCAAGTTGATCGTCTGGTAATAGTTGTTTTATGAGGTTAACCGCTACCGGGACAGGAAAATGGTCTGTTGGT 
D G S V Q L A D H Y Q Q N T P I G D G P V L L P D N H >  
_ _ _ _ _ _ _ _ _ _ _ _ _ _  DPOA:GFP >
X X X
GFP >
1 0 2 5 0  1 0 2 6 0  1 0 2 7 0  1 0 2 8 0  1 0 2 9 0  1 0 3 0 0  1 0 3 1 0  1 0 3 2 0
* * * * * * * * * * * * * * * *
TTACCTGTCCACACAATCTGCCCTTTCGAAAGATCCCAACGAAAAGAGAGACCACATGGTCCTTCTTGAGTTTGTAACAG
AATGGACAGGTGTGTTAGACGGGAAAGCTTTCTAGGGTTGCTTTTCTCTCTGGTGTACCAGGAAGAACTCAAACATTGTC
Y L S T Q S A L S K D P N E K R D H M V L L E F V T >
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
1 0 3 3 0  1 0 3 4 0  1 0 3 5 0  1 0 3 6 0  1 0 3 7 0  1 0 3 8 0  1 0 3 9 0  1 0 4 0 0
* * * * * * * * * * * * * * *  *
CTGCTGGGATTACACATGGCATGGATGAACTATACAAAGAGAATTCAGAGCTCGGATCCACTCGAGATGCATTAGAACAA
GACGACCCTAATGTGTACCGTACCTACTTGATATGTTTCTCTTAAGTCTCGAGCCTAGGTGAGCTCTACGTAATCTTGTT
A A G I T H G M D E L Y K E N S E L G S T R D A L E Q >
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ >
GFP >
1 0 4 1 0  1 0 4 2 0  1 0 4 3 0  1 0 4 4 0  1 0 4 5 0
* * * * * * * * * *
AAATTATTATCAGAAGAAGATTTAAATTAATCTAGAGGATCAATTCAAGTTTT
TTTAATAATAGTCTTCTTCTAAATTTAATTAGATCTCCTAGTTAAGTTCAAAA
K L L S E E D L N * >
_ _ _ _ _ _ _ _ _ _ DPOA: GFP_ _ _ _ _ _ _ _ _ _ _ _ >
_ _ _ _ _ _ _ _ _ _ _ _ _ GFP_ _ _ _ _ _ _ _ _ _ _ _ _ _ >
C-MYC >
